ALSFOUK AISHA A (SA)
AMMAR USAMA (GB)
ANTHONY NAHOUM G (GB)
BAIGET JESSICA (GB)
BERRETTA GIACOMO (GB)
BREEN DAVID (GB)
HUGGAN JUDITH (GB)
LAWSON CHRISTOPHER (GB)
MASCI DOMIZIANA (IT)
LLONA-MINGUEZ SABIN (GB)
RILEY CHRISTOPHER (GB)
SUCKLING COLIN J (GB)
WEST CHRISTOPHER (GB)
WO2008132121A1 | 2008-11-06 | |||
WO2008154241A1 | 2008-12-18 | |||
WO2001094341A1 | 2001-12-13 | |||
WO1999002166A1 | 1999-01-21 | |||
WO2000040529A1 | 2000-07-13 | |||
WO2000041669A2 | 2000-07-20 | |||
WO2001092224A1 | 2001-12-06 | |||
WO2002004434A1 | 2002-01-17 | |||
WO2002008213A1 | 2002-01-31 |
RAZANI BREICHARDT ADCHENG G.: "Non-canonical NF- B signaling activation and regulation: principles and perspectives.", IMMUNOL REV., vol. 244, no. 1, November 2011 (2011-11-01), pages 44 - 54, XP055097058, DOI: 10.1111/j.1600-065X.2011.01059.x
CILDIR GLOW KCTERGAONKAR V.: "Noncanonical NF- B Signaling in Health and Disease", TRENDS MOL MED., vol. 22, no. 5, May 2016 (2016-05-01), pages 414 - 429
SUN SC.: "The non-canonical NF- B pathway in immunity and inflammation.", NAT REV IMMUNOL., vol. 17, no. 9, September 2017 (2017-09-01), pages 545 - 558
XIA LTAN SZHOU YLIN JWANG HOYANG LTIAN YLIU LSU MWANG H: "Role of the NF B-signaling pathway in cancer.", ONCO TARGETS THER, vol. 11, 11 April 2018 (2018-04-11), pages 2063 - 2073
PERKINS ND.: "Integrating cell-signalling pathways with NF-kappaB and IKK function.", NAT REV MOL CELL BIOL., vol. 8, no. 1, January 2007 (2007-01-01), pages 49 - 62, XP009150545
GAMBLE CMCLNTOSH KSCOTT RHO KHPLEVIN RPAUL A.: "Inhibitory kappa B Kinases as targets for pharmacological regulation.", BR J PHARMACOL., vol. 165, no. 4, February 2012 (2012-02-01), pages 802 - 19, XP071171407, DOI: 10.1111/j.1476-5381.2011.01608.x
LIAO GZHANG MHARHAJ EWSUN SC: "Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation", J BIOL CHEM., vol. 279, no. 25, 18 June 2004 (2004-06-18), pages 26243 - 50
VALLABHAPURAPU SMATSUZAWA AZHANG WTSENG PHKEATS JJWANG HVIGNALI DABERGSAGEL PLKARIN M.: "Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.", NAT IMMUNOL., vol. 9, no. 12, December 2008 (2008-12-01), pages 1364 - 70
VINCE JEWONG WWKHAN NFELTHAM RCHAU DAHMED AUBENETATOS CACHUNDURU SKCONDON SMMCKINLAY M: "IAP antagonists target clAP1 to induce TNFalpha-dependent apoptosis.", CELL, vol. 131, no. 4, 16 November 2007 (2007-11-16), pages 682 - 93, XP002608625, DOI: 10.1016/j.cell.2007.10.037
VARFOLOMEEV EBLANKENSHIP JWWAYSON SMFEDOROVA AVKAYAGAKI NGARG PZOBEL KDYNEK JNELLIOTT LOWALLWEBER HJ: "IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.", CELL, vol. 131, no. 4, 16 November 2007 (2007-11-16), pages 669 - 81
ZARNEGAR BJWANG YMAHONEY DJDEMPSEY PWCHEUNG HHHE JSHIBA TYANG XYEH WCMAK TW: "Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors clAP1, clAP2, TRAF2 and TRAF3 and the kinase NIK.", NAT IMMUNOL, vol. 9, no. 12, December 2008 (2008-12-01), pages 1371 - 8
XIAO GFONG ASUN SC.: "Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation.", J BIOL CHEM., vol. 279, no. 29, 16 July 2004 (2004-07-16), pages 30099 - 105
XIAO GHARHAJ EWSUN SC.: "NF-kappaB-inducing kinase regulates the processing of NF-kappaB2 p100.", MOL CELL., vol. 7, no. 2, February 2001 (2001-02-01), pages 401 - 9, XP002349294, DOI: 10.1016/S1097-2765(01)00187-3
LIANG CZHANG MSUN SC.: "beta-TrCP binding and processing of NF-kappaB2/p100 involve its phosphorylation at serines 866 and 870.", CELL SIGNAL., vol. 18, no. 8, August 2006 (2006-08-01), pages 1309 - 17
SENFTLEBEN UCAO YXIAO GGRETEN FRKRAHN GBONIZZI GCHEN YHU YFONG ASUN SC: "Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.", SCIENCE, vol. 293, no. 5534, 24 August 2001 (2001-08-24), pages 1495 - 9, XP000962410, DOI: 10.1126/science.1062677
CLAUDIO EBROWN KPARK SWANG HSIEBENLIST U.: "BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells.", NAT IMMUNOL., vol. 3, no. 10, October 2002 (2002-10-01), pages 958 - 65
DEJARDIN EDROIN NMDELHASE MHAAS ECAO YMAKRIS CLI ZWKARIN MWARE CFGREEN DR.: "The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways.", IMMUNITY., vol. 17, no. 4, October 2002 (2002-10-01), pages 525 - 35
WANG RPZHANG MLI YDIAO FCCHEN DZHAI ZSHU HB: "Differential regulation of IKK alpha-mediated activation of IRF3/7 by NIK.", MOL IMMUNOL., vol. 45, no. 7, April 2008 (2008-04-01), pages 1926 - 34, XP022478955, DOI: 10.1016/j.molimm.2007.10.034
TU ZPRAJAPATI SPARK KJKELLY NJYAMAMOTO YGAYNOR RB.: "IKK alpha regulates estrogen-induced cell cycle progression by modulating E2F1 expression", J BIOL CHEM., vol. 281, no. 10, 10 March 2006 (2006-03-10), pages 6699 - 706
AMMIRANTE MKURAISHY ALSHALAPOUR SSTRASNER ARAMIREZ-SANCHEZ CZHANG WSHABAIK AKARIN M: "An IKKa-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence.", GENES DEV, vol. 27, no. 13, 1 July 2013 (2013-07-01), pages 1435 - 40
LAMBERTI CLIN KMYAMAMOTO YVERMA UVERMA IMBYERS SGAYNOR RB.: "Regulation of beta-catenin function by the IkappaB kinases", J BIOL CHEM., vol. 276, no. 45, 9 November 2001 (2001-11-09), pages 42276 - 86
HUANG WCJU TKHUNG MCCHEN CC: "Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB.", MOL CELL., vol. 26, no. 1, 13 April 2007 (2007-04-13), pages 75 - 87
HOBERG JEPOPKO AERAMSEY CSMAYO MW: "IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of ReIA/p65 by p300.", MOL CELL BIOL., vol. 26, no. 2, January 2006 (2006-01-01), pages 457 - 71
KWAK YTLI RBECERRA CRTRIPATHY DFRENKEL EPVERMA UN.: "IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation", J BIOL CHEM., vol. 280, no. 40, 7 October 2005 (2005-10-07), pages 33945 - 52
LIU BYANG YCHERNISHOF VLOO RRJANG HTAHK SYANG RMINK SSHULTZ DBELLONE CJ: "Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity.", CELL, vol. 129, no. 5, 1 June 2007 (2007-06-01), pages 903 - 14
PARK KJKRISHNAN VO'MALLEY BWYAMAMOTO YGAYNOR RB.: "Formation of an IKKalpha-dependent transcription complex is required for estrogen receptor-mediated gene activation", MOL CELL., vol. 18, no. 1, 1 April 2005 (2005-04-01), pages 71 - 82
JAIN GVOOGDT CTOBIAS ASPINDLER KDMOLLER PCRONAUER MVMARIENFELD RB: "I B kinases modulate the activity of the androgen receptor in prostate carcinoma cell lines", NEOPLASIA, vol. 14, no. 3, March 2012 (2012-03-01), pages 178 - 89
WU RCQIN JHASHIMOTO YWONG JXU JTSAI SYTSAI MJO'MALLEY BW: "Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by I kappa B kinase.", MOL CELL BIOL., vol. 22, no. 10, May 2002 (2002-05-01), pages 3549 - 61
WU RCQIN JYI PWONG JTSAI SYTSAI MJO'MALLEY BW: "Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways.", MOL CELL., vol. 15, no. 6, 24 September 2004 (2004-09-24), pages 937 - 49
PRAJAPATI STU ZYAMAMOTO YGAYNOR RB: "IKKalpha regulates the mitotic phase of the cell cycle by modulating Aurora A phosphorylation.", CELL CYCLE., vol. 5, no. 20, October 2006 (2006-10-01), pages 2371 - 80
IRELAN JTMURPHY TJDEJESUS PDTEO HXU DGOMEZ-FERRERIA MAZHOU YMIRAGLIA LJRINES DRVERMA IM: "A role for IkappaB kinase 2 in bipolar spindle assembly", PROC NATL ACAD SCI USA., vol. 104, no. 43, 23 October 2007 (2007-10-23), pages 16940 - 5
SCHUMM KROCHA SCAAMANO JPERKINS ND.: "Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit", EMBO J., vol. 25, no. 20, 18 October 2006 (2006-10-18), pages 4820 - 32
LANNETTI ALEDOUX ACTUDHOPE SJSELLIER HZHAO BMOWLA SMOORE AHUMMERICH HGEWURZ BECOCKELL SJ: "Regulation of p53 and Rb links the alternative NF- B pathway to EZH2 expression and cell senescence.", PLOS GENET, vol. 10, no. 9, 25 September 2014 (2014-09-25), pages e1004642, XP055152312, DOI: 10.1371/journal.pgen.1004642
LEDOUX ACSELLIER HGILLIES KLANNETTI AJAMES JPERKINS ND.: "NF B regulates expression of Polo-like kinase 4.", CELL CYCLE., vol. 12, no. 18, 15 September 2013 (2013-09-15), pages 3052 - 62
HANAHAN DWEINBERG RA: "The hallmarks of cancer.", CELL., vol. 100, no. 1, 7 January 2000 (2000-01-07), pages 57 - 70, XP055447752
HANAHAN DWEINBERG RA: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 4 March 2011 (2011-03-04), pages 646 - 74, XP028185429, DOI: 10.1016/j.cell.2011.02.013
LI XMASSA PEHANIDU APEET GWARO PSAVITT AMISCHE SLI JMARCU KB: "IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program.", J BIOL CHEM., vol. 277, no. 47, 22 November 2002 (2002-11-22), pages 45129 - 40
MASSA PELI XHANIDU ASIAMAS JPARIALI MPAREJA JSAVITT AGCATRON KMLI JMARCU KB: "Gene expression profiling in conjunction with physiological rescues of IKKalpha-null cells with wild type or mutant IKKalpha reveals distinct classes of IKKalpha/NF-kappaB-dependent genes", J BIOL CHEM., vol. 280, no. 14, 8 April 2005 (2005-04-08), pages 14057 - 69
NADIMINTY NDUTT STEPPER CGAO AC.: "Microarray analysis reveals potential target genes of NF-kappaB2/p52 in LNCaP prostate cancer cells.", PROSTATE, vol. 70, no. 3, 15 February 2010 (2010-02-15), pages 276 - 87
WHARRY CEHAINES KMCARROLL RGMAY MJ: "Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells.", CANCER BIOL THER., vol. 8, no. 16, August 2009 (2009-08-01), pages 1567 - 76
AMMIRANTE MSHALAPOUR SKANG YJAMIESON CAKARIN M.: "Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts", PROC NATL ACAD SCI USA., vol. 111, no. 41, 14 October 2014 (2014-10-14), pages 14776 - 81, XP055312059, DOI: 10.1073/pnas.1416498111
AMMIRANTE MLUO JLGRIVENNIKOV SNEDOSPASOV SKARIN M: "B-cell-derived lymphotoxin promotes castration-resistant prostate cancer", NATURE, vol. 464, no. 7286, 11 March 2010 (2010-03-11), pages 302 - 5
LI YZHOU QLSUN WCHANDRASEKHARAN PCHENG HSYING ZLAKSHMANAN MRAJU ATENEN DGCHENG SY: "Non-canonical NF- B signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.", NAT CELL BIOL., vol. 17, no. 10, October 2015 (2015-10-01), pages 1327 - 38
MARGALEF PFERNANDEZ-MAJADA VVILLANUEVA AGARCIA-CARBONELL RIGLESIAS MLOPEZ LMARTINEZ-LNIESTA MVILLA-FREIXA JMULERO MCANDREU M: "A truncated form of IKKa is responsible for specific nuclear IKK activity in colorectal cancer.", CELL REP, vol. 2, no. 4, 25 October 2012 (2012-10-25), pages 840 - 54
MARGALEF PCOLOMER CVILLANUEVA AMONTAGUT CIGLESIAS MBELLOSILLO BSALAZAR RMARTINEZ-LNIESTA MBIGAS AESPINOSA L.: "BRAF-induced tumorigenesis is IKKa-dependent but NF- B-independent.", SCI SIGNAL, vol. 8, no. 373, 21 April 2015 (2015-04-21), pages 38
JERRY MARCH: "Advanced Organic Chemistry", 2001, JOHN WILEY AND SONS, pages: 131 - 133
L. W. DEADY, SYN. COMM., vol. 7, 1977, pages 509 - 514
"Methods in Enzymology", vol. 42, 1985, ACADEMIC PRESS, pages: 309 - 396
H. BUNDGAARD, ADVANCED DRUG DELIVERY REVIEWS, vol. 8, 1992, pages 113 - 191
H. BUNDGAARD ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 77, 1988, pages 285
N. KAKEYA ET AL., CHEM. PHARM. BULL., vol. 32, 1984, pages 692
T. HIGUCHIV. STELLA: "Pro-Drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
"Bioreversible Carriers in Drug Design", 1987, PERGAMON
DURAN CLLEE DWJUNG JURAVI SPOGUE CBTOUSSAINT LGBAYLESS KJSITCHERAN R: "NIK regulates MT1-MMP activity and promotes glioma cell invasion independently of the canonical NF- B pathway.", ONCOGENESIS, vol. 5, no. 6, 6 June 2016 (2016-06-06), pages e231
CHERRY ELEE DJUNG JSITCHERAN R: "Non-canonical nf-kb signaling drives the aggressive invasiveness of glioblastoma", NEURO-ONCOLOGY, vol. 16, 2014
LESSARD LBEGIN LRGLEAVE MEMES-MASSON AMSAAD F.: "Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.", BR J CANCER., vol. 93, no. 9, 31 October 2005 (2005-10-31), pages 1019 - 23, XP002526077, DOI: 10.1038/SJ.BJC.6602796
LESSARD LSAAD FLE PAGE CDIALLO JSPEANT BDELVOYE NMES-MASSON AM.: "NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells.", CELL SIGNAL., vol. 19, no. 5, May 2007 (2007-05-01), pages 1093 - 100, XP026104416, DOI: 10.1016/j.cellsig.2006.12.012
DOPPLER HLIOU GYSTORZ P.: "Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity.", PLOS ONE., vol. 8, no. 1, 2013, pages e53676
THU YMRICHMOND A.: "NF- B inducing kinase: a key regulator in the immune system and in cancer.", CYTOKINE GROWTH FACTOR REV., vol. 21, no. 4, August 2010 (2010-08-01), pages 213 - 26, XP027267636
NISHINA TYAMAGUCHI NGOHDA JSEMBA KINOUE J.: "NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells.", BIOCHEM BIOPHYS RES COMMUN., vol. 388, no. 1, 9 October 2009 (2009-10-09), pages 96 - 101, XP026501127, DOI: 10.1016/j.bbrc.2009.07.125
CHANDLER NMCANETE JJCALLERY MP.: "Increased expression of NF-kappa B subunits in human pancreatic cancer cells.", J SURG RES., vol. 118, no. 1, 1 May 2004 (2004-05-01), pages 9 - 14
ISHIKAWA HAKEDO ISUZUKI TNARAHARA HOTANI T.: "Adverse effects of sulindac used for prevention of colorectal cancer.", J NATL CANCER INST., vol. 89, no. 18, 17 September 1997 (1997-09-17), pages 1381
LUA JQAYYUM, T.EDWARDS, J.ROSEWEIR, A. K.: "The prognostic role of the non-canonical NF-kappa B pathway in renal cell carcinoma patients.", UROLOGIA INTERNATIONALIS., 2018
JAMIESON SFULLER PJ.: "Characterization of the inhibitor of kappaB kinase (IKK) complex in granulosa cell tumors of the ovary and granulosa cell tumor-derived cell lines.", HORM CANCER., vol. 4, October 2013 (2013-10-01), pages 277 - 92, XP037322470, DOI: 10.1007/s12672-013-0146-x
CILDIR GLOW KCTERGAONKAR V.: "Noncanonical NF-kappa B Signaling in Health and Disease.", TRENDS MOL MED., vol. 22, May 2016 (2016-05-01), pages 414 - 29
QIN HZHOU JZHOU PXU JTANG ZMA HGUO F.: "Prognostic significance of RelB overexpression in non-small cell lung cancer patients.", THORAC CANCER., vol. 7, no. 4, July 2016 (2016-07-01), pages 415 - 21
SHEN MDUAN XZHOU PZHOU WWU XXU SCHEN YTAO Z.: "Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor- B-dependent manner.", MOL MED REP., vol. 11, no. 2, February 2015 (2015-02-01), pages 783 - 90
SOVAK MABELLAS REKIM DWZANIESKI GJROGERS AETRAISH AMSONENSHEIN GE: "Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.", J CLIN INVEST., vol. 100, no. 12, 15 December 1997 (1997-12-15), pages 2952 - 60
BENNETT LQUINN JMCCALL PMALLON EAHORGAN PGMCMILLAN DCPAUL AEDWARDS J.: "High IKKa expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.", INT J CANCER., vol. 140, no. 7, 1 April 2017 (2017-04-01), pages 1633 - 1644, XP071290151, DOI: 10.1002/ijc.30578
CAO YBONIZZI GSEAGROVES TNGRETEN FRJOHNSON RSCHMIDT EVKARIN M.: "IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development.", CELL, vol. 107, no. 6, 14 December 2001 (2001-12-14), pages 763 - 75, XP000962404, DOI: 10.1016/S0092-8674(01)00599-2
YANG ZWANG XLBAI RLIU WYLI XLIU MTANG H.: "miR-23a promotes IKKa expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.", BR J CANCER., vol. 115, no. 6, 6 September 2016 (2016-09-06), pages 731 - 40
CONNELLY LROBINSON-BENION CCHONT MSAINT-JEAN LLI HPOLOSUKHIN WBLACKWELL TSYULL FE.: "A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis", J BIOL CHEM., vol. 282, no. 13, 30 March 2007 (2007-03-30), pages 10028 - 35
KARIN MBONNIZI GCAO Y.: "NF-kB: a factor that provides a link between stress, inflammation and cancer.", EUROPEAN JOURNAL OF CANCER., vol. 38, November 2002 (2002-11-01), pages S116, XP004403830
KARIN MCAO YXGRETEN FRLI ZW: "NF-kappa B in cancer: From innocent bystander to major culprit.", NATURE REVIEWS CANCER., vol. 2, April 2002 (2002-04-01), pages 301 - 10
KARIN MLIN A.: "NF-kappa B at the crossroads of life and death.", NAT IMMUNOL., vol. 3, March 2002 (2002-03-01), pages 221 - 7
COGSWELL PCGUTTRIDGE DCFUNKHOUSER WKBALDWIN AS, JR: "Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3.", ONCOGENE, vol. 19, 24 February 2000 (2000-02-24), pages 1123 - 31
DAN HCANTONIA RJBALDWIN AS.: "PI3K/Akt promotes feedforward mTORC2 activation through IKK alpha.", ONCOTARGET, vol. 7, 19 April 2016 (2016-04-19), pages 21064 - 75
ESPINOSA LMARGALEF PBIGAS A.: "Non-conventional functions for NF-kappa B members: the dark side of NF-kappa B.", ONCOGENE., vol. 34, 30 April 2015 (2015-04-30), pages 2279 - 87
RIZZO PMIAO HD'SOUZA GOSIPO CSONG LLYUN JZHAO HMASCARENHAS JWYATT DANTICO G: "Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches", CANCER RES., vol. 68, no. 13, 1 July 2008 (2008-07-01), pages 5226 - 35
HAO LRIZZO POSIPO CPANNUTI AWYATT DCHEUNG LWSONENSHEIN GOSBORNE BAMIELE L.: "Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells", ONCOGENE, vol. 29, no. 2, 14 January 2010 (2010-01-14), pages 201 - 13
ROSEWEIR AKBENNETT LDICKSON ACHENG KQUINTAYO MABAYANI JMCMILLAN DCHORGAN PGVAN DE VELDE CJHSEYNAEVE C: "Predictive Biomarkers for Endocrine Therapy: Retrospective Study in Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial.", J NATL CANCER INST., vol. 110, no. 6, 1 June 2018 (2018-06-01), pages 616 - 627
MERGA YJO'HARA ABURKITT MDDUC4CWORTH CAPROBERT CSCAMPBELL BJPRITCHARD DM.: "Importance of the alternative NF- B activation pathway in inflammation-associated gastrointestinal carcinogenesis.", AM J PHYSIOL GASTROINTEST LIVER PHYSIOL., vol. 310, no. 11, 1 June 2016 (2016-06-01), pages G1081 - 90
JIN LVU TYUAN GDATTA PK.: "STRAP Promotes Sternness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway.", CANCER RES., vol. 77, no. 20, 15 October 2017 (2017-10-15), pages 5464 - 5478
LEOPIZZI MCOCCHIOLA RMILANETTI ERAIMONDO DPOLITI LGIORDANO CSCANDURRA RSCOTTO D'ABUSCO A: "IKKa inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line.", CHEM BIOL INTERACT., vol. 262, 25 January 2017 (2017-01-25), pages 19 - 28, XP029871707, DOI: 10.1016/j.cbi.2016.12.005
CHENG KKWBENNETT LEDWARDS J.: "Identification of a novel biomarker of IKK alpha-dependent NF-kappa B signalling in oestrogen receptor (ER)-positive breast cancer.", SCOT MED J., vol. 61, November 2016 (2016-11-01), pages 55
LUO JLTAN WRICONO JMKORCHYNSKYI OZHANG MGONIAS SLCHERESH DAKARIN M.: "Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin", NATURE, vol. 446, no. 7136, 5 April 2007 (2007-04-05), pages 690 - 4
AMMIRANTE MDE LAURENZI VGRAZIANO VTURCO MCROSATI A.: "BAG3 is required for IKKa nuclear translocation and emergence of castration resistant prostate cancer.", CELL DEATH DIS., vol. 2, 31 March 2011 (2011-03-31), pages e139
RIZEL LSAFIEH CSHALEV SAMEZER EJABALY-HABIB HBEN-NERIAH ZCHERVINSKY EBRISCOE DBEN-YOSEF T.: "Novel mutations of MYO7A and USH1G in Israeli Arab families with Usher syndrome type 1.", MOL VIS., vol. 17, 2011, pages 3548 - 55
BEN-NERIAH YKARIN M.: "Inflammation meets cancer, with NF-kappa B as the matchmaker", NAT IMMUNOL., vol. 12, August 2011 (2011-08-01), pages 715 - 23
KARIN MGRETEN FR.: "NF kappa B: Linking inflammation and immunity to cancer development and progression.", NATURE REVIEWS IMMUNOLOGY., vol. 5, October 2005 (2005-10-01), pages 749 - 59
SEPULVEDA ASORIANO HESPINO A.: "Gastrointestinal tract involvement in Klippel-Trenaunay syndrome.", LANCET GASTROENTEROL HEPATOL., vol. 3, no. 7, July 2018 (2018-07-01), pages 518
JIA JSHI YYAN BXIAO DLAI WPAN YJIANG YCHEN LMAO CZHOU J: "LGR5 expression is controled by IKKa in basal cell carcinoma through activating STAT3 signaling pathway.", ONCOTARGET, vol. 7, no. 19, 10 May 2016 (2016-05-10), pages 27280 - 94
MANNA SSINGHA BPHYO SAGATLA HRCHANG TPSANACORA SRAMASWAMI SVANCUROVA I.: "Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKa", J IMMUNOL., vol. 191, no. 5, 1 September 2013 (2013-09-01), pages 2837 - 46
KONG SDONG HSONG JTHIRUPPATHI MPRABHAKAR BSQIU QLIN ZCHINI EZHANG BFANG D.: "Deleted in Breast Cancer 1 Suppresses B Cell Activation through RelB and Is Regulated by IKKa Phosphorylation", J IMMUNOL., vol. 195, no. 8, 15 October 2015 (2015-10-15), pages 3685 - 93
QU LLHE LZHAO XXU W.: "Downregulation of miR-518a-3p activates the NIK-dependent NF-kappa B pathway in colorectal cancer.", INT J MOL MED., vol. 35, May 2015 (2015-05-01), pages 1266 - 72
FRELIN CIMBERT VGRIESSINGER EPEYRON ACROCHET NPHILIP PDAGEVILLE CSIRVENT AHUMMELSBERGER MBERARD E: "Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells", BLOOD, vol. 105, no. 2, 15 January 2005 (2005-01-15), pages 804 - 11
HEHNER SPHOFMANN TGDRDGE WSCHMITZ ML: "The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex", J IMMUNOL., vol. 163, no. 10, 15 November 1999 (1999-11-15), pages 5617 - 23
HIDESHIMA TCHAUHAN DKIZILTEPE TIKEDA HOKAWA YPODAR KRAJE NPROTOPOPOV AMUNSHI NCRICHARDSON PG: "Biologic sequelae of l{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.", BLOOD, vol. 113, no. 21, 21 May 2009 (2009-05-21), pages 5228 - 36, XP055434498, DOI: 10.1182/blood-2008-06-161505
COOPE HJATKINSON PGHUHSE BBELICH MJANZEN JHOLMAN MJKLAUS GGJOHNSTON LHLEY SC., CD40 REGULATES THE PROCESSING OF NF-KAPPAB2 P100 TO P52
KAYAGAKI NYAN MSESHASAYEE DWANG HLEE WFRENCH DMGREWAL ISCOCHRAN AGGORDON NCYIN J: "BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2.", IMMUNITY, vol. 17, no. 4, October 2002 (2002-10-01), pages 515 - 24, XP002321480, DOI: 10.1016/S1074-7613(02)00425-9
NOVACK DVYIN LHAGEN-STAPLETON ASCHREIBER RDGOEDDEL DVROSS FP, TEITELBAUM SL.THE IKAPPAB FUNCTION OF NF-KAPPAB2 P100 CONTROLS STIMULATED OSTEOCLASTOGENESIS
SUN S.C.: "The non-canonical NF- B pathway.", IMMUNOL. REV., vol. 246, 2012, pages 125 - 140
SCARFO LFERRERI AJGHIA P.: "Chronic lymphocytic leukaemia.", CRIT REV ONCOL HEMATOL., vol. 104, 2016, pages 169 - 82, XP029634673, DOI: 10.1016/j.critrevonc.2016.06.003
CUNI S.PEREZ-ACIEGO P.PEREZ-CHACON G.VARGAS J.ASANCHEZ A.MARTIN-SAAVEDRA F.M.BALLESTER S.GARCIA-MARCO JJORDA J.DURANTEZ A.: "A sustained activation of P13K/NF- B pathway is critical for the survival of chronic lymphocytic leukemia B cells.", LEUKEMIA, vol. 18, 2004, pages 1391 - 1400, XP037781886, DOI: 10.1038/sj.leu.2403398
HEWAMANA SALGHAZAL SLIN TTCLEMENT MJENKINS CGUZMAN MLJORDAN CTNEELAKANTAN SCROOKS PABURNETT AK: "The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.", BLOOD, vol. 111, no. 9, 1 May 2008 (2008-05-01), pages 4681 - 9
MANSOURI LSUTTON LALJUNGSTROM VBONDZA SARNGARDEN LBHOI SLARSSON JCORTESE DKALUSHKOVA APLEVOVA K: "Functional loss of I B leads to NF- B deregulation in aggressive chronic lymphocytic leukemia", J EXP MED., vol. 212, no. 6, 1 June 2015 (2015-06-01), pages 833 - 43
FABBRI GRASI SROSSI DTRIFONOV VKHIABANIAN HMA JGRUNN AFANGAZIO MCAPELLO DMONTI S: "Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation", J EXP MED., vol. 208, no. 7, 4 July 2011 (2011-07-04), pages 1389 - 401, XP055053050, DOI: 10.1084/jem.20110921
ROSATI ESABATINI RRAMPINO GTABILIO ADI LANNI MFETTUCCIARI KBARTOLI ACOACCIOLI SSCREPANTI IMARCONI P.: "Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells.", BLOOD, vol. 113, no. 4, 22 January 2009 (2009-01-22), pages 856 - 65
BALIAKAS PHADZIDIMITRIOU ASUTTON LAROSSI DMINGA EVILLAMOR NLARRAYOZ MKMINKOVA JAGATHANGELIDIS ADAVIS Z: "Recurrent mutations refine prognosis in chronic lymphocytic leukemia.", EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC). LEUKEMIA., vol. 29, no. 2, February 2015 (2015-02-01), pages 329 - 36, XP036972394, DOI: 10.1038/leu.2014.196
CHIARETTI SMARINELLI MDEL GIUDICE IBONINA SPICIOCCHI AMESSINA MVIGNETTI MROSSI DDI MAIO VMAURO FR: "NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.", LEUK LYMPHOMA., vol. 55, no. 12, December 2014 (2014-12-01), pages 2785 - 92
DEJARDIN E.: "The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development", BIOCHEM PHARMACOL., vol. 72, no. 9, 2006, pages 1161 - 79
ROSSI D1RASI SFABBRI GSPINA VFANGAZIO MFORCONI FMARASCA RLAURENTI LBRUSCAGGIN ACERRI M: "Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia.", BLOOD, vol. 119, no. 2, 12 January 2012 (2012-01-12), pages 521 - 9, XP055096013, DOI: 10.1182/blood-2011-09-379966
DEMCHENKO YNGLEBOV OKZINGONE AKEATS JJBERGSAGEL PLKUEHL WM.: "Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.", BLOOD, vol. 115, no. 17, 2010, pages 3541 - 52
COOPE HJ1ATKINSON PGHUHSE BBELICH MJANZEN JHOLMAN MJKLAUS GGJOHNSTON LHLEY SC.: "CD40 regulates the processing of NF-kappaB2 p100 to p52", EMBO J., 2002
HAUER JPÜSCHNER SRAMAKRISHNAN PSIMON UBONGERS MFEDERLE CENGELMANN H: "TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs", PROC NATL ACAD SCI USA., vol. 102, no. 8, 2005, pages 2874 - 9
PEREZ-ANDRES M1ALMEIDA JMARTIN-AYUSO MDE LAS HERAS NMORO MJMARTIN-NUNEZ GGALENDE JCUELLO RABUIN !MORENO I: "Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease", INT J CANCER., vol. 124, no. 2, 2009, pages 367 - 75, XP071284640, DOI: 10.1002/ijc.23941
RICHARDSON PSCHLOSSMAN RJAGANNATH SALSINA MDESIKAN RBLOOD EWELLER EMITSIADES CHIDESHIMA TDAVIES F: "Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.", MAYO CLIN PROC., vol. 79, no. 7, 2004, pages 875 - 82
MCMILLIN DWNEGRI JMMITSIADES CS.: "The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.", NAT REV DRUG DISCOV., vol. 12, no. 3, 2013, pages 217 - 28, XP055090758, DOI: 10.1038/nrd3870
CHAUHAN DUCHIYAMA HAKBARALI YURASHIMA MYAMAMOTO KLIBERMANN TAANDERSON KC.: "Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.", BLOOD., vol. 87, no. 3, 1996, pages 1104 - 12
BOMMERT KBARGOU RCSTUHMER T.: "Signalling and survival pathways in multiple myeloma.", EUR J CANCER., vol. 42, no. 11, 2006, pages 1574 - 80, XP025104747, DOI: 10.1016/j.ejca.2005.12.026
J. MED. CHEM., vol. 47, 2004
STERN ET AL., CRITICAL REVIEWS IN ONCOLOGY/HAEMATOLOGY, vol. 54, 2005, pages 11 - 29
CLAIMS 1. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, having the structural Formula (I), shown below: wherein: R1 is selected from hydrogen, halogen, (1-6C)alkyl, (2-6C)alkynyl, (3-7C) cycloalkyl, aryl, heteroaryl and heterocyclyl, and wherein said (1-6C)alkyl, (2-6C)alkynyl, (3-7C) cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by one or more R100 substituents; wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, (CH2)zC(O)Rf, (CH2)zC(O)ORf, (CH2)zOC(O)Rf, (CH2)zC(O)N(Rj)Rh, (CH2)zN(Rg)C(O)Rf, (CH2)zS(O)yRf, (CH2)zSO2N(Rj)Rh, (CH2)zN(Rg)SO2Rf, (CH2)zNRjRh, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zaryl; and wherein: (i) Rf and Rg are each independently selected from hydrogen, (1-6C)alkyl or phenyl; and wherein Rh and Rj are each independently selected from hydrogen, (1- 6C)alkyl or phenyl or Rh and Rj together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (1-4C)alkyl, (3-7C)cycloalkyl, heterocyclyl, heteroaryl or aryl in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORk, C(O)Rk, C(O)ORk, OC(O)Rk, C(O)N(Rl)Rk, N(Rl)C(O)Rk, S(O)yRk, SO2N(Rl)Rk, N(Rl)SO2Rk, or NRlRk, wherein Rk and Rl are selected from hydrogen or (1-2C)alkyl; X is N or CR2; wherein R2 is selected from hydrogen, halogen, (1-8C)alkyl, (2-8C)alkenyl, (2- 8C)alkynyl, (3-7C)cycloalkyl, aryl, heteroaryl and heterocyclyl, wherein said (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-7C)cycloalkyl, aryl, heteroaryl and heterocyclyl are optionally substituted by one or more R200 substituents; wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zaryl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or aryl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1- 2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1-2C)alkyl; R3 is selected from hydrogen, cyano, (1-8C)alkyl, (3-7C)cycloalkyl, (CH2)1-3(3-7C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl, a carbon-linked 5 to 6 membered heteroaryl, -C(O)-(1-8C)alkyl, -C(O)(CH2)0-3(3-7C)cycloalkyl, -C(O)[5 or 6-membered heteroaryl], -C(O)phenyl, -C(O)O(1-8C)alkyl, -C(O)O(3-7C)cycloalkyl, -C(O)O(CH2)1-3(3-7C)cycloalkyl, -C(O)NH2, -C(O)NH-(1-8C)alkyl, -C(O)NH-(CH2)0-3(3-7C)cycloalkyl, -C(O)NH-(CH2)0-3heterocyclyl, -C(O)NH-(CH2)0-3[5 or 6-membered heteroaryl], -C(O)NH-(CH2)0- 3phenyl, -S(O)2H or -S(O)2-(1-8C)alkyl; wherein any alkyl, cycloalkyl, phenyl, heteroaryl or heterocyclyl moiety is optionally substituted by one or more R300 substituents; wherein R300 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORs, (CH2)zC(O)Rs, (CH2)zC(O)ORs, (CH2)zOC(O)Rs, (CH2)zC(O)N(Rv)Ru, (CH2)zN(Rt)C(O)Rs, (CH2)zN(Rt)C(O)ORs, (CH2)zS(O)yRs, (CH2)zSO2N(Rv)Ru, (CH2)zN(Rt)SO2Rs, (CH2)zNRuRv; and wherein: (i) Rs and Rt are each independently selected from hydrogen, (1-6C)alkyl or (CH2)zphenyl; Ru and Rv are each independently selected from hydrogen, (1- 6C)alkyl or (CH2)zphenyl or Ru and Rv, together with the nitrogen atom to which they are attached, form a 3-7 membered ring which may optionally include further heteroatoms, and wherein any 3-7 membered ring formed Ro and Rp, and any alkyl or phenyl group present for Rs, Rt, Ru and Rv is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1- 2C)alkyl; and (ii) any alkyl, cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R300 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORw, C(O)Rw, C(O)ORw, OC(O)Rw, C(O)N(Rw)Rx, N(Rx)C(O)Rw, S(O)yRw, SO2N(Rx)Rw, N(Rx)SO2Rw, or NRwRx, wherein Rw is hydrogen, (1-2C)alkyl or phenyl, and Rx are selected from hydrogen or (1-2C)alkyl; or R2 and R3 are linked such that together they form a -CH=CQ- or -N=CQ- group; Q is hydrogen, halo, cyano or a group of the formula: -L1-Y1-L2-Q1 wherein: L1 is absent or (1-3C)alkylene; Y1 is absent or O, S, SO, SO2, N(Ry1), C(O), C(O)O, OC(O), C(O)N(Ry1), or N(Ry1)C(O), wherein Ry1 is selected from hydrogen or (1-4C)alkyl; L2 is absent or (1-3C)alkylene; and Q1 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, (3- 8C)cycloalkyl, heteroaryl or heterocyclyl; wherein Q is optionally further substituted by one or more substituent groups independently selected from oxo, hydroxy, (1-6C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)aminoalkyl, (1-4C)hydroxyalkyl, cyano, or by one or more group(s) of the formula: -L3-Y2-L4-W1 wherein: L3 is absent or (1-3C)alkylene; Y2 is absent or selected from or O, S, SO, SO2, N(Ry2), C(O), C(O)O, OC(O), C(O)N(Ry2), or N(Ry2)C(O), S(O)2N(Ry2), N(Ry2)SO2 wherein Ry2 is selected from hydrogen or (1-3C)alkyl; L4 is absent or (1-3C)alkylene; and W1 is hydrogen, (1-6C)alkyl, phenyl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; wherein W1 is optionally substituted by one or more substituents selected from oxo, (1-4C)alkyl, halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1- 4C)alkoxy, amino, (1-4C)alkylamino, di[(1-4C)alkyl]amino C(O)OH, C(O)O(1-4C)alkyl, (CH2)0-3-heterocyclyl or cyano; R4 is selected from hydrogen, halo, cyano or amino; X1 is N when R2 and R3 are linked such that together they form a -CH=CH- group; or CR5 wherein R5 is selected from hydrogen, halo, cyano or amino; y is independently selected from 0, 1 or 2; z is independently selected from 0, 1, 2 or 3; with the proviso that: (i) R1 is not hydrogen when R2 and R3 are both hydrogen; (ii) R2 is not hydrogen when R1 and R3 are both hydrogen; (iii) R1 is not hydrogen when R2 and R3 are linked to form a -CH=CH- group; (iv) R1 is not hydrogen when X is N and R3 is hydrogen; and (v) Q1 is not aryl or heteroaryl when all of L1, Y1 and L2 are absent. 2. A compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound is a compound having the structural formula (Ia), (Ib), (Ic), (Id) or (Ie) shown below: (Id) (Ie) (If) wherein R1, X, R3, R4, R5 and Q are each as defined in claim 1. 3. A compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from hydrogen, halogen, (1-6C)alkyl, (2-6C)alkynyl, (3- 7C)cycloalkyl, phenyl, a 5 or 6-membered heteroaryl or a 4 to 7-membered heterocyclyl, wherein said (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, heteroaryl and heterocyclyl are optionally substituted by one or more R100 substituents; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, (CH2)zC(O)Rf, (CH2)zC(O)ORf, (CH2)zOC(O)Rf, (CH2)zC(O)N(Rj)Rh, (CH2)zN(Rg)C(O)Rf, (CH2)zS(O)yRf, (CH2)zSO2N(Rj)Rh, (CH2)zN(Rg)SO2Rf, (CH2)zNRjRh, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1-2C)alkyl; and wherein Rh and Rj are each independently selected from hydrogen or (1- 2C)alkyl or Rh and Rj together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms; and (ii) any (1-4C)alkyl, (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORk, C(O)Rk, C(O)ORk, OC(O)Rk, C(O)N(Rl)Rk, N(Rl)C(O)Rk, S(O)yRk, SO2N(Rl)Rk, N(Rl)SO2Rk, or NRlRk, wherein Rk and Rl are selected from hydrogen or (1- 2C)alkyl. 4. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from hydrogen, halogen, (1-6C)alkyl, (2-6C)alkynyl, phenyl or a 5 or 6-membered heteroaryl, wherein said (2-6C)alkynyl, phenyl or heteroaryl are optionally substituted by one or more R100 substituents; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, (CH2)zC(O)Rf, (CH2)zC(O)ORf, (CH2)zOC(O)Rf, (CH2)zC(O)N(Rj)Rh, (CH2)zN(Rg)C(O)Rf, (CH2)zS(O)yRf, (CH2)zSO2N(Rj)Rh, (CH2)zN(Rg)SO2Rf, (CH2)zNRjRh, (CH2)z(3-7C)cycloalkyl, (CH2)z-[4-6 membered heterocyclyl], (CH2)z-[5 or 6 membered heteroaryl] or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1-2C)alkyl; and wherein Rh and Rj are each independently selected from hydrogen or (1- 2C)alkyl or Rh and Rj together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms; and (ii) any (1-4C)alkyl, (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl ORk, C(O)Rk, C(O)ORk, OC(O)Rk, C(O)N(Rl)Rk, N(Rl)C(O)Rk, S(O)yRk, SO2N(Rl)Rk, N(Rl)SO2Rk, or NRlRk, wherein Rk and Rl are selected from hydrogen or (1- 2C)alkyl. 5. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from hydrogen, halogen, (1-6C)alkyl, (2-6C)alkynyl, phenyl or a 5 or 6-membered heteroaryl, wherein said (2-6C)alkynyl, phenyl or heteroaryl are optionally substituted by one or more R100 substituents; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, (CH2)zC(O)Rf, (CH2)zC(O)ORf, (CH2)zOC(O)Rf, (CH2)zC(O)N(Rj)Rh, (CH2)zN(Rg)C(O)Rf, (CH2)zS(O)yRf, (CH2)zSO2N(Rj)Rh, (CH2)zN(Rg)SO2Rf, (CH2)zNRjRh, (CH2)z(3-7C)cycloalkyl, (CH2)z-[4-6 membered heterocyclyl], (CH2)z-[5 or 6 membered heteroaryl] or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1-2C)alkyl; and (ii) any (1-4C)alkyl, (3-7C)cycloalkyl, heterocyclyl, heteroaryl or aryl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl or ORk, wherein Rk is selected from hydrogen or (1-2C)alkyl. 6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from hydrogen, (2-6C)alkynyl, phenyl or a 5 or 6-membered heteroaryl, wherein said (2-6C)alkynyl, phenyl or heteroaryl are optionally substituted by one or more R100 substituents; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, C(O)Rf, C(O)ORf, OC(O)Rf, C(O)N(Rj)Rh, N(Rg)C(O)Rf, S(O)yRf, SO2N(Rj)Rh, N(Rg)SO2Rf, NRjRh, (CH2)z-[4-6 membered heterocyclyl], or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1-2C)alkyl; and (ii) any (1-4C)alkyl, heterocyclyl, or phenyl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl or ORk, wherein Rk is selected from hydrogen or (1- 2C)alkyl. 7. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from: (i) hydrogen; (ii) halo; (iii) methyl; (iv) CF3; (v) ethynyl, i.e. which is optionally substituted by R100; (vi) phenyl, which is optionally substituted by R100; (vii) a 5 or 6-membered heteroaryl, which is optionally substituted by R100; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, C(O)Rf, C(O)ORf, OC(O)Rf, C(O)N(Rj)Rh, N(Rg)C(O)Rf, S(O)yRf, SO2N(Rj)Rh, N(Rg)SO2Rf, NRjRh, (CH2)z-[4-6 membered heterocyclyl], or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1-2C)alkyl; and (ii) any (1-4C)alkyl, (3-7C)cycloalkyl, heterocyclyl, heteroaryl or aryl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl or ORk, wherein Rk is selected from hydrogen or (1-2C)alkyl. 8 A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from: (i) hydrogen; (ii) halo; (iii) methyl; (iv) CF3; (v) ethynyl, i.e. which is optionally substituted by R100; (vi) phenyl, which is optionally substituted by R100; (vii) a 5 or 6-membered heteroaryl, which is optionally substituted by R100; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, C(O)Rf, C(O)ORf, OC(O)Rf, C(O)N(Rj)Rh, N(Rg)C(O)Rf, S(O)yRf, SO2N(Rj)Rh, N(Rg)SO2Rf, NRjRh, (CH2)z-[4-6 membered heterocyclyl], or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1- 2C)alkyl; and (ii) any (1-4C)alkyl, heterocyclyl or phenyl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl or ORk, wherein Rk is selected from hydrogen or (1-2C)alkyl. 9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is selected from: (i) hydrogen; (ii) ethynyl, i.e. which is optionally substituted by R100; (iii) phenyl, which is optionally substituted by R100; (iv) a 5 or 6-membered heteroaryl; and wherein R100 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORf, C(O)Rf, C(O)ORf, OC(O)Rf, C(O)N(Rj)Rh, N(Rg)C(O)Rf, S(O)yRf, SO2N(Rj)Rh, N(Rg)SO2Rf, NRjRh, (CH2)z-[4-6 membered heterocyclyl], or (CH2)zphenyl; and wherein: (i) Rf and Rg are each independently selected from hydrogen or (1- 2C)alkyl; and (ii) any (1-4C)alkyl, heterocyclyl or phenyl moiety in a R100 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl or ORk, wherein Rk is selected from hydrogen or (1-2C)alkyl; 10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from hydrogen, halogen, (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-7C)cycloalkyl, phenyl, a 5 or 6- membered heteroaryl or a 4 to 7-membered heterocyclyl, wherein said (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, a 5 or 6-membered heteroaryl or a 4 to 7-membered heterocyclyl are optionally substituted by one or more R200 substituents; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1- 2C)alkyl. 11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from hydrogen, halogen, (1-8C)alkyl, (2-8C)alkynyl, (3-7C)cycloalkyl, phenyl, a 5 or 6-membered heteroaryl or a 4 to 7-membered heterocyclyl, wherein said (2-6C)alkynyl, (3-7C)cycloalkyl, phenyl, heteroaryl and heterocyclyl are optionally substituted by one or more R200 substituents; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1- 2C)alkyl. 12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from hydrogen, fluoro, (1-8C)alkyl, (2-8C)alkynyl, (3- 7C)cycloalkyl, phenyl, or a 5 or 6-membered heteroaryl, wherein said (1-6C)alkynyl, (3-7C)cycloalkyl, phenyl, heteroaryl and heterocyclyl are optionally substituted by one or more R200 substituents; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1- 2C)alkyl. 13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from hydrogen, fluoro, (1-8C)alkyl, (3-7C)cycloalkyl, or (2-6C)alkynyl, wherein said (2-6C)alkynyl is optionally substituted by one or more R200 substituents; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1- 2C)alkyl. 14. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from: (i) hydrogen; (ii) fluoro; (iii) ethynyl, i.e. which is optionally substituted by R200; (vi) phenyl, which is optionally substituted by R200; (vii) a 5 or 6-membered heteroaryl, which is optionally substituted by R200; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1- 2C)alkyl. 15. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N or CR2; wherein R2 is selected from: (i) hydrogen; or (ii) ethynyl, i.e. which is optionally substituted by R200; and wherein R200 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, (CH2)zORm, (CH2)zC(O)Rm, (CH2)zC(O)ORm, (CH2)zOC(O)Rm, (CH2)zC(O)N(Ro)Rp, (CH2)zN(Rn)C(O)Rm, (CH2)zS(O)yRm, (CH2)zSO2N(Ro)Rp, (CH2)zN(Rn)SO2Rm, (CH2)zNRoRp, (CH2)z(3-7C)cycloalkyl, (CH2)zheterocyclyl, (CH2)zheteroaryl, or (CH2)zphenyl; and wherein: (i) Rm and Rn are each independently selected from hydrogen, (1-6C)alkyl or phenyl; Ro and Rp are each independently selected from hydrogen, (1-6C)alkyl or phenyl or Ro and Rp together with the nitrogen atom to which they are attached form a 3-7 membered ring which may optionally include further heteroatoms and is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any (3-7C)cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R200 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1- 2C)alkyl, (1-2C)haloalkyl, (1-2C)hydroxyalkyl, ORq, C(O)Rq, C(O)ORq, OC(O)Rq, C(O)N(Rq)Rr, N(Rr)C(O)Rq, S(O)yRq, SO2N(Rr)Rq, N(Rr)SO2Rq, or NRrRq, wherein Rq is hydrogen, (1-2C)alkyl or phenyl, and Rr are selected from hydrogen or (1-2C)alkyl. 16. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein X is CR2. 17. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen, cyano, (1-8C)alkyl, (3- 7C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl, a carbon-linked 5 to 6 membered heteroaryl, -(CH2)1-3(3-7C)cycloalkyl, -C(O)-(1-8C)alkyl, -C(O)-(CH2)0-3(3-7C)cycloalkyl, -C(O)phenyl, -C(O)O(1-8C)alkyl, -C(O)NH2, -C(O)NH-(1-8C)alkyl, -C(O)NH-(CH2)0-3(3- 7C)cycloalkyl, -C(O)NH-(CH2)0-3[5 or 6-membered heteroaryl], -C(O)NH-(CH2)0-3phenyl, -S(O)2H or -S(O)2-(1-6C)alkyl; wherein any alkyl, cycloalkyl, phenyl, or heteroaryl moiety is optionally substituted by one or more R300 substituents; wherein R300 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, ORs, C(O)Rs, C(O)ORs, OC(O)Rs, C(O)N(Rv)Ru, N(Rt)C(O)Rs, N(Rt)C(O)ORs, S(O)yRs, SO2N(Rv)Ru, N(Rt)SO2Rs, (CH2)zNRuRv; and wherein: (i) Rs and Rt are each independently selected from hydrogen, (1-6C)alkyl or (CH2)zphenyl; Ru and Rv are each independently selected from hydrogen, (1-6C)alkyl or (CH2)zphenyl or Ru and Rv, together with the nitrogen atom to which they are attached, form a 3-7 membered ring which may optionally include further heteroatoms, and wherein any 3-7 membered ring formed Ro and Rp, and any alkyl or phenyl group present for Rs, Rt, Ru and Rv is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, carboxyl, carbamoyl, sulphamoyl, and (1-2C)alkyl; and (ii) any cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R300 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, or (1-2C)alkyl; 18. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen, cyano, (1-8C)alkyl, (3- 7C)cycloalkyl, -(CH2)1-3(3-7C)cycloalkyl, a carbon-linked 4 to 7 membered heterocyclyl, a carbon-linked 5 to 6 membered heteroaryl, -C(O)-(1-8C)alkyl, -C(O)(3-7C)cycloalkyl, -C(O)phenyl, -C(O)O(1-8C)alkyl, -C(O)NH2, -C(O)NH-(1-8C)alkyl, -C(O)NH-(CH2)0-3(3- 7C)cycloalkyl, -C(O)NH-(CH2)0-3[5 or 6-membered heteroaryl], -C(O)NH-(CH2)0-3phenyl, -S(O)2H or -S(O)2-(1-6C)alkyl; wherein any alkyl, cycloalkyl, phenyl, or heteroaryl moiety is optionally substituted by one or more R300 substituents; wherein R300 is selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, (1-4C)alkyl, (1-4C)hydroxyalkyl, ORs, C(O)N(Rv)Ru, S(O)yRs, (CH2)zNRuRv; and wherein: (i) Rs and Rt are each independently selected from hydrogen, (1-6C)alkyl or (CH2)zphenyl; Ru and Rv are each independently selected from hydrogen, (1- 6C)alkyl or (CH2)zphenyl or Ru and Rv, together with the nitrogen atom to which they are attached, form a 3-7 membered ring which may optionally include further heteroatoms; and (ii) any cycloalkyl, heterocyclyl, heteroaryl or phenyl moiety in a R300 substituent group is optionally further substituted by one or more substituents selected from halo, trifluoromethyl, trifluoromethoxy, cyano, hydroxyl, or (1-2C)alkyl; 19. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R3 is selected from hydrogen or acetyl. 20. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R4 is selected from hydrogen or fluoro. 21. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein R5 is selected from hydrogen, cyano or fluoro. 22. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is hydrogen, or a group of the formula: -L1-Y1-L2-Q1 wherein: L1 is absent or (1-3C)alkylene; Y1 is absent or O, S, SO, SO2, N(Ry1), C(O), C(O)O, C(O)N(Ry1), or N(Ry1)C(O), wherein Ry1 is selected from hydrogen or (1-4C)alkyl; L2 is absent or (1-3C)alkylene; and Q1 is hydrogen, (1-6C)alkyl, phenyl, (3-8C)cycloalkyl, heteroaryl or heterocyclyl; wherein Q is optionally further substituted by one or more substituent groups independently selected from oxo, hydroxy, (1-6C)alkyl, halo, (1-4C)haloalkyl, (1- 4C)haloalkoxy, (1-4C)aminoalkyl, (1-4C)hydroxyalkyl, cyano, or by one or more group(s) of the formula: -L3-Y2-L4-W1 wherein: L3 is absent; Y2 is absent or selected from or O, S, SO, SO2, N(Ry2), C(O), C(O)O, OC(O), C(O)N(Ry2), or N(Ry2)C(O), S(O)2N(Ry2), N(Ry2)SO2 wherein Ry2 is selected from hydrogen or (1-3C)alkyl; L4 is absent or (1-3C)alkylene; and W1 is hydrogen, (1-6C)alkyl, or phenyl; wherein W1 is optionally substituted by one or more substituents selected from (1-2C)alkyl, or halo; with the proviso that Q1 is not aryl or heteroaryl when L1, Y1 and L2 are absent. 23. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, selected from 5-(2-aminopyridin-4-yl)-7-chloro-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-methyl-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(trifluoromethyl)-1H-indazol-3-amine; 7-chloro-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-ethynyl-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-phenyl-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(tert-butyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid; 7-bromo-5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indazol-3-amine 5-(2-(ethylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(propylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(isopropylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((cyclopropylmethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(isopentylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(hexylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(cyclohexylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-{2-[(Trans-4-methylcyclohexyl)amino]pyridin-4-yl}-1H-indazol-3-amine; 2-((4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)amino)ethan-1-ol; 3-((4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)amino)propan-1-ol; 4-((4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)amino)butan-1-ol; 5-((4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)amino)pentan-1-ol; 5-{2-[(trans-4-hydroxycyclohexyl)amino]pyridin-4-yl}-1H-indazol-3-amine; 5-(2-((2-methoxyethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((3-methoxypropyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((3-isopropoxypropyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 3-((4-(3-amino-1H-indazol-5-yl)pyrimidin-2-yl)amino)propan-1-ol; 3-((4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)(methyl)amino)propan-1-ol; 5-(2-((2-morpholinoethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((2-(piperidin-1-yl)ethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; N1-(4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)-N3-methylpropane-1,3-diamine; N-(4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide; N-(4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)benzamide; ethyl (4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)carbamate; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-ethylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-ethylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-propylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-isopentylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-cyclopentylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-cyclohexylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(2-hydroxyethyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-hydroxypropyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(2-methoxyethyl)urea; 3-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-1-(2-hydroxyethyl)-1-methylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-benzylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-phenethylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(pyridine-2-ylmethyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(pyridine-3-ylmethyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(pyridine-4-ylmethyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-phenylurea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-fluorophenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-chlorophenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-isopropylphenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-(hydroxymethyl)phenyl)urea; 3-(3-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)ureido)benzamide; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-phenoxyphenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-(benzyloxy)phenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-((4-fluorobenzyl)oxy)phenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-((3-fluorobenzyl)oxy)phenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(3-((2-fluorobenzyl)oxy)phenyl)urea; 3-(3-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)ureido)-N-phenylbenzamide; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(4-fluorophenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(4-chlorophenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(4-(tert-butyl)phenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(4-(methylsulfonyl)phenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)-3-(o-tolyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(2-ethylphenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(2-isopropylphenyl)urea; 1-(4-(3-amino-1H-indazol-5-yl)pyridine-2-yl)-3-(pyridine-3-yl)urea; 5-(2-amino-3-ethynylpyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(cyclopropylethynyl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(3,3-dimethylbut-1-yn-1-yl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(cyclopentylethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(cyclohexylethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(phenylethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-((4-aminophenyl)ethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-((3-aminophenyl)ethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-((2-aminophenyl)ethynyl)pyridine-4-yl)-1H-indazol-3-amine; methyl 3-((2- amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl)benzoate; methyl 4-((2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl)benzoate; 5-(2-amino-3-((2-methoxyphenyl)ethynyl)pyridine-4-yl)-1H-indazol-3-amine; 5-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-1-phenylpent-4-yn-1-one; 3-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)prop-2-yn-1-ol; 4-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)but-3-yn-1-ol; 5-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)pent-4-yn-1-ol; 6-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-2-methylhex-5-yn-2-ol; 4-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-2-methylbut-3-yn-2-ol; 5-(2-amino-3-(3-(tert-butoxy)prop-1-yn-1-yl)pyridine-4-yl)-1H-indazol-3-amine; 1-((2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl)cyclopentan-1-ol; 1-((2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl)cyclohexan-1-ol; 1-((2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl)cycloheptan-1-ol; 5-(2-amino-3-(3-amino-3-methylbut-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(4-(piperidin-1-yl)but-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(4-morpholinobut-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(5-(piperidin-1-yl)pent-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(5-morpholinopent-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl)-1H-indazol-3-amine; 3-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)-N-methylpropiolamide; 5-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-1-morpholinopent-4-yn-1-one; 5-(2-amino-3-cyclopropylpyridin-4-yl)-1H-indazol-3-amine; 4-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)butan-1-ol; 1-(2-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)ethyl)cyclohexan-1-ol; 5-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)pentan-1-ol; 5-(2-aminopyridin-4-yl)-7-phenyl-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3-fluorophenyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3-(trifluoromethyl)phenyl)-1H-indazol-3-amine; 7-(3-aminophenyl)-5-(2-aminopyridin-4-yl)-1H-indazol-3-amine; 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenol; 5-(2-aminopyridin-4-yl)-7-(3-methoxyphenyl)-1H-indazol-3-amine; (3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)methanol; 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzaldehyde; ethyl 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzoate; 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzamide; 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzenesulfonamide; 5-(2-aminopyridin-4-yl)-7-(3-(methylsulfonyl)phenyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3-(morpholinomethyl)phenyl)-1H-indazol-3-amine; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenol; (4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)methanol; 5-(2-aminopyridin-4-yl)-7-(4-(dimethylamino)phenyl)-1H-indazol-3-amine; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzamide; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzenesulfonamide; 5-(2-aminopyridin-4-yl)-7-(4-(morpholinomethyl)phenyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(4-(tert-butyl)phenyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(2-chlorophenyl)-1H-indazol-3-amine; (2-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)methanol; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)-3-methylbenzenesulfonamide; 5-(2-aminopyridin-4-yl)-7-(pyridin-3-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(pyridin-4-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(furan-3-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(thiophen-3-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(thiophen-2-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(thiazol-5-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(1H-pyrazol-5-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3-methylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(pent-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(cyclopropylethynyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(phenylethynyl)-1H-indazol-3-amine; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)but-3-yn-1-ol; 4-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)-2-methylbut-3-yn-2-ol; 5-(2-aminopyridin-4-yl)-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-indazol-3-amine; 5-(2-aminopyrimidin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(3,3-dimethylbutyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(2-cyclohexylethyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-(2-cyclopropylethyl)-1H-indazol-3-amine; 5-(2-aminopyridin-4-yl)-7-phenethyl-1H-indazol-3-amine; 5-(2-amino-5-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-amino-3-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-amino-6-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridine-2,6-diamine; 6-amino-4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)nicotinonitrile; 5-(2-(cyclopropylamino)pyridine-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-(cyclobutylamino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(cyclopentylamino)pyridine-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-((cyclopropylmethyl)amino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((2,2,2-trifluoroethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 3-((4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)amino)propanenitrile; 2-((4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)amino)ethan-1-ol; N1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)ethane-1,2-diamine; 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((2-methoxyethyl)amino)pyridin-4-yl)-1H-indazol-3-amine; 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((3-methoxypropyl)amino)pyridine-4-yl)-1H-indazol-3-amine; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)acetamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)propionamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-3,3,3- trifluoropropanamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2- yl)cyclopropanecarboxamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)isobutyramide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)pivalamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-2- cyclopropylacetamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridine-2-yl)-3-methylbutanamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2- yl)cyclobutanecarboxamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2- yl)cyclopentanecarboxamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-2-hydroxyacetamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-2-methoxyacetamide; 5-(2-(cyclopropylamino)pyridine-4-yl)-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-3-amine; N-(4-(3-amino-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-5-yl)pyridin-2-yl)acetamide; N-(4-(3-amino-7-(phenylethynyl)-1H-indazol-5-yl)pyridin-2-yl)acetamide; methyl (4-(3-amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; methyl (4-(3-amino-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; methyl (4-(3-amino-7-(3-amino-3-methylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; methyl (4-(3-amino-7-(3-methoxy-3-methylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2- yl)carbamate; methyl (4-(3-amino-7-(3-morpholinoprop-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(4-morpholinobut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; 1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)urea; 1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-3-methylurea; 1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-3-ethylurea; 1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-3-propylurea; 1-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridine-2-yl)-3-phenylurea; methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; ethyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; tert-butyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)sulfamic acid; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)methanesulfonamide; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-6-fluoropyridin-2-yl)acetamide; N-(4-(3-amino-7-phenyl-1H-indazol-5-yl)pyridin-2-yl)acetamide; N-(4-(3-amino-7-(pyridin-4-yl)-1H-indazol-5-yl)pyridin-2-yl)acetamide; 7-(furan-3-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-ethynyl-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(3,3-dimethylbut-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(cyclopropylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(cyclopentylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(cyclohexylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 3-(3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)prop-2-yn-1-ol; 4-(3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)-2-methylbut-3-yn-2-ol; 1-((3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)ethynyl)cyclopentan-1-ol; 1-((3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)ethynyl)cyclohexan-1-ol; 1-((3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)ethynyl)cycloheptan-1-ol; 7-(5-morpholinopent-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(4-(piperidin-1-yl)but-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(5-(piperidin-1-yl)pent-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(6-(piperidin-1-yl)hex-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 6-(3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)hex-5-ynoic acid; 7-(3-amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl)hept-6-ynoic acid; 7-(4-phenoxybut-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 7-(6-phenoxyhex-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(tert-butyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-neopentyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(cyclohexylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(2-cyclohexylethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-benzyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; (4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methanol; 2-(4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)propan-2-ol; 3-(4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)pentan-3-ol; 5-(2-(tert-butoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(tetrahydro-2H-pyran-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid; methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate; ethyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxylate; 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; (4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(pyrrolidin-1-yl)methanone; 4-(3-amino-1H-indazol-5-yl)-N-cyclopentyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-cyclohexyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-isopentyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-phenethyl-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(3-phenylpropyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(2-methoxyethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(2-aminoethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(2-(dimethylamino)ethyl)-1H-pyrrolo[2,3-b]pyridine-2- carboxamide; (4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(4-methylpiperazin-1-yl)methanone; 4-(3-amino-1H-indazol-5-yl)-N-(2-(piperidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine-2-carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(2-(butyl(ethyl)amino)ethyl)-1H-pyrrolo[2,3-b]pyridine-2- carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(2-(diisopropylamino)ethyl)-1H-pyrrolo[2,3-b]pyridine-2- carboxamide; 4-(3-amino-1H-indazol-5-yl)-N-(3-(dimethylamino)propyl)-1H-pyrrolo[2,3-b]pyridine-2- carboxamide; 5-(2-((tert-butylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine 5-(2-((isopentylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine;; 5-(2-(piperidin-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((cyclohexylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((phenylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(((2-(benzyloxy)phenyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(((2-methoxyethyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; N1-((4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)-N2,N2-dimethylethane- 1,2-diamine; 5-(2-(((3-methoxypropyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(((3-isopropoxypropyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; N1-((4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)methyl)-N3,N3-dimethylpropane- 1,3-diamine; 5-(2-((isopropyl(methyl)amino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(piperidin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((4,4-difluoropiperidin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(morpholinomethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((4-methylpiperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((4-(tert-butyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(azepan-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-((4-methyl-1,4-diazepan-1-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(2-(piperidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-indazol-3-amine; 5-(2-(2-morpholinoethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(3-(piperidin-1-yl)propyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(3-(cyclohexylamino)propyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(3-morpholinopropyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; 5-(2-((1-benzylpiperidin-4-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine; N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)oxazol-2-amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3,3,3-trifluoropropyl)amino)pyridin-4-yl)-1H-indazol-3- amine; 7-(Cyclopropylethynyl)-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-3-amine; Methyl (4-(3-amino-7-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate; Methyl (4-(3-amino-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; 4-(3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-7-yl)-2-methylbut-3-yn-2-ol; 5-(2-(Oxetan-3-ylamino)pyridin-4-yl)-7-((tetrahydro-2H-pyran-4-yl)ethynyl)-1H-indazol-3-amine; N-(4-(3-Amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin-2-yl)cyclopropanecarboxamide; N-(4-(3-Amino-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2- yl)cyclopropanecarboxamide; Methyl (4-(3-amino-7-(5-morpholinopent-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; N-(4-(3-Amino-7-(3-hydroxy-3-methylbutyl)-1H-indazol-5-yl)pyridin-2- yl)cyclopropanecarboxamide; Methyl (4-(3-amino-7-(3,3-dimethylbutyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; 5-(2-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3- amine; 5-(2-Cyclopentyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3- amine; 5-(2-(tert-Butyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; (4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2- yl)methanol; 2-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2- yl)propan-2-ol; Methyl 4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2- carboxylate; 5-(2-(Difluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3- amine; 5-(2-Cyclobutyl-3H-imidazo[4,5-b]pyridin-7-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3- amine; N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)cyanamide; 5-(2-((1H-Pyrazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-((1H-Pyrazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-4-yl)-1H-indazol-3- amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3-methyl-1H-pyrazol-4-yl)amino)pyridin-4-yl)-1H-indazol-3- amine; N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)thiazol-2-amine; N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-4-methyloxazol-2- amine; N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-4- (trifluoromethyl)oxazol-2-amine; N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyridin-2-yl)-3,5-dimethylisoxazol- 4-amine; 5-(2-((1H-Imidazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3-amine; 5-(2-((4H-1,2,4-Triazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-3- amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((2-methyl-2H-tetrazol-5-yl)amino)pyridin-4-yl)-1H-indazol-3- amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(pyrimidin-2-ylamino)pyridin-4-yl)-1H-indazol-3-amine; 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((tetrahydrofuran-3-yl)amino)pyridin-4-yl)-1H-indazol-3- amine; Methyl (4-(3-Amino-7-(4-hydroxyphenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; 4-(3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-7-yl)phenol; Methyl (4-(3-amino-7-(4-aminophenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(7-(4-acetamidophenyl)-3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(4-carbamoylphenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(4-(morpholinomethyl)phenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; 5-(2-Aminopyridin-4-yl)-7-(4-(2-morpholinoethyl)phenyl)-1H-indazol-3-amine; Methyl (4-(3-amino-7-(4-(2-morpholinoethyl)phenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(4-(methylsulfonyl)phenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(3-hydroxyphenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(3-carbamoylphenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; Methyl (4-(3-amino-7-(3-(morpholinomethyl)phenyl)-1H-indazol-5-yl)pyridin-2-yl)carbamate; N-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-2-cyclohexylacetamide; 6-Amino-4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)nicotinonitrile. 24. A pharmaceutical composition comprising a compound according in any anyone of claims 1 to 23, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient. 25. A compound according to any one of claims 1 to 23, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical formulation according to claim 24: (i) for use in therapy; (ii) for use in the treatment of a disease or condition responsive to IKKalpha modulation; (iii) for use in the treatment of a proliferative disorder (e.g. cancer); or (iv) for use in the treatment of inflammation. |
Example 58 1-(4-(3-Amino-1H-indazol-5-yl)pyridin2-yl)-3-(3-((4-fluorobe nzyl)oxy)phenyl)urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.056 g, 0.19 mmol), bismuth(III)trifluoromethanesulfonate (0.052 g, 0.08 mmol), 3-(4- fluorobenzyloxy)phenylamine (0.21 mL, 0.96 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (t R = 25 min) to afford the title compound as the TFA salt (0.0057 g, 0.012 mmol, 6.5%). 1 H NMR (DMSO-d6): ^ 5.08 (s, 2H), 6.70 (m, 1H), 7.05 (m, 1H), 7.23 (m, 3H), 7.34 (m, 2H), 7.41 (m, 1H), 7.52 (m, 2H), 7.66 (d, J = 7.6 Hz, 1H), 7.86 (s, 1H), 8.22 (s, 1H), 8.33 (d, J = 4.4 Hz, 1H), 9.52 (br s, 1H), 10.44 (br s, 1H), 11.85 (br s, 1H). HRMS: For C 26 H 22 O 2 N 6 F requires 469.1783 found 469.1780. Example 59 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(3-((3-fluorob enzyl)oxy)phenyl)urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.054 g, 0.18 mmol), bismuth(III)trifluoromethanesulfonate (0.050 g, 0.08 mmol), 3-(3- fluorobenzyloxy)phenylamine (0.20 g, 0.91 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (tR = 24 min) to afford the title compound as the TFA salt (0.0032 g, 0.007 mmol, 3.8%). 1 H NMR (DMSO-d 6 ): ^ 5.13 (s, 2H), 6.70 (dd, J = 2.0, 7.6 Hz, 1H), 7.06 (m, 1H), 7.17 (m, 1H), 7.23 (t, J = 8.2 Hz, 2H), 7.32 (m, 4H), 7.40 (d, J = 8.8 Hz, 1H), 7.45 (m, 1H), 7.63 (dd, J = 1.6, 8.8 Hz, 1H), 7.85 (br s, 1H), 8.20 (s, 1H), 8.32 (d, J = 5.2 Hz, 1H), 9.50 (br s, 1H), 10.47 (br s, 1H), 11.80 (br s, 1H). HRMS: For C26H22O2N6F requires 469.1783 found 469.1781. Example 60 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(3-((2-fluorob enzyl)oxy)phenyl)urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.065 g, 0.22 mmol), bismuth(III)trifluoromethanesulfonate (0.061 g, 0.09 mmol), 3-(2- fluorobenzyloxy)phenylamine (0.22 g, 1.01 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (tR = 25 min) to afford the title compound as the TFA salt (0.00656 g, 0.014 mmol, 6.4%). 1 H NMR (DMSO-d6): ^ 5.14 (s, 2H), 6.72 (dd, J = 2.0, 8.0 Hz, 1H), 7.07 (m, 1H), 7.25 (m, 3H), 7.34 (m, 2H), 7.43 (m, 2H), 7.58 (dt, J = 1.6, 7.6 Hz, 1H), 7.65 (dd, J = 1.6, 8.8 Hz, 1H), 7.85 (s, 1H), 8.22 (s, 1H), 8.33 (d, J = 5.6 Hz, 1H), 9.52 (br s, 1H), 10.44 (br s, 1H). HRMS: For C 26 H 22 O 2 N 6 F requires 469.1783 found 469.1779. Example 61 3-(3-(4-(3-Amino-1H-indazol-5-yl)pyridine-2-yl)ureido)-N-phe nylbenzamide A suspension of 3-(3-(4-bromopyridin-2-yl)ureido)-N-phenylbenzamide (0.060 g, 0.13 mmol), 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.054 g, 0.19 mmol), tetrakis(triphenylphosphine)palladium(0) catalyst (0.010 g) in EtOH/H2O (2:1 mL) was degassed with nitrogen. Potassium phosphate monobasic (0.050 g, 0.22 mmol) was added and the mixture was heated to 80 °C for 16 hrs. The reaction mixture was concentrated to give the crude product. Purification by HPLC afforded the title compound as an off-white solid (0.013 g, 0.02 mmol, 22 %). 1 H NMR (400 MHz, DMSO-d6): ^ 4.50 (d, J = 5.6 Hz, 2H), 5,56 (s, 2H), 7.4 (m, 7H), 7.38 (m, 2H), 7.60 (d, J = 7.6 Hz, 1H), 7.86 (s,1H), 8.03 (s, 1H), 8.18 (s, 1H), 8.32 (d, J = 5.5 Hz, 1H), 9.06 (s, 1H), 9.56 (s, 1H), 10.68 (s, 1H), 11.61 (s, 1H). LRMS: C 19 H 16 N 6 O requires 463.18, found 464.2 (M+H). Example 62 1-(4-(3-Amino-1H-indazol-5-yl)pyridine-2-yl)-3-(4-fluorophen yl)urea A suspension of ethyl (4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate (EXAMPLE 35) (0.050 g, 0.17 mmol), 4-fuoroanaline (60µL), in dioxane (3 ml) was degassed with nitrogen. Bismuth triflate (0.008 g ) was added and the mixture was heated in the microwave at 120 °C for 80 min. The reaction mixture was concentrated and the residue purifiyed by HPLC to afforded the title compound as a yellow off-white solid (0.005 g, 0.02 mmol, 13 %). 1 H NMR (400 MHz, DMSO-d6): ^ 7.16 (m, 2H), 7.32 (d, J = 5.52 Hz, 1H), 7.40 (d, J = 8.44 Hz, 1H), 7.57 (m, 3H), 7.83 (s, 1H), 8.19 (s, 1H), 8.34 (d, J = 5.5 Hz, 1H), 9.49 (s, 1H), 10.51 (s, 1H). LRMS: C 19 H 16 N 6 O requires 362.13, found 363.13 (M+H) + . Example 63 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(4-chloropheny l)urea Ethyl (4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate (EXAMPLE 35) (0.050 g, 0.17 mmol) and 4-chloroaniline (0.026 g, 0.20 mmol, 1.2 eq) were placed in a 0.5-2 ml microwave vial with dioxane (2 ml). The solution was then degassed with nitrogen for 5 min, before bismuth triflate (0.006 g, 0.01 mmol, 5 mol %) was added, the vial was then sealed and heated to 120°C for 60 min. The solution was allowed to cool and the solvent removed under reduced pressure. The crude residue was then dissolved in DMF (0.5 ml) and purified by HPLC to give the desired product. (0.007 g, 0.02 mmol, 11 %) δ H (d 6 - DMSO): 7.32 (m, 4H), 7.57 (d, J = 8.9 Hz, 1H), 7.62 (dd, J = 8.5 and 1.5 Hz, 1H), 7.84 (s, 1H), 8.20 (s, 1H), 8.32 (d, J = 5.5 Hz, 1H), 9.54 (s, 1H), 10.55 (s, 1H). HRMS: C 19 H 15 ClN 6 O requires 378.0996, found 379.1069 (M+H) + . Example 64 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(4-(tert-butyl )phenyl)urea Ethyl (4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate (EXAMPLE 35) (0.050 g, 0.17 mmol) and 4-t-butylaniline (32 µl, 0.20 mmol, 1.2 eq) were placed in a 0.5-2 ml microwave vial with dioxane (2 ml). The solution was then degassed with nitrogen for 5 min, before bismuth triflate (0.006 g, 0.009 mmol, 5 mol %) was added, the vial was then sealed and heated to 120°C for 60 min. The solution was allowed to cool and the solvent removed under reduced pressure. The crude residue was then dissolved in DMF (0.5 ml) and purified by HPLC to give the desired product. (0.018 g, 0.05 mmol, 27 %) δ H (d 6 - DMSO): 1.29 (s, 9H), 7.33 (m, 3H), 7.41 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 6.8 Hz, 1H), 7.66 (dd, J = 8.5 and 1.5 Hz, 1H), 7.86 (s, 1H), 8.22 (s, 1H), 8.32 (d, J = 5.6 Hz, 1H), 9.47 (s, 1H), 10.29 (s, 1H). HRMS: C 23 H 24 N 6 O requires 400.2012, found 401.2084 (M+H) + . Example 65 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(4-(methylsulf onyl)phenyl)urea Ethyl (4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate (EXAMPLE 35) (0.050 g, 0.17 mmol) and 4-(methylsulfonyl)aniline (0.034 g, 0.20 mmol, 1.2 eq) were placed in a 0.5-2 ml microwave vial with dioxane (2 ml). The solution was then degassed with nitrogen for 5 min, before bismuth triflate (0.006 g, 0.01 mmol, 5 mol %) was added, the vial was then sealed and heated to 120°C for 60 min. The solution was allowed to cool and the solvent removed under reduced pressure. The crude residue was then dissolved in DMF (0.5 ml) and purified by HPLC to give the desired product. (0.011 g, 0.03 mmol, 15 %) δ H (d 6 - DMSO): 3.16 (s, 3H), 7.34 (dd, J = 5.5 and 1.5 Hz, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.64 (dd, J = 9.0 and 1.5 Hz, 1H), 7.77 (d, J = 8.5 Hz, 2H,), 7.85 (d, J = 8.5 Hz, 2H), 8.21 (s, 1H), 8.34 (d, J = 5.5 Hz, 1H), 9.61 (s, 1H), 10.80 (s, 1H), 11.80 (s, 1H). HRMS: C 20 H 18 N 6 O 3 S requires 422.1161, found 423.1234 (M+H) + . Example 66 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(o-tolyl)urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.060 g, 0.20 mmol), bismuth(III)trifluoromethanesulfonate (0.043 g, 0.067 mmol), o-toluidine (0.1 mL, 0.94 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (t R = 16 min) to afford the title compound as the TFA salt (0.0042 g, 0.011 mmol, 7.3%). 1 H NMR (DMSO-d6): ^ 2.35 (s, 3H), 6.98 (dt, J = 7.4 Hz, 1H), 7.18 (t, J = 7.4 Hz, 1H), 7.23 (d, J = 7.2 Hz, 1H), 7.32 (dd, J = 1.6, 5.6 Hz, 1H), 7.42 (d, J = 8.8 Hz, 1H), 7.64 (m, 2H), 8.04 (d, J = 7.6 Hz, 1H), 8.22 (s, 1H), 8.32 (d, J = 5.2 Hz, 1H), 9.85 (br s, 1H), 10.89 (br s, 1H). HRMS: C 20 H 19 ON 6 requires 359.1615 found 359.1606. Example 67 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(2-ethylphenyl )urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.054 g, 0.18 mmol), bismuth(III)trifluoromethanesulfonate (0.050 g, 0.08 mmol), 2-ethylaniline (0.11 mL, 0.89 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (tR = 18 min) to afford the title compound as the TFA salt (0.0043 g, 0.012 mmol, 6.4%). 1 H NMR (DMSO-d 6 ): ^ 1.25 (t, J = 7.6 Hz, 3H), 2.72 (q, J = 7.5 Hz, 2H), 7.02 (dt, J = 1.2, 7.6 Hz, 1H), 7.18 (dt, J = 2.0, 8.0 Hz, 1H), 7.23 (dd, J = 1.6, 7.6 Hz, 1H), 7.32 (dd, J = 1.6, 5.6 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.58 (br s, 1H), 7.62 (dd, J = 1.6, 8.8 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 8.20 (s, 1H), 8.31 (5.2 Hz, 1H), 9.84 (br s, 1H), 11.04 (br s, 1H), 11.85 (br s, 1H). HRMS: For C21H21ON6 requires 373.1771 found 373.1773. Example 68 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(2-isopropylph enyl)urea A suspension of ethyl [4-(3-amino-1H-indazol-5-yl)pyridin-2-yl]carbamate (EXAMPLE 35) (0.053 g, 0.18 mmol), bismuth(III)trifluoromethanesulfonate (0.055 g, 0.08 mmol), 2- isopropylaniline (0.13 mL, 0.9 mmol) in 1,4-dioxane (4 mL) was degassed for 5 min using a steady stream of nitrogen. The reaction mixture was reacted in the microwave at 120 ^C for 1 h prior to being cooled to room temperature and concentrated under reduced pressure. Crude reaction mixture was taken up in DMF (0.5 mL) and purified by HPLC (t R = 20 min) to afford the title compound as the TFA salt (0.002 g, 0.005 mmol, 2.9%). 1 H NMR (DMSO-d6): ^ 1.28 (d, J = 6.8 Hz, 6H), 3.24 (m, 1H), 7.10 (m, 1H), 7.18 (m, 1H), 7.31 (m, 1H), 7.33 (s, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.59 (s, 1H), 7.62 (dd, J = 1.6, 8.8 Hz, 1H), 7.95 (d, J = 7.2 Hz, 1H), 8.20 (s, 1H), 8.29 (d, J = 5.6 Hz, 1H), 9.82 (s, 1H), 11.01 (br s, 1H), 11.79 (br s, 1H). HRMS: For C 22 H 23 ON 6 requires 387.1928 found 387.1922. Example 69 1-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-3-(pyridin-3-yl) urea Ethyl (4-(3-amino-1H-indazol-5-yl)pyridin-2-yl)carbamate (EXAMPLE 35) (0.050 g, 0.17 mmol) and 3-aminopyridine (0.019 g, 0.20 mmol, 1.2 eq) were placed in a 0.5-2 ml microwave vial with dioxane (2 ml). The solution was then degassed with nitrogen for 5 min, before bismuth triflate (0.006 g, 0.009 mmol, 5 mol %) was added, the vial was then sealed and heated to 120°C for 60 min. The solution was allowed to cool and the solvent removed under reduced pressure. The crude residue was then dissolved in DMF (0.5 ml) and purified by HPLC to give the desired product. (0.004 g, 0.01 mmol, 7 %) δ H (d 6 - DMSO): 7.36 (dd, J = 5.6 and 1.6 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.63 (m, 3H), 7.84 (s, 1H), 8.22 (s, 1H), 8.35 (d, J = 5.6 Hz, 1H), 8.91 (d, J = 2.0 Hz, 1H), 9.77 (s, 1H), 10.89 (s, 1H). LRMS: found: 346.00 (M+1), calculated C 18 H 15 N 7 O: 345.13. HRMS: C18H15N7O requires 345.1338, found 346.1352 (M+H) + . Section 6 – compounds of the formula: General procedure A: A suspension of required chloroaryl (1 eq.), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- indazol-3-amine (1.2-1.5 eq.), base (2 eq.) in 1:3 of solvent was deoxygenated with nitrogen in sealed tube. Then [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.05 eq.) was added then the tube was sealed and the mixture allowed to stirred at 90-100 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and water were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography. Example 70 4-Chloro-3-((triisopropylsilyl)ethynyl)pyridin-2-amine A solution of 4-chloro-3-iodopyridin-2-amine (1.00 g, 3.9 mmol), copper (I) iodide (38 mg, 0.20 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.28 g, 0.4 mmol) in 16 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of ethynyltriisopropylsilane (3.6 mL, 16.0 mmol). The reaction mixture was heated to 80 °C, o/n. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (petroleum ether 60- 80%/acetone 9:1) to give the product as a brown solid. (1.01 g, 84%). 1 H NMR (500 MHz, (CD 3 ) 2 CO): ^ 0.83 – 0.89 (m, 3H), 1.15 – 1.19 (m, 18H), 5.88 (br s, 2H), 6.74 (d, J = 5.4 Hz, 1H), 7.92 (d, J = 5.4 Hz, 1H). LRMS: Calculated for C16H25ClN2Si 308.2 found 309.2 (M+1). 5-(2-amino-3-((triisopropylsilyl)ethynyl)pyridin-4-yl)-2-flu orobenzonitrile A solution of 4-chloro-3-((triisopropylsilyl)ethynyl)pyridin-2-amine (1.05 g, 3.9 mmol), K 3 PO 4 (5.40 g, 25.5 mmol), Sphos (0.14 g, 0.34 mmol), palladium(II) chloride (0.76 g, 0.34 mmol) and 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz onitrile (2.10 g, 8.5 mmol) in 22 ml of dioxane-water (5:1) was degassed in sealed tube and submitted to reaction. The reaction mixture was heated to 80 °Cfor 4 hours. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (petroleum ether 60-80%/acetone 7:3) to give the product as a brown solid. (0.62 g, 41%). 1 H NMR (500 MHz, (CD3)2CO): ^ 1.05 – 1.09 (m, 21H), 5.84 (br s, 2H), 6.72 (d, J = 5.2 Hz, 1H), 7.55 (app t, J H-H; H-F = 8.8 Hz, 1H), 8.00 (ddd, J H-H; H-F; H-H = 8.8, 5.2, 2.3 Hz, 1H), 8.07 (d, J = 5.2 Hz, 1H), 8.09 (dd, J H-F; H-H = 6.2, 2.3 Hz, 1H). LRMS: Calculated for C 23 H 28 FN 3 Si 393.2 found 394.1 (M+1). 5-(2-Amino-3-ethynylpyridin-4-yl)-2-fluorobenzonitrile To a solution of 5-(2-amino-3-((triisopropylsilyl)ethynyl)pyridin-4-yl)-2-flu orobenzonitrile (0.6 g, 1.53 mmol) in 6 ml of THF was added TBAF (2.0 g, 7.7 mmol). The reaction was stirred at RT for 1 hour. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue purified by column chromatography (petroleum ether 60-80%/acetone 7:3) to give the product as a brown solid. (0.323 g, 89%) 1 H NMR (400 MHz, (CD3)2CO): 4.08 (s, 1H), 5.97 (br s, 2H), 6.71 (d, J = 5.2 Hz, 1H), 7.55 (app t, JH-H; H-F = 9.0 Hz, 1H), 7.99 – 8.11 (m, 3H). LRMS: Calculated for C14H8FN3237.1 found 238.1 (M+1). 5-(2-Amino-3-ethynylpyridin-4-yl)-1H-indazol-3-amine To a solution of 5-(2-amino-3-ethynylpyridin-4-yl)-2-fluorobenzonitrile (90 mg, 0.4 mmol) in 0.5 ml of EtOH was added hydrazine (1.5 mL, 1 Mol solution in EtOH). The reaction was stirred at 80 °C, o/n. The resulting mixture was diluted with EtOAc, washed with water, concentrated under reduced pressure and the residue purified by HPLC to give the product as a yellow solid. (11 mg, 11%) 1 H NMR (400 MHz, MeOD): ^ 3.88 (s, 1H), 6.74 (d, J = 5.4 Hz, 1H), 7.34 (dd, J = 8.7, 0.8 Hz, 1H), 7.63 (dd, J = 8.7, 1.7 Hz, 1H), 7.93 (d, J = 5.4 Hz, 1H), 7.99 (dd, J = 1.7, 0.8 Hz, 1H), 5 protons missing. LRMS: Calculated for C 14 H 11 N 5 249.1 found 250.1 (M+1). Example 71 4-Chloro-3-(cyclopropylethynyl)pyridin-2-amine A solution of 4-chloro-3-iodopyridin-2-amine (1.00 g, 3.9 mmol), copper (I) iodide (38 mg, 0.2 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.28 g, 0.4 mmol) in 16 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of ethynylcyclopropane (1.35 mL, 16.0 mmol). The reaction mixture was heated to 80 °C for 5 hours. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (petroleum ether 60- 80%/acetone 9:1) to give the product as a brown solid. (0.68 g, 91%). 1 H NMR (400 MHz, (CD3)2CO): ^ 0.80 – 0.86 (m, 2H), 0.90 – 1.00 (m, 2H), 1.61 (tt, J = 8.2, 5.0 Hz, 1H), 5.88 (br s, 2H), 6.65 (d, J = 5.5 Hz, 1H), 7.82 (d, J = 5.5 Hz, 1H). LRMS: Calculated for C10H9ClN2192.1 found 193.1 (M+1). 5-(2-amino-3-(cyclopropylethynyl)pyridin-4-yl)-2-fluorobenzo nitrile A solution of 4-chloro-3-(cyclopropylethynyl)pyridin-2-amine (0.70 g, 3.64 mmol), K 3 PO 4 (5.80 g, 27.3 mmol), Sphos (0.14 g, 0.34 mmol), palladium(II) acetate (76 mg, 0.34 mmol) and 2- fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzon itrile (2.10 g, 8.5 mmol) in 22 ml of dioxane-water (5:1) was degassed in sealed tube and submitted to reaction. The reaction mixture was heated to 80 °C for 4 hours. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (petroleum ether 60-80%/acetone 7:3) to give the product as a dark yellow solid. (0.82 g, 81%).1H NMR (500 MHz, (CD3)2CO): ^ 0.68 – 0.73 (m, 2H), 0.85 – 0.90 (m, 2H), 1.49 (tt, J = 8.2, 5.0 Hz, 1H), 5.83 (br s, 2H), 6.68 (d, J = 5.2 Hz, 1H), 7.54 (app t, J H-H; H-F = 9.0 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 8.01 (ddd, JH-H; H-F; H-H = 9.0, 5.2, 2.4 Hz, 1H), 8.08 (dd, JH-F; H- H = 6.2, 2.4 Hz, 1H). LRMS: Calculated for C17H12FN3277.1 found 278.1 (M+1). 5-(2-Amino-3-(cyclopropylethynyl)pyridin-4-yl)-1H-indazol-3- amine To a solution of 5-(2-amino-3-(cyclopropylethynyl)pyridin-4-yl)-2-fluorobenzo nitrile (75 mg, 0.19 mmol) in 0.3 ml of EtOH was added hydrazine (0.75 mL, 1 Mol solution in EtOH). The reaction was stirred at 80 °C, o/n. The resulting mixture was diluted with EtOAc, washed with water, concentrated under reduced pressure and the residue purified by HPLC to give the product as a yellow solid. (21 mg, 38%) 1 H NMR (400 MHz, DMSO-d6): ^ 0.66 – 0.72 (m, 2H), 0.76 – 0.82 (m, 2H), 1.46 (tt, J = 8.2, 5.0 Hz, 1H), 5.49 (br s, 2H), 6.06 (br s, 2H), 6.59 (d, J = 5.2 Hz, 1H), 7.26 (dd, J = 8.7, 0.8 Hz, 1H), 7.48 (dd, J = 8.7, 1.7 Hz, 1H), 7.89 (d, J = 5.2 Hz, 1H), 7.96 (dd, J = 1.7, 0.8 Hz, 1H), 11.48 (br s, 1H). LRMS: Calculated for C 17 H 15 N 5 289.1 found 290.2 (M+1). Example 72 N-(4-Chloropyridin-2-yl)pivalamide To mixture of 4-chloropyridin-2-amine (4.96g, 38.61 mmol),THF 50 mL and triethylamine (13.47 mL, 96.53 mmol) ) in a sealed flask flushed with argon and cooled to 0 o C, was added pivaloyl chloride (5.58g, 46.33 mmol) and stirred vigorously at this temperature for 1 hour, then allowed to warm up to room temperature overnight. The reaction was then diluted with EtOAC and partitioned with H 2 O. The organic layer was collected and the aqueous layer extracted (2 X 30 mL). The combined organic layer was dried over anhydrous magnesium sulfate, concentrated and purified by flash column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) affording the target compound 6.4 g (78%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.09 (s, 1H), 8.32 (d, J = 5.4 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 7.25 (dd, J = 5.4, 1.9 Hz, 1H), 1.24 (s, 9H). LRMS (ESI) m/z [M] + .For C10H13ClN2O Molecular weight 212.6770 found 213.5. N-(4-Chloro-3-iodopyridin-2-yl)pivalamide To a solution of N-(4-chloropyridin-2-yl)pivalamide (8.0g, 37.72 mmol) in anhydrous THF flushed with argon and cooled to -78 o C was added n-BuLi (38 mL, 94.4mmol of 2.5 M soln in hexanes). The resulting mixture was allowed to warm up to -20 o C and stirred for 1 hour before cooling back down to -78 o C and iodine (94.4 mmol) and TiMEDA (14.14 mL, 94.4 mmol) added. The reaction was then allowed to warm up to room temperature and stirred for a further 8 hours. The reaction was cooled to -78 o C and quenched by addition of NH4Cl (aq). The reaction was then partitioned between EtOAC and water and the organic layer collected. The aqueous layer was extracted (2 X 30 ML) and the combined organic layer dried over anhydrous magnesium sulfate, concentrated and purified by flash column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) affording the target compound 5.7 g (45%). 1 H NMR (500 MHz, DMSO-d6) δ 9.86 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 7.54 (d, J = 5.2 Hz, 1H), 1.25 (s, 9H). LRMS (ESI) m/z [M] + .For C10H12ClIN2O Molecular weight 338.5735 found 339.5 4-Chloro-3-iodopyridin-2-amine To a solution of N-(4-chloro-3-iodopyridin-2-yl)pivalamide (0.35g, 1.03 mmol) in methanol was added 5M HCl (5 mL) and stirred at reflux overnight. The reaction was then concentrated and purified by flash column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) affording the target compound in quantitative yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.85 (d, J = 5.2 Hz, 1H), 6.73 (d, J = 5.2 Hz, 1H), 6.41 (s, 2H). LRMS (ESI) m/z [M] + .For C 5 H 4 ClN 2 Molecular weight 254.4555 found 255.3 4-Chloro-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.18 mmol) copper (I) iodide (0.0225 g, 0.118 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.0829 g, 0.1181 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of (0.1164 g, 0.173 mL, 1.417 mmol) of 3,3-dimethylbut-1-yne. The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to give the product as a brown (0.267 g, Quant). 1 H NMR (500 MHz, DMSO-d6) δ 7.84 (d, J = 5.4 Hz, 1H), 6.68 (d, J = 5.4 Hz, 1H), 6.31 (s, 2H), 1.33 (s, 9H). LRMS (ESI) m/z [M] + .For C11H13ClN2 Molecular weight 208.689 found 209.3 5-(2-Amino-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-4-yl)-2-fluo robenzonitrile To a mixture of 4-chloro-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-amine (0.267 g, 1.28 mmol, 1.0 eq), 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz onitrile (0.380 g, 1.54 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.042 g, 0.064 mmol, 5 mol%) and cesium carbonate (1.33 g, 4.106 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:23 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford the desired product (0.105 g, 28%) 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.20 (dd, J = 6.3, 2.3 Hz, 1H), 8.03 – 7.96 (m, 2H), 7.65 (t, J = 9.1 Hz, 1H), 6.67 (d, J = 5.2 Hz, 1H), 6.19 (s, 2H), 1.22 (s, 9H). 5-(2-Amino-3-(3,3-dimethylbut-1-yn-1-yl)pyridine-4-yl)-1H-in dazol-3-amine 5-(2-Amino-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-4-yl)-2-fluo robenzonitrile (0.09g, 0.3 mmol) was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled, concentrated and purified by HPLC affording the target compound as a yellow powder 0.028 g (26%). 1 H NMR (500 MHz, DMSO- d6) δ 8.21 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 6.6 Hz, 1H), 7.69 (dd, J = 8.8, 1.8 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 6.99 (d, J = 6.6 Hz, 1H), 2.54 – 2.48 (m, 9H). LRMS (ESI) m/z [M] + .For C18H19N5 Molecular Weight: 305.3850 found 306.3 Example 73 4-Chloro-3-(cyclopentylethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.59 mmol), copper (I) iodide (0.0113 g, 0.059 mmo)l and bis(triphenylphosphine) palladium(II) chloride (g, 0.059 mmol) in 3 ml of N,N- dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of ethynylcyclopentane (0.0667 g, 0.082 mL, 0.059 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a brown solid (0.061 g, 47%). 1 H NMR (500 MHz, DMSO-d6) δ 7.83 (d, J = 5.5 Hz, 1H), 6.67 (d, J = 5.5 Hz, 1H), 6.33 (s, 2H), 2.97 (p, J = 7.4 Hz, 1H), 1.97 (dddd, J = 12.1, 7.1, 4.2, 1.4 Hz, 2H), 1.76 – 1.66 (m, 4H), 1.61 – 1.53 (m, 2H). LRMS (ESI) m/z [M] + .For C12H13ClN2 Molecular weight 220.7000 found 221.1 5-(2-Amino-3-(cyclopentylethynyl)pyridin-4-yl)-2-fluorobenzo nitrile To a mixture 4-chloro-3-(cyclopentylethynyl)pyridin-2-amine (0.061 g, 0.28 mmol, 1.0 eq), 2- fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzon itrile (0.082 g, 0.33 mmol), [1,1′- bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.009 g, 0.014 mmol, 5 mol%) and cesium carbonate (0.27 g, 0.832 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:23 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography to afford 5-(2-amino-3- (cyclopentylethynyl)pyridin-4-yl)-2-fluorobenzonitrile (0.105 g, 35%), 1 H NMR (500 MHz, DMSO-d6) δ 8.17 (dd, J = 6.3, 2.3 Hz, 1H), 8.03 – 7.95 (m, 2H), 7.64 (t, J = 9.0 Hz, 1H), 6.65 (d, J = 5.2 Hz, 1H), 6.21 (s, 2H), 2.87 (tt, J = 8.3, 6.3 Hz, 1H), 1.87 (ddd, J = 10.4, 5.2, 3.1 Hz, 2H), 1.64 – 1.50 (m, 6H). 5-(2-Amino-3-(cyclopentylethynyl)pyridine-4-yl)-1H-indazol-3 -amine 5-(2-Amino-3-(cyclopentylethynyl)pyridin-4-yl)-2-fluorobenzo nitrile (0.09g, 0.295 mmol) was dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder 0.028 g (26%). 1 H NMR (500 MHz, DMSO- d6) δ 8.20 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 6.6 Hz, 1H), 7.81 (s, 2H), 7.66 (dd, J = 8.7, 1.7 Hz, 1H), 7.35 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 6.5 Hz, 1H), 2.91 (ddd, J = 14.3, 7.6, 6.3 Hz, 1H), 1.88 (ddt, J = 9.8, 7.7, 3.2 Hz, 2H), 1.66 – 1.44 (m, 6H). LRMS (ESI) m/z [M] + .For C 19 H 19 N 5 Molecular weight 317.396 found 318.3 Example 74 4-Chloro-3-(cyclohexylethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.20 g/.855 mmol) copper (I) iodide (0.010 g/0.051 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.036 g/0.051 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of ethynylcyclohexane ( 0.132 g/ 1.23 mmol) The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a light brown solid( 0.181 g 75%). 1 H NMR(500MHz, DMSO-d6) δ = 7.85 (d,J=5.8, 1H), 6.68 (d,J=5.3, 1H), 6.33 (s, 2H), 2.76 (tt, J=8.4, 3.9, 1H), 1.84 (ddd,J=13.0, 6.7, 3.2, 2H), 1.70 (ddp,J=10.7, 6.9, 3.8, 3.1, 2H), 1.61 – 1.43 (m, 3H), 1.43 – 1.30 (m, 3H). LRMS (ESI) m/z [M] + .For C 13 H 15 ClN 2 Molecular weight 234.7270 found 235.5. 5-(2-Amino-3-(cyclohexylethynyl)pyridin-4-yl)-2-fluorobenzon itrile To a mixture 4-chloro-3-(cyclohexylethynyl)pyridin-2-amine (0.20 g, 0.854 mmol, 1.0 eq), 2- fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzon itrile (0.0823 g, 1.025 mmol), [1,1′- bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.055 g, 0.0845 mmol, 5 mol%), cesium carbonate (0.918 g, 2.818 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 5 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-(cyclohexylethynyl)pyridin-4-yl)-2- fluorobenzonitrile (0.195 g, 72%). 1 H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.96 (d, J = 6.5 Hz, 1H), 7.74 (s, 1H), 7.67 (d, J = 8.9 Hz, 1H), 7.33 (d, J = 8.8 Hz, 1H), 6.96 (d, J = 6.5 Hz, 1H), 2.67 (dt, J = 8.7, 4.7 Hz, 1H), 1.81 – 1.70 (m, 2H), 1.58 – 1.47 (m, 2H), 1.42 (dt, J = 8.0, 3.4 Hz, 3H), 1.30 – 1.16 (m, 3H). 5-(2-Amino-3-(cyclohexylethynyl)pyridine-4-yl)-1H-indazol-3- amine 5-(2-Amino-3-(cyclohexylethynyl)pyridin-4-yl)-2-fluorobenzon itrile (0.1 g, 0.31 mmol) was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder 0.032 g (15%). 1 H NMR (500 MHz, DMSO- d 6 ) δ 8.21 (d, J = 1.6 Hz, 1H), 7.99 (d, J = 6.6 Hz, 1H), 7.88 (s, 2H), 7.69 (dd, J = 8.7, 1.7 Hz, 1H), 7.35 (d, J = 8.7 Hz, 1H), 6.99 (d, J = 6.6 Hz, 1H), 2.68 (dt, J = 9.2, 4.9 Hz, 1H), 1.75 (d, J = 8.6 Hz, 2H), 1.56 – 1.48 (m, 2H), 1.44 (ddt, J = 15.4, 10.9, 5.3 Hz, 3H), 1.29 – 1.18 (m, 3H). LRMS (ESI) m/z [M] + .For C 20 H 21 N 5 Molecular weight 331.423 found 332.3. Example 75 4-Chloro-3-(phenylethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.265 g, 1.023 mmol), copper (I) iodide (0.0195 g, 0.1023 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.036 g, 0.0512 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of ethynylbenzene (0.1255 g, 0.135 mL, 1.23 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to give the product as a light brown solid (0.22 g, 93%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.92 (d, J = 5.4 Hz, 1H), 7.70 – 7.65 (m, 2H), 7.44 (dd, J = 5.0, 1.9 Hz, 3H), 6.75 (d, J = 5.4 Hz, 1H), 6.68 (s, 2H). LRMS (ESI) m/z [M] + .For C 13 H 9 ClN 2 Molecular Weight: 228.6790 found 229.5 5-(2-Amino-3-(phenylethynyl)pyridine-4-yl)-1H-indazol-3-amin e 4-Chloro-3-(phenylethynyl)pyridin-2-amine (0.22 g, 0.973 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.288 g, 1.168 mmol), cesium carbonate (0.951 g, 2.92 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.032 g, 0.049 mmol, 5 mol%) in 3 mL of a degassed mixture of dioxane and water (18:25 mL) was stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2- amino-3-(phenylethynyl)pyridin-4-yl)-2-fluorobenzonitrile. The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder 0.055 g (18%). 1 H NMR (500 MHz, DMSO-d6) δ 8.31 (d, J = 1.6 Hz, 1H), 8.05 (d, J = 6.3 Hz, 1H), 7.80 (s, 2H), 7.72 (dd, J = 8.7, 1.7 Hz, 1H), 7.59 – 7.55 (m, 2H), 7.44 – 7.38 (m, 4H), 7.00 (d, J = 6.4 Hz, 1H). LRMS (ESI) m/z [M] + . For C20H15N5 Molecular Weight: 325.3750 found 326.2 Example 76 4-Chloro-3-(4-aminophenyl)ethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.18 mmol), copper (I) iodide (0.0225 g, 0.118 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.118 mmol) in 5 mL of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 4-ethynylaniline (0.166 g, 0.148 mL, 1.418 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a dark brown oil (0.077 g, 27%) 5-(2-Amino-3-((4-aminophenyl)ethynyl)pyridine-4-yl)-1H-indaz ol-3-amine 4-Chloro-3-(4-aminophenyl)ethynyl)pyridin-2-amine (0.077 g, 0.317 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.35 g, 1.418 mmol), cesium carbonate (1.35 g, 4.14 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.077 g, 1.181 mmol) in 3 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography to afford 5-(2-amino-3- ((4-aminophenyl)ethynyl)pyridin-4-yl)-2-fluorobenzonitrile. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.24 (dd, J = 6.2, 2.3 Hz, 1H), 8.09 (ddd, J = 8.1, 5.3, 2.4 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.69 (t, J = 9.0 Hz, 1H), 7.17 – 7.13 (m, 2H), 6.70 (d, J = 5.1 Hz, 1H), 6.55 – 6.50 (m, 2H), 6.34 (s, 2H), 5.57 (s, 2H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder 0.012 g (11%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.50 (s, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 5.2 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.60 (dd, J = 8.7, 1.7 Hz, 1H), 7.32 (d, J = 8.6 Hz, 1H), 7.15 (d, J = 8.5 Hz, 3H), 6.69 – 6.64 (m, 2H), 6.52 – 6.48 (m, 2H), 6.15 (s, 2H), 5.49 (s, 2H), 5.45 (s, 2H). LRMS (ESI) m/z [M] + . For C 20 H 16 N 6 Molecular Weight: 340.3900 found 341.3 Example 77 4-Chloro-3-(3-aminophenyl)ethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.18 mmol), copper (I) iodide (0.0225 g, 0.118 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.118 mmol) in 5 mL of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 3-ethynylaniline (0.166 g, 0.148 mL, 1.418 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a dark brown oil (0.103 g, 36%) 5-(2-Amino-3-((3-aminophenyl)ethynyl)pyridine-4-yl)-1H-indaz ol-3-amine 4-Chloro-3-(3-aminophenyl)ethynyl)pyridin-2-amine (0.103 g, 0.424 mmol) 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.35 g, 1.418 mmol) cesium carbonate (1.35 g, 4.14 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.077 g, 1.181 mmol) in 3 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography to afford 5-(2-amino-3- ((3-aminophenyl)ethynyl)pyridin-4-yl)-2-fluorobenzonitrile. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.28 (dd, J = 6.2, 2.3 Hz, 1H), 8.18 (ddd, J = 8.9, 5.3, 2.4 Hz, 1H), 8.11 (d, J = 5.2 Hz, 1H), 7.77 (t, J = 9.0 Hz, 1H), 7.09 (t, J = 8.0 Hz, 1H), 6.79 (d, J = 5.1 Hz, 1H), 6.70 (dq, J = 4.0, 1.3 Hz, 2H), 6.65 (ddd, J = 8.0, 2.4, 1.1 Hz, 1H), 6.50 (s, 2H), 5.25 (s, 2H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder 0.010 g (10%). 1 H NMR (500 MHz, DMSO-d6) δ 11.59 (s, 1H), 8.14 – 8.10 (m, 1H), 8.03 (d, J = 5.3 Hz, 1H), 7.66 (dd, J = 8.7, 1.7 Hz, 1H), 7.41 – 7.35 (m, 1H), 7.04 (t, J = 7.8 Hz, 1H), 6.76 – 6.66 (m, 3H), 6.60 (ddd, J = 8.1, 2.4, 1.1 Hz, 1H), 5.53 (s, 2H), 5.17 (s, 2H). LRMS (ESI) m/z [M] + . For C20H16N6 Molecular Weight: 340.3900 found 341.3 Example 78 4-Chloro-3-(2-aminophenyl)ethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g. 0.1181 mmol), and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 2-ethynylaniline (0.166 g, 1.42 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a dark brown oil (0.093 g, 32%) 5-(2-Amino-3-((2-aminophenyl)ethynyl)pyridine-4-yl)-1H-indaz ol-3-amine 4-Chloro-3-(2-aminophenyl)ethynyl)pyridin-2-amine (0.093 g, 0.382 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.113 g, 0.459 mmol), cesium carbonate (0.374 g, 1.147 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.025 g, 0.038 mmol) in 5 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography to afford 5-(2- amino-3-((2-aminophenyl)ethynyl)pyridin-4-yl)-2-fluorobenzon itrile. The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.008 g, 6%). 1 H NMR (500 MHz, DMSO-d6) δ 11.53 (s, 1H), 8.07 (d, J = 1.5 Hz, 1H), 7.99 (d, J = 5.2 Hz, 1H), 7.61 (dd, J = 8.7, 1.6 Hz, 1H), 7.33 (d, J = 8.6 Hz, 1H), 6.99 (t, J = 7.8 Hz, 1H), 6.68 (d, J = 5.2 Hz, 2H), 6.64 (d, J = 7.5 Hz, 1H), 6.55 (dd, J = 8.0, 2.2 Hz, 1H), 6.23 (s, 2H), 5.48 (s, 2H), 5.12 (s, 2H). LRMS (ESI) m/z [M] + . For C20H16N6 Molecular Weight: 340.3900 found 341.3 Example 79 Methyl 3-((2-amino-4-chloropyridin-3-yl)ethynyl)benzoate A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g. 0.1181 mmol), and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of methyl 3-ethynylbenzoate (0.227g, 1.417 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a light brown solid (0.062 g, 18 %) Methyl 3-((2-amino-4-(3-amino-1H-indazol-5-yl)149yridine-3-yl)ethyn yl)benzoate Methyl 3-((2-amino-4-chloropyridin-3-yl)ethynyl)benzoate (0.062 g, 0.216 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.064 g, 0.259 mmol), cesium carbonate (0.211 g, 0.648 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.014 g, 0.0216 mmol) in 5 mL of a degassed mixture of dioxane and water (18:2 5 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford methyl 3-((2-amino-4-(3-cyano-4-fluorophenyl)pyridin-3- yl)ethynyl)benzoate. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.26 (dd, J = 6.3, 2.4 Hz, 1H), 8.13 – 8.05 (m, 3H), 7.94 (dt, J = 7.9, 1.5 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.55 (t, J = 7.8 Hz, 1H), 6.74 – 6.66 (m, 3H), 3.89 (s, 3H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.017 g, 6%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.19 (s, 1H), 11.64 (s, 1H), 8.53 (d, J = 5.0 Hz, 1H), 7.90 – 7.85 (m, 2H), 7.74 – 7.66 (m, 1H), 7.42 – 7.34 (m, 2H), 7.22 (d, J = 5.0 Hz, 1H), 6.57 (d, J = 9.8 Hz, 1H), 5.51 (s, 2H). (CH 3 Hidden under 3.3 H 2 0 signal). LRMS (ESI) m/z [M] + . For C 22 H 17 N 5 O 2 Molecular Weight: 383.4110 found 384.3 Example 80 Methyl 4-((2-amino-4-chloropyridin-3-yl)ethynyl)benzoate A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g. 0.1181 mmol), and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of methyl 4-ethynylbenzoate (0.227g, 1.417 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a brown solid. (0.169 g, 50%). Methyl 4-((2-amino-4-(3-amino-1H-indazol-5-yl)150yridine-3-yl)ethyn yl)benzoate Methyl 3-((2-amino-4-chloropyridin-3-yl)ethynyl)benzoate (0.169 g, 0.589 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.175 g, 0.707 mmol), cesium carbonate (0.576 g, 1.767 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.038 g, 0.0589 mmol) in 5 mL of a degassed mixture of dioxane and water (18:2 5 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford methyl 4-((2-amino-4-(3-cyano-4-fluorophenyl)pyridin-3- yl)ethynyl)benzoate. The obtained methyl 4-((2-amino-4-(3-cyano-4-fluorophenyl)pyridin-3-yl)ethynyl)b enzoate was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.017 g, 6%). 1 H NMR (500 MHz, DMSO- d 6 ) δ 11.55 (s, 1H), 9.81 (s, 1H), 8.13 (s, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.57 (dd, J = 20.2, 8.3 Hz, 2H), 7.35 (d, J = 8.7 Hz, 1H), 6.70 (d, J = 5.2 Hz, 1H), 6.43 (s, 2H), 5.50 (s, 2H), 3.88 (s, 3H).. LRMS (ESI) m/z [M] + . For C22H17N5O2 Molecular Weight: 383.411 found 384.3 Example 814-Chloro-3-(2-methoxyphenyl)ethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g, 0.1181 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 1-ethynyl-2-methoxybenzene (0.187g 1.417 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a dark brown solid ( 0.215 g, 70 %). 5-(2-Amino-3-((2-methoxyphenyl)ethynyl)pyridine-4-yl)-1H-ind azol-3-amine 4-Chloro-3-(2-methoxyphenyl)ethynyl)pyridin-2-amine (0.215 g, 0.831 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.247 g, 0.997 mmol) cesium carbonate (0.814 g, 2.5 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.0543 g, 0.08327 mmol) in 5 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-((2- methoxyphenyl)ethynyl)pyridin-4-yl)-2-fluorobenzonitrile. The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in Ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.045 g, 15%). 1 H NMR (500 MHz, DMSO-d6) δ 8.26 (d, J = 1.6 Hz, 1H), 8.06 (d, J = 6.2 Hz, 1H), 7.78 (dd, J = 8.8, 1.7 Hz, 1H), 7.49 (dd, J = 7.6, 1.7 Hz, 1H), 7.44 – 7.37 (m, 3H), 7.10 (d, J = 8.4 Hz, 1H), 6.98 (t, J = 7.0 Hz, 2H), 3.80 (s, 3H). LRMS (ESI) m/z [M] + . For C21H17N5O Molecular Weight: 355.4010 found 356.3 Example 82 5-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-1-pheny lpent-4-yn-1-one A solution of 5-(2-amino-3-bromopyridin-4-yl)-1H-indazol-3-amine (0.12 g, 0.48 mmol), copper (I) iodide (0.004 g, 0.024 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.016 g, 0.024 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 1-phenylpent-4-yn-1-one (0.13 g, 0.58 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (20% EtOAc in petroleum ether 60-80%) to give the product as yellow off white solid (0.13 g, 77%), 1 H NMR (400 MHz, DMSO-d 6 ) δ 2.75 (t, J=12.3 Hz, 2 H), 2.75 (t, J=12.3 Hz, 2 H), 5.41 (br. s., 2 H) 6.25 (br. s., 2 H), 6.63 (d, J=5.71 Hz, 1 H), 7.28 (m, , 2 H), 7.75 (s, 1H), 7.95 (m, 2H),11.55 (s, 1H), LRMS: C 23 H 19 N 5 O requires 381.2, found 382.1 (M+H). Example 83 3-(2-Amino-4-chloropyridin-3-yl)prop-2-yn-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g, 0.1181 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of propagyl alcohol (0.0795 g, 0.083 mL, 1.42 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to give the product as a dark brown solid ( 0.087 g, 40 %). 1 H NMR (500 MHz, DMSO-d6) δ 7.87 (d, J = 5.4 Hz, 1H), 6.68 (d, J = 5.5 Hz, 1H), 6.56 (s, 2H), 5.35 (t, J = 6.0 Hz, 1H), 4.38 (d, J = 6.0 Hz, 2H). LRMS (ESI) m/z [M] + . For C 8 H 7 ClN 2 O Molecular Weight: 182.6070 found 183.1 3-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)prop-2-y n-1-ol 3-(2-Amino-4-chloropyridin-3-yl)prop-2-yn-1-ol (0.087 g, 0.476 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.141 g, 0.572 mmol) cesium carbonate (0.465 g, 1.428 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.031 g, 0.0476 mmol) in 5 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-(3-hydroxyprop-1-yn-1- yl)pyridin-4-yl)-2-fluorobenzonitrile. The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a cream powder (0.060 g, 45%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.21 (d, J = 1.6 Hz, 1H), 8.01 (d, J = 6.5 Hz, 1H), 7.80 (s, 2H), 7.69 (dd, J = 8.8, 1.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.98 (d, J = 6.5 Hz, 1H), 4.31 (s, 2H). LRMS (ESI) m/z [M] + .For C 15 H 13 N 5 O Molecular Weight: 279.3030 found 280.1 Example 84 3-(2-Amino-4-chloropyridin-3-yl)but-3-yn-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g, 0.1181 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 3-butyn-1-ol (0.0993 g, 0.107 mL, 1.42 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a brown solid (0.184 g, 79%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.91 (s, 1H), 6.73 (d, J = 5.3 Hz, 1H), 6.54 (s, 2H), 5.05 (t, J = 5.6 Hz, 1H), 3.68 (td, J = 6.6, 5.4 Hz, 2H), 2.71 (t, J = 6.6 Hz, 2H). LRMS (ESI) m/z [M] + . For C 9 H 9 ClN 2 O Molecular Weight: 196.6340 found 197.1 4-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)but-3-yn -1-ol 3-(2-Amino-4-chloropyridin-3-yl)but-3-yn-1-ol (0.184 g, 0.93 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.278 g, 1.12 mmol), cesium carbonate (0.303 g, 2.79 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.0606 g, 0.093 mmol) in 5 mL of a degassed mixture of dioxane and water (18:25 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-(4-hydroxybut-1-yn-1- yl)pyridin-4-yl)-2-fluorobenzonitrile. 1 H NMR (500 MHz, DMSO-d6) δ 8.16 (dd, J = 6.2, 2.4 Hz, 1H), 8.05 (ddd, J = 8.8, 5.3, 2.4 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.62 (t, J = 9.0 Hz, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.36 (s, 2H), 4.93 (t, J = 5.6 Hz, 1H), 3.53 (td, J = 6.7, 5.5 Hz, 2H), 2.54 (d, J = 6.7 Hz, 2H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a cream powder (0.059 g, 22%). 1 H NMR (400 MHz, DMSO-d6) δ 8.26 (d, J = 1.7 Hz, 1H), 7.70 (dd, J = 8.6, 1.9 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.99 (d, J = 6.6 Hz, 1H), 2.59 (t, J = 6.6 Hz, 2H). LRMS (ESI) m/z [M] + .For C16H15N5O Molecular Weight: 293.3300 found 294.1 Example 85 3-(2-Amino-4-chloropyridin-3-yl)pent-4-yn-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g/1.18 mmol), copper (I) iodide (0.0225 g, 0.118 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.0829 g, 0.118 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 4-pentyn-1-ol (0.119 g, 0.132 mL, 1.417 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a brown solid (0.192 g, 77%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.84 (s, 1H), 6.67 (d, J = 5.4 Hz, 1H), 6.44 (s, 2H), 4.59 (t, J = 5.2 Hz, 1H), 3.54 (td, J = 6.1, 5.1 Hz, 2H), 2.56 (t, J = 7.0 Hz, 2H), 1.76 – 1.67 (m, 2H). LRMS (ESI) m/z [M] + .For C 10 H 11 ClN 2 O Molecular weight 210.6610 found 211.5. 5-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)pent-4-y n-1-ol 3-(2-Amino-4-chloropyridin-3-yl)pent-4-yn-1-ol (0.192 g, 0.914 mmol), 2-fluoro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.2709 g, 1.096 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0297 g, 0.0457 mmol, 5 mol%) and cesium carbonate (0.952 g, 2.92 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-(5-hydroxypent-1-yn-1-yl)pyridin-4-yl)-2- fluorobenzonitrile (0.117 g, 43%). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.090 g, 32%). 1 H NMR (500 MHz, DMSO-d6) δ 8.14 (dd, J = 6.3, 2.3 Hz, 1H), 8.02 (ddd, J = 8.8, 5.3, 2.4 Hz, 1H), 7.96 (d, J = 5.2 Hz, 1H), 7.63 (t, J = 9.1 Hz, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.31 (s, 2H), 4.51 (t, J = 5.2 Hz, 1H), 3.40 (q, J = 5.9 Hz, 2H), 2.44 (t, J = 7.0 Hz, 2H), 1.66 – 1.55 (m, 2H). LRMS (ESI) m/z [M] + .For C17H17N5O Molecular Weight: 307.3570 found 308.1 Example 86 6-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-2-methy lhex-5-yn-2-ol A 2-5 mL Biotage MW tube was charged with 6-(2-amino-4-chloropyridin-3-yl)-2-methylhex-5- yn-2-ol (100 mg, 0.3 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (103 mg, 0.4 mmol, 1.3 eq.), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (9.8 mg, 0.015 mmol, 5 mol%) and dioxane (1.8 mL). The resulting suspension was purged with nitrogen for 5 minutes before adding 1 M aq. K 3 PO 4 (1.8 mL). The reaction mixture was heated to 110 °C for 16 hrs. The reaction mixture was then allowed to cool to room temperature, before being diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic fractions were then dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure. The crude product was then purified by HPLC to give the desired product as a pale yellow solid (23 mg). 1 H NMR (500 MHz, DMSO- D 6 ) δ 1.54 (s, 6H), 2.28 (t, J = 6.9 Hz, 1H), 2.56 (t, J = 7.0 Hz, 1H), 6.72 (d, J = 6.6 Hz, 1H), 7.27 (d, J = 8.7 Hz, 1H), 7.68 (dd, J = 8.4 and 1.6 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 8.24 (s, 1H), 11.48 (s, 1H). LRMS: Calculated for C 19 H 21 N 5 O 335.17; Found: 336.25 Example 87 3-(2-Amino-4-chloropyridin-3-yl)-2-methylbut-3-yn-2-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.26 g, 1.02 mmol), copper (I) iodide (0.0097 g, 0.051 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.0358 g, 0.051 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 2-methyl-3-butyn-2-ol (0.103 g, 0.119 mL, 1.228 mmol).The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a light brown solid. (0.177 g, 84%). 1 H NMR (500 MHz, DMSO-d6) δ 7.93 (d, J = 23.9 Hz, 1H), 6.70 (d, J = 4.7 Hz, 1H), 6.48 (s, 2H), 5.59 (s, 1H), 1.49 (s, 6H). LRMS (ESI) m/z [M] + . C 10 H 11 ClN 2 O Molecular Weight: 210.6610 found 221.5 4-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-2-methy lbut-3-yn-2-ol 3-(2-Amino-4-chloropyridin-3-yl)-2-methylbut-3-yn-2-ol (0.244 g, 1.161 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.344 g, 1.39 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.038 g, 0.058 mmol, 5 mol%), cesium carbonate (0.952 g, 2.92 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:27 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to afford 5-(2-amino-3-(3-hydroxy-3-methylbut-1-yn-1-yl)pyridin-4-yl)- 2-fluorobenzonitrile (0.231 g, 67%). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.054 g, 15%). 1 H NMR (500 MHz, DMSO-d6) δ 8.25 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 6.5 Hz, 1H), 7.68 (dd, J = 8.8, 1.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.00 (d, J = 6.5 Hz, 1H), 1.40 (s, 6H). LRMS (ESI) m/z [M] + . C17H17N5O Molecular Weight: 307.3570 found 308.1 Example 88 3-(3-(Tert-butoxy)prop-1-yn-1-yl)-4-chloropyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.25 g, 0.98 mmol), copper (I) iodide (0.01 g, 0.05 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.03 g, 0.05 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 3-(tert-butoxy)prop-1-yne (0.2 ml, 1.4 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.116 g, 49%). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.22 (s, 9 H) 4.39 (s, 2 H) 6.51 (br. s., 2 H) 6.69 (d, J=5.49 Hz, 1 H) 7.87 (d, J=5.34 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 27.91, 40.28, 51.31, 64.79, 77.20, 99.49, 112.76, 115.07, 148.83, 161.65. m/z (ESI-MS) [M] + 239.0. 5-(2-Amino-3-(3-(tert-butoxy)prop-1-yn-1-yl)pyridine-4-yl)-1 H-indazol-3-amine 3-(3-(Tert-butoxy)prop-1-yn-1-yl)-4-chloropyridin-2-amine (0.028 g, 0.11 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.045 g, 0.17 mmol), 1M potassium phosphate solution (0.23 ml, 0.23 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst 2 (0.004 g, 0.005 mmol) in 0.7 ml ethanol were reacted as described in general procedure and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as brown solid (12.3 mg, 33 %).. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.11 (s, 9 H) 4.27 (s, 2 H) 5.41 (s, 2 H) 6.17 (br. s., 2 H) 6.62 (d, J= 5.19 Hz, 1 H) 7.25 (d, J=8.70 Hz, 1 H) 7.53 (dd, J=8.70, 1.53 Hz, 1 H) 7.95 (m, 2 H) 11.49 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 27.83, 40.27, 51.27, 80.18, 97.07, 99.45, 109.24, 113.28, 121.09, 127.43, 128.32, 134.19, 141.55, 144.83, 147.75, 150.25, 152.16. m/z (ESI-HRMS) calculated for C19H22ON5 = 336.1819 found=336.1816. Example 89 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cyclopentan-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.105, 0.416 mmol), copper (I) iodide (0.0079 g, 0.0416 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.029 g, 0.0416 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 1-ethynylcyclopentan-1-ol (0.055 g, 0.49 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and washed with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a brown solid (0.088 g, 90%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.86 (d, J = 5.4 Hz, 1H), 6.69 (d, J = 5.4 Hz, 1H), 6.50 – 6.32 (m, 2H), 5.45 (s, 1H), 1.92 (q, J = 5.6, 4.6 Hz, 4H), 1.81 – 1.62 (m, 4H). LRMS (ESI) m/z [M] + . C 12 H 13 ClN 2 O Molecular Weight: 236.6990 found 237.1 1-((2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl )cyclopentan-1-ol 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cyclopentan-1-ol (0.088 g, 0.372 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.1102 g, 0.44 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0121 g, 0.018 mmol, 5 mol%), cesium carbonate (0.363 g, 1.115 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-((1-hydroxycyclopentyl)ethynyl)pyridin-4-yl)-2- fluorobenzonitrile. The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in Ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.022 g, 18%). 1 H NMR (500 MHz, DMSO-d6) δ 8.12 (d, J = 2.3 Hz, 1H), 8.03 (d, J = 6.1 Hz, 1H), 7.97 (dd, J = 8.9, 2.4 Hz, 1H), 7.38 (d, J = 9.0 Hz, 1H), 6.94 (d, J = 6.1 Hz, 1H), 1.88 – 1.83 (m, 4H), 1.75 – 1.70 (m, 2H), 1.61 (tq, J = 7.1, 3.8, 2.7 Hz, 2H). LRMS (ESI) m/z [M] + . C19H19N5O Molecular Weight: 333.3950 found 334.3 Example 90 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cyclohexan-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.4 g, 1.575 mmol), copper (I) iodide (0.015 g, 0.079 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.055 g, 0.079 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 1-ethynylcyclohexan-1-ol (0.234 g, 1.89 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a light brown solid (0.282 g, 71%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.86 (d, J = 5.5 Hz, 1H), 6.69 (d, J = 5.5 Hz, 1H), 6.46 (s, 2H), 5.61 (s, 1H), 1.88 (dd, J = 9.2, 5.4 Hz, 2H), 1.74 – 1.60 (m, 2H), 1.53 (d, J = 8.6 Hz, 5H), 1.30 – 1.13 (m, 1H). LRMS (ESI) m/z [M] + . C 13 H 15 ClN 2 O Molecular Weight: 250.7260 found 251.1 1-((2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl )cyclohexan-1-ol 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cyclohexan-1-ol (0.088 g, 0.372 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.1102 g, 0.44 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0121 g, 0.018 mmol, 5 mol%), cesium carbonate (0.363 g, 1.115 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-((1-hydroxycyclohexyl)ethynyl)pyridin-4-yl)-2- fluorobenzonitrile (0.332 g, 88%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.16 (dd, J = 6.3, 2.3 Hz, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.97 (ddd, J = 8.7, 5.3, 2.3 Hz, 1H), 7.64 (t, J = 9.1 Hz, 1H), 6.64 (d, J = 5.2 Hz, 1H), 6.37 (s, 2H), 5.56 (s, 1H), 4.04 (q, J = 7.1 Hz, 1H), 2.00 (s, 1H), 1.77 (d, J = 12.4 Hz, 2H), 1.61 – 1.51 (m, 2H), 1.44 (td, J = 11.9, 11.4, 3.6 Hz, 3H), 1.26 – 1.07 (m, 3H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in Ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.076 g, 59%). 1 H NMR (500 MHz, DMSO-d6) δ 8.18 (d, J = 1.6 Hz, 1H), 8.03 (d, J = 6.4 Hz, 1H), 7.80 (s, 2H), 7.68 (dd, J = 8.7, 1.7 Hz, 1H), 7.36 (d, J = 8.7 Hz, 1H), 6.99 (d, J = 6.5 Hz, 1H), 1.81 (dt, J = 9.2, 5.0 Hz, 2H), 1.53 – 1.41 (m, 4H), 1.36 – 1.28 (m, 1H), 1.26 – 1.05 (m, 3H).LRMS (ESI) m/z [M] + . C20H21N5O Molecular Weight: 347.4220 found 348.1 Example 91 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cycloheptan-1-ol A solution of 4-chloro-3-iodo-pyridine-2-amine (0.383 g, 1.50 mmol), copper (I) iodide (0.029 g, 0.150 mmol) and bis(triphenylphosphine) palladium(II) chloride (.0103 g, 0.150 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 1-ethynylcycloheptan-1-ol (0.250 g, 1.81 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a light brown solid (0.251 g, 63%). 1 H NMR (500 MHz, DMSO-d6) δ 7.96 (s, 1H), 7.87 (d, J = 5.4 Hz, 2H), 6.70 (d, J = 5.4 Hz, 2H), 6.46 (s, 3H), 5.49 (s, 2H), 2.00 (dd, J = 13.8, 7.3 Hz, 2H), 1.85 – 1.72 (m, 2H), 1.68 – 1.46 (m, 8H). LRMS (ESI) m/z [M] + . C14H17ClN2O Molecular Weight: 264.7530 found 265.1 1-((2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)ethynyl )cycloheptan-1-ol 1-((2-Amino-4-chloropyridin-3-yl)ethynyl)cycloheptan-1-ol (0.251 g, 0.946 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.3508 g, 1.42 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0308 g, 0.0473 mmol, 5 mol%), cesium carbonate (1.079 g, 3.313 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-((1-hydroxycyclohexyl)ethynyl)pyridin-4-yl)-2- fluorobenzonitrile (0.332 g, 88%). 1 H NMR (500 MHz, DMSO-d6) δ 8.16 (dd, J = 6.2, 2.3 Hz, 1H), 8.00 (d, J = 5.2 Hz, 1H), 7.96 (ddd, J = 8.7, 5.3, 2.4 Hz, 1H), 7.64 (t, J = 9.1 Hz, 1H), 6.65 (d, J = 5.2 Hz, 1H), 6.36 (s, 2H), 5.42 (s, 1H), 1.87 (dd, J = 13.7, 8.2 Hz, 2H), 1.74 – 1.66 (m, 2H), 1.57 – 1.43 (m, 6H), 1.26 (td, J = 9.3, 8.8, 4.6 Hz, 2H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled, concentrated and purified by HPLC affording the target compound as a yellow powder (0.049 g, 14%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.18 (d, J = 1.6 Hz, 1H), 8.02 (d, J = 6.4 Hz, 1H), 7.67 (dd, J = 8.7, 1.7 Hz, 1H), 7.35 (d, J = 8.7 Hz, 1H), 7.15 (d, J = 51.1 Hz, 2H), 7.02 – 6.96 (m, 2H), 1.96 – 1.89 (m, 2H), 1.77 – 1.68 (m, 3H), 1.50 – 1.37 (m, 6H), 1.27 (d, J = 15.3 Hz, 3H). LRMS (ESI) m/z [M] + . C 21 H 23 N 5 O Molecular Weight: 361.4490 found 362.3 Example 92 3-(3-Amino-3-methylbut-1-yn-1-yl)-4-chloropyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.3 g, 1.181 mmol), copper (I) iodide (0.023 g, 0.1181 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.083 g, 0.1181 mmol) in 5 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 2-methylbut-3-yn-2-amine (0.116 g, 0.147 mL, 1.42 mmol).The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to give the product as (0.1941 g, 78%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.84 (d, J = 5.5 Hz, 1H), 6.67 (d, J = 5.5 Hz, 1H), 6.48 (s, 2H), 2.90 (s, 2H), 1.40 (s, 6H). LRMS (ESI) m/z [M] + . C 10 H 12 ClN 3 Molecular Weight: 209.6770 found 210.1 5-(2-Amino-3-(3-amino-3-methylbut-1-yn-1-yl)pyridin-4-yl)-1H -indazol-3-amine 3-(3-Amino-3-methylbut-1-yn-1-yl)-4-chloropyridin-2-amine (0.194 g, 0.93 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.275 g, 1.11 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0325 g, 0.0464 mmol, 5 mol%), cesium carbonate (0.907 g, 2.784 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afford 5-(2-amino-3-((1-hydroxycyclohexyl)ethynyl)pyridin-4-yl)-2- fluorobenzonitrile (0.199 g, 88%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.21 (dd, J = 6.2, 2.4 Hz, 1H), 8.03 (ddd, J = 8.8, 5.2, 2.4 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.64 (t, J = 9.1 Hz, 1H), 6.67 (d, J = 5.2 Hz, 1H), 6.35 (s, 2H), 1.29 (s, 6H). The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.149 g, 54%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.51 (s, 4H), 8.22 (d, J = 1.7 Hz, 1H), 8.07 (d, J = 6.1 Hz, 1H), 7.65 (dd, J = 8.7, 1.8 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 6.93 (d, J = 6.2 Hz, 1H), 2.54 (t, J = 5.5 Hz, 2H), 1.55 (s, 6H).LRMS (ESI) m/z [M] + . C 17 H 18 N 6 Molecular Weight: 306.3730 found 307.1 Example 93 4-Chloro-3-(4-(piperidin-1-yl)but-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 4 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 4-(but-3-yn-1-yl)piperidine (0.12 ml, 0.88 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.063 g, 40%), . 1H NMR (400 MHz, DMSO-d6) δ ppm 1.39 (d, J=5.19 Hz, 2 H) 1.52 (quin, J=5.57 Hz, 4 H) 2.39 (br. s., 4 H) 2.52-2.55 (m, 2 H) 2.64-2.72 (m, 2 H) 6.65 (d, J=5.34 Hz, 3 H) 6.83 (d, J=5.49 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 18.07, 24.52, 25.83, 54.08, 57.34, 74.94, 101.20, 102.19, 112.47, 143.22, 148.05, 161.96. m/z (ESI-MS) [M] + 264.0. 5-(2-Amino-3-(4-(piperidin-1-yl)but-1-yn-1-yl)pyridin-4-yl)- 1H-indazol-3-amine 4-Chloro-3-(4-(piperidin-1-yl)but-1-yn-1-yl)pyridin-2-amine (0.075 g, 0.28 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (97) (0.115 g, 0.42 mmol), 1M potassium phosphate solution (0.6 ml, 0.6 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.003 g, 0.014 mmol) in 1.7 ml ethanol were reacted as described in General procedure A and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as yellow solid (63.3 mg, 35%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.31-1.42 (m, 2 H) 1.42-1.55 (m, 4 H) 2.33 (br. s., 4 H) 2.45 (d, J=5.71 Hz, 2 H) 2.52-2.59 (m, 2 H) 5.44 (s, 2 H) 6.42 (s, 2 H) 6.58 (d, J= 5.27 Hz, 1 H) 7.26 (d, J= 8.79 Hz, 1 H) 7.53 (dd, J=8.79, 1.32 Hz, 1 H) 7.90 (d, J= 5.27 Hz, 1 H) 7.96 (s, 1 H) 11.49 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 18.09, 25.85, 54.09, 57.40, 60.32, 77.85, 98.27, 100.45, 109.35, 112.97, 114.58, 121.15, 127.48, 128.63, 141.61, 147.12, 150.32, 151.02, 161.73. m/z (ESI-HRMS) calculated for C 21 H 25 N 6 = 361.2135 found= 361.2132. Example 94 4-Chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 4 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of 4-(but-3-yn-1-yl)morpholine (122) (0.12 ml, 0.88 mmol). The reaction mixture was stirred at 80 °C for 3 h. The reaction mixture was diluted with EtOAc and extracted with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.139 g, 89%),. 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 2.43 (br. s., 4 H) 2.56 (t, J=6.81 Hz, 2 H) 3.70 (t, J=6.81 Hz, 2 H) 3.59 (t, J=4.61 Hz, 4 H) 6.51-6.78 (m, 3 H) 6.84 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.85, 53.45, 57.05, 66.58, 75.05, 101.03, 102.25, 112.61, 143.38, 148.20, 162.01. m/z (ESI-MS) [M] + 266.0. 5-(2-Amino-3-(4-morpholinobut-1-yn-1-yl)pyridin-4-yl)-1H-ind azol-3-amine 4-Chloro-3-(4-morpholinobut-1-yn-1-yl)pyridin-2-amine (0.029 g, 0.1 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (97) (0.042 g, 0.16 mmol), 1M potassium phosphate solution (0.2 ml, 0.2 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.001 g, 0.005 mmol) in 0.6 ml ethanol were reacted as described in General procedure A and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as yellow solid (28 mg, 78%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.36 (br. s., 4 H) 2.42-2.48 (m, 2 H) 2.53-2.60 (m, 2 H) 3.55 (t, J=4.39 Hz, 4 H) 5.45 (s, 2 H) 6.43 (s, 2 H) 6.58 (d, J= 5.27 Hz, 1 H) 7.26 (d, J= 8.79 Hz, 1 H) 7.49-7.56 (m, 1 H) 7.91 (d, J= 5.27 Hz, 1 H) 7.96 (s, 1 H) 11.49 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 17.98, 53.40, 57.07, 66.53, 71.18, 98.07, 100.43, 109.36, 113.00, 121.15, 123.89, 127.47, 128.60, 141.60, 147.15, 150.33, 152.06, 161.69. m/z (ESI-HRMS) calculated for C20H23ON6 = 363.1928 found= 363.1925. Example 95 4-Chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 4 ml of tetrahydrofuran – triethylamine (1:4) was degassed in sealed tube followed by addition of 5- chloro-1-pentyne (0.1 ml, 0.9 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc and extracted with water. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude then purified using column chromatography (10% EtOAc in petroleum ether 60-80%) to give the product as yellow oil (0.102 g, 75%). 1H NMR (400 MHz, DMSO-d6) δ ppm 2.03 (quin, J=6.70 Hz, 2 H) 2.67 (t, J=6.81 Hz, 2 H) 3.79 (t, J=6.59 Hz, 2 H) 6.48 (br.s., 2 H) 6.67 (d, J=5.27 Hz, 1 H) 6.84 (d, J=4.83 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.48, 31.37, 44.58, 74.36, 100.42, 102.02, 112.80, 144.48, 148.25, 161.55. m/z (ESI-MS) [M] + 229.0. 4-Chloro-3-(5-piperdinopent-1-yn-1yl)pyridin-2-amine In sealed tube, a mixture of 4-chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.4 mmol), piperdine (0.5 ml) and potassium iodide (0.04 g, 0.22 mmol) in N,N-dimethylamide (1.5 ml) was heated to 110 °C for 50 min. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow oil (0.1 g, 90 %),. 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.37 (d, J=5.49 Hz, 2 H) 1.48 (quin, J=5.49 Hz, 4 H) 2.03 (quin, J=7.05 Hz, 2 H) 2.31 (br. s., 4 H) 2.36 (t, J=7.14 Hz, 2 H) 2.67 (t, J=4.61 Hz, 2 H) 6.41 (br. s., 2 H) 6.66 (dd, J=5.49, 2.93 Hz, 1 H) 7.83 (d, J=5.49 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 16.88, 25.58, 30.77, 44.24, 54.10, 57.43, 73.76, 101.61, 102.30, 112.19, 143.70, 147.65, 160.95. m/z (ESI-MS) [M] + 292.1. 5-(2-Amino-3-(5-(piperidin-1-yl)pent-1-yn-1-yl)pyridin-4-yl) -1H-indazol-3-amine 4-Chloro-3-(4-(piperidin-1-yl)pent-1-yn-1-yl)pyridin-2-amine (0.087 g, 0.31 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (97) (0.122 g, 0.47 mmol), 1M potassium phosphate solution (0.6 ml, 0.6 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.003 g, 0.015 mmol) in 1.8 ml ethanol were reacted as described in General procedure A and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as yellow solid (48 mg, 42 %),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.34 (br. s., 2 H) 1.39-1.49 (m, 4 H) 1.54-1.67 (m, 2 H) 2.18 (br. s., 6 H) 2.39 (t, J=6.81 Hz, 2 H) 5.43 (br. s., 2 H) 6.10 (br. s., 2 H) 6.59 (d, J= 5.27 Hz, 1 H) 7.25 (d, J= 8.79 Hz, 1 H) 7.51 (dd, J=8.57, 1.10 Hz, 1 H) 7.91 (d, J= 5.27 Hz, 1 H) 7.94 (s, 1 H) 11.49 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 24.43, 25.65, 45.57, 51.56, 52.49, 54.38, 59.87, 91.29, 100.62, 109.26, 113.36, 114.55, 121.19, 127.55, 128.62, 141.57, 147.05, 150.30, 151.91, 161.11. m/z (ESI-HRMS) calculated for C 22 H 27 N 6 = 375.2292 found= 375.2292. Example 96 4-Chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine In sealed tube, a mixture of 4-chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.4 mmol), morpholine (0.5 ml) and potassium iodide (0.04 g, 0.22 mmol) in N,N-dimethylamide (1.5 ml) was heated to 110 °C for 50 min. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow oil (115 mg, 90 %),.1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.73 (quin, J=7.14 Hz, 2 H) 2.35 (br. s., 4 H) 3.41 (t, J=7.03 Hz, 2 H) 2.52-2.56 (m, 2 H) 3.57 (t, J=4.61 Hz, 4 H) 6.42 (br. s., 2 H) 6.66 (d, J=5.71 Hz, 1 H) 7.82 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.77, 25.57, 53.95, 57.69, 66.77, 79.36, 100.30, 102.30, 112.82, 144.29, 148.05, 161.50. m/z (ESI- MS) [M] + 280.1. 5-(2-Amino-3-(5-morpholinopent-1-yn-1-yl)pyridin-4-yl)-1H-in dazol-3-amine 4-Chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine (0.11 g, 0.4 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (97) (0.15 g, 0.6 mmol), 1M potassium phosphate solution (0.8 ml, 0.8 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.005 g, 0.02 mmol) in 2.4 ml ethanol were reacted as described in General procedure A and chromatographic purification (90% EtOAc in petroleum ether 60-80%), gave the titled compound as green crystals (102 mg, 68%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.58 (quin, J=7.03 Hz, 2 H) 2.11-2.20 (m, 6 H) 2.40 (t, J=6.81 Hz, 2 H) 3.49 (t, J=4.61 Hz, 4 H) 5.43 (s, 2 H) 6.10 (s, 2 H) 6.59 (d, J= 5.27 Hz, 1 H) 7.20-7.29 (m, 1 H) 7.50 (dd, J=8.79, 1.76 Hz, 1 H) 7.90 (d, J= 4.83 Hz, 1 H) 7.94 (s, 1 H) 11.48 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.71, 25.43, 53.79, 57.61, 66.72, 76.73, 99.22, 100.67, 109.27, 113.36, 114.54, 121.19, 127.54, 128.62, 141.57, 147.03, 150.31, 151.96, 161.09. m/z (ESI-HRMS) calculated for C 20 H 23 ON 7 = 377.1959 found= 377.1959. Example 97 tert-Butyl 4-((2-amino-4-chloropyridin-3-yl)ethynyl)methyl)piperidine-1 -carboxylate A solution of 4-chloro-3-iodo-pyridine-2-amine (0.12 g, 0.48 mmol), copper (I) iodide (0.004 g, 0.024 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.016 g, 0.024 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (0.13 g, 0.58 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extracted with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (20% EtOAc in petroleum ether 60-80%) to give the product as yellow oil (0.13 g, 77%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.11-1.28 (m, 4 H) 1.39 (s, 9 H) 1.43-1.45 (m, 1 H) 1.74 (d, J=9.67 Hz, 4 H) 3.96 (d, J=12.30 Hz, 2 H) 6.41 (br. s., 2 H) 6.67 (d, J=5.71 Hz, 1 H) 7.82 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 26.62, 28.66, 31.33, 35.35, 36.34, 74.92, 79.02, 100.39, 102.25, 112.84, 144.39, 148.11, 154.42, 161.47. m/z (ESI-MS) [M-tert-butyl] + 294.0. 5-(2-Amino-3-(3-(piperidin-4-yl)prop-1-yn-1-yl)pyridin-4-yl) -1H-indazol-3-amine tert-Butyl 4-((2-amino-4-chloropyridin-3-yl)ethynyl)methyl)piperidine-1 -carboxylate (0.012 g, 0.048 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (0.018 g, 0.072 mmol), 1M potassium phosphate solution (0.1 ml, 0.1 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.002 mmol) in 0.3 ml ethanol were reacted as described in general procedure A. The crude product was dissolved in THF (20 mL) and TBAF (5 mL, 1M solution in THF) added and refluxed for 8 hours, cooled, concentrated and purified by HPLC to give the titled compound as yellow solid (3.75 mg, 22 %). . 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.29-1.41 (m, 2 H) 1.75-1.87 (m, 3 H) 2.51 (d, J=6.71 Hz, 2 H) 2.74-2.83 (m, 2 H) 3.23 (d, J= 12.36 Hz, 2 H) 7.00 (d, J= 6.41 Hz, 1 H) 7.42 (d, J= 8.70 Hz, 1 H) 7.63 (d, J= 1.53 Hz, 1 H) 2.92 (br.s., 1 H) 8.06 (d, J= 6.56 Hz, 1 H) 8.26 (s, 1H) 8.28-8.38 (m, 1 H) 8.57-8.72 (m, 1H) 11.88 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.29, 28.33, 23.80, 43.40, 77.64, 97.87, 107.50, 109.98, 113.70, 114.24, 122.56, 127.48, 127.53, 141.94, 147.97, 150.26, 151.36, 163.86. m/z (ESI-HRMS) calculated for C 20 H 23 N 6 = 347.1979 found=347.1977. Example 98 3-(2-Amino-4-chloropyridin-3-yl)-N-methylpropiolamide A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.59 mmol), copper (I) iodide (0.006 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.004 g, 0.03 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of N-methylpropiolamide (0.059 g, 0.7089 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was then diluted with EtOAc and extract with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over anhydrous magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a dark brown oil (0.073 g, 59%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.77 (d, J = 5.1 Hz, 1H), 7.98 (d, J = 5.4 Hz, 1H), 6.88 (s, 2H), 6.74 (d, J = 5.4 Hz, 1H), 2.71 (d, J = 4.8 Hz, 3H). LRMS (ESI) m/z [M] + . For C 9 H 8 ClN 3 O Molecular Weight: 209.6330 found 210.5 3-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)-N-methyl propiolamide 3-(2-Amino-4-chloropyridin-3-yl)-N-methylpropiolamide (0.073 g, 0.349 mmol), 2-fluoro-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.1035 g, 0.419 mmol), [1,1′-bis(di- tert-butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0114 g, 0.0174 mmol, 5 mol%), Cesium carbonate (0.341 g, 1.047 mmol) in a sealed tube flushed with argon was added a degassed mixture of dioxane and water (18:2 7 mL) and stirred at 110 o C for 18 hours, concentrated and purified by flash chromatography (50% EtOAc and 1% triethylamine in petroleum ether 60-80%)to afford 3-(2-amino-4-(3-cyano-4-fluorophenyl)pyridin-3-yl)-N- methylpropiolamide The obtained fluorobenzonitrile was then dissolved in ethanol (8 ml) and hydrazine, (2 mL, 1 Mol solution in ethanol) added. The resulting mixture was stirred at reflux for 2 hours, cooled concentrated and purified by HPLC affording the target compound as a yellow powder (0.015 g, 14%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.27 (s, 1H), 8.54 (d, J = 4.8 Hz, 2H), 8.39 (d, J = 4.9 Hz, 1H), 8.13 (d, J = 2.4 Hz, 1H), 8.08 (dd, J = 8.8, 2.3 Hz, 2H), 7.45 (d, J = 8.8 Hz, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.28 (d, J = 4.9 Hz, 1H), 2.83 (d, J = 4.6 Hz, 3H). LRMS (ESI) m/z [M] + . C 16 H 14 N 6 O Molecular Weight: 306.3290 found 307.1 Example 99 5-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridine-3-yl)-1-morph olinopent-4-yn-1-one A 2-5 mL Biotage MW tube was charged with 5-(2-amino-4-chloropyridin-3-yl)-1- morpholinopent-4-yn-1-one (100 mg, 0.3 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine (103 mg, 0.4 mmol, 1.3 eq.), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (9.8 mg, 0.015 mmol, 5 mol%) and dioxane (1.8 mL). The resulting suspension was purged with nitrogen for 5 minutes before adding 1 M aq. K 3 PO 4 (1.8 mL). The reaction mixture was heated to 110 °C for 16 hrs. The reaction mixture was then allowed to cool to room temperature, before being diluted with water (10 mL) and extracted with ethyl acetate (3 x 20 mL). The combined organic fractions were then dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure. The crude product was then purified by HPLC to give the desired product as a pale yellow solid (14 mg). 1 H NMR (500 MHz, DMSO-D 6 ) δ 1.12 (m, 4H), 1.64 (m, 4H), 2.38 (t, J = 6.9 Hz, 1H), 2.66 (t, J = 7.0 Hz, 1H), 6.96 (d, J = 6.6 Hz, 1H), 7.31 (d, J = 8.7 Hz, 1H), 7.68 (dd, J = 8.4 and 1.6 Hz, 1H), 7.84 (d, J = 7.8 Hz, 1H), 8.24 (s, 1H). LRMS: Calculated for C 21 H 22 N 6 O 2 390.18; Found: 391.20. Example 100 5-(2-Amino-3-cyclopropylpyridin-4-yl)-1H-indazol-3-amine A 0.5-2 mL MW tube was charged with a mixture of 4-chloro-3-cyclopropylpyridin-2-amine (29.5 mg, 0.175 mmol, 1 eq.) and 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (59 mg, 0.228 mmol, 1.3 eq.), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst 5.7 mg, 0.00875 mmol, in EtOH (0.7 mL) was stirred under argon before adding 1 M aq. K3PO4 (0.35 mL). The reaction was heated to 50 °C under a gentle flow of argon for 10 minutes, then at 100 °C for 24 hours. The stirred reaction mixture was then cooled to room temperature and slowly diluted with water (7 mL) to precipitate a solid, which was filtered and washed with 1 M aq. Na2CO3 (10 mL x 3), water (10 mL) and hexane (2 mL) to give the title compound as a beige solid (26 mg). 1 H NMR (400 MHz, DMSO-D6) δ -0.18 – -0.10 (m, 2H), 0.66 – 0.75 (m, 2H), 1.63 – 1.75 (m, 1H), 5.39 (s, 2H), 5.79 (s, 2H), 6.47 (d, J = 5.2 Hz, 1H), 7.23 (d, J = 8.5 Hz, 1H), 7.33 (dd, J = 8.6, 1.6 Hz, 1H), 7.76 (s, 1H), 7.82 (d, J = 5.2 Hz, 1H), 11.42 (s, 1H). Example 101 4-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)butan-1-o l To a solution of 4-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)but-3-yn- 1-ol (Example 84 SU1503) (42 mg, 0.14 mmol) in 1.2 ml of dry MeOH was added 10% Pd/C (20 mg, 0.19 mmol). The reaction was stirred at RT, o/n under a hydrogen atmosphere. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue purified by HPLC to afford the title compound as a white solid (21 mg, 0.07 mmol, 52%). 1 H NMR (400 MHz, MeOD): ^ 1.36 – 1.50 (m, 2H), 1.54 – 1.66 (m, 2H), 2.60 – 2.71 (m, 2H), 3.44 (t, J = 6.3 Hz, 2H), 6.81 (d, J = 6.3 Hz, 1H), 7.29 (dd, J = 8.6, 1.7 Hz, 1H), 7.42 (dd, J = 8.6, 0.9 Hz, 1H), 7.71 (dd, J = 1.7, 0.9 Hz, 1H), 7.77 (d, J = 6.3 Hz, 1H), 8.30 (br s, 1H), 5 protons missing. LRMS: Calculated for C16H19N5O 297.2 found 298.3 (M+1). Example 102 1-(2-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)ethyl) cyclohexan-1-ol To a solution of 1-((2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)ethynyl) cyclohexan-1-ol (Example 90) (90 mg, 0.26 mmol) in 2.7 ml of dry MeOH was added 10% Pd/C (40 mg, 0.38 mmol). The reaction was stirred at RT, o/n under a hydrogen atmosphere. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue purified by HPLC to afford the title compound as a white solid (67 mg, 0.19 mmol, 71%).1H NMR (400 MHz, MeOD): ^ 1.20 – 1.51 (m, 10H), 1.58 – 1.67 (m, 2H), 2.55 – 2.64 (m, 2H), 6.77 (d, J = 5.2 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 7.70 (s, 1H), 7.76 (d, J = 5.2 Hz, 1H), 8.56 (br s, 1H), 4 protons missing. LRMS: Calculated for C20H25N5O 351.2 found 352.2 (M+1). Example 103 5-(2-Amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)pentan-1- ol To a solution of 5-(2-amino-4-(3-amino-1H-indazol-5-yl)pyridin-3-yl)pent-4-yn -1-ol (Example 85) (68 mg, 0.22 mmol) in 1.7 ml of dry MeOH was added 10% Pd/C (35 mg, 0.33 mmol). The reaction was stirred at RT, o/n under a hydrogen atmosphere. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue purified by HPLC to afford the title compound as a white solid (45 mg, 0.15 mmol, 65%). 1 H NMR (400 MHz, MeOD): ^ 1.19 – 1.29 (m, 2H), 1.31 – 1.41 (m, 2H), 1.45 – 1.56 (m, 2H), 2.54 – 2.61 (m, 2H), 3.41 (t, J = 6.4 Hz, 2H), 6.68 (d, J = 5.8 Hz, 1H), 7.25 (dd, J = 8.6, 1.6 Hz, 1H), 7.39 (dd, J = 8.6, 0.9 Hz, 1H), 7.66 (dd, J = 1.6, 0.9 Hz, 1H), 7.77 (d, J = 5.8 Hz, 1H), 6 protons missing. LRMS: Calculated for C17H21N5O 311.2 found 312.2 (M+1). Section 7 – compounds of the formula: General method for preparation of 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine To a solution of 3-chloro-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzonitrile (0.4 g, 1.4 mmol) in ethanol (20 ml), hydrazine hydrate (0.22 ml, 2.47 g, 6.8 mmol, 50-60 %) was added and the reaction stirred at reflux for 18 h. The solvent was evaporated and the residue was triturated with 12 ml EtOAc and petroleum ether (1:1) and then filtered under vacuum and washed with water then petroleum ether 60-80% to give the desired compound as a yellow solid (320 mg, 75 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.01 (s, 1H), 8.18 – 8.12 (m, 1H), 7.45 (s, 1H), 5.68 (s, 2H), 1.31 (s, 12H). General method for preparation of 3-bromo-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzonitrile A solution of bis(pinacolato)diboron (1.5 g, 5.99 mmol, 1.2 Eq), 4,4’-di-tert-butyl-2,2’-dipyridyl (67 mg, 0.25 mmol, 0.05 Eq) and (1,5-cyclooctadiene)(methoxy)iridium(I) dimer (132 mg, 0.2 mmol, 0.04 Eq) in anhydrous MTBE (10 mL) in a sealed vial (20 mL) was stirred at rt for 1 h. Then a solution of 3-bromo-2-fluorobenzonitrile (1 g, 5 mmol, 1 Eq) in anhydrous MTBE (2 mL) was added and the resulting reaction mixture was allowed to stir at 80 ºC for 18 h. The reaction was evaporated under reduced pressure. The crude residue was purified by flash column chromatography (eluting with a gradient of diethyl ether:petroleum ether 0% to 10%) to give the titled product as a white solid (1.3 g, 4.0 mmol, 80%). 1H NMR (500 MHz, DMSO) δ 1.32 (s, 12H), 8.05 (dd, J = 6.2, 1.5 Hz, 1H), 8.16 (dd, J = 7.2, 1.5 Hz, 1H). 19 F NMR (471 MHz, DMSO-d 6 ) δ -98.28. LRMS (ESI) m/z [M] + 325.03, 327.03. General method for preparation of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine 3-Bromo-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -yl)benzonitrile (1 g, 3.1 mmol, 1 Eq) was stirred with hydrazine solution (1M in THF, 6.2 mL, 6.2 mmol, 2 Eq) under reflux for 18 h. The reaction mixture was concentrated under reduced pressure, cooled and extracted between EtOAc (50 mL) and water (30 mL). The organic layer was dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude product was washed crystalized from MeOH to give the titled product as a pale brown solid (0.8 g, 2.37 mmol, 76%). 1 H NMR (500 MHz, DMSO-d6) δ 11.93 (s, 1H), 8.19 (s, 1H), 7.60 (s, 1H), 5.68 (s, 2H), 1.31 (s, 12H). LRMS (ESI-MS) m/z [M] + 337.01 (100%), 339.01 (100%). General method for the synthesis of 5-(2-aminopyridin-4-yl)-7-bromo-3-amino-1H- indazole 5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-7-bromo-3-am ino-1H-indazole (176.1 mg, 0.6 mmol), 2-amino-4-bromopyridine (86.5 mg, 0.5 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (16.3 mg, 0.025 mmol) were placed in a 2-5 mL microwave vial which was sealed and purged with nitrogen. Ethanol (1.5 mL) was added and the suspension brought to 50 °C with stirring before addition of K3PO4 (O2-free, 1 M, 0.75 mL). Stirring continued for 24 hours. Resultant solution was diluted in EtOAc, washed with water and adsorbed onto silica under reduced pressure. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0%, 6 CV; 0-2%, 1 CV; 2%, 3 CV; 2- 10%, 1CV; 10%, 4 CV) yielded product as a yellow solid (42 mg, 32%). 1H (DMSO-d6, 400 MHz) δ 5.64 (s, 2H), 5.92 (s, 2H), 6.72 (s, 1H), 6.80 (dd, J = 5.4 & 1.1 Hz, 1H), 7.71 (s, 1H), 7.95 (d, J = 5.6 Hz, 1H), 8.11 (s, 1H),11.93 (br s, 1H); LR-MS ESI 304.02 (100%), 306.02 (100%). HRMS (ESI +ve): For C 12 H 11 N 5 Br requires 304.0198 found 304.0200. 5-(2-Aminopyridin-4-yl)-7-((trimethylsilyl)ethynyl)-1H-indaz ol-3-amine (DB14/71). 5-(2-Aminopyridin-4-yl)-7-bromo-3-amino-1H-indazole (0.030 g, 0.1 mmol), TMS acetylene (28µL, 0.2 mmol) and Tetrakis(triphenylphosphine)palladium(0) catalyst (0.012 g, 0.01 mmol) and CuI (0.002 g, 0.01 mmol) were placed in a 2-5 mL microwave vial which was sealed and purged with nitrogen. DMF (1.5 mL) and Net 3 (1.5 mL) were added and the suspension brought to 60 °C with stirring and maintained for 16 hrs. Resultant solution was diluted in EtOAc, washed with water and adsorbed onto silica under reduced pressure. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0%-10%, 1CV; 10%, 4 CV) yielded product as a yellow solid (42 mg, 32%). 1 H (DMSO-d 6 , 500 MHz) δ 0.28(s, 9H) 5.61 (s, 2H), 5.90 (s, 2H), 6.73 (s, 1H), 6.80 (s, 1H), 7.57 (s, 1H), 7.94 (s, 1H), 8.13 (s, 1H), 11.89 (br s, 1H); LR-MS ESI 322.27 (100%). HRMS (ESI +ve): For C 17 H 20 N 5 Si requires 322.1488 found 322.1490. Example 104 5-(2-Aminopyridin-4-yl)-7-phenyl-1H-indazol-3-amine 5-(2-Aminopyridin-4-yl)-7-chloro-3-amino-1H-indazole (Example 1) (0.050 g, 0.19 mmol), phenylboronic acid (0.046 g, 0.38 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.006 g, 0.01 mmol) were placed in a 2-5 mL microwave vial which was sealed and purged with nitrogen. Ethanol (1.5 mL) was added and the suspension brought to 90 °C with stirring before addition of K3PO4 (O2-free, 1 M, 0.60 mL). Stirring continued for 24 hours. Resultant solution was diluted in EtOAc, washed with water and adsorbed onto silica under reduced pressure. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as a pale yellow solid (0.024 g, 42 %). 1 H (DMSO-d 6 , 500 MHz) δ 5.53 (s, 2H), 5.87 (s, 2H), 6.79 (s, 1H), 6.87 (d, J = 1.1 Hz, 1H), 7.46 (m, 1H), 7.53 (m, 3H),7.74 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 4.7 Hz, 1H) 8.08 (s, 1H),11.65 (br s, 1H); LR-MS ESI 302.24 (100%). HRMS (ESI +ve): For C 18 H 15 N 5 requires 302.1406 found 302.1402. Example 105 5-(2-Aminopyridin-4-yl)-7-(3-fluorophenyl)-1H-indazol-3-amin e This compound was prepared using an analogous procedure for Example 104 using 3- fluorophenylboronic acid (0.062 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off- white solid (0.017 g, 27 %). 1 H (DMSO-d6, 500 MHz) δ 5.58 (s, 2H), 5.87 (s, 2H), 6.79 (s, 1H), 6.89 (d, J = 6.5 Hz, 1H), 7.26 (s, 1H), 7.59 (m, 2H), 7.95 (d, J = 5.0 Hz, 1H), 8.12 (s, 1H), 11.74 (br s, 1H); LR-MS ESI 320.20 (100%). LRMS: For C18H14FN5 requires 319.12 found 320.13. Example 106 5-(2-Aminopyridin-4-yl)-7-(3-(trifluoromethyl)phenyl)-1H-ind azol-3-amine This compound was prepared using an analogous procedure for Example 104 using 3- trifluoromethyl phenylboronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as an off-white solid (0.023 g, 33 %) ; 1 H (DMSO-d 6 , 500 MHz) δ 5.60 (s, 2H), 5.94 (s, 2H), 6.80 (s, 1H), 6.90 (dd, J = 1.3 & 5.4 Hz, 1H), 7.60 (d, J = 1.4 Hz, 1H), 7.76 (m, 2H), 7.96 (d, J = 5.4 Hz, 1H) 8.08 (m, 2H), 8.14 (d, J = 1.6 Hz, 1H) 11.80 (br s, 1H); LR-MS ESI 370.18 (100%). LRMS (ESI +ve): For C 19 H 15 F 3 N 5 O requires 369.12 found 370.13. Example 107 7-(3-Aminophenyl)-5-(2-aminopyridin-4-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104using 3- aminophenylboronic acid (0.082 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off- white solid (0.021 g, 35 %). ; 1 H (DMSO-d6, 500 MHz) 5.11 (s, 2H), 5.49 (s, 2H), 5.88 (s, 2H), 6.61 (d, J = 5.2 Hz, 1H), 6.77 (s, 1H), 6.86 (m, 2H), 6.92 (s, 1H), 7.15 (t, J = 5.3 Hz, 1H), 7.49 (s, 1H), 7.94 (d, J = 5.4 Hz, 1H), 8.03 (s, 1H), 11.49 (br s, 1H); LR-MS ESI 317.23 (100%). LRMS : For C 18 H 17 N 6 requires 316.14 found 317.14 Example 108 3-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenol This compound was prepared using an analogous procedure for Example 104Example 104 using 3-hydroxyphenylboronic acid (0.032 g, 0.23 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.010 g, 17 %). ; 1 H (DMSO-d6, 500 MHz) δ 5.51 (s, 2H), 5.88 (s, 2H), 6.80 (m, 3H), 7.09 (s, 1H), 7.15 (d, J = 5.3 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H) 7.49 (s, 1H), 7.96 (d, J = 5.4 Hz, 1H), 8.06 (m, 1H), 11.59 (br s, 1H); LR-MS ESI 318.15 (100%). HRMS (ESI +ve): For C18H16N5O requires 317.13 found 318.13. Example 109 5-(2-Aminopyridin-4-yl)-7-(3-methoxyphenyl)-1H-indazol-3-ami ne This compound was prepared using an analogous procedure for Example 104 using 3- methoxyphenylboronic acid (0.057 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EEtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as an off-white solid (0.032 g, 51 %) ; 1 H (DMSO-d6, 500 MHz) δ 3.85 (s, 3H), 5.53 (s, 2H), 5.91 (s, 2H), 6.79 (s, 1H), 6.88 (dd, J = 1.6 & 5.4 Hz, 1H), 6.88 (dd, J = 2.2 & 7.8 Hz, 1H) 7.24 (s, 1H), 7.28 (d, J = 7.5 Hz, 1H), 7.42 (t, J =7.9 Hz, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 5.7 Hz, 1H) 8.08 (d, J = 1.6 Hz, 1H), 11.66 (br s, 1H); LR-MS ESI 332.21 (100%). HRMS (ESI +ve): For C19H18N5O requires 332.14 found 332.15. Example 110 3-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)me thanol This compound was prepared using an analogous procedure for Example 104 using 3- hydroxymethylphenylboronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.016 g, 25 %) ; 1 H (DMSO-d 6 , 500 MHz) δ 4.61 (d, J = 6.0 Hz, 2H), 5.17 (t, J = 1.6 Hz, 1H), 5.54 (s, 2H), 5.88 (s, 2H), 6.78 (s, 1H), 6.86 (dd, J = 1.6 & 5.4 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.56 (d, J = 1.6 Hz, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.65 (s, 1H), 7.94 (d, J = 5.4 Hz, 1H), 8.07 (d, J = 1.3 Hz, 1H), 11.61 (br s, 1H); LR-MS ESI 332.22 (100%). LRMS: For C 19 H 18 N 5 O requires 331.14 found 332.14. Example 111 3-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzaldeh yde This compound was prepared using an analogous procedure for Example 104 using 3- formylphenylboronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off- white solid (0.021 g, 32 %). 1 H (DMSO-d6, 500 MHz) δ 5.51 (s, 2H), 5.88 (s, 2H), 6.79 (s, 1H), 6.85 (m, 2H), 7.09 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.30 (t, J = 7.9 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.94 (d, J = 5.4 Hz, 1H), 8.06 (d, J = 1.3 Hz, 1H), 9.52 (s, 1H), 11.58 (br s, 1H); LRMS : For C19H15N5O requires 329.14 found 330.13. Example 112 Ethyl 3-(3-amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzoate This compound was prepared using an analogous procedure for Example 104 using (3- (ethoxycarbonyl)phenyl)boronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.024 g, 34 %). ; 1 H (DMSO-d 6 , 500 MHz) δ 1.34 (t, J = 7.2 Hz, 3H), 4.36 (q, J = 6.9 Hz, 2H), 5.62 (s, 2H), 5.89 (s, 2H), 6.79 (s, 1H), 6.88 (d, J = 4.4 Hz, 1H), 7.56 (s, 1H) , 7.68 (t, J = 7.9 Hz, 1H), 7.99 (m, 3H), 8.13 (s, 1H), 8.23 (s, 1H), 11.74 (br s, 1H); LR-MS ESI 374.20 (100%). HRMS (ESI +ve): For C 21 H 20 N 5 O 2 requires 373.15 found 374.16. Example 113 3-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzamide This compound was prepared using an analogous procedure for Example 104 using (3- carbamoylphenyl)boronic acid (0.075 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.011 g, 16 %). 1 H (DMSO-d6, 500 MHz) δ 5.57 (s, 2H), 5.89 (s, 2H), 6.79 (s, 1H), 6.88 (d, J = 1.9 & 6.9 Hz, 1H), 7.42 (s, 2H), 7.61 (m, 2H), 7.87 (t, J = 7.5 Hz, 2H), 7.96 (d, J = 5.3 Hz, 1H), 7.98 (m, 2H), 8.11 (m, 3H), 11.73 (br s, 1H); LRMS : For C19H16N6O requires 344.14 found 345.14. Example 114 3-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzenesu lfonamide This compound was prepared using an analogous procedure for Example 104 using (3- sulfamoylphenyl)boronic acid (0.076 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.023 g, 24 %). 1 H (DMSO-d6, 500 MHz) δ 5.66 (s, 2H), 5.94 (s, 2H), 6.78 (s, 1H), 6.88 (d, J = 1.9 & 6.9 Hz, 1H), 7.38 (s, 2H), 7.61 (d, J = 1.9 Hz, 1H), 7.73 (t, J = 9.8 Hz, 1H), 7.87 (d, J = 10.3 Hz, 1H), 7.98 (m, 2H), 8.16 (m, 2H), 11.70 (br s, 1H); LR-MS ESI 381.16 (100%). HRMS (ESI +ve): For C18H17N6O2S requires 381.1134 found 381.1145. Example 115 5-(2-Aminopyridin-4-yl)-7-(4-(methylsulfonyl)phenyl)-1H-inda zol-3-amine This compound was prepared using an analogous procedure for Example 104 using (3- (methylsulfonyl)phenyl)boronic acid (0.074 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.036 g, 32 %). 1 H (DMSO-d6, 500 MHz) δ 3.33 (s, 3H), 5.62 (s, 2H), 5.89 (s, 2H), 6.78 (s, 1H), 6.89 (dd, J = 1.6 & 5.4 Hz, 1H), 7.63 (d, J = 1.3 Hz, 1H) , 7.79 (t, J = 7.9 Hz, 1H), 7.96 (d, J = 5.7 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 8.18 (s, 1H), 8.19 (s, 1H), 11.82 (br s, 1H); LR-MS ESI 380.13 (100%). HRMS (ESI +ve): For C19H18N6OS requires 380.1181 found 380.1201. Example 116 5-(2-Aminopyridin-4-yl)-7-(3-(morpholinomethyl)phenyl)-1H-in dazol-3-amine This compound was prepared using an analogous procedure for Example 104 using (3- (morpholinomethyl)phenyl)boronic acid(0.051 g, 0.23 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.017 g, 34 %). 1 H (DMSO-d 6 , 500 MHz) δ 2.40 (m, 4H), 3.57 (m, 6H), 5.54 (s, 2H), 5.88 (s, 1H) 6.78 (s, 1H), 6.87 (d, J = 5.5 Hz, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.55 (s, J = 1.6 Hz, 1H), 7.62 (m, 2H) , 7.95 (d, J = 5.4 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 11.63 (br s, 1H); LR-MS ESI 401.22 (100%). HRMS (ESI +ve): For C 23 H 25 N 6 O requires 401.2090 found 401.2096. Example 117 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenol This compound was prepared using an analogous procedure for Example 104 using 4- hydroxyphenylboronic acid (0.032 g, 0.23 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.021 g, 39 %). 1 H (DMSO-d 6 , 500 MHz) δ 5.48 (s, 2H), 5.86 (s, 2H), 6.77 (s, 1H) 6.85 (d, J = 5.4 Hz, 1H), 6.90 (d, J = 8.5 Hz, 1H), 7.46 (s, 1H), 7.55 (d, J = 8.5 Hz, 1H) , 7.94 (d, J = 5.4 Hz, 1H), 7.99 (m, 1H), 11.53 (br s, 1H); LR-MS ESI 318.15 (100%). HRMS (ESI +ve): For C 18 H 16 N 5 O requires 317.1355 found 317.1358. Example 118 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)me thanol This compound was prepared using an analogous procedure for Example 104 using 3- hydroxymethylphenylboronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.012 g, 22 %). 1 H (DMSO-d6, 500 MHz) δ 4.59 (d, J = 6.3 Hz, 2H), 5.29 (br s, 1H), 5.56 (s, 2H), 5.91 (s, 2H), 6.79 (s, 1H), 6.88 (d, J = 6.0 Hz, 1H), 7.48 (d, J = 9.4 Hz, 2H), 7.56 (s, 1H), 7.71 (d, J = 9.4 Hz, 1H), 7.97 (d, J = 6.6 Hz, 1H), 8.08 (s, 1H), 11.67 (br s, 1H); LR-MS ESI 332.22 (100%). HRMS (ESI +ve): For C19H18N5O requires 332.1511 found 332.1523. Example 119 5-(2-Aminopyridin-4-yl)-7-(4-(dimethylamino)phenyl)-1H-indaz ol-3-amine This compound was prepared using an analogous procedure for Example 104 using (4- (dimethylamino)phenyl)boronic acid (0.064 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.016 g, 25 %). 1 H (DMSO-d 6 , 500 MHz) δ 2.98 (s, 6H), 5.51 (s, 2H), 5.97 (s, 2H), 6.80 (s, 1H), 6.89 (m, 3H), 7.58 (s, 1H), 7.60 (d, J = 11.0 Hz, 2H), 7.96 (d, J = 7.0 Hz, 1H), 8.99 (d, J = 1.9 Hz, 1H), 11.56 (br s, 1H); LR-MS ESI 345.26 (100%). HRMS (ESI +ve): For C 20 H 21 N 6 requires 345.1828 found 345.1840. Example 120 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzamide This compound was prepared using an analogous procedure for Example 104 using (4- carbamoylphenyl)boronic acid (0.062 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.013 g, 21 %). 1 H (DMSO-d6, 500 MHz) δ 5.58 (s, 2H), 5.95 (s, 2H), 6.81 (s, 1H), 6.90 (d, J = 4.1 Hz, 1H), 7.40 (s, 1H), 7.62 (s, 1H) , 7.82 (d, J = 8.2 Hz, 1H), 7.96 (d, J = 5.3 Hz, 1H), 8.03 (m, 3H), 8.12 (s, 1H), 11.72 (br s, 1H); LR-MS ESI 345.17 (100%). HRMS (ESI +ve): For C19H17N6O requires 345.1464 found 345.1466. Example 121 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)benzenesu lfonamide This compound was prepared using an analogous procedure for Example 104 using (4- sulfamoylphenyl)boronic acid(0.076 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.011 g, 13 %). 1 H (DMSO-d6, 500 MHz) δ 5.60 (s, 2H), 5.89 (s, 2H), 6.79 (s, 1H), 6.89 (d, J = 4.1 Hz, 1H), 7.45 (s, 2H), 7.63 (s, 1H), 7.95 (m, 5H), 8.14 (s, 1H), 11.77 (br s, 1H); LR-MS ESI 381.30 (100%). HRMS (ESI +ve): For C18H17N6O2S requires 381.1134 found 381.1145. Example 122 5-(2-Aminopyridin-4-yl)-7-(4-(morpholinomethyl)phenyl)-1H-in dazol-3-amine This compound was prepared using an analogous procedure for Example 104 using (4- (morpholinomethyl)phenyl)boronic acid (0.051 g, 0.23 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.020 g, 21 %). 1 H (DMSO-d6, 500 MHz) δ 2.41 (m, 4H), 3.54 (s, 2H), 3.60 (m, 4H), 5.53 (s, 2H), 5.93 (s, 2H), 6.80 (s, 1H) 6.88 (d, J = 5.7 Hz, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.70 (d, J = 7.9 Hz, 2H) , 7.94 (d, J = 5.7 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 11.63 (br s, 1H); LR-MS ESI 401.22 (100%). HRMS (ESI +ve): For C23H25N6O requires 401.2090 found 401.2096. Example 123 tert-Butyl (4-iodopyridin-2-yl)carbamate To a solution of 4-iodopyridin-2-amine (2.7 g 12.27 mmol) in dioxane (10 mL) was added DMAP (1.79 g, 14.72 mmol) under a blanket of argon followed by Boc2O (2.812 g, 12.88 mmol). The resulting reaction mixture was stirred at 80 °C for 12 hours. The reaction was then cooled and quenched by pouring into water 20 mL, extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as an off white solid ( 2.94 g, 75%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.94 (s, 1H), 8.24 (d, J = 1.4 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.42 (dd, J = 5.2, 1.5 Hz, 1H), 1.48 (s, 9H). LRMS (ESI +ve): C 10 H 13 IN 2 O 2 Molecular Weight: 320.1305 found 321.0 tert-Butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (1.3 g, 3.64 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added cesium carbonate (3.556 g, 10.9 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (1.28 g, 3.818 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.143 g, 0.204 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a light brown solid (1.05 g, 64%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.99 (s, 1H), 9.79 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.19 (d, J = 1.4 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.33 (dd, J = 5.3, 1.7 Hz, 1H), 5.72 (s, 2H), 1.51 (s, 9H). LRMS (ESI +ve): For C 17 H 18 BrN 5 O 2 Molecular Weight: 404.2680 found 404.0, 405.0. 5-(2-Aminopyridin-4-yl)-7-(4-(tert-butyl)phenyl)-1H-indazol- 3-amine To a solution of tert-butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.095 g, 0.235 mmol) and 4-tert-butylphenylboronic acid (0.050 g, 0.282 mmol) in a degassed solution of dioxane:H2O (18:2 5 mL) was added sodium carbonate ( 0.075 g, 0.705 mmol), and dichloro[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium (II) catalyst (0.0082 g, 0.012 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then treated with TBAF to deprotect, diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by HPLC to give the desired compound as a yellow powder (0.012 g, 11 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.38 (d, J = 1.7 Hz, 1H), 8.11 – 8.06 (m, 1H), 8.01 (d, J = 6.2 Hz, 2H), 7.78 – 7.75 (m, 2H), 7.73 (d, J = 1.7 Hz, 1H), 7.66 – 7.60 (m, 2H), 7.39 – 7.36 (m, 2H), 1.42 (s, 9H). LRMS (ESI +ve): For C 22 H 23 N 5 Molecular weight 357.4610 found 358.2. Example 124 5-(2-Aminopyridin-4-yl)-7-(2-chlorophenyl)-1H-indazol-3-amin e This compound was prepared using an analogous procedure for Example 104 using 2- chlorophenylboronic acid (0.060 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off- white solid (0.028 g, 25 %). 1 H (DMSO-d6, 500 MHz) δ 5.50 (s, 2H), 5.87 (s, 2H), 6.75 (s, 1H), 6.83 (d, J = 4.0 Hz, 1H), 7.45 (m, 2H), 7.51 (m, 1H), 7.60 (m, 1H), 7.95 (d, J = 5.3 Hz, 1H), 8.13 (s, 1H), 11.43 (br s, 1H); LR-MS ESI 336.22 (100%), 338.22 (35%). HRMS (ESI +ve): For C18H15ClN5 requires 336.1016 found 336.1032. Example 125 2-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)phenyl)me thanol This compound was prepared using an analogous procedure for Example 104 using 2- hydroxymethylphenylboronic acid (0.072 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.017 g, 14 %). 1 H (DMSO-d6, 500 MHz) δ 4.34 (d, J = 5.1 Hz, 2H), 5.08 (t, J = 5.0 Hz, 1H), 5.49 (s, 2H), 5.85 (s, 2H), 6.75 (s, 1H), 6.83 (dd, J = 1.6 & 5.4 Hz, 1H), 7.36 (m, 3H), 7.45 (t, J = 7.6 Hz, 1H), 7.65 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 5.4 Hz, 1H), 8.07 (d, J = 1.3 Hz, 1H), 11.61 (br s, 1H); LR-MS ESI 332.22 (100%). HRMS (ESI +ve): For C19H18N5O requires 332.1511 found 332.1523. Example 126 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)-3-methyl benzenesulfonamide This compound was prepared using an analogous procedure for Example 104 using (2-methyl- 4-sulfamoylphenyl)boronic acid(0.074 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.024 g, 16 %). 1 H (DMSO-d 6 , 500 MHz) δ 5.52 (s, 2H), 2.22 (s, 3H), 5.85 (s, 2H), 6.76 (s, 1H), 6.84 (s, 1H), 7.33 (s, 1H), 7.40 (s, 2H), 7.51 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 7.9 Hz, 1H), 7.81 (s, 1H), 7.94 (m, 2H), 8.13 (s, 1H), 11.44 (br s, 1H); LR-MS ESI 395.26 (100%). HRMS (ESI +ve): For C 19 H 19 N 6 O 2 S requires 395.1290 found 395.1290. Example 127 5-(2-Aminopyridin-4-yl)-7-(pyridin-4-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using pyridin-3- ylboronic acid (0.046 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.031 g, 27 %). 1 H (DMSO-d6, 500 MHz) δ 5.59 (s, 2H), 5.89 (s, 2H), 6.81 (s, 1H), 6.90 (d, J = 4.4 Hz, 1H), 7.54 (m, 1H), 7.61 (s, 1H), 7.96 (d, J = 4.7 Hz, 1H), 8.14 (s, 1H), 8.62 (d, J = 3.8 Hz, 1H), 11.81 (br s, 1H); LR-MS ESI 303.10 (100%). HRMS (ESI +ve): For C17H15N6 requires 303.1358 found 303.1346. Example 128 5-(2-Aminopyridin-4-yl)-7-(pyridin-4-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using pyridin-4- ylboronic acid (0.075 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.010 g, 11 %). 1 H (DMSO-d 6 , 500 MHz) δ 5.63 (s, 2H), 5.91 (s, 2H), 6.80 (s, 1H), 6.88 (d, 4.5 Hz, 1H), 7.69 (s, 1H), 7.76 (s, 1H), 7.96 (d, J = 4.8 Hz, 1H), 8.19 (s, 1H), 8.68 (d, J = 3.9 Hz, 1H), 11.82 (br s, 1H); LR-MS ESI 303.10 (100%). HRMS (ESI +ve): For C 17 H 15 N 6 requires 303.1358 found 303.1346. Example 129 5-(2-Aminopyridin-4-yl)-7-(furan-3-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using furan-3- ylboronic acid (0.056 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.022 g, 25 %). 1 H (DMSO-d6, 500 MHz) 5.58 (s, 2H), 5.87 (s, 2H), 6.78 (s, 1H), 6.87 (dd, J = 1.6 & 5.4Hz, 1H), 7.19 (s, 1H), 7.73 (s, 1H), 7.82 (s, 1H), 7.96 (d, J = 5.0 Hz, 1H), 8.01 (s, 1H), 8.40 (s, 1H), 11.48 (br s, 1H); LR-MS ESI 292.20 (100%). HRMS (ESI +ve): For C16H14N5O requires 292.1198 found 292.1203. Example 130 5-(2-Aminopyridin-4-yl)-7-(thiophen-3-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using thiophen- 3-ylboronic acid (0.058 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off- white solid (0.042 g, 48 %). 1 H (DMSO-d6, 500 MHz) 5.57 (s, 2H), 5.89 (s, 2H), 6.79 (s, 1H), 6.89 (d, J = 5.4Hz, 1H), 7.70 (m, 3H), 7.95 (d, J = 5.0 Hz, 1H), 7.99 (s, 1H), 8.05 (s, 1H), 11.6 (br s, 1H); LR-MS ESI 308.22 (100%). HRMS (ESI +ve): For C16H14N5S requires 308.0970 found 308.0972. Example 131 5-(2-Aminopyridin-4-yl)-7-(thiophen-2-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using thiophen- 2-ylboronic acid (0.058 g, 0.38 mmol). HLPC purification (see general experimental section) yielded product as off-white solid (0.031 g, 27 %). 1 H (DMSO-d6, 500 MHz) 7.25 (m, 3H), 7.70 (m, 3H), 7.89 (s, 2H), 8.02 (d, J = 5.0 Hz, 1H), 8.30 (s, 1H), 11.95 (br s, 1H), 13.23 (br s, 1H); LR-MS ESI 308.27 (100%). HRMS (ESI +ve): For C16H14N5S requires 308.0970 found 308.0972. Example 132 5-(2-Aminopyridin-4-yl)-7-(thiazol-5-yl)-1H-indazol-3-amine This compound was prepared using an analogous procedure for Example 104 using thiazol-5- ylboronic acid (0.049 g, 0.38 mmol). Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.034 g, 27 %). 1 H (DMSO-d6, 500 MHz) 5.72 (s, 2H), 5.96 (s, 2H), 6.76 (s, 1H), 6.85 (d, J = 3.8 Hz, 1H), 7.67 (s, 1H), 7.98 (d, J = 5.5 Hz, 1H), 8.15 (s, 1H), 8.47 (s, 1H), 9.20 (s, 1H), 11.81 (br s, 1H); LR-MS ESI 309.21 (100%). HRMS (ESI +ve): For C 15 H 13 N 6 S requires 309.0922 found 309.0972. Example 133 5-(2-Aminopyridin-4-yl)-7-(1H-pyrazol-5-yl)-1H-indazol-3-ami ne A 2-5 mL MW tube was charged with a mixture of 5-(2-aminopyridin-4-yl)-7-chloro-1H-indazol- 3-amine (Example 1) (52 mg, 0.2 mmol, 1 eq.), potassium trifluoro(1H-pyrazol-5-yl)borate (52 mg, 0.2 mmol, 1.5 mmol, 1.5 eq.), XphosG2 (7.9 mg, 0.01 mmol, 5mol%) in 1,4-dioxane (oxygen-free, 1.8 mL) was heated to 60 °C under a gentle flow of nitrogen for 5 minutes, then 1 M aq. K 2 CO 3 (oxygen-free, 0.6 mL, 1 mmol, 3 eq.) was added and the reaction mixture was heated to 110 °C for 15 hours. The reaction mixture was then cooled to room temperature, diluted with water (50 mL) and 1 M aq. K 2 CO 3 (1 mL), and extracted with EtOAc (80 mL). The organic layer was separated and washed with water (50 mL), dried (MgSO 4 ) and purified by flash chromatography to give the title compound as a yellow solid (27 mg). 1 H NMR (400 MHz, DMSO-D 6 ) δ 5.57 (s, 2H), 5.92 (s, 2H), 6.79 (s, 1H), 6.88 (d, J = 5.3 Hz, 1H), 7.01 (d, J = 2.2 Hz, 1H), 7.88 (s, 1H), 7.91 – 8.00 (m, 2H), 8.04 (s, 1H), 11.11 (s, 1H), 13.09 (s, 1H). Example 134 5-(2-Aminopyridin-4-yl)-7-(3-methylbut-1-yn-1-yl)-1H-indazol -3-amine In a sealed tube, a solution of 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-amine (0.03 g, 0.09 mmol), copper (I) iodide (0.0008 g, 0.0045 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.003 g, 0.0045 mmol) in 0.27 ml of tetrahydrofuran:triethylamine (1:4) was degassed followed by addition of 3-methylbut-1- yne (0.013 ml, 0.13 mmol) . The reaction mixture was stirred at room temperature for 16 h. After the reaction was completed, the reaction mixture was diluted with EtOAc and extracted with water. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was then purified by HPLC to give the titled compound as yellow solid (15 mg, 57 %). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.30 (d, J=6.78 Hz, 6 H) 2.90 (spt, J=6.86 Hz, 1 H) 7.20-7.25 (m, 2 H) 7.63 (d, J=1.51 Hz, 1 H) 7.89 (br. s., 2 H) 8.00 (d, J=7.53 Hz, 1 H) 8.29 (d, J=1.51 Hz, 1 H) 12.08 (br. s., 1 H). m/z (ESI-HRMS) calculated for C17H28N5 = 292.1484 found=292.1551. Example 135 4-Iodopyridin-2-amine In a sealed 25 mL microwave vial, equipped with a magnetic stir bar, 2-fluoro-4-iodopyridine (1.5 g, 6.72 mmol, 1 Eq) was dissolved in 2 mL of Dioxane. 10 mL of ammonium hydroxide solution (28% in H2O) was added, and the resulting reaction mixture was heated at 110 ºC under microwave irradiation for 4 hours. After cooling the reaction was filtered under vacuum and washed three times with water and petroleum ether to obtain white crystals of the titled compound (1.25 g, 5.712 mmol, 85%). 1 H NMR (500 MHz, DMSO-d6) δ 7.61 (d, J=5.34 Hz, 1 H), 6.86 (br. s., 1 H) 6.81 (dd, J = 5.3, 1.4 Hz, 1 H), 6.07 (s, 2 H) ppm. 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-amine To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (200 mg, 0.59 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodopyridin-2-amine (118.34 mg, 0.537 mmol, 1 Eq), cesium carbonate (524.89 g, 1.611 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (37.69 mg, 0.0537 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0– 100%) to afford the titled compound (138.82 mg, 0.456 mmol, 85%). 1 H NMR (500 MHz, DMSO-d6) δ 11.92 (br. s., 1 H), 8.11 (s, 1 H), 7.95 (d, J = 5.3 Hz, 1 H), 7.71 (s, 1 H), 6.86 – 6.76 (m, 1 H), 6.71 (s, 1 H), 5.92 (s, 2 H), 5.64 (br. s., 2 H) ppm. LRMS (ESI +ve): For C12H10BrN5 Molecular Weight: 304.15 found 304.1, 306.1, 307.0 (M+H). 5-(2-Aminopyridin-4-yl)-7-(pent-1-yn-1-yl)-1H-indazol-3-amin e To a solution of 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-amine (130 mg, 0.427 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (16.26 mg, 0.0854 mmol, 0.2 Eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) catalyst (31.24 mg, 0.0427 mmol, 0.1 Eq) and 1-pentyne (43.63 mg, 0.063 mL, 0.64 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0– 100% and 10% MeOH) followed by HPLC purification to give the titled product (111.96 mg, 0.384 mmol, 90%). 1 H NMR (500 MHz, CD3OD) δ 8.05 (d, J = 2.0 Hz, 1H), 7.90 (d, J = 6.1 Hz, 1H), 7.66 (d, J = 1.8 Hz, 1H), 7.04 (dd, J = 6.0, 1.9 Hz, 1H), 6.98 (br s, 1H), 2.53 (t, J = 7.1 Hz, 2H), 1.71 (sextet, J = 7.2 Hz, 2H), 1.29 (br. s, 2H), 1.11 (t, J = 7.4 Hz, 3H) ppm. LRMS: For C17H17N5 requires 291.3 found 292.1 (M+H). Example 136 tert-Butyl (4-iodopyridin-2-yl)carbamate To a solution of 4-iodopyridin-2-amine (1 g, 4.54 mmol, 1 Eq) in dioxane (10 mL) was added DMAP (666.13 mg, 5.45 mmol, 1.2 Eq) under a blanket of argon followed by the addition of Boc2O (1.04 g, 4.77 mmol, 1.05 Eq). The resulting reaction mixture was stirred at 80 °C overnight. The reaction was then cooled and quenched by pouring into water (10 mL), extracted with EtOAc (3 x 15 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0–50%) to afford the target compound as a white solid (1.162 g, 3.632 mmol, 80%). 1 H NMR (500 MHz, DMSO-d6) δ 9.94 (s, 1H), 8.24 (d, J = 1.4 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.42 (dd, J = 5.2, 1.5 Hz, 1H), 1.48 (s, 9H). LRMS (ESI +ve): C10H13IN2O2 Molecular Weight: 320.1305 found 321.0 (M+H). tert-butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (1.353 g, 4.00 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (10 mL), were added tert-butyl (4-iodopyridin-2-yl)carbamate (1.3 g, 3.64 mmol, 1 Eq), cesium carbonate (3.557 g, 10.92 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (255.49 mg, 0.364 mmol, 0.1 Eq) under argon atmosphere. The reaction was then sealed and stirred at 70 ºC overnight. After cooling, the reaction was with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting with a gradient of EtOAc : Petroleum Ether (50–100%) to afford the desired compound as an off white solid (941.78 mg, 2.329 mmol, 64%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.99 (s, 1H), 9.79 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.19 (d, J = 1.4 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.33 (dd, J = 5.3, 1.7 Hz, 1H), 5.72 (s, 2H), 1.51 (s, 9H). LRMS (ESI +ve): For C 17 H 18 BrN 5 O 2 Molecular Weight: 404.2680 found 404.0, 405.0 (M+H). tert-Butyl (4-(3-amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin-2 -yl)carbamate To a solution of tert-butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (230 mg, 0.568 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (21.63 mg, 0.113 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (41.56 mg, 0.056 mmol, 0.1 Eq) and ethynylcyclopropane (56.38 mg, 0.072 mL, 0.853 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0–100%) to afford the titled product (88.48 mg, 0.227 mmol, 40%). 1 H NMR (500 MHz, DMSO-d6) δ 11.86 (br. s., 1 H), 9.76 (s, 1 H), 8.26 (d, J = 5.2 Hz, 1 H), 8.12 (s, 1 H), 8.08 (s, 1 H), 7.51 – 7.57 (m, 2 H), 7.30 (d, J = 5.2 Hz, 1 H), 5.62 (br. s., 2 H), 1.65 – 1.59 (m, 1 H), 1.50 (s, 9 H), 0.94 – 0.90 (m, 4 H) ppm. 5-(2-Aminopyridin-4-yl)-7-(cyclopropylethynyl)-1H-indazol-3- amine SU1674 Trifluoroacetic acid (233.74 mg, 0.157 mL, 2.05 mmol, 20 Eq) was added to a solution of tert- butyl (4-(3-amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin-2 -yl)carbamate (80 mg, 0.205 mmol, 1 Eq) in DCM (2 mL) at 0 ºC. The reaction mixture was then allowed to stir at room temperature for 3 h. The reaction was quenched with saturated solution of NaHCO 3 (5 mL). The organic layer was washed with brine (2 x 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0–100%) to afford the titled product as a yellow solid (41.5 mg, 0.143 mmol, 70%). 1 H NMR (500 MHz, DMSO) δ 11.79 (s, 1H), 8.03 (d, J = 1.7 Hz, 1H), 7.93 (d, J = 5.3 Hz, 1H), 7.48 (d, J = 1.7 Hz, 1H), 6.78 (dd, J = 5.4, 1.8 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 5.88 (s, 2H), 5.54 (s, 2H), 1.63 – 1.58 (m, 1H), 0.94 – 0.87 (m, 4H) ppm. LRMS (ESI +ve): For C17H15N5 Molecular Weight: 289.34 found 290.1 (M+H). 5-(2-Aminopyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-ind azol-3-amine A 2-5 mL MW tube was charged with a mixture of 5-(2-aminopyridin-4-yl)-7-chloro-1H-indazol- 3-amine (Example 1) (52 mg, 0.2 mmol, 1 eq.), (3,3-dimethylbut-1-yn-1-yl)trifluoroborate (75 mg, 0.4 mmol, 0.4 mmol, 2 eq.), XphosG2 (7.9 mg, 0.01 mmol, 5mol%) in 1,4-dioxane (oxygen- free, 1.8 mL) was heated to 60 °C under a gentle flow of nitrogen for 5 minutes, then 2 M aq. K2CO3 (oxygen-free, 0.6 mL, 1.2 mmol, 6 eq.) was added and the reaction mixture was heated to 110 °C for 11 hours. The reaction mixture was then cooled to room temperature, diluted 1 M aq. K2CO3 (100 mL), and extracted with EtOAc (100 mL). The organic layer was separated and washed 1 M aq. K2CO3 (100 mL), dried (MgSO4) and purified by flash chromatography (Silica, 50 g, 2-8% MeOH in AcOEt containing 1% triethylamine) to give the title compound as a yellow solid (46 mg, 75%). 1 H NMR (500 MHz, DMSO) δ 1.36 (s, 9H), 5.57 (s, 2H), 5.88 (s, 2H), 6.72 (s, 1H), 6.79 (dd, J = 5.3, 1.6 Hz, 1H), 7.46 (d, J = 1.4 Hz, 1H), 7.93 (d, J = 5.4 Hz, 1H), 8.05 – 8.07 (m, 1H), 11.76 (s, 1H). HRMS: Calculated for C 18 H 19 N 5 305.1640; Found: LRMS (ESI +ve): For C 18 H 19 N 5 Molecular weight 305.3850 found 306.3. Example 138 5-(2-Aminopyridin-4-yl)-7-(phenylethynyl)-1H-indazol-3-amine 5-(2-Aminopyridin-4-yl)-7-bromo-3-amino-1H-indazole (0.030 g, 0.1 mmol), phenylacetylene (37 µL, 0.34 mmol) and Tetrakis(triphenylphosphine)palladium(0) catalyst (0.012 g, 0.01 mmol) and CuI (0.002 g, 0.01 mmol) were placed in a 2-5 mL microwave vial which was sealed and purged with nitrogen. DMF (1.5 mL) and Net3 (1.5 mL) were added and the suspension brought to 60 °C with stirring and maintained for 16 hrs. Resultant solution was diluted in EtOAc, washed with water and adsorbed onto silica under reduced pressure. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EEtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.017 g, 27 %). 1 H (DMSO-d6, 500 MHz) 5.63 (s, 2H), 5.90 (s, 2H), 6.76 (s, 1H), 6.82 (d, J = 3.8 Hz, 1H), 7.44 (m, 4H), 7.67 (s, 1H), 7.73 (d, J = 5.5 Hz, 1H), 7.96 (s, 1H), 8.15 (s, 1H), 12.06 (br s, 1H); LR-MS ESI 326.33 (100%). HRMS (ESI +ve): For C20H16N5 requires 326.1406 found 326.1406. Example 139 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)but-3-yn- 1-ol 5-(2-Aminopyridin-4-yl)-7-bromo-3-amino-1H-indazole (0.030 g, 0.1 mmol), but-3-yn-1-ol (31 µL, 0.34 mmol) and Pd(PPh 3 ) 4 (0.012 g, 0.01 mmol) and CuI (0.002 g, 0.01 mmol) were placed in a 2-5 mL microwave vial which was sealed and purged with nitrogen. DMF (1.5 mL) and Net 3 (1.5 mL) were added and the suspension brought to 60 °C with stirring and maintained for 16 hrs. Resultant solution was diluted in EtOAc, washed with water and adsorbed onto silica under reduced pressure. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/methanol, 0-10%, 8 CV; 10%, 4 CV) yielded product as off-white solid (0.013 g, 44 %). 1 H (DMSO-d 6 , 500 MHz) 3.65 (m, 2H), 4.07 (m, 2H), 4.92 (m, 1H), 5.55 (s, 2H), 5.87 (s, 2H), 6.70 (s, 1H), 6.77 (d, J = 3.8 Hz, 1H), 7.50 (s, 1H), 7.92 (s, 1H), 8.05 (s, 1H), 11.78 (br s, 1H); LR-MS ESI 294.27 (100%). HRMS (ESI +ve): For C 16 H 16 N 5 O requires 294.1355 found 294.1355. Example 140 4-(3-Amino-5-(2-aminopyridin-4-yl)-1H-indazol-7-yl)-2-methyl but-3-yn-2-ol A 2-5 mL MW tube was charged with a mixture of 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3- amine (50 mg, 0.15 mmol, 1 eq.), 2-methylbut-3-yn-2-ol (30 uL, 0.3 mmol, 2 eq.), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and triethylamine (1 mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with ethyl acetate (3 x 10 mL) and the organic fractions combined and dried over anhydrous magnesium sulfate, filtered and the solvent removed under high vacum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (22 mg, 0.05 mmol, 37 %). 1 H NMR (500 MHz, DMSO-D 6 ) δ 1.54 (s, 6H), 5.42 (s, 1H), 5.61 (s, 2H), 5.90 (s, 2H), 6.72 (s, 1H), 6.80 (d, J = 1.5 Hz, 1H) 7.50 (s, 1H), 7.95 (d, J = 1.8 Hz, 1H), 8.10 (s, 1H), 11.76 (s, 1H). LRMS: Calculated for C 17 H 17 N 5 O 307.14; Found: 308.20. Example 141 5-(2-Aminopyridin-4-yl)-7-((3-methyloxetan-3-yl)ethynyl)-1H- indazol-3-amine In a sealed tube, a solution of 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-amine (0.05 g, 0.15 mmol), copper (I) iodide (0.0014 g, 0.0075 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.005 g, 0.0075 mmol) in 0.45 ml of tetrahydrofuran:triethylamine (1:4) was degassed followed by addition of 3-ethynyl-3- methyloxetane (0.02 ml, 0.22 mmol) . The reaction mixture was stirred at room temperature for 16 h. After the reaction was completed, the reaction mixture was diluted with EtOAc and extracted with water. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was then purified by HPLC to give the titled compound as yellow solid (32 mg, 66 %). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.70 (s, 3 H) 4.46 (d, J=5.27 Hz, 2 H) 4.89 (d, J=5.27 Hz, 2 H) 7.21-7.24 (m, 2 H) 7.68-7.72 (m, 1 H) 7.92 (br. s., 2 H) 8.01 (d, J=6.59 Hz, 1 H) 8.32 (m, 1 H). m/z (ESI-HRMS) calculated for C 18 H 18 ON 5 = 320.1433 found=320.1505. Example 142 5-(2-Aminopyridin-4-yl)-7-((tetrahydro-2H-pyran-4-yl)ethynyl )-1H-indazol-3-amine In a sealed tube, a solution of 5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-amine (0.05 g, 0.15 mmol), copper (I) iodide (0.0014 g, 0.0075 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.005 g, 0.0075 mmol) in 0.45 ml of tetrahydrofuran:triethylamine (1:4) was degassed followed by addition of 4- ethynyltetrahydro-2H-pyran (0.02 ml, 0.22 mmol) . The reaction mixture was stirred at room temperature for 16 h. After the reaction was completed, the reaction mixture was diluted with EtOAc and extracted with water. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude product was then purified by HPLC to give the titled compound as yellow solid (41.8 mg, 84 %). 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.67-1.78 (m, 2 H) 1.86-1.94 (m, 2 H) 2.98 (tt, J=8.90, 4.28 Hz, 1 H) 3.48 (ddd, J=11.53, 9.12, 2.64 Hz, 2 H) 3.86 (dt, J=11.75, 4.23 Hz, 2 H) 7.19-7.25 (m, 2 H) 7.67 (d, J=1.76 Hz, 1 H) 7.93 (br. s., 2 H) 8.00 (d, J=7.03 Hz, 1 H) 8.30 (d, J=1.30 Hz, 1 H) 12.12 (br. s., 1 H). m/z (ESI- HRMS) calculated for C19H20ON5 = 334.1590 found=334.1655. Example 143 5-(2-Aminopyrimidin-4-yl)-7-bromo-1H-indazol-3-amine To a solution of 4-iodopyrimridin-2-amine (0.3 g, 1.38 mmol) in a degassed solution of dioxane:H 2 O (18:2 5 mL) was added cesium carbonate (1.35 g, 4.14 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.558 g, 1.66 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.097 g, 0.138 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by HPLC to give the desired compound as a dark brown solid (0.07 g, 17 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.04 (s, 1H), 8.52 (s, 1H), 8.35 – 8.26 (m, 2H), 7.09 (d, J = 5.3 Hz, 1H), 6.62 (s, 2H), 5.69 (s, 2H). LRMS: Calculated for C 11 H 9 BrN 6 304.01; Found: 307.0; 305.0 (M+H) 5-(2-Aminopyrimidin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-i ndazol-3-amine To a solution of 5-(2-aminopyrimidin-4-yl)-7-bromo-1H-indazol-3-amine (0.05 g, 0.16 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.011 g, 0.016 mmol) and 3,3- dimethylbut-1-yne (0.017 g, 0.2 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a brown solid (0.013g, 26%). NMR 1 H NMR (500 MHz, DMSO-d6) δ 11.87 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 7.07 (d, J = 5.3 Hz, 1H), 6.58 (s, 2H), 5.62 (s, 2H), 1.37 (s, 9H). LRMS: Calculated for C17H18N6306.16; Found 307.16 (M+H) Example 144 5-(2-Aminopyridin-4-yl)-7-(3,3-dimethylbutyl)-1H-indazol-3-a mine To a solution of 5-(2-aminopyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-yl)-1H-ind azol-3-amine (Example 137) (30 mg, 0.098 mmol, 1 Eq) in dry MeOH (2 mL) was added 10% Pd/C (10.42 mg, 0.098 mmol, 1 Eq). The reaction mixture was allowed to stir under H2 atmosphere at room temperature overnight. The reaction was then diluted with MeOH, filtered through celite, concentrated under reduced pressure and the crude residue was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0–80%) to afford the target compound (15 mg, 0.048 mmol, 50%). 1 H NMR (500 MHz, DMSO-d6) δ 11.56 (s, 1 H), 7.92 (d, J = 5.5 Hz, 1 H), 7.87 (d, J = 1.7 Hz, 1 H), 7.30 (d, J = 1.7 Hz, 1 H), 6.79 (dd, J = 5.5, 1.7 Hz, 1 H), 6.72 (d, J = 1.8 Hz, 1 H), 5.88 (s, 2 H), 5.42 (s, 2 H), 2.81 – 2.73 (m, 2 H), 1.62 – 1.55 (m, 2 H), 0.99 (s, 9 H) ppm. LRMS: For C 18 H 23 N 5 requires 309.41 found 310.3 (M+H). Example 145 5-(2-Aminopyridin-4-yl)-7-(2-cyclohexylethyl)-1H-indazol-3-a mine SU1672 To a solution of 5-(2-aminopyridin-4-yl)-7-(cyclohexylethynyl)-1H-indazol-3-a mine (35 mg, 0.11 mmol) in 1.0 ml of dry MeOH was added 10% Pd/C (17 mg, 0.16 mmol). The reaction was stirred at RT, o/n under a hydrogen atmosphere. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue purified by HPLC to afford the title compound as a white solid (32 mg, 0.09 mmol, 77%). 1H NMR (400 MHz, MeOD): ^ 0.64 – 0.77 (m, 2H), 1.00 – 1.57 (m, 11H), 2.48 – 2.56 (m, 2H), 6.58 (d, J = 5.2 Hz, 1H), 7.23 (dd, J = 8.6, 1.6 Hz, 1H), 7.36 (dd, J = 8.6, 0.8 Hz, 1H), 7.61 (app s, 1H), 7.78 (app s, 1H), 5 protons missing. LRMS: Calculated for C20H25N5335.2 found 336.2 (M+1). Example 146 5-(2-Aminopyridin-4-yl)-7-(2-cyclopropylethyl)-1H-indazol-3- amine To a solution of 5-(2-aminopyridin-4-yl)-7-(cyclopropylethynyl)-1H-indazol-3- amine (Example 136) (30 mg, 0.103 mmol, 1 Eq) in dry MeOH (2 mL) was added 10% Pd/C (10.96 mg, 0.103 mmol, 1 Eq). The reaction mixture was allowed to stir under H 2 atmosphere at room temperature overnight. The reaction was then diluted with MeOH, filtered through celite, concentrated under reduced pressure and the crude residue was purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0–100%) followed by HPLC purification to afford the target compound (12.99 mg, 0.044 mmol, 43%). 1 H NMR (500 MHz, CD 3 OD) δ 7.90 (d, J = 5.6 Hz, 1H), 7.87 (br. s, 1H), 7.44 (d, J = 1.7 Hz, 1H), 6.95 (dd, J = 5.6, 1.7 Hz, 1H), 6.88 (d, J = 1.7 Hz, 1H), 2.98 (t, J = 7.6 Hz, 2H), 1.65 (q, J = 7.0 Hz, 2H), 0.81 – 0.74 (m, 1H), 0.45 – 0.40 (m, 2H), 0.09 – 0.06 (m, 2H) ppm. LRMS (ESI +ve): For C 17 H 19 N 5 Molecular Weight: 293.37 found 294.1 (M+H). Example 147 5-(2-Aminopyridin-4-yl)-7-phenethyl-1H-indazol-3-amine Pd/C 5% (10 mg, 10%) was added to a solution of 5-(2-aminopyridin-4-yl)-7-(phenylethynyl)- 1H-indazol-3-amine (100 mg, 0.31 mmol) in MeOH (5 mL). The reaction mixture was allowed to stir under H 2 atmosphere at rt for 18 h. Pd/C was filtered off through celite. The organic solvent was removed under reduced pressure. The crude residue was purified using column chromatography (5% MeOH in EtOAc) followed by HPLC purification (60% MeCN in H 2 O) to give the titled product as yellow solid (70 mg, 0.21 mmol, 69%). 1 H NMR (500 MHz, DMSO-d6) δ 3.01 (dd, J = 10.4, 6.0 Hz, 2H), 3.13 (dd, J = 10.1, 6.2 Hz, 2H), 7.14 – 7.25 (m, 3H), 7.26 – 7.38 (m, 5H), 7.49 (d, J = 1.7 Hz, 1H), 8.02 (d, J = 6.8 Hz, 1H), 8.11 (s, 2H), 8.19 (d, J = 1.7 Hz, 1H). LRMS: For C 20 H 19 N 5 requires 329.41 found 330.1 (M+H). Section 8 – compounds of the formula: where R 2 , R 4 and R 5 are H, F or NH 2 . General method for preparation of 3-bromo-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)benzonitrile Preparation of stock solution: [Ir(OMe)cod]2 ([(1,5-cyclooctadiene) (methoxy) iridium (I) dimer]) (104 mg, 0.312 mmol), dtbpy (di-tert-butyl-2,2′dipyridyl) (84 mg, 0.312 mmol) and B2pin2 (bis (pinacolato) diboron) (2644 mg, 10.4 mmol) were mixed in volumetric flask and diluted up to 25 ml with MTBE (tert-butyl methylether). 2.5 ml of the stock solution (catalyst loading = 3 mol%, 1.0 mmol B2pin2) was added to 3- bromo-2-fluorobenzonitrile (2.0 g, 10 mmol) in a microwave vial under nitrogen. The reaction was then degassed, sealed and heated to 80 °C overnight. The solvent was evaporated and residue purified by flash column chromatography eluting with a gradient of diethyl ether/petroleum ether (60-80%) 0-50% to give the target compound as a white solid 2.54 g, 78%. 1 H NMR (500 MHz, DMSO-d6) δ 8.15 (dd, J = 7.2, 1.5 Hz, 1H), 8.05 (dd, J = 6.2, 1.5 Hz, 1H), 1.32 (s, 12H). 19 F NMR (471 MHz, DMSO-d6) δ -98.28. LRMS (ESI) m/z [M] + 325.03, 327.03. General method for preparation of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine To a solution of 3-bromo-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -yl)benzonitrile (2.0 g, 6.0 mmol) in ethanol (20 ml), hydrazine hydrate (22 ml, 340 mmol, 50-60 %) was added and the reaction stirred at reflux for 18 h. The solvent was evaporated and the residue was triturated with 12 ml EtOAc and petroleum ether (1:1) and then filtered under vacuum and washed with water then petroleum ether 60-80% to give the desired compound as a yellow solid (1.51 g, 73 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.93 (s, 1H), 8.19 (s, 1H), 7.60 (s, 1H), 5.68 (s, 2H), 1.31 (s, 12H). LRMS (ESI-MS) m/z [M] + 337.01 (100%), 339.01 (100%). General method for preparation of 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine To a solution of 3-chloro-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzonitrile (0.4 g, 1.4 mmol) in ethanol (20 ml), hydrazine hydrate (0.22 ml, 2.47 g, 6.8 mmol, 50-60 %) was added and the reaction stirred at reflux for 18 h. The solvent was evaporated and the residue was triturated with 12 ml EtOAc and petroleum ether (1:1) and then filtered under vacuum and washed with water then petroleum ether 60-80% to give the desired compound as a yellow solid (320 mg, 75 %). 1 H NMR (500 MHz, DMSO-d6) δ 12.01 (s, 1H), 8.18 – 8.12 (m, 1H), 7.45 (s, 1H), 5.68 (s, 2H), 1.31 (s, 12H). Example 148 5-(2-Amino-5-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-y l)-1H-indazol-3-amine A 0.5-2 mL MW tube was charged with a mixture of 5-(2-amino-5-fluoropyridin-4-yl)-7-chloro- 1H-indazol-3-amine (33 mg, 0.12 mmol, 1 eq.), (3,3-dimethylbut-1-yn-1-yl)trifluoroborate (36 mg, 0.92 mmol, 1.6 eq.), XphosG2 (4.7 mg, 0.006 mmol, 5mol%) in 1,4-dioxane (oxygen-free, 1.1 mL) was heated to 60 °C under a gentle flow of nitrogen for 5 minutes, then 2 M aq. K 2 CO 3 (oxygen-free, 0.36 mL, 0.72 mmol, 6 eq.) was added and the reaction mixture was heated to 110 °C for 12 hours. The reaction mixture was then cooled to room temperature, diluted 1 M aq. K 2 CO 3 (50 mL), and extracted with EtOAc (50 mL). The organic layer was separated and washed 1 M aq. K 2 CO 3 (50 mL), dried (MgSO 4 ) and purified by HPLC. 1 H NMR (400 MHz, DMSO) δ 1.35 (s, 9H), 6.87 (d, J = 6.2 Hz, 1H), 7.42 (t, J = 1.6 Hz, 1H), 8.05 (t, J = 1.6 Hz, 1H), 8.12 (d, J = 4.2 Hz, 1H), 12.00 (s, 1H). NH2 peaks not observed. 19 F NMR (471 MHz, DMSO) δ -74.10 (s, 3F), -148.76 (bs, 1F) HRMS: LRMS: Calculated for C18H18FN5323.15; Found: 324.2 [M+H] + Example 149 5-(2-Amino-3-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-y l)-1H-indazol-3-amine A 0.5-2 mL MW tube was charged with a mixture of 5-(2-amino-3-fluoropyridin-4-yl)-7-chloro- 1H-indazol-3-amine (33 mg, 0.12 mmol, 1 eq.), (3,3-dimethylbut-1-yn-1-yl)trifluoroborate (36 mg, 0.92 mmol, 1.6 eq.), XphosG2 (4.7 mg, 0.006 mmol, 5mol%) in 1,4-dioxane (oxygen-free, 1.1 mL) was heated to 60 °C under a gentle flow of nitrogen for 5 minutes, then 2 M aq. K2CO3 (oxygen-free, 0.36 mL, 0.72 mmol, 6 eq.) was added and the reaction mixture was heated to 110 °C for 12 hours.The reaction mixture was then cooled to room temperature, diluted 1 M aq. K2CO3 (50 mL), and extracted with EtOAc (50 mL). The organic layer was washed 1 M aq. K 2 CO 3 (50 mL), dried (MgSO 4 ) and purified by flash chromatography (Silica, 50 g, 2-5% MeOH in AcOEt) to give the title compound as a pale yellow solid (16 mg, 17%). 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.35 (s, 9H), 5.61 (s, 2H), 6.22 (s, 2H), 6.67 (t, J = 5.1 Hz, 1H), 7.39 (d, J = 1.7 Hz, 1H), 7.76 (d, J = 5.0 Hz, 1H), 7.98 (s, 1H), 11.83 (s, 1H). LRMS: Calculated for C 18 H 18 FN 5 323.15; Found: 324.3 [M+H] + Example 150 6-Fluoro-4-iodopyridin-2-amine To a solution of 2, 6-difluoro-4-iodopyridine (1.15 g, 4.77 mmol) in dioxane (5mL) was added ammonium hydroxide (10mL 28% in H2O). The reaction was the flushed with argon, sealed and stirred at 80°C for 3 hours by microwave irradiation. The reaction was cooled, partitioned between EtOAc and H2O and the aqueous layer washed a further 2 times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as a clear oil (0.90 g, 79%). 1 H NMR (400 MHz, DMSO-d6) δ 7.61 (d, J = 5.4 Hz, 1H), 6.87 (d, J = 1.5 Hz, 1H), 6.82 (dd, J = 5.3, 1.5 Hz, 1H), 6.08 (s, 2H). 5-(2-Amino-6-fluoropyridin-4-yl)-7-bromo-1H-indazol-3-amine To a solution of 6-fluoro-4-iodopyridin-2-amine (0.3 g, 1.26 mmol) in a degassed solution of dioxane:H2O (18:2 5 mL) was added cesium carbonate (1.23 g, 3.78 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.511 g, 1.51 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.44 g, 0.63 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a light brown solid (0.31 g, 76 %). 1 H NMR (400 MHz, DMSO-d6) δ 11.98 (s, 1H), 8.16 (d, J = 1.5 Hz, 1H), 7.75 (d, J = 1.5 Hz, 1H), 6.60 (t, J = 1.6 Hz, 1H), 6.44 (d, J = 1.1 Hz, 1H), 6.37 (s, 2H), 5.66 (s, 2H). LRMS (ESI +ve): For C 12 H 9 FBrN 5 Molecular weight 322.1414 found 323.0, 324.0. 5-(2-Amino-6-fluoropyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1-y l)-1H-indazol-3-amine To a solution of 5-(2-amino-6-fluoropyridin-4-yl)-7-bromo-1H-indazol-3-amine (0.31 g, 0.96 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added Copper iodide (0.18 g, 0.096 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) as catalyst (0.067 g, 0.096 mmol) and 3,3-dimethylbut-1-yne (0.946 g, 0.142 mL, 1.15 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc followed by preparative HPLC to afford the target compound as a cream coloured powder (0.065 g. 21 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.82 (s, 1H), 8.11 (d, J = 1.6 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 6.62 (d, J = 1.5 Hz, 1H), 6.43 (d, J = 1.1 Hz, 1H), 6.33 (s, 2H), 5.59 (s, 2H), 1.37 (s, 9H). 19 F NMR (471 MHz, DMSO-d6) δ -71.84. LRMS (ESI +ve): For C18H18FN5 Molecular weight 323.3754 found 324.2. Example 151 4-Iodopyridine-2,6-diamine To a solution of 2, 6-difluoro-4-iodopyridine (0.5 g, 4.77 mmol) in dioxane (5mL) was added Ammonium Hydroxide (10mL 28% in H 2 O) the reaction was the flushed with argon, sealed and stirred at 130°C for 3 hours by microwave irradiation. The reaction was cooled, partitioned between EtOAc and H 2 O and the aqueous layer washed a further 2 times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as a clear oil (0.4 g, 83%). 1 H NMR (500 MHz, DMSO-d6) δ 6.01 (s, 2H), 5.56 (s, 4H). LRMS (ESI +ve): For C5H6IN3 Molecular Weight: 234.9606 found 326.0 4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridine-2,6-diamine To a solution of 4-iodopyridin-2,6-diamine (0.4 g, 1.7024 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added cesium carbonate (1.664 g, 5.1072 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.69 g, 2.043 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.060 g, 0.0851 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography NH silica cartridges from Biotage eluting from 50 -100% petroleum ether - EtOAc + 10% MeOH to afford the desired compound as a grey solid (0.487 g, 90 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.78 (s, 1H), 7.38 (s, 1H), 5.73 (s, 2H), 5.42 (s, 2H), 5.24 (s, 4H).LRMS (ESI +ve): For C12H11BrN6 Molecular Weight: 318.00229 found 319.0, 320.0 4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyr idine-2,6-diamine To a solution of 4-(3-amino-7-bromo-1H-indazol-5-yl)pyridine-2,6-diamine (0.487 g, 1.531 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.1075 g, 0.1531 mmol) and 3,3-dimethylbut-1-yne (0.1509 g, 0.100 mL, 1.837 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether - EtOAc + 10% MeOH to afford the target compound as a greyish brown solid (0.274 g, 56 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.70 (s, 1H), 7.93 (d, J = 1.6 Hz, 1H), 7.37 (d, J = 1.6 Hz, 1H), 5.95 (s, 2H), 5.54 (s, 2H), 5.41 (s, 4H), 1.36 (s, 9H). LRMS (ESI +ve): For C18H20N6 Molecular weight 320.4000 found 321.2. Example 153 N-Cyclopropyl-4-iodopyridin-2-amine To a solution of 2-fluoro-4-iodopyridine (0.45 g, 2.02 mmol) in dioxane (5mL) was added cyclopropylamine (0.28 mL, 4.05 mmol) the reaction was the flushed with argon, sealed and stirred at 130 for 3 hours. The reaction was cooled, partitioned between EtOAc and H 2 O and the aqueous layer washed a further 2 times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as an off white solid (0.2 g, 38%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.71 (d, J = 5.3 Hz, 1H), 6.97 (d, J = 1.4 Hz, 1H), 6.94 (d, J = 2.5 Hz, 1H), 6.90 (dd, J = 5.2, 1.5 Hz, 1H), 2.47 (dq, J = 6.6, 3.4 Hz, 1H), 0.69 (td, J = 6.7, 4.5 Hz, 2H), 0.43 – 0.38 (m, 2H). LRMS (ESI +ve): For C 8 H 9 IN 2 Molecular Weight: 260.0785 found 261.1 7-Bromo-5-(2-(cyclopropylamino)pyridin-4-yl)-1H-indazol-3-am ine To a solution of N-cyclopropyl-4-iodopyridin-2-amine (0.2 g, 0.769 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added cesium carbonate (0.751 g, 2.307 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.312 g, 0.923 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.054 g, 0.0769 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a a yellow solid (0.032 g, 12 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.93 (s, 1H), 8.14 (d, J = 1.4 Hz, 1H), 8.04 (d, J = 5.3 Hz, 1H), 7.76 (d, J = 1.4 Hz, 1H), 6.86 (dd, J = 5.2, 1.6 Hz, 1H), 6.83 (d, J = 1.6 Hz, 1H), 6.77 (d, J = 2.6 Hz, 1H), 5.66 (s, 2H), 2.60 (tq, J = 6.6, 3.4 Hz, 1H), 0.75 (td, J = 6.7, 4.6 Hz, 2H), 0.50 – 0.43 (m, 2H). LRMS (ESI +ve): For C 15 H 14 BrN 5 Molecular Weight: 344.2160 found 344.0, 345.0 5-(2-(Cyclopropylamino)pyridine-4-yl)-7-(3,3-dimethylbut-1-y n-1-yl)-1H-indazol-3-amine To a solution of 7-bromo-5-(2-(cyclopropylamino)pyridin-4-yl)-1H-indazol-3-am ine (0.32 g, 0.93 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.068 g, 0.093 mmol), copper iodide (0.035 g, 0.186 mmol) and 3,3-dimethylbut-1-yne (0.0912 g, 0.135 mL, 1.110 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by HPLC to afford the target compound as a yellow (0.012 g. 4 %). 1 H NMR (500 MHz, DMF-d7) δ 13.59 (s, 1H), 12.48 (s, 1H), 9.31 (s, 1H), 8.71 (d, J = 1.7 Hz, 1H), 8.45 (d, J = 6.8 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.71 (dd, J = 6.8, 1.8 Hz, 1H), 7.65 (s, 1H), 1.79 (s, 9H), 1.38 (dt, J = 7.0, 3.4 Hz, 2H), 1.09 (dt, J = 7.2, 3.6 Hz, 2H). LRMS (ESI +ve): For C21H23N5 Molecular Weight: 345.4500 found 346.2. Example 154 N-Cyclobutyl-4-iodopyridin-2-amine In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 1 mL of Dioxane. Then cyclobutylamine (255.16 mg, 0.3 mL, 3.58 mmol, 4 Eq) was added and the resulting reaction mixture was heated at 150 ºC under microwave irradiation for 4 hours. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (20% EtOAc in petroleum ether) to give the titled product (170.7 mg, 0.62 mmol, 70%). 1 H NMR (500 MHz, DMSO-d6) δ 7.65 (d, J = 5.2 Hz, 1H), 6.90 (d, J = 7.2 Hz, 1H), 6.81 – 6.79 (m, 2H), 4.21 (sxt, J = 7.78 Hz, 1H), 2.24 (dtt, J = 13.6, 5.1, 5.1, 2.8, 2.8 Hz, 2H), 1.87 – 1.79 (m, 2H), 1.70 – 1.60 (m, 2H) ppm. 7-Bromo-5-(2-(cyclobutylamino)pyridin-4-yl)-1H-indazol-3-ami ne To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (230.5 mg, 0.68 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-cyclobutyl-4-iodopyridin-2-amine (170.7 mg, 0.62 mmol, 1 Eq), cesium carbonate (606.02 mg, 1.86 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (43.52 mg, 0.062 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (100% EtOAc), to afford the titled compound as a solid (185 mg, 0.514 mmol, 83%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.92 (br. s., 1 H), 8.10 (d, J = 1.2 Hz, 1 H), 7.99 (d, J = 5.3 Hz, 1 H), 7.73 – 7.72 (m, 1H), 6.78 (dd, J = 5.42, 1.45 Hz, 1 H), 6.74 (d, J = 7.48 Hz, 1 H), 6.64 (s, 1 H), 5.64 (br. s., 2 H), 4.33 (sxt, J = 7.84 Hz, 1 H), 2.33 – 2.28 (m, 2H), 1.93 – 1.85 (m, 2H), 1.73 – 1.63 (m, 2H) ppm. 5-(2-(Cyclobutylamino)pyridin-4-yl)-7-(3,3-dimethylbut-1-yn- 1-yl)-1H-indazol-3-amine To a solution of 7-bromo-5-(2-(cyclobutylamino)pyridin-4-yl)-1H-indazol-3-ami ne (185 mg, 0.514 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (19.57 mg, 0.102 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (37.61 mg, 0.051 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (63.33 mg, 0.949 mL, 0.771 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (20% to 90% EtOAc in petroleum ether) followed by HPLC purification to give the titled product (129.3 mg, 0.359 mmol, 70%). 1 H NMR (500 MHz, DMSO-d6) δ 11.78 (br. s, 1H), 8.07 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 5.5 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 6.86 (br. s, 1H), 6.81 (dd, J = 5.5, 1.6 Hz, 1H), 6.69 (s, 1H), 5.59 (br. s, 2H), 4.34 (h, J = 7.8 Hz, 1H), 2.32 (qd, J = 7.8, 5.3 Hz, 2H), 1.89 (pd, J = 9.2, 2.7 Hz, 2H), 1.73 – 1.63 (m, 2H), 1.36 (s, 9H) ppm. LRMS (ESI +ve): For C 22 H 25 N 5 requires 359.48 found 360.3 (M+H). Example 155 4-Iodo-N-(oxetan-3-yl)pyridin-2-amine In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 3 mL of DMSO. Then 3-aminooxetane (97.57 mg, 0.936 mL, 1.78 mmol, 1.5 Eq) was added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (110.57 mg, 0.40 mmol, 45%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.67 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 6.0 Hz, 1H), 6.95 – 6.83 (m, 2H), 4.88 – 4.80 (m, 1H), 4.77 (dd, J = 7.3, 5.8 Hz, 2H), 4.40 (t, J = 6.1 Hz, 2H). ppm. 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)-1H-indazol-3- amine A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (1.00 g, 3.0 mmol), copper (I) iodide (0.100 g, 0.5 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol) in 10 ml of N,N-dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of 3,3-dimethylbut-1-yne (1.46 mL, 17.8 mmol). The reaction mixture was heated to 80 °C for 1h20. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (first column: petroleum ether 60-80%/EtOAc 6:4; second column: DCM, 2% MeOH) to give the product as a dark green solid. (0.65 g, 64%). 1 H NMR (400 MHz, (CD 3 ) 2 CO): ^ 1.34 (s, 12H), 1.37 (s, 9H), 5.10 (br s, 2H), 7.64 (d, J = 0.9 Hz, 1H), 8.08 (d, J = 0.9 Hz, 1H), 11.03 (br s, 1H). LRMS: Calculated for C19H26BN3O2 339.2 found 340.1 (M+1). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(oxetan-3-ylamino)pyridin -4-yl)-1H-indazol-3-amine To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)- 1H-indazol-3-amine (149.27 mg, 0.44 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodo-N-(oxetan-3-yl)pyridin-2-amine (110.57 mg, 0.40 mmol, 1 Eq), cesium carbonate (390.98 mg, 1.2 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (28.07 mg, 0.04 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a pale yellow solid (73.73 mg, 0.204 mmol, 51%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.79 (s, 1H), 8.07 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 5.4 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 6.3 Hz, 1H), 6.85 (dd, J = 5.4, 1.7 Hz, 1H), 6.75 (d, J = 1.6 Hz, 1H), 5.58 (s, 2H), 4.96 (h, J = 6.6 Hz, 1H), 4.83 (t, J = 6.7 Hz, 2H), 4.46 (t, J = 6.2 Hz, 2H), 1.36 (s, 9H) ppm. LRMS (ESI +ve): For C21H23N5O requires 361.45 found 362.3 (M+H). Example 156 N-Cyclopentyl-4-iodopyridin-2-amine To a solution of 2-fluoro-4-iodopyridine (0.45 g, 2.02 mmol) in dioxane (5mL) was added cyclopentylamine (0.189 g, 0. 22 mL, 2.22 mmol) the reaction was the flushed with argon, sealed and stirred at 130 °C for 3 hours. The reaction was cooled, partitioned between EtOAc and H2O and the aqueous layer washed a further 2 times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as an off white solid (0.178 g, 34%). LRMS (ESI +ve): For C 10 H 13 IN 2 Molecular Weight: 288.1325 found 289.1 7-Bromo-5-(2-(cyclopentylamino)pyridin-4-yl)-1H-indazol-3-am ine To a solution of N-cyclopentyl-4-iodopyridin-2-amine (0.18 g, 0.625 mmol) in a degassed solution of dioxane:H2O (18:25 mL) was added potassium carbonate (0.270 g, 1.954 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.253 g, 0.75 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.023 g, 0.031 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a bark brown solid (0.105 g, 45 %). 5-(2-(Cyclopentylamino)pyridine-4-yl)-7-(3,3-dimethylbut-1-y n-1-yl)-1H-indazol-3-amine To a solution of 7-bromo-5-(2-(cyclopentylamino)pyridin-4-yl)-1H-indazol-3-am ine (0.10 g, 0.269 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.010 g, 0.0134 mmol) and 3,3- dimethylbut-1-yne (0.0265 g, 0.040 mL, 0.323 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.018 g.18 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.71 (s, 1H), 8.31 (d, J = 1.7 Hz, 1H), 7.97 (d, J = 6.8 Hz, 1H), 7.65 (s, 1H), 7.28 (d, J = 1.8 Hz, 1H), 7.21 (dd, J = 6.9, 1.8 Hz, 1H), 2.05 (dd, J = 12.5, 6.4 Hz, 2H), 1.74 (hept, J = 4.9, 3.6 Hz, 2H), 1.67 – 1.53 (m, 4H), 1.37 (s, 9H). LRMS (ESI +ve): For Chemical Formula: C 23 H 27 N 5 Molecular Weight: 373.5040 found 374.3. Example 157 N-(Cyclopropylmethyl)-4-iodopyridin-2-amine In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 1 mL of Dioxane. Then cyclopropylmethylamine (126.59 mg, 0.154 mL, 1.78 mmol, 2 Eq) was added and the resulting reaction mixture was heated at 150 ºC under microwave irradiation for 4 hours. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (231.75 mg, 0.845 mmol, 95%). 1 H NMR (500 MHz, DMSO-d6) δ 7.65 (d, J = 5.3 Hz, 1H), 6.91 (d, J = 1.2 Hz, 1H), 6.78 (dd, J = 5.3, 1.4 Hz, 1H), 6.72 (t, J = 5.3 Hz, 1H), 3.08 (dd, J = 6.4, 5.8 Hz, 2H), 1.04 – 0.96 (m, 1H), 0.45 – 0.40 (m, 2H), 0.20 – 0.15 (m, 2H) ppm. 7-Bromo-5-(2-((cyclopropylmethyl)amino)pyridin-4-yl)-1H-inda zol-3-amine To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (311.99 mg, 0.923 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(cyclopropylmethyl)-4-iodopyridin-2-amine (230 mg, 0.839 mmol, 1 Eq), cesium carbonate (820.08 mg, 2.517 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (64.78 mg, 0.092 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (20 % to 100% EtOAc in petroleum ether), to afford the titled compound as a solid (246.46 mg, 0.687 mmol, 82%). 1 H NMR (500 MHz, DMSO-d6) δ 11.93 (br. s., 1H), 8.11 (d, J = 1.2 Hz, 1H), 8.00 (d, J = 5.3 Hz, 1H), 7.74 – 7.73 (m, 1H), 6.77 (dd, J = 5.4, 1.3 Hz, 1H), 6.75 (s, 1H), 6.54 (t, J = 5.6 Hz, 1H), 5.64 (br. s., 2H), 3.17 (t, J = 6.2 Hz, 2H), 1.11 – 1.03 (m, 1H), 0.46 – 0.42 (m, 2H), 0.23 – 0.21 (m, 2H) ppm. 5-(2-((Cyclopropylmethyl)amino)pyridin-4-yl)-7-(3,3-dimethyl but-1-yn-1-yl)-1H-indazol-3- amine To a solution of 7-bromo-5-(2-((cyclopropylmethyl)amino)pyridin-4-yl)-1H-inda zol-3-amine (240 mg, 0.669 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (25.51 mg, 0.133 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (48.95 mg, 0.0669 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (82.42 mg, 0.123 mL, 1.003 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (20% to 100% EtOAc in petroleum ether) followed by HPLC purification to give the titled product (173.14 mg, 0.48 mmol, 72%). 1 H NMR (500 MHz, DMSO-d6) δ 11.76 (br. s, 1H), 8.07 (d, J = 1.7 Hz, 1H), 7.98 (d, J = 5.4 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 6.79 (d, J = 1.6 Hz, 1H), 6.77 (s, 1H), 6.57 (s, 1H), 5.57 (s, 2H), 3.17 (dd, J = 6.7, 5.6 Hz, 2H), 1.10 – 1.03 (m, 1H), 0.44 – 0.42 (m, 2H), 0.23 – 0.20 (m, 2H) ppm. LRMS (ESI +ve): For C22H25N5 requires 359.48 found 360.3 (M+H). Example 158 4-Iodo-N-(2,2,2-trifluoroethyl)pyridin-2-amine Lithium bis(trimethylsilyl)amide (1M in hexane, 4.5 mL, 4.48 mmol, 2 Eq) was added dropwise to a solution of 2,2,2-trifluoroethan-1-amine (0.33 g, 0.3 mL, 3.36 mmol, 1.5 Eq) in anhydrous THF (5 mL) at -78 ºC. The reaction mixture was allowed to stir at -78 ºC for 30 min. A solution of 2-fluoro-4-iodopyridine (0.5 g, 2.24 mmol, 1 Eq) in anhydrous THF (0.5 mL) was added dropwise at -78 ºC. The reaction mixture was stirred at rt for 3 h. The reaction was quenched with saturated solution of NH 4 Cl (3 mL) then extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (10% EtOAc in petroleum ether) to give the titled product as white solid (0.2 g, 0.66 mmol, 30%). 1 H NMR (500 MHz, DMSO) δ 4.15 (qd, J = 9.8, 6.6 Hz, 2H), 6.97 (dd, J = 5.4, 1.5 Hz, 1H), 7.08 (d, J = 1.6 Hz, 1H), 7.27 (t, J = 6.6 Hz, 1H), 7.75 (d, J = 5.3 Hz, 1H). Example 159 3-((4-Iodopyridin-2-yl)amino)propanenitrile In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 5 mL of DMSO. Then 3-Aminopropionitrile (stabilised with K2CO3) (93.57 mg, 0.982 mL, 1.335 mmol, 1.5 Eq) was added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (121.52 mg, 0.445 mmol, 50%). 1 H NMR (500 MHz, DMSO-d6) δ 7.71 (d, J = 5.3 Hz, 1H), 7.07 (t, J = 5.9 Hz, 1H), 6.97 (d, J = 1.4 Hz, 1H), 6.88 (dd, J = 5.4, 1.5 Hz, 1H), 3.48 (q, J = 6.3 Hz, 2H), 2.72 (t, J = 6.5 Hz, 2H) ppm. 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)-1H-indazol-3- amine A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (1.00 g, 3.0 mmol), copper (I) iodide (0.100 g, 0.5 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol) in 10 ml of N,N-dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of 3,3-dimethylbut-1-yne (1.46 mL, 17.8 mmol). The reaction mixture was heated to 80 °C for 1h20. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (first column: petroleum ether 60-80%/EtOAc 6:4; second column: DCM, 2% MeOH) to give the product as a dark green solid. (0.65 g, 64%). 1 H NMR (400 MHz, (CD3)2CO): ^ 1.34 (s, 12H), 1.37 (s, 9H), 5.10 (br s, 2H), 7.64 (d, J = 0.9 Hz, 1H), 8.08 (d, J = 0.9 Hz, 1H), 11.03 (br s, 1H). LRMS: Calculated for C 19 H 26 BN 3 O 2 339.2 found 340.1 (M+1). 3-((4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl )pyridin-2- yl)amino)propanenitrile To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)- 1H-indazol-3-amine (166.06 mg, 0.489 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 3-((4-iodopyridin-2-yl)amino)propanenitrile (121.52 mg, 0.445 mmol, 1 Eq), cesium carbonate (434.97 mg, 1.335 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (31.23 mg, 0.044 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (127.60 mg, 0.356 mmol, 80%). 1 H NMR (500 MHz, DMSO-d6) δ 11.77 (s, 1H), 8.08 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 5.4 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 6.90 (t, J = 5.9 Hz, 1H), 6.86 (dd, J = 5.5, 1.6 Hz, 1H), 6.80 (d, J = 1.6 Hz, 1H), 5.58 (s, 2H), 3.56 (q, J = 6.3 Hz, 2H), 2.78 (t, J = 6.4 Hz, 2H), 1.36 (s, 9H) ppm. LRMS (ESI +ve): For C21H22N6 requires 358.45 found 359.3 (M+H). Example 160 2-((4-Iodopyridin-2-yl)amino)ethan-1-ol A solution of 2-fluoro-4-iodopyridine (1 g, 4.49 mmol, 1 Eq), 2-aminoethan-1-ol (1.4 g, 1.4 mL, 22.45 mmol, 5 Eq) and triethylamine (1.4 g, 2 mL, 13.47 mmol, 3 Eq) in DMSO (5 mL) was stirred in a sealed vial (10 mL) at 95 ºC for 18 h. Cold water (10 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 5 mL) then petroleum ether (2 × 5 mL). The solid product was dried to give the titled product as white solid (0.6 g, 2.27 mmol, 51%). 1 H NMR (500 MHz, DMSO) δ 3.29 (q, J = 5.9 Hz, 2H), 3.50 (q, J = 5.8 Hz, 2H), 4.69 (t, J = 5.4 Hz, 1H), 6.66 (t, J = 5.8 Hz, 1H), 6.80 (dd, J = 5.3, 1.5 Hz, 1H), 6.94 (d, J = 1.4 Hz, 1H), 7.66 (d, J = 5.3 Hz, 1H). 2-((4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl )pyridin-2-yl)amino)ethan-1-ol SU1697 To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)- 1H-indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), 2-((4-iodopyridin-2-yl)amino)ethan-1-ol (0.4 g, 1.47 mmol, 1 Eq), cesium carbonate (1.4 g, 4.41 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (157 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was stirred under nitrogen atmosphere at 70 ºC for 18 h. Cold water (5 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 3 mL). The crude product was dried and purified using column chromatography (10% MeOH in EtOAc) followed by HPLC purification (60% MeCN in H 2 O) to give the titled product as yellow solid (0.2 g, 0.57 mmol, 39%). 1 H NMR (500 MHz, DMSO) δ 1.37 (s, 9H), 3.38 (q, J = 6.0 Hz, 2H), 3.56 (t, J = 6.0 Hz, 2H), 4.76 (s, 1H), 5.57 (s, 2H), 6.45 (t, J = 5.7 Hz, 1H), 6.75 – 6.82 (m, 2H), 7.48 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 5.3 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 11.76 (s, 1H). LRMS: For C 20 H 23 N 5 O requires 349.44 found 350.3 (M+H). Example 161 N 1 -(4-Iodopyridin-2-yl)ethane-1,2-diamine A solution of 2-fluoro-4-iodopyridine (1 g, 4.49 mmol, 1 Eq), ethane-1,2-diamine (2.7 g, 3 mL, 45 mmol, 10 Eq) and triethylamine (1.4 g, 2 mL, 13.47 mmol, 3 Eq) in DMSO (5 mL) was stirred in a sealed vial (20 mL) at 95 ºC for 18 h. Cold water (10 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 5 mL) then petroleum ether (2 × 5 mL). The solid product was dried to give the titled product as yellow solid (0.4 g, 1.5 mmol, 33%). 1 H NMR (500 MHz, DMSO) δ 1.44 (s, 2H), 2.66 (t, J = 6.4 Hz, 2H), 3.19 (q, J = 6.2 Hz, 2H), 6.66 (t, J = 5.6 Hz, 1H), 6.72 – 6.82 (m, 1H), 6.90 (d, J = 1.4 Hz, 1H), 7.66 (d, J = 5.3 Hz, 1H). N 1 -(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol- 5-yl)pyridin-2-yl)ethane-1,2- diamine SU1698 A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)-1H- indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), N 1 -(4-iodopyridin-2-yl)ethane-1,2-diamine (0.39 g, 1.47 mmol, 1 Eq), cesium carbonate (1.4 g, 4.41 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (157 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was stirred under nitrogen atmosphere at 70 ºC for 18 h. Cold water (5 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 3 mL). The crude product was dried and purified using column chromatography (10% MeOH and 1% Et 3 N in EtOAc) followed by HPLC purification (60% MeCN in H 2 O) to give the titled product as yellow solid (0.1 g, 0.29 mmol, 20%). 1 H NMR (500 MHz, DMSO) δ 1.37 (s, 9H), 3.02 (d, J = 6.4 Hz, 2H), 3.53 (d, J = 6.1 Hz, 2H), 5.59 (s, 2H), 6.72 (d, J = 5.7 Hz, 1H), 6.80 (s, 1H), 6.90 (d, J = 5.5 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.70 (s, 2H), 8.05 (d, J = 5.4 Hz, 1H), 8.09 (d, J = 1.6 Hz, 1H), 11.81 (s, 1H). LRMS: For C 20 H 24 N 6 requires 348.45 found 349.3 (M+H). Example 162 4-iodo-N-(2-methoxyethyl)pyridin-2-amine In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 1 mL of Dioxane. Then 2-methoxyethylamine (133.69 mg, 0.155 mL, 1.78 mmol, 2 Eq) was added and the resulting reaction mixture was heated at 150 ºC under microwave irradiation for 4 hours. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (240.1 mg, 0.86 mmol, 97%). 1 H NMR (500 MHz, DMSO-d6) δ 7.66 (d, J = 5.2 Hz, 1H), 6.94 (d, J = 1.2 Hz, 1H), 6.79 (dd, J = 5.3, 1.5 Hz, 1H), 6.71 (t, J = 5.3 Hz, 1H), 3.43 – 3.41 (m, 2H), 3.39 – 3.36 (m, 2H), 3.25 (s, 3H) ppm. 7-bromo-5-(2-((2-methoxyethyl)amino)pyridin-4-yl)-1H-indazol -3-amine To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (307.51 mg, 0.909 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodo-N-(2-methoxyethyl)pyridin-2-amine (230 mg, 0.827 mmol, 1 Eq), cesium carbonate (808.36 mg, 2.48 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (58.05 mg, 0.082 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (100% EtOAc), to afford the titled compound as a solid (224.67 mg, 0.620 mmol, 75%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.92 (br. s., 1H), 8.11 (d, J = 1.4 Hz, 1H), 8.01 (d, J = 5.3 Hz, 1H), 7.73 (d, J = 1.4 Hz, 1H), 6.80 – 6.76 (m, 2H), 6.51 – 6.49 (m, 1H), 5.64 (br. s., 2H), 3.49 – 3.46 (m, 4H), 3.28 (s, 3H) ppm. 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((2-methoxyethyl)amino)py ridin-4-yl)-1H-indazol-3- amine To a solution of 7-bromo-5-(2-((2-methoxyethyl)amino)pyridin-4-yl)-1H-indazol -3-amine (220 mg, 0.607 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (23.12 mg, 0.12 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (44.41 mg, 0.0607 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (74.78 mg, 0.112 mL, 0.91 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (20% to 100% EtOAc in petroleum ether) followed by HPLC purification to give the titled product (196.4 mg, 0.546 mmol, 90%). 1 H NMR (500 MHz, DMSO- d6) δ 11.78 (br. s, 1H), 8.07 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 5.5 Hz, 1H), 7.48 (d, J = 1.6 Hz, 1H), 6.86 (br. s, 1H), 6.81 (dd, J = 5.5, 1.6 Hz, 1H), 6.69 (s, 1H), 5.59 (br. s, 2H), 4.34 (h, J = 7.8 Hz, 1H), 2.32 (qd, J = 7.8, 5.3 Hz, 2H), 1.89 (pd, J = 9.2, 2.7 Hz, 2H), 1.73 – 1.63 (m, 2H), 1.36 (s, 9H) ppm. LRMS (ESI +ve): For C22H25N5 requires 359.48 found 360.3 (M+H). Example 163 4-Iodo-N-(3-methoxypropyl)pyridin-2-amine To anhydrous THF cooled to -78 °C was added nBuLi 4.5 mL (1 eq, 1M solution in THF) followed by DIA 0.633 mL (1eq) dropwise and then a solution of 2-fluoro-3-iodopyridine (1.0 g, 4.48 mmol) slowly. The reaction was allowed to warm up to room temperature and aged for 30 minutes at this temperature before cooling back down to -78 °C and quenching by pouring over ice: H2O (20 mL). The reaction was then extracted with diethyl ether (3 x 50 mL), and the combined organic layers washed with brine dried over magnesium chloride and concentrated under reduced pressure to afford crude 2-fluoro-4-iodopyridine. This was then dissolved in dioxane (5 mL) in a 20 mL microwave vail to which 3-methoxypropan-1-amine was added seal and stirred at 120 °C under microwave irradiation for 3 hours. The reaction was cooled, partitioned between EtOAc and H 2 O and the aqueous layer washed a further two times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as a white solid (0.43, 38%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.84 (d, J = 5.5 Hz, 1H), 6.76 (t, J = 5.6 Hz, 1H), 6.67 (d, J = 1.7 Hz, 1H), 6.63 (dd, J = 5.5, 1.7 Hz, 1H), 3.37 (t, J = 6.3 Hz, 2H), 3.26 (td, J = 6.9, 5.6 Hz, 2H), 3.23 (s, 3H), 1.73 (p, J = 6.6 Hz, 2H). LRMS (ESI +ve): For C 9 H 13 IN 2 O Molecular Weight: 292.1205 found 293.0 7-Bromo-5-(2-((3-methoxypropyl)amino)pyridin-4-yl)-1H-indazo l-3-amine To a solution of 4-iodo-N-(3-methoxypropyl)pyridin-2-amine (0.21 g, 0.73 mmol) in a degassed solution of dioxane:H2O (18:25 mL) was added cesium carbonate (0.713 g, 2.188 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.270 g, 0.802 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.026 g, 0.037 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.175 g, 64 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.93 (s, 1H), 8.12 (d, J = 1.4 Hz, 1H), 8.01 (d, J = 5.4 Hz, 1H), 7.74 (d, J = 1.4 Hz, 1H), 6.78 (dd, J = 5.4, 1.6 Hz, 1H), 6.71 (d, J = 1.6 Hz, 1H), 6.49 (t, J = 5.6 Hz, 1H), 5.65 (s, 2H), 3.42 (t, J = 6.3 Hz, 2H), 3.33 (d, J = 6.2 Hz, 7H), 3.25 (s, 3H), 1.79 (p, J = 6.6 Hz, 2H). LRMS (ESI +ve): For Chemical Formula: C16H18BrN5O Molecular Weight: 376.2580 found 376.0, 377.0 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3-methoxypropyl)amino)p yridine-4-yl)-1H-indazol-3- amine To a solution of 7-bromo-5-(2-((3-methoxypropyl)amino)pyridin-4-yl)-1H-indazo l-3-amine (0.175 g, 0.466 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.034 g, 0.046 mmol) and 3,3- dimethylbut-1-yne ( 0.046 g, 0.085 mL, 0.559 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.044 g. 25 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.26 (t, J = 1.6 Hz, 1H), 8.06 (d, J = 6.5 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 8.00 (t, J = 1.5 Hz, 1H), 7.27 (s, 1H), 7.23 (dd, J = 6.5, 1.7 Hz, 1H), 3.44 (t, J = 6.1 Hz, 4H), 3.26 (s, 3H), 1.85 (p, J = 6.5 Hz, 2H), 1.33 (s, 9H).LRMS (ESI +ve): For Chemical Formula: C 22 H 27 N 5 O Molecular Weight: 377.4920 found 378.3 Example 164 N-(4-Iodopyridin-2-yl)acetamide To a solution of 4-iodopyridin-2-amine (0.5g 2.27 mmol) in dioxane cooled to 0 °C was added NaH (0.181 g, 4.54 mmol, 60 % suspension, 2 eq) under a blanket of argon. Acetyl Chloride (0.18 g, 0.16 mmol) was then added dropwise and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 3 hours. The reaction was then quenched by pouring over ice/water 20 mL, extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash eluting with a gradient of EtOAc:Petroleum Ether (50-100%) to afford the target compound as an off white solid ( 0.40 g, 67%). 1 H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 8.52 (d, J = 1.7 Hz, 1H), 8.03 (dd, J = 5.2, 0.6 Hz, 1H), 7.50 (dd, J = 5.2, 1.5 Hz, 1H), 2.09 (s, 3H). LRMS (ESI +ve): For C7H7IN2O Molecular Weight: 262.0505 found 263.4 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide To a solution of N-(4-iodopyridin-2-yl)acetamide (0.4 g, 1.526 mmol) in a degassed solution of dioxane:H 2 O (18:2 5 mL) was added cesium carbonate (1.492 g, 4.579 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.617 g, 1.831 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.054 g, 0.0763 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.51 g, 96 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.01 (s, 1H), 10.54 (s, 1H), 8.40 (s, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.4 Hz, 1H), 7.79 (s, 1H), 7.40 (dd, J = 5.4, 1.7 Hz, 1H), 5.72 (s, 2H), 2.14 (s, 3H). LRMS (ESI +ve): C 14 H 12 BrN 5 O Molecular Weight: 346.1880 found 346.0, 347.0 N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)acetamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide (0.5 g, 1.444 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.051 g, 0.072 mmol) and 3,3- dimethylbut-1-yne (0.14 g, 0.213 mL, 1.733 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc (plus NH3 in MeOH 7M) (50-100%) to afford the target compound as a cream coloured solid (0.38 g. 76 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.85 (s, 1H), 10.52 (s, 1H), 8.39 (s, 1H), 8.33 (d, J = 5.3 Hz, 1H), 8.15 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 5.2, 1.7 Hz, 1H), 5.65 (s, 2H), 2.14 (s, 3H), 1.38 (s, 9H). LRMS (ESI +ve): C20H21N5O Molecular Weight: 347.4220 found 348.3. Example 165 N-(4-Iodopyridin-2-yl)propionamide To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise propionyl chloride (252.02 mg, 0.238 mL, 2.72 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (60% DCM in EtOAc) to give the titled product as a solid (526.4 mg, 1.91 mmol, 84%).1H NMR (500 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.55 (d, J = 1.1 Hz, 1H), 8.02 (d, J = 5.2 Hz, 1H), 7.48 (dd, J = 5.2, 1.5 Hz, 1H), 2.39 (q, J = 7.5 Hz, 2H), 1.05 (t, J = 7.5 Hz, 3H) ppm. N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)propionam ide To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (472.2 mg, 1.39 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(4-iodopyridin-2-yl)propionamide (350 mg, 1.27 mmol, 1 Eq), cesium carbonate (1.241 g, 3.81 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (89.14 mg, 0.127 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (100% EtOAc), to afford the titled compound as a solid (366 mg, 1.02 mmol, 80%). 1 H NMR (500 MHz, DMSO-d6) δ 11.99 (br. s, 1H), 10.47 (s, 1H), 8.43 (s, 1H), 8.33 (d, J = 5.2 Hz, 1H), 8.21 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.39 (dd, J = 5.3, 1.8 Hz, 1H), 5.72 (s, 2H), 2.43 (q, J = 7.6 Hz, 2H), 1.09 (t, J = 7.6 Hz, 3H) ppm. LRMS (ESI +ve): For C15H14BrN5O Molecular Weight: 360.22 found 360.0, 361.0, 362.0, 363.0 (M+H). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)propionamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)propionam ide (250 mg, 0.694 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (26.43 mg, 0.138 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (50.78 mg, 0.069 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (85.50 mg, 0.128 mL, 1.041 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (50% EtOAc in petroleum ether, then 100% EtOAc) followed by HPLC purification to give the titled product as a pale-yellow solid (178.2 mg, 0.493 mmol, 71%). 1 H NMR (500 MHz, DMSO-d6) δ 11.83 (br. s, 1H), 10.46 (s, 1H), 8.42 (s, 1H), 8.31 (d, J = 5.5 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 7.52 (d, J = 1.7 Hz, 1H), 7.38 (dd, J = 5.3, 1.8 Hz, 1H), 5.65 (s, 2H), 2.43 (q, J = 7.5 Hz, 2H), 1.37 (s, 9H), 1.09 (t, J = 7.5 Hz, 3H) ppm. LRMS (ESI +ve): For C21H23N5O Molecular Weight: 361.45 found 362.1 (M+H). Example 166 tert-Butyl(7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan -2-yl)-1H-indazol-3-yl)(tert- butoxycarbonyl)carbamate Di-tert-butyl decarbonate (2.58 g, 2.7 mL, 11.84 mmol, 4 Eq) was added to a solution of 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (1 g, 2.96 mmol, 1 Eq), 4-(dimethylamino)pyridine (0.7 g, 5.92 mmol, 2 Eq), triethylamine (0.9 g, 1.2 mL, 8.88 mmol, 3 Eq) in anhydrous dioxane (5 mL). The reaction mixture was stirred at rt for 30 h. The reaction mixture was extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (10% EtOAc in petroleum ether) to give the titled product as white solid (0.6 g, 1.12 mmol, 38%). 1 H NMR (500 MHz, DMSO) δ 1.31 (s, 12H), 1.38 (s, 18H), 5.68 (s, 2H), 7.61 (s, 1H), 8.17 (s, 1H), 12.01 (s, 1H). tert-Butyl (5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-yl)(tert- butoxycarbonyl)carbamate A solution of tert-butyl(7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan -2-yl)-1H-indazol-3- yl)(tert-butoxycarbonyl)carbamate (1 g, 1.86 mmol, 1 Eq), 4-iodopyridin-2-amine (0.41 g, 1.86 mmol, 1 Eq), cesium carbonate (1.82 g, 5.58 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (197 mg, 0.28 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 60 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (15 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was dried and purified using column chromatography (50% EtOAc in petroleum ether) to give the titled product as yellow solid (0.5 g, 0.99 mmol, 53%). tert-Butyl(5-(2-aminopyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1 -yl)-1H-indazol-3-yl)(tert- butoxycarbonyl)carbamate 3,3-Dimethylbut-1-yne (163 mg, 240 µL, 1.98 mmol, 2 Eq) was added to a solution of tert-butyl (5-(2-aminopyridin-4-yl)-7-bromo-1H-indazol-3-yl)(tert-butox ycarbonyl)carbamate (0.5 g, 0.99 mmol, 1 Eq), copper(I) iodide (38 mg, 0.2 mmol, 0.2 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (73 mg, 0.1 mmol, 0.1 Eq) in anhydrous DMF (1 mL) and triethylamine (1 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 50 ºC for 18 h. The reaction mixture was extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as yellow solid (0.3 g, 0.6 mmol, 60%). tert-Butyl(tert-butoxycarbonyl)(7-(3,3-dimethylbut-1-yn-1-yl )-5-(2-(3,3,3- trifluoropropanamido)pyridin-4-yl)-1H-indazol-3-yl)carbamate A solution of tert-butyl(5-(2-aminopyridin-4-yl)-7-(3,3-dimethylbut-1-yn-1 -yl)-1H-indazol-3- yl)(tert-butoxycarbonyl)carbamate (0.5 g, 0.6 mmol, 1 Eq), (1-[bis(dimethylamino)methylene]- 1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (274 mg, 0.72 mmol, 1.2 Eq), N,N-diisopropylethylamine (155 mg, 0.2 mL, 1.2 mmol, 2 Eq) in DMF (5 mL) was allowed to stir at rt for 18 h. The reaction mixture was extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (40% EtOAc in petroleum ether) to give the titled product as purple crystals (0.3 g, 0.49 mmol, 82%). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-3,3,3- trifluoropropanamide Trifluoroacetic acid (1.49 g, 1 mL, 13.1 mmol, 82 Eq) was added to a solution of tert-butyl(tert- butoxycarbonyl)(7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-(3,3,3-tr ifluoropropanamido)pyridin-4-yl)-1H- indazol-3-yl)carbamate (100 mg, 0.16 mmol, 1 Eq) in DCM (4 mL) at 0 ºC. The reaction mixture was stirred at rt for 3 h. The reaction was quenched with saturated solution of NaHCO3 (5 mL). The organic layer was washed with brine (2 × 3 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (60% EtOAc in petroleum ether) followed by HPLC purification (70% MeCN in H 2 O) to give the titled product as yellow solid (20 mg, 0.05 mmol, 31%). 1 H NMR (500 MHz, DMSO) δ 1.38 (s, 9H), 3.68 (q, J = 11.2 Hz, 2H), 5.67 (s, 2H), 7.48 (dd, J = 5.3, 1.8 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.37 (d, J = 5.4 Hz, 2H), 10.91 (s, 1H), 11.85 (s, 1H). LRMS: For C 21 H 20 F 3 N 5 O requires 415.42 found 416.2 (M+H). Example 167 N-(4-Iodopyridin-2-yl)cyclopropanecarboxamide To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise cyclopropanecarbonyl chloride (285.07 mg, 0.247 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (30% EtOAc in petroleum ether) to give the titled product (622 mg, 2.16 mmol, 95%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.90 (s, 1 H), 8.54 (d, J = 1.2 Hz, 1 H), 8.04 (d, J = 5.2 Hz, 1 H), 7.49 (dd, J = 5.2, 1.5 Hz, 1 H), 2.00 (quin, J = 6.2 Hz, 1 H), 0.84 (s, 2 H), 0.82 (s, 2 H) ppm. N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cycloprop anecarboxamide To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (796.30 mg, 2.35 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(4-iodopyridin-2-yl)cyclopropanecarboxamide (617 mg, 2.14 mmol, 1 Eq), cesium carbonate (2.09 g, 6.42 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (150.32 mg, 0.214 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (90% EtOAc in petroleum ether), to afford the titled compound (644 mg, 1.71 mmol, 80%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.99 (br. s., 1 H), 10.84 (s, 1 H), 8.41 (s, 1 H), 8.34 (d, J = 5.2 Hz, 1 H), 8.19 (s, 1 H), 7.78 (s, 1 H), 7.49 (dd, J = 5.2, 1.5 Hz, 1 H), 5.71 (br. s., 2 H), 2.07 – 2.02 (m, 1H), 0.86 – 0.82 (m, 4H) ppm. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)cyclopropane carboxamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cycloprop anecarboxamide (200 mg, 0.53 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (20.46 mg, 0.11 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (39.31 mg, 0.053 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (66.20 mg, 0.099 mL, 0.80 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (20 to 95% EtOAc in petroleum ether) followed by HPLC purification to give the titled product (152.40 mg, 0.40 mmol, 77%). 1 H NMR (500 MHz, DMSO-d6) δ 11.83 (br. s, 1H), 10.84 (s, 1H), 8.41 (d, J = 1.8 Hz, 1H), 8.34 (d, J = 5.3 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 5.3, 1.8 Hz, 1H), 5.65 (s, 2H), 2.08 – 2.03 (m, 1H), 1.38 (s, 9H), 0.88 – 0.81 (m, 4H) ppm. LRMS (ESI +ve): For C22H23N5O Molecular Weight: 373.46 found 374.3 (M+H). Example 168 tert-Butyl (4-iodopyridin-2-yl)carbamate To a solution of 4-iodopyridin-2-amine (2.7 g 12.27 mmol) in dioxane (10 mL) was added DMAP (1.79 g, 14.72 mmol) under a blanket of argon followed by Boc 2 O (2.812 g, 12.88 mmol). The resulting reaction mixture was stirred at 80 °C for 12 hours. The reaction was then cooled and quenched by pouring into water 20 mL, extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as an off white solid ( 2.94 g, 75%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.94 (s, 1H), 8.24 (d, J = 1.4 Hz, 1H), 7.97 (d, J = 5.2 Hz, 1H), 7.42 (dd, J = 5.2, 1.5 Hz, 1H), 1.48 (s, 9H). LRMS (ESI +ve): For C 10 H 13 IN 2 O 2 Molecular Weight: 320.1305 found 321.0 N-(4-Iodopyridin-2-yl)isobutyramide To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.56 mmol) in dioxane (2 mL) was added NaHMDS (1.2 eq, 1M solution in THF) at 0 °C under a blanket of argon followed by isobutyryl chloride (0.183 g, 0.181 mL, 1.716 mmol) and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 12 hours. The reaction was then quenched by pouring over ice/water 20 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was taken up in dichloromethane (5 mL) and stirred at 0 °C with 2 ml TFA (1Maq) for 3 hours, then quenched by pouring over ice/saturated NaHCO3Aq 10 mL and extracted with EtOAc (3 x 30 mL), washed with brine (10 mL), concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as a cream coloured solid (0.35 g, 78%). 1 H NMR (500 MHz, DMSO-d6) δ 10.54 (s, 1H), 8.57 (d, J = 1.5 Hz, 1H), 8.04 (d, J = 5.2 Hz, 1H), 7.50 (dd, J = 5.2, 1.5 Hz, 1H), 2.75 (h, J = 6.8 Hz, 1H), 1.08 (d, J = 6.8 Hz, 6H). LRMS (ESI +ve): For C 9 H 11 IN 2 O Molecular Weight: 290.1045 found 291.0 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)isobutyra mide To a solution of N-(4-iodopyridin-2-yl)isobutyramide (035 g, 1.21 mmol) in a degassed solution of dioxane:H 2 O (18:2 5 mL) was added cesium carbonate (1.18 g, 363 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.488 g, 1.45 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.084 g, 0.121 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and the crude product used directly in the subsequent reaction. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)isobutyramide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)isobutyra mide in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.089 g, 0.121 mmol) and 3,3- dimethylbut-1-yne (0.099 g, 0.146 mL, 1.21 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow (0.035 g.8 % over two steps). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.91 – 11.81 (m, 1H), 10.47 (s, 1H), 8.45 (d, J = 1.7 Hz, 1H), 8.33 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 1.6 Hz, 1H), 7.96 (s, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 5.2, 1.7 Hz, 1H), 5.66 (s, 2H), 2.80 (p, J = 6.8 Hz, 1H), 1.38 (s, 9H), 1.12 (d, J = 6.8 Hz, 6H).LRMS (ESI +ve): For C 22 H 25 N 5 O Molecular Weight: 375.4760 found 376.3 Example 169 N-(4-Iodopyridin-2-yl)pivalamide To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.56 mmol) in dioxane (2 mL) was added NaHMDS (1.2 eq, 1M solution in THF) at 0 °C under a blanket of argon followed pivaloyl chloride 0.19 g, 0.188 mL, 1.72 mmol) and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 12 hours. The reaction was then quenched by pouring over ice/water 20 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was taken up in dichloromethane (5 mL) and stirred at 0 °C with 2 ml TFA (1M aq ) for 3 hours, then quenched by pouring over ice/saturated NaHCO 3Aq 10 mL and extracted with EtOAc (3 x 30 mL), washed with brine (10 mL), concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:petroleum Ether (0-50%) to afford the target compound as a cream coloured solid 0.28 g, 60%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.93 (s, 1H), 8.52 (d, J = 1.7 Hz, 1H), 8.06 (d, J = 5.2 Hz, 1H), 7.52 (dd, J = 5.2, 1.5 Hz, 1H), 1.23 (s, 9H). LRMS (ESI +ve): For C 10 H 13 IN 2 O Molecular Weight: 304.1315 found 305.0 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)pivalamid e To a solution of N-(4-iodopyridin-2-yl)pivalamide (0.28 g, 0.921 mmol) in a degassed solution of dioxane:H2O (18:2 5 mL) was added cesium carbonate (0.899 g, 2.762 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.373 g, 1.105 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.0646 g, 0.092 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and the crude product used directly in the subsequent reaction. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)pivalamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)pivalamid e in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0674 g, 0.092 mmol) copper iodide (0.035 g, 0.184 mmol) and 3,3-dimethylbut-1-yne (0.0756 g, 0.113 mL, 0.921 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.014 g, 4 % over two steps). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.10 (s, 1H), 8.37 (d, J = 5.5 Hz, 1H), 8.34 (d, J = 1.7 Hz, 1H), 8.26 (d, J = 1.6 Hz, 1H), 7.62 (d, J = 1.5 Hz, 1H), 7.54 (dd, J = 5.4, 1.7 Hz, 1H), 1.38 (s, 9H), 1.29 (s, 9H). LRMS (ESI +ve): For C 23 H 27 N 5 O Molecular Weight: 389.5030 found 390.1 Example 170 2-Cyclopropyl-N-(4-iodopyridin-2-yl)acetamide To a solution of 2-cyclopropylacetic acid (0.56 ml, 5.6 mmol) in 9.6 ml of THF cold down at 0 °C was added oxalyl chloride (0.54 ml, 6.4 mmol) followed by DMF (0.10 ml, 1,3 mmol) and was let run for 10 min. A solution of 4-iodopyridin-2-amine (400 mg, 1.8 mmol) in 4 ml of THF was added followed by triethylamine (0.93 ml, 6.7 mmol). The reaction mixture was run at RT for 2 hours. The resulting mixture was diluted with EtOAc, quenched with NaOH, extracted with EtOAc, washed with NaHCO 3, dry over MgSO 4 , concentrated under reduced pressure and the residue was filtrated through silica (First column Petrol 40-60/EtOAc 88:12; Second column Toluene/EtOAc 9:1) to give the crude product as a yellow solid. (374 mg, 69%). 1 H NMR (400 MHz, (CD3)2CO): ^ 0.21 – 0.29 (m, 2H), 0.52 – 0.58 (m, 2H), 1.10 – 1.19 (m, 1H), 2.39 (d, J = 7.1 Hz, 2H), 7.48 (dd, J = 5.2, 1.5 Hz, 1H), 7.99 (dd, J = 5.2, 0.6 Hz, 1H), 8.74 (dd, J = 1.5, 0.6 Hz, 1H), 9.35 (br s, 1H). LRMS: Calculated for C 10 H 11 IN 2 O 302.0 found 303.1 (M+1). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-2- cyclopropylacetamide A solution of 2-cyclopropyl-N-(4-iodopyridin-2-yl)acetamide (60 mg, 0.20 mmol), Cs2CO3 (200 mg, 0.60 mmol), bis(triphenylphosphine) palladium(II) chloride (25 mg, 0.04 mmol) and 7-(3,3- dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-1H-indazol-3-amine (80 mg, 0.23 mmol) in 1 ml of dioxane-water (4:1) was degassed in sealed tube and submitted to reaction. The reaction mixture was heated to 80 °C for 5 hours. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by HPLC to afford the title compound as a yellow solid. (11 mg, 14%). 1 H NMR (400 MHz, DMSO-d6): ^ 0.16 – 0.26 (m, 2H), 0.44 – 0.55 (m, 2H), 1.00 – 1.15 (m, 1H), 1.37 (s, 9H), 2.33 (d, J = 7.0 Hz, 2H), 7.45 (dd, J = 5.4, 1.8 Hz, 1H), 7.59 (d, J = 1.7 Hz, 1H), 8.22 (d, J = 1.7 Hz, 1H), 8.33 (d, J = 5.4 Hz, 1H), 8.38 (app s, 1H), 10.56 (br s, 1H), 3 protons missing. LRMS: Calculated for C 19 H 21 N 5 O 2 S 387.2 found 388.1 (M+1). Example 171 N-(4-Iodopyridin-2-yl)-3-methylbutanamide To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.56 mmol) in dioxane (2 mL) was added NaHMDS (1.2 eq, 1M solution in THF) at 0 °C under a blanket of argon followed by 3-methylbutyryl chloride (0.207 g, 0.213 mL 1.716 mmol) and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 12 hours. The reaction was then quenched by pouring over ice/water 20 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was taken up in dichloromethane (5 mL) and stirred at 0 °C with 2 ml TFA (1M aq ) for 3 hours, then quenched by pouring over ice/saturated NaHCO 3Aq 10 mL and extracted with EtOAc (3 x 30 mL), washed with brine (10 mL), concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as as a cream coloured solid 0.32 g, 68%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.54 (s, 1H), 8.57 (d, J = 1.5 Hz, 1H), 8.03 (d, J = 5.2 Hz, 1H), 7.50 (dd, J = 5.2, 1.5 Hz, 1H), 2.28 (d, J = 7.1 Hz, 2H), 2.07 (dt, J = 13.6, 6.9 Hz, 1H), 0.92 (d, J = 6.7 Hz, 6H). LRMS (ESI +ve): For C 10 H 13 IN 2 O Molecular Weight: 304.1315 found 305.0 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-methyl butanamide To a solution of N-(4-iodopyridin-2-yl)-3-methylbutanamide (0.32 g, 1.052 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added cesium carbonate (0.977 g, 3.156 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.4255 g, 1.262 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.074 g, 0.1052 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and the crude product used directly in the subsequent reaction. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridine-2-yl)-3- methylbutanamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-methyl butanamide in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.07697 g, 0.1052 mmol) and 3,3-dimethylbut-1-yne (0.0864 g, 0.129 mL, 1.052 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow (0.013 g. 3% over two steps). 1 H NMR (400 MHz, DMSO-d6) δ 11.84 (s, 1H), 10.46 (s, 1H), 8.43 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H), 7.53 (d, J = 1.7 Hz, 1H), 7.40 (dd, J = 5.3, 1.7 Hz, 1H), 5.66 (s, 2H), 2.32 (d, J = 7.2 Hz, 2H), 2.11 (dt, J = 13.5, 6.8 Hz, 1H), 1.38 (s, 9H), 0.95 (d, J = 6.5 Hz, 6H). LRMS (ESI +ve): For C23H27N5O Molecular Weight: 389.5030 found 390.3 Example 172 N-(4-Iodopyridin-2-yl)cyclobutanecarboxamide To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise cyclobutanecarbonyl chloride (322.95 mg, 0.310 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (30% EtOAc in petroleum ether) to give the titled product (583 mg, 1.93 mmol, 85%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 1 H NMR (500 MHz, DMSO-d 6 ) 10.41 (s, 1H), 8.58 (s, 1H), 8.01 (d, J = 5.2 Hz, 1H), 7.48 (dd, J = 5.2 Hz, 1.37 Hz, 1H), 3.38 – 3.32 (m, 1H), 2.23 – 2.16 (m, 2H), 2.12 – 2.06 (m, 2H), 1.96 – 1.87 (m, 1H), 1.83 – 1.76 (m, 1H) ppm. N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cyclobuta necarboxamide To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (615.35 mg, 1.82 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(4-iodopyridin-2-yl)cyclopropanecarboxamide (500 mg, 1.65 mmol, 1 Eq), cesium carbonate (1.61 g, 4.95 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (115.81 mg, 0.165 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (10% to 90% EtOAc in petroleum ether), to afford the titled compound (573.58 mg, 1.48 mmol, 90%). 1 H NMR (500 MHz, DMSO-d6) δ 12.02 (br. s., 1H), 10.37 (s, 1H), 8.48 (s, 1H), 8.34 (d, J = 5.0 Hz, 1H), 8.23 (s, 1H), 7.82 (s, 1H), 7.42 – 7.39 (m, 1H), 5.74 (br. s., 2H), 3.42 (quin, J = 8.3 Hz, 1H), 2.30 – 2.21 (m, 2H), 2.16 – 2.10 (m, 2H), 1.98 – 1.92 (m, 1H), 1.87 – 1.79 (m, 1H) ppm. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2- yl)cyclobutanecarboxamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cyclobuta necarboxamide (300 mg, 0.776 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (29.58 mg, 0.155 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (56.34 mg, 0.077 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (95.61 mg, 0.143 mL, 1.164 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (10 to 100% EtOAc in petroleum ether) followed by HPLC purification to give the titled product (150.34 mg, 0.388 mmol, 50%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.84 (s, 1H), 10.33 (s, 1H), 8.45 (s, 1H), 8.31 (d, J = 5.2 Hz, 1H), 8.16 (s, 1H), 7.53 (d, J = 1.5 Hz, 1H), 7.39 (d, J = 5.2 Hz, 1H), 5.66 (br. s, 2H), 3.41 (q, J = 8.3 Hz, 2H), 2.24 (dq, J = 11.1, 8.7 Hz, 2H), 2.12 (tq, J = 9.3, 4.8 Hz, 2H), 1.94 (h, J = 9.0 Hz, 1H), 1.83 (dd, J = 12.1, 7.5 Hz, 1H), 1.37 (s, 9H) ppm. LRMS (ESI +ve): For C 23 H 25 N 5 O requires 387.49 found 388.2 (M+H). Example 173 N-(4-Iodopyridin-2-yl)cyclopentanecarboxamide To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.56 mmol) in dioxane (2 mL) was added NaHMDS (1.2 eq, 1M solution in THF) at 0 °C under a blanket of argon followed by cyclopentanoyl chloride (0.2275 g, 1.716 mmol) and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 12 hours. The reaction was then quenched by pouring over ice/water 20 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was taken up in dichloromethane (5 mL) and stirred at 0 °C with 2 ml TFA (1M aq ) for 3 hours, then quenched by pouring over ice/saturated NaHCO 3 10 mL and extracted with EtOAc (3 x 30 mL), washed with brine (10 mL), concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as as a cream coloured solid (0.29 g, 58%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.55 (s, 1H), 8.57 (d, J = 1.4 Hz, 1H), 8.03 (d, J = 5.2 Hz, 1H), 7.49 (dd, J = 5.2, 1.5 Hz, 1H), 2.92 (q, J = 7.7 Hz, 1H), 1.84 (ddt, J = 13.4, 5.6, 3.0 Hz, 2H), 1.74 – 1.62 (m, 5H), 1.57 – 1.49 (m, 2H). LRMS (ESI +ve): For C 11 H 13 IN 2 O Molecular Weight: 316.1425 found 317.0 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cyclopent anecarboxamide To a solution of N-(4-iodopyridin-2-yl)cyclopentanecarboxamide (0.29 g, 0.917 mmol) in a degassed solution of dioxane:H2O (18:25 mL) was added cesium carbonate (0.896 g, 2.751 mmol), 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (0.370 g, 1.10 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.077 g, 0.110 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and the crude product used directly in the subsequent reaction. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2- yl)cyclopentanecarboxamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)cyclopent anecarboxamide in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.067 g, 0.0917 mmol) copper iodide (0.0349 g, 0.1834 mmol) and 3,3-dimethylbut-1-yne (0.0753 g, 0.917 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.018 g.5 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.64 (s, 1H), 8.38 (d, J = 1.8 Hz, 1H), 8.34 (d, J = 5.4 Hz, 1H), 8.22 (d, J = 1.7 Hz, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.46 (dd, J = 5.4, 1.7 Hz, 1H), 2.99 (p, J = 7.9 Hz, 1H), 1.94 – 1.84 (m, 2H), 1.80 – 1.65 (m, 4H), 1.59 (ddt, J = 11.8, 8.9, 3.9 Hz, 2H), 1.38 (s, 9H). LRMS (ESI +ve): For C 24 H 27 N 5 O Molecular Weight: 401.5140 found 402.3. Example 174 2-((4-Iodopyridin-2-yl)amino)-2-oxoethyl acetate A solution of 2-chloro-2-oxoethyl acetate (0.62 g, 0.5 mL, 4.55 mmol, 1 Eq) in anhydrous DCM (1 mL) was added dropwise to a solution of 4-iodopyridin-2-amine (1 g, 4.55 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 2 Eq) in Dioxane (5 mL) at 5 ºC. The reaction mixture was allowed to stir at rt for 6 h. The reaction was extracted between EtOAc (10 mL) and saturated solution of NaHCO 3 (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% EtOAc in petroleum ether) to give the titled product as white crystals (0.8 g, 2.5 mmol, 55%). 2-((4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)amino)-2 -oxoethyl acetate To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (1 g, 2.96 mmol, 1 Eq), 2-((4-iodopyridin-2-yl)amino)-2-oxoethyl acetate (0.95 g, 2.96 mmol, 1 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (312 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 80 ºC for 18 h. Cold water (10 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 5 mL). The crude product was dried and purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as brown solid (0.7 g, 1.73 mmol, 58%). 2-((4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl )pyridin-2-yl)amino)-2- oxoethyl acetate 3,3-Dimethylbut-1-yne (204 mg, 0.3 mL, 2.48 mmol, 2 Eq) was added to a solution of 2-((4-(3- amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl acetate (0.5 g, 1.24 mmol, 1 Eq), copper(I) iodide (47 mg, 0.24 mmol, 0.2 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (91 mg, 0.13 mmol, 0.1 Eq) in anhydrous DMF (2 mL) and triethylamine (2 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 60 ºC for 18 h. The reaction mixture was extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as green solid (0.2 g, 0.49 mmol, 40%). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-2- hydroxyacetamide A solution of K 2 CO 3 (138 mg, 1 mmol, 4 Eq) in water (0.5 mL) was added to a solution of 2-((4- (3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)pyrid in-2-yl)amino)-2-oxoethyl acetate (100 mg, 0.25 mmol, 1 Eq) in MeOH (2 mL). The reaction mixture was stirred at rt for 1 h. The produced precipitate was filtered, washed with water (2 × 1 mL), dried and purified using HPLC (60% MeCN in H2O) to give the titled product as white solid (50 mg, 0.14 mmol, 56%). 1 H NMR (500 MHz, DMSO) δ 1.38 (s, 9H), 4.09 (d, J = 5.9 Hz, 2H), 5.66 (s, 2H), 5.82 (t, J = 5.9 Hz, 1H), 7.46 (dd, J = 5.3, 1.7 Hz, 1H), 7.55 (d, J = 1.7 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.42 (d, J = 1.7 Hz, 1H), 9.70 (s, 1H), 11.86 (s, 1H). LRMS: For C 20 H 21 N 5 O 2 requires 363.42 found 364.3 (M+H). Example 175 N-(4-Iodopyridin-2-yl)-2-methoxyacetamide A solution of 2-methoxyacetyl chloride (0.49 g, 0.4 mL, 4.55 mmol, 1 Eq) in anhydrous DCM (1 mL) was added dropwise to a solution of 4-iodopyridin-2-amine (1 g, 4.55 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 2 Eq) in Dioxane (5 mL) at 5 ºC. The reaction mixture was allowed to stir at rt for 6 h. The reaction was extracted between EtOAc (10 mL) and saturated solution of NaHCO 3 (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% EtOAc in petroleum ether) to give the titled product as white crystals (0.9 g, 3.1 mmol, 68%). 1 H NMR (500 MHz, DMSO) δ 3.37 (s, 3H), 4.07 (s, 2H), 7.54 (dd, J = 5.2, 1.5 Hz, 1H), 8.05 (d, J = 5.2 Hz, 1H), 8.52 (d, J = 1.5 Hz, 1H), 10.15 (s, 1H). N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-2-methox yacetamide A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (1 g, 2.96 mmol, 1 Eq), N-(4-iodopyridin-2-yl)-2-methoxyacetamide (0.9 g, 2.96 mmol, 1 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (312 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 70 ºC for 18 h. Cold water (10 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 5 mL). The crude product was dried and purified using column chromatography (95% EtOAc in petroleum ether) to give the titled product as yellow solid (0.4 g, 1.1 mmol, 37%). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-2- methoxyacetamide 3,3-Dimethylbut-1-yne (204 mg, 0.3 mL, 2.48 mmol, 2 Eq) was added to a solution of N-(4-(3- amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-2-methoxyacetami de (0.47 g, 1.24 mmol, 1 Eq), copper(I) iodide (47 mg, 0.24 mmol, 0.2 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (91 mg, 0.13 mmol, 0.1 Eq) in anhydrous DMF (2 mL) and triethylamine (2 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 60 ºC for 18 h. The reaction mixture was extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (95% EtOAc in petroleum ether) followed by HPLC purification (60% MeCN in H2O) to give the titled product as white solid (0.25 g, 0.66 mmol, 53%). 1 H NMR (500 MHz, DMSO) δ 1.38 (s, 9H), 3.41 (s, 3H), 4.12 (s, 2H), 5.67 (s, 2H), 7.45 (dd, J = 5.3, 1.7 Hz, 1H), 7.55 (d, J = 1.6 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.40 (s, 1H), 10.03 (s, 1H), 11.86 (s, 1H). LRMS: For C 21 H 23 N 5 O 2 requires 377.45 found 378.4 (M+H). Example 176 5-(2-(Cyclopropylamino)pyridine-4-yl)-7-((3-methyloxetan-3-y l)ethynyl)-1H-indazol-3- amine To a solution of 7-bromo-5-(2-(cyclopropylamino)pyridin-4-yl)-1H-indazol-3-am ine (0.100 g, 0.290 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.015 g, 0.010 mmol) and 3- ethynyl-3-methyloxetane (0.0341 g, 0.348 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a cream coloured solid (0.028 g, 27 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.93 (s, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 5.3 Hz, 1H), 7.60 (d, J = 1.6 Hz, 1H), 6.88 (dd, J = 5.3, 1.7 Hz, 1H), 6.85 (d, J = 1.6 Hz, 1H), 6.77 (d, J = 2.5 Hz, 1H), 5.63 (s, 2H), 4.92 – 4.90 (m, 2H), 4.46 (d, J = 5.3 Hz, 2H), 2.60 (dh, J = 6.5, 3.3 Hz, 1H), 1.72 (s, 3H), 0.75 (td, J = 6.7, 4.6 Hz, 2H), 0.48 – 0.45 (m, 2H). LRMS (ESI +ve): For C 21 H 21 N 5 O Molecular Weight: 359.4330 found 360.3 Example 177 N-(4-(3-Amino-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-5- yl)pyridin-2-yl)acetamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide (0.1 g, 0.288 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.021 g, 0.0288 mmol) Copper Iodide (0.011 g, 0.0576 mmol), and 3-ethynyl-3-methyloxetane (0.033 g, 0.3456 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a dark brown solid (0.025 g.24 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.99 (s, 1H), 10.53 (s, 1H), 8.40 (s, 1H), 8.33 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 7.61 (d, J = 1.6 Hz, 1H), 7.40 (dd, J = 5.3, 1.7 Hz, 1H), 5.68 (s, 2H), 4.92 (d, J = 5.4 Hz, 2H), 4.45 (d, J = 5.4 Hz, 2H), 2.14 (s, 3H), 1.72 (s, 3H). LRMS (ESI +ve): For C20H19N5O2 Molecular Weight: 361.4050 found 362.2 Example 178 N-(4-(3-Amino-7-(phenylethynyl)-1H-indazol-5-yl)pyridin-2-yl )acetamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide (0.1 g, 0.289 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0395 g, 0.0289 mmol), copper iodide (0.015 g, 0.0789 mmol) and ethynylbenzene (0.0354 g, 0.038 mL, 0.346 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow (0.063 g, 57 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.15 (s, 1H), 10.55 (s, 1H), 8.43 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 8.25 (d, J = 1.5 Hz, 1H), 7.76 (dd, J = 5.8, 1.9 Hz, 3H), 7.52 – 7.43 (m, 4H), 5.73 (s, 2H), 2.15 (s, 3H). LRMS (ESI +ve): For C 22 H 17 N 5 O Molecular Weight: 367.4120 found 368.3. Example 179 Methyl (4-iodopyridin-2-yl)carbamate To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise methyl chloroformate (257.71 mg, 0.21 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% EtOAc in petroleum ether) to give the titled product as a white solid (380 mg, 60%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.33 (s, 1H), 8.26 (d, J = 1.4 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.45 (dd, J = 5.2, 1.5 Hz, 1H), 3.68 (s, 3H) ppm. Methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (508.14 mg, 1.50 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added methyl (4-iodopyridin-2-yl)carbamate (380 mg, 1.36 mmol, 1 Eq), cesium carbonate (1.33 g, 4.08 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (95.46 mg, 0.136 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (90% EtOAc in petroleum ether), to afford the titled compound as a green solid (404 mg, 1.115 mmol, 82%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.00 (s, 1H), 10.23 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.72 (s, 2H), 3.71 (s, 3H) ppm. LRMS (ESI +ve): For C 14 H 12 BrN 5 O 2 requires 362.19 found 362.1, 363.0, 364.0, 365.0 (M+H). Methyl (4-(3-amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin-2 -yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (128.6 mg, 0.355 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (3 mL) were added copper(I) iodide (13.52 mg, 0.071 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (25.97 mg, 0.035 mmol, 0.1 Eq) and ethynylcyclopropane (35.19 mg, 0.045 mL, 0.532 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (73.99 mg, 0.213 mmol, 60%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.87 (s, 1H), 10.20 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.13 (t, J = 1.6 Hz, 2H), 7.56 (d, J = 1.7 Hz, 1H), 7.34 (dd, J = 5.3, 1.7 Hz, 1H), 5.62 (s, 2H), 3.70 (s, 3H), 1.65 – 1.58 (m, 1H), 0.93 – 0.90 (m, 4H) ppm. LRMS (ESI +ve): For C 19 H 17 N 5 O 2 requires 347.38 found 348.1 (M+H). Example 180 Methyl (4-(3-amino-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indazol-5 -yl)pyridin-2- yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.552 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (21 mg, 0.11 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (40.4 mg, 0.055 mmol, 0.1 Eq) and 2-methylbut-3-yn-2-ol (69.64 mg, 0.080 mL, 0.828 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (147.23 mg, 0.402 mmol, 73%). 1 H NMR (500 MHz, DMSO-d6) δ 11.84 (s, 1H), 10.22 (s, 1H), 8.29 (d, J = 5.3 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.57 (d, J = 1.6 Hz, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.67 (s, 2H), 5.46 (s, 1H), 3.71 (s, 3H), 1.54 (s, 6H) ppm. LRMS (ESI +ve): For C19H19N5O3 requires 365.39 found 366.2 (M+H). Example 181 Methyl (4-(3-amino-7-(3-amino-3-methylbut-1-yn-1-yl)-1H-indazol-5-y l)pyridin-2- yl)carbamate1 To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (219 mg, 0.605 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (23.04 mg, 0.121 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (44.26 mg, 0.0605 mmol, 0.1 Eq) and 1,1-dimethyl-prop-2-ynylamine (75.50 mg, 0.095 mL, 0.9082 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 20% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (154.32 mg, 0.423 mmol, 70%). 1 H NMR (500 MHz, DMSO-d6) δ 11.86 (s, 1H), 10.23 (s, 1H), 8.31 – 8.26 (m, 1H), 8.20 – 8.12 (m, 2H), 7.53 (d, J = 1.6 Hz, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.67 (s, 2H), 3.71 (s, 3H), 2.41 (s, 2H), 1.44 (s, 6H) ppm. LRMS (ESI +ve): For C19H20N6O2 requires 364.41 found 365.2 (M+H). Example 182 Methyl (4-(3-amino-7-(3-methoxy-3-methylbut-1-yn-1-yl)-1H-indazol-5 -yl)pyridin-2- yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.552 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (21 mg, 0.11 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (40.4 mg, 0.055 mmol, 0.1 Eq) and 3-methoxy-3-methylbut-1-yne (81.26 mg, 0.1 mL, 0.828 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (115.19 mg, 0.303 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.92 (s, 1H), 10.21 (s, 1H), 8.29 (d, J = 5.3 Hz, 1H), 8.21 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.37 (dd, J = 5.3, 1.7 Hz, 1H), 5.68 (s, 2H), 3.71 (s, 3H), 3.37 (s, 3H), 1.56 (s, 6H) ppm. LRMS (ESI +ve): For C 20 H 21 N 5 O 3 requires 379.42 found 380.2 (M+H). Example 183 Methyl (4-(3-amino-7-(3-morpholinoprop-1-yn-1-yl)-1H-indazol-5-yl)p yridin-2- yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.552 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (21 mg, 0.11 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (40.4 mg, 0.055 mmol, 0.1 Eq) and N-prop-2-ynyl-morpholine (103.63 mg, 0.103 mL, 0.828 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 20% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (157.05 mg, 0.386 mmol, 70%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.93 (s, 1H), 10.21 (s, 1H), 8.29 (d, J = 5.3 Hz, 1H), 8.19 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.64 (d, J = 1.7 Hz, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.66 (s, 2H), 3.71 (s, 3H), 3.63 (t, J = 4.7 Hz, 4H), 3.60 (s, 2H), 2.61 – 2.56 (t, J = 4.8 Hz, 4H) ppm. LRMS (ESI +ve): For C21H22N6O3 requires 406.45 found 407.3 (M+H). Example 184 Methyl (4-(3-amino-7-(4-morpholinobut-1-yn-1-yl)-1H-indazol-5-yl)py ridin-2-yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.552 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (5 mL) were added copper(I) iodide (21 mg, 0.11 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (40.4 mg, 0.055 mmol, 0.1 Eq) and 4-(but-3-yn-1-yl)morpholine (115.24 mg, 0.118 mL, 0.828 mmol, 1.5 Eq), under an tmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a solid (116.05 mg, 0.276 mmol, 50%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.88 (s, 1H), 10.21 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.20 – 8.09 (m, 2H), 7.57 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 5.2, 1.7 Hz, 1H), 5.64 (s, 2H), 3.71 (s, 3H), 3.60 (t, J = 4.6 Hz, 4H), 2.69-2.65 (m, 4H), 2.47 (t, J = 4.7 Hz, 4H) ppm. LRMS (ESI +ve): For C 22 H 24 N 6 O 3 requires 420.47 found 421.3 (M+H). Example 185 1-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)urea In a sealed 10 mL microwave vial methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol- 5-yl)pyridin-2-yl)carbamate (Example 190) (30mg, 0.082 mmol, 1 Eq) was dissolved in 2 mL of THF, then ammonia solution 0.5M in THF (55.85 mg, 0.066 mL, 3.28 mmol, 40 Eq) was added under argon atmosphere. The resulting reaction mixture was heated at 180 °C under microwave irradiation for 2 hours. The reaction mixture was then cooled to ca.40 °C and diluted by dropwise addition of water (5 mL) via syringe. The mixture was stirred and sonicated for 30 minutes and allowed to cool to room temperature. The cap was then removed and a solid was filtered, washed with water (2 X 4 mL) and dried to afford a crude that was purified by HPLC to obtain the titled compound as a yellow solid (9.99 mg, 0.0287 mmol, 35%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.85 (s, 1H), 9.11 (s, 1H), 8.22 (d, J = 5.3 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.74 (s, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.24 (dd, J = 5.5, 1.7 Hz, 1H), 6.97 (br. s. 2H), 5.64 (s, 2H), 1.38 (s, 9H) ppm. LRMS: For C 19 H 20 N 6 O requires 348.41 found 349.3 (M+H). Example 186 1-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-3-methylurea In a sealed 10 mL microwave vial methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol- 5-yl)pyridin-2-yl)carbamate (Example 190) (30mg, 0.082 mmol, 1 Eq) was dissolved in 2 mL of THF, then methylamine 2M in THF (76.91 mg, 0.090 mL, 2.47 mmol, 30 Eq) was added under argon atmosphere. The resulting reaction mixture was heated at 180 °C under microwave irradiation for 2 hours. The reaction mixture was then cooled to ca.40 °C and diluted by dropwise addition of water (5 mL) via syringe. The mixture was stirred and sonicated for 30 minutes and allowed to cool to room temperature. The cap was then removed and a solid was filtered, washed with water (2 x 4 mL) and dried to afford the title compound as a brown solid (20.21 mg, 0.055 mmol, 68%). 1 H NMR (500 MHz, DMSO-d6) δ 11.84 (s, 1H), 9.19 (s, 1H), 8.20 (d, J = 5.4 Hz, 1H), 8.11 (d, J = 1.7 Hz, 1H), 8.10 – 8.02 (m, 1H), 7.65 (s, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.22 (dd, J = 5.4, 1.7 Hz, 1H), 5.62 (s, 2H), 2.75 (d, J = 4.6 Hz, 3H), 1.37 (s, 9H) ppm. LRMS: For C20H22N6O requires 362.44 found 363.1 (M+H). Example 187 1-(4-Iodopyridin-2-yl)-3-ethylurea To a solution of 2-amino-4-iodopyridine (0.38g, 1.73 mmol) in THF (2 mL) in a sealed microwave tube flushed with argon was added ethyl isocyanate (0.123 g, 0.136 mL, 1.73 mmol) under a blanket of argon and heated in a microwave reactor at 100 for 3 hours. The reaction was then quenched by pouring into water 10 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was then purified by flash column chromatography eluting with a gradient of DCM:DCM:NH 3 MeOH 10% (0-50%) to afford the target compound as white solid (0.35 g, 69%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.17 (s, 1H), 7.93 (d, J = 1.5 Hz, 1H), 7.90 (d, J = 5.3 Hz, 1H), 7.71 (s, 1H), 7.31 (dd, J = 5.3, 1.5 Hz, 1H), 3.17 (qd, J = 7.2, 5.4 Hz, 2H), 1.08 (t, J = 7.2 Hz, 3H). LRMS (ESI +ve): For C 8 H 10 IN 3 O Molecular Weight: 291.0925 found 291.7 1-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-ethylu rea To a solution of 1-(4-iodopyridine-2-yl)-3-ethylurea (0.35 g, 1.2 mmol) in a degassed solution of dioxane:H2O (18:2 5 mL) was added cesium carbonate (1.175 g, 3.607 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.485 g, 1.44 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.0842 g, 0.12 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.12 g, 27%). 1 H NMR (500 MHz, DMSO-d6) δ 12.01 (s, 1H), 9.14 (s, 1H), 8.23 (d, J = 5.4 Hz, 1H), 8.17 (d, J = 1.4 Hz, 1H), 8.03 (s, 1H), 7.75 (d, J = 1.3 Hz, 1H), 7.71 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 5.5, 1.7 Hz, 1H), 5.70 (s, 2H), 3.21 (dtd, J = 15.8, 8.6, 7.9, 5.4 Hz, 2H), 1.12 (t, J = 7.2 Hz, 3H). LRMS (ESI +ve): For C15H15BrN6O Molecular Weight: 375.2300 found 375.0, 376.0 1-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-3-ethylurea To a solution of 1-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-ethylu rea (0.12 g, 0.320 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0234 g, 0.032 mmol) copper iodide (0.012 g, 0.064 mmol) and 3,3-dimethylbut-1-yne (0.0315 g, 0.0473 mL, 0.384 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.028 g. 23 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.85 (s, 1H), 9.11 (s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 8.08 (s, 1H), 7.70 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 7.23 (dd, J = 5.5, 1.7 Hz, 1H), 5.63 (s, 2H), 3.22 (qd, J = 7.1, 5.4 Hz, 2H), 1.38 (s, 9H) 1.12 (t, J = 7.2 Hz, 3H). LRMS (ESI +ve): For C21H24N6O Molecular Weight: 376.4640 found 377.3 Example 188 1-(4-Iodopyridin-2-yl)-3-propylurea To a solution of 2-amino-4-iodopyridine (0.38g, 1.73 mmol) in THF (2 mL) in a sealed microwave tube flushed with argon was added propyl isocyanate (0.147 g, 0.163 mL, 1.73 mmol) under a blanket of argon and heated in a microwave reactor at 100 o C for 3 hours. The reaction was then quenched by pouring into water 10 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was then purified by flash column chromatography eluting with a gradient of DCM:DCM:NH3 MeOH 10% (0-50%) to afford the target compound as white solid (0.37 g, 70%). 1 H NMR (500 MHz, DMSO-d6) δ 9.17 (s, 1H), 7.93 (d, J = 1.4 Hz, 1H), 7.90 (d, J = 5.3 Hz, 1H), 7.76 (t, J = 5.4 Hz, 1H), 7.31 (dd, J = 5.3, 1.5 Hz, 1H), 3.11 (q, J = 6.6 Hz, 2H), 1.47 (h, J = 7.3 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H). LRMS (ESI +ve): For Chemical Formula: C9H12IN3O Molecular Weight: 305.1195 found 306.0 1-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-propyl urea To a solution of 1-(4-iodopyridine-2-yl)-3-propylurea (0.37 g, 1.21 mmol) in a degassed solution of dioxane:H 2 O (18:2 5 mL) was added cesium carbonate (1.17 g, 3.6 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.485 g, 1.44 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.085 g, 0.12 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.16 g, 34%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.01 (s, 1H), 9.15 (s, 1H), 8.23 (d, J = 5.4 Hz, 1H), 8.17 (d, J = 1.4 Hz, 1H), 8.09 (s, 1H), 7.75 (d, J = 1.4 Hz, 1H), 7.72 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 5.4, 1.7 Hz, 1H), 5.70 (s, 2H), 3.16 (q, J = 6.6 Hz, 2H), 1.51 (h, J = 7.2 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H). LRMS (ESI +ve): For C16H17BrN6O Molecular Weight: 389.2570 found 389.0, 390.0 1-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-3-propylurea To a solution of 1-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-propyl urea (0.16 g, 0.411 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added copper iodide (0.015 g, 0.082 mmol) [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) catalyst (0.03 g, 0.0411 mmol) and 3,3-dimethylbut-1-yne ( 0.0405 g, 0.060 mL, 0.493 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.036 g.23 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.84 (s, 1H), 9.12 (s, 1H), 8.21 (d, J = 5.4 Hz, 1H), 8.13 (d, J = 1.6 Hz, 2H), 7.71 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 7.23 (dd, J = 5.4, 1.7 Hz, 1H), 5.63 (s, 2H), 3.16 (q, J = 6.6 Hz, 2H), 1.51 (h, J = 7.3 Hz, 2H), 1.38 (s, 9H) 0.92 (t, J = 7.4 Hz, 3H). LRMS (ESI +ve): For C 22 H 26 N 6 O Molecular Weight: 390.4910 found 391.3 Example 189 1-(4-Iodopyridin-2-yl)-3-phenylurea To a solution of 2-amino-4-iodopyridine (0.38g, 1.73 mmol) in THF (2 mL) in a sealed microwave tube flushed with argon was added phenyl isocyanate (0.206 g, 0.189 mL, 1.73 mmol) under a blanket of argon and heated in a microwave reactor at 100 °C for 3 hours. The reaction was then quenched by pouring into water 10 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was then purified by flash column chromatography eluting with a gradient of DCM:DCM:NH3 MeOH 10% (0-50%) to afford the target compound as a white solid (0.41 g, 70%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.04 (s, 1H), 9.42 (s, 1H), 8.08 (d, J = 1.4 Hz, 1H), 8.00 (d, J = 5.3 Hz, 1H), 7.53 – 7.49 (m, 2H), 7.42 (dd, J = 5.3, 1.5 Hz, 1H), 7.35 – 7.30 (m, 2H), 7.06 – 7.02 (m, 1H). LRMS (ESI +ve): For C12H10IN3O Molecular Weight: 339.1365 found 339.7 1-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-phenyl urea To a solution of 1-(4-iodopyridine-2-yl)-3-phenylurea (0.41 g, 1.21 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added cesium carbonate (1.182 g, 3.627 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.488 g, 1.45 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.085 g, 0.121 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.17 g, 33%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.03 (s, 1H), 10.40 (s, 1H), 9.43 (s, 1H), 8.33 (d, J = 5.5 Hz, 1H), 8.22 (d, J = 1.5 Hz, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.80 (d, J = 1.5 Hz, 1H), 7.57 – 7.54 (m, 2H), 7.36 – 7.31 (m, 4H), 7.05 (d, J = 7.4 Hz, 1H), 5.73 (s, 2H). LRMS (ESI +ve): For Chemical Formula: C 19 H 15 BrN 6 O Molecular Weight: 423.2740 found 423.0, 424.0 1-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridine-2-yl)-3-phenylurea To a solution of 1-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)-3-phenyl urea (0.17 g, 0.402 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.029 g, .0402 mmol), copper Iodide (0.0153 g, 0.0803 mmol) and 3,3-dimethylbut-1-yne (0.0396 g, 0.0594 mL 0.482 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a an off-white powder (0.043 g.25 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.87 (s, 1H), 10.48 (s, 1H), 9.42 (s, 1H), 8.32 (d, J = 5.4 Hz, 1H), 8.17 (d, J = 1.6 Hz, 1H), 7.87 – 7.83 (m, 1H), 7.58 – 7.53 (m, 3H), 7.36 – 7.31 (m, 3H), 7.04 (tt, J = 7.3, 1.2 Hz, 1H), 5.66 (s, 2H), 1.38 (s, 9H). LRMS (ESI +ve): For C25H24N6O Molecular Weight: 424.5080 found 425.3. Example 190 Methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)py ridin-2-yl)carbamate To a solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.552 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) was added copper(I) iodide (21 mg, 0.11 mmol, 0.2 Eq), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) catalyst (40.4 mg, 0.055 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (68.03 mg, 0.102 mL, 0.828 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (95% EtOAc in petroleum ether) followed by HPLC purification to give the titled product as white solid (122.4 mg, 0.33 mmol, 61%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.83 (s, 1H), 10.21 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.14 (dd, J = 9.8, 1.8 Hz, 2H), 7.52 (s, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.64 (s, 2H), 3.71 (s, 3H), 1.37 (s, 9H) ppm. LRMS (ESI +ve): For C 20 H 21 N 5 O 2 Molecular Weight: 363.42 found 364.0 (M+H). Example 191 Ethyl (4-iodopyridin-2-yl)carbamate To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise ethyl chloroformate (295.60 mg, 0.260 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% EtOAc in petroleum ether) to give the titled product as a white solid (380 mg, 1.30 mmol, 80%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.25 (s, 1H), 8.26 (d, J = 1.1 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.44 (dd, J = 5.2, 1.5 Hz, 1H), 4.14 (q, J = 7.1 Hz, 2H), 1.24 (t, J = 7.1 Hz, 3H) ppm. Ethyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate To a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (508.14 mg, 1.50 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added ethyl (4-iodopyridin-2-yl)carbamate (380 mg, 1.36 mmol, 1 Eq), cesium carbonate (1.33 g, 4.08 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (95.46 mg, 0.136 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (90% EtOAc in petroleum ether), to afford the titled compound as a green solid (404 mg, 1.115 mmol, 82%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.00 (s, 1H), 10.23 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.36 (dd, J = 5.3, 1.7 Hz, 1H), 5.72 (s, 2H), 3.71 (s, 3H) ppm. Ethyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)py ridin-2-yl)carbamate To a solution of ethyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (200 mg, 0.532 mmol, 1 Eq) in a degassed 4:1 solution of DMF/triethylamine (2 mL) were added copper(I) iodide (20.26 mg, 0.106 mmol, 0.2 Eq), [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (38.93 mg, 0.053 mmol, 0.1 Eq) and 3,3-dimethylbut-1-yne (65.55 mg, 0.098 mL, 0.798 mmol, 1.5 Eq), under an atmosphere of argon. The reaction was then sealed and heated at 70 °C for 18 hours. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (95% EtOAc in petroleum ether) followed by HPLC purification to give the titled product as a yellow solid (120.5 mg, 0.32 mmol, 60%). 1 H NMR (500 MHz, DMSO-d6) δ 11.83 (br. s, 1H), 10.12 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 8.14 (dd, J = 10.0, 1.7 Hz, 2H), 7.52 (d, J = 1.7 Hz, 1H), 7.35 (dd, J = 5.3, 1.7 Hz, 1H), 5.64 (s, 2H), 4.17 (q, J = 7.1 Hz, 2H), 1.27 (t, J = 7.1 Hz, 3H) ppm. LRMS (ESI +ve): For C21H23N5O2 Molecular Weight: 377.45 found 378.1 (M+H). Example 192 tert-Butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.344 g, 1.081 mmol) in a degassed solution of dioxane:H 2 O (18:25 mL) was added ceasium carbonate (1.056 g, 3.24 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.437 g, 1.297 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.038 g, 0.054 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a brown solid (0.214 g, 49%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.99 (s, 1H), 9.79 (s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.19 (d, J = 1.4 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.79 (d, J = 1.5 Hz, 1H), 7.33 (dd, J = 5.3, 1.7 Hz, 1H), 5.72 (s, 2H), 1.51 (s, 9H). LRMS (ESI +ve): For C 17 H 18 BrN 5 O 2 Molecular Weight: 404.2680 found 404.0, 405.0 tert-Butyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)py ridin-2- yl)carbamate To a solution of tert-Butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.25 g, 0.62 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.045 g, 0.062 mmol) and copper iodide (0.0236 g, 0.124 mmol), 3,3-dimethylbut-1-yne (0.061 g, 0.092 mL, 0.744 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a brown solid (0.186 g, 35 %). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.83 (s, 1H), 9.77 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 1.7 Hz, 1H), 7.32 (dd, J = 5.2, 1.7 Hz, 1H), 5.65 (s, 2H), 1.51 (s, 9H), 1.38 (s, 9H). LRMS (ESI +ve): For Chemical Formula: C 23 H 27 N 5 O 2 Molecular Weight: 405.5020 found 406.3 Example 193 N-(4-Iodopyridin-2-yl)methanesulfonamide To a solution of tert-butyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.56 mmol) in dioxane (2 mL) was added NaHMDS (1.2 eq, 1M solution in THF) at 0 °C under a blanket of argon followed by methanesulfonyl chloride (0.57 g, 5 mmol) and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 12 hours. The reaction was then quenched by pouring over ice/water 20 mL and extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated to afford the crude product which was taken up in DCM (5 mL) and stirred at 0 °C with 2 ml TFA (1Maq) for 3 hours, then quenched by pouring over ice/saturated NaHCO3Aq 10 mL and extracted with EtOAc (3 x 30 mL), washed with brine (10 mL), concentrated and purified by flash column chromatography eluting with a gradient of EtOAc:Petroleum Ether (0-50%) to afford the target compound as a light yellow coloured solid (0.34 g, 73%). 1 H NMR (500 MHz, DMSO-d6) δ 8.24 (d, J = 5.2 Hz, 1H), 8.00 (d, J = 1.4 Hz, 1H), 7.91 (dd, J = 5.1, 1.5 Hz, 1H), 3.52 (s, 3H), 1.40 (s, 9H).LRMS (ESI +ve): For C11H15IN2O4S Molecular weight 398.2155 found 399.0 tert-Butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)(methylsulf onyl)carbamate To a solution of tert-butyl (4-iodopyridin-2-yl)(methylsulfonyl)carbamate (0.11 g, 0.28 mmol) in a degassed solution of dioxane:H2O (18:25 mL) was added caesium carbonate (0.274 g, 0.84 mmol), 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (0.113 g, 0.34 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.020 g, 0.028 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50-100% petroleum ether: EtOAc to afford the desired compound as a dark brown oil (0.089 g, 65%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.09 (s, 1H), 8.57 (d, J = 5.2 Hz, 1H), 8.42 (s, 1H), 8.04 (d, J = 1.5 Hz, 1H), 8.01 – 7.92 (m, 2H), 5.73 (s, 2H), 3.58 (s, 3H), 1.43 (s, 9H). LRMS (ESI +ve): For C 18 H 20 BrN 5 O 4 S Molecular weight 482.3530 found 482.1 N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridine-2- yl)methanesulfonamide To a solution of tert-butyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2- yl)(methylsulfonyl)carbamate (0.089 g, 0.184 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.010 g, 0.013 mmol), copper iodide (0.005 g, 0.026 mmol) and 3,3-dimethylbut-1-yne (0.018 g, 0.027 mL 0.219 mmol), under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and treated with TFA/DCM (1%) at 0 °C for 1 hour quenched with saturated sodium bicarbonate (10 mL) and the organic layer concentrated under reduced pressure followed by purification by HPLC to afford the target compound as a yellow solid (0.023 g. 33 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.48 – 8.46 (m, 1H), 8.44 (d, J = 5.4 Hz, 1H), 8.32 – 8.28 (m, 2H), 7.94 (dd, J = 5.0, 1.1 Hz, 1H), 7.69 (d, J = 1.7 Hz, 1H), 7.56 (dd, J = 5.4, 1.8 Hz, 1H), 7.26 (dd, J = 5.0, 3.8 Hz, 1H), 1.39 (s, 9H). LRMS (ESI +ve): For C19H21N5O2S Molecular Weight: 383.4700 found 386.2. Example 194 N-(4-iodopyridin-2-yl)methanesulfonamide To a solution of 4-iodopyridin-2-amine (380 mg, 1.36 mmol) in 3.4 ml of pyridine cold down at 0 °C was added methyl sulfonyl chloride (0.12 mL, 1.52 mmol). The reaction mixture was run at RT for 2 hours. The resulting mixture was diluted with EtOAc, quenched with NaHCO 3 , extracted with EtOAc, dry over MgSO 4 , concentrated under reduced pressure and the residue was purified by column chromatography (First column: Toluene/EtOAc 7:3; Second column Petrol 60-80/Acetone 8:2) to give the product as an orange solid. (120 mg, 30%). 1 H NMR (400 MHz, DMSO-d6 and (CD3)2CO): ^ 3.14 (s, 3H), 7.41 (dd, J = 5.4, 1.5 Hz, 1H), 7.45 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 5.4 Hz, 1H), 10.74 (br s, 1H). LRMS: Calculated for C 19 H 26 BN 3 O 2 297.9 found 298.9 (M+1) N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2- yl)methanesulfonamide A solution of N-(4-iodopyridin-2-yl)methanesulfonamide (60 mg, 0.20 mmol), Cs2CO3 (217 mg, 0.67 mmol), bis(triphenylphosphine) palladium(II) chloride (38 mg, 0.05 mmol) and 7-(3,3- dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-1H-indazol-3-amine (76 mg, 0.22 mmol) in 1 ml of dioxane-water (4:1) was degassed in sealed tube and submitted to reaction. The reaction mixture was heated to 80 °C, o/n. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by HPLC to afford the title compound as a dark yellow solid. (12 mg, 16%). 1 H NMR (400 MHz, (CD 3 ) 2 CO): ^ 1.38 (s, 9H), 3.30 (s, 3H), 5.13 (br s, 2H), 7.36 (dd, J = 5.5, 1.7 Hz, 1H), 7.44 (dd, J = 1.7, 0.8 Hz, 1H), 7.65 (d, J = 1.6 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 8.29 (dd, J = 5.5, 0.8 Hz, 1H), 11.15 (br s, 1H), 1 proton missing. LRMS: Calculated for C19H21N5O2S 383.1 found 384.1 (M+1). Example 195 6-Fluoro-4-iodopyridin-2-amine To a solution of 2, 6-difluoro-4-iodopyridine (1.15 g, 4.77 mmol) in dioxane (5mL) was added ammonium hydroxide (10mL 28% in H2O) the reaction was the flushed with argon, sealed and stirred at 80°C for 3 hours by microwave irradiation. The reaction was cooled, partitioned between EtOAc and H 2 O and the aqueous layer washed a further 2 times with EtOAc (2 x 30 mL). The combined organic layers were washed with brine and concentrated under reduced pressure. Purification by flash column chromatography afforded the desired compound as a clear oil (0.90 g, 79%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 7.61 (d, J = 5.4 Hz, 1H), 6.87 (d, J = 1.5 Hz, 1H), 6.82 (dd, J = 5.3, 1.5 Hz, 1H), 6.08 (s, 2H). 19 F NMR (471 MHz, DMSO-d 6 ) δ -70.62. LRMS (ESI +ve): For C 5 H 4 IFN 2 Molecular weight 238.0039 found 239.0 N-(6-Fluoro-4-iodopyridin-2-yl)acetamide To a solution of 6-fluoro-4-iodopyridin-2-amine (0.3g, 0.3 mmol) in dioxane cooled to 0 °C was added NaH (0.181 g, 4.54 mmol, 60 % suspension, 2 eq) under a blanket of argon. Acetyl chloride (0.18 g, 0.16 mmol) was then added dropwise and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 3 hours. The reaction was then quenched by pouring over ice/water 20 mL, extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash eluting with a gradient of EtOAc:Petroleum Ether (50-100%) to afford the target compound as a cream coloured solid (0.21 g, 60%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.77 (s, 1H), 8.41 (t, J = 1.3 Hz, 1H), 7.34 (dd, J = 2.8, 1.0 Hz, 1H), 2.09 (s, 3H). 19 F NMR (376 MHz, DMSO-d6) δ -69.67. N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)-6-fluoropyridin-2-yl) acetamide To a solution of N-(6-fluoro-4-iodopyridin-2-yl)acetamide (0.21 g, 0.75 mmol) in a degassed solution of dioxane:H2O (18:25 mL) was added cesium carbonate (0.733 g, 2.25 mmol), 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (0.303 g, 0.90 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.053 g, 0.075 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a yellow solid (0.177 g, 65%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.06 (s, 1H), 10.71 (s, 1H), 8.33 (d, J = 1.7 Hz, 1H), 8.25 (d, J = 1.5 Hz, 1H), 7.85 (d, J = 1.5 Hz, 1H), 7.17 (s, 1H), 5.75 (s, 2H), 2.14 (s, 3H). 19 F NMR (471 MHz, DMSO-d 6 ) δ -70.62. LRMS (ESI +ve): For C 14 H 11 BrFN 5 O Molecular Weight: 364.1784 found 364.0, 365.0 N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) -6-fluoropyridin-2- yl)acetamide To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)-6-fluoropyridin-2-yl) acetamide (0.35 g, 0.961 mmol) in a degassed 4:1 solution of DMF:triethylamine (5 mL) was added [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.035 g, 0.048 mmol) copper iodide (0.018 g, 0.096 mmol) and 3,3-dimethylbut-1-yne (0.082 g, 1.0 mmol) under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatographyutilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a cream colored solid (0.112 g.32 %). 1 H NMR (500 MHz, DMSO-d6) δ 11.91 (s, 1H), 10.70 (s, 1H), 8.32 (s, 1H), 8.21 (s, 1H), 7.57 (s, 1H), 7.15 (s, 1H), 5.68 (s, 2H), 2.14 (s, 3H), 1.38 (s, 9H). 19 F NMR (471 MHz, DMSO-d6) δ -70.80. LRMS (ESI +ve): For C20H20FN5O Molecular Weight: 365.4124 found 366.3 Examples 196 and 197 N-(4-Iodopyridin-2-yl)acetamide To a solution of 4-iodopyridin-2-amine (0.5g 2.27 mmol) in dioxane cooled to 0 °C was added NaH (0.181 g, 4.54 mmol, 60 % suspension, 2 eq) under a blanket of argon. Acetyl Chloride (0.18 g, 0.16 mmol) was then added dropwise and the resulting reaction mixture allowed to warm up to room temperature and stirred at this temperature for 3 hours. The reaction was then quenched by pouring over ice/water 20 mL, extracted with EtOAc (3 x 30 mL) and washed with brine (10 mL). The combined organic layers were concentrated and purified by flash eluting with a gradient of EtOAc:Petroleum Ether (50-100%) to afford the target compound as an off white solid ( 0.40 g, 67%) 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.59 (s, 1H), 8.52 (d, J = 1.7 Hz, 1H), 8.03 (dd, J = 5.2, 0.6 Hz, 1H), 7.50 (dd, J = 5.2, 1.5 Hz, 1H), 2.09 (s, 3H). LRMS (ESI +ve): For C 7 H 7 IN 2 O Molecular Weight: 262.0505 found 263.4 N-(4-(3-Amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide To a solution of N-(4-iodopyridin-2-yl)acetamide (0.2 g, 0.755 mmol) in a degassed solution of dioxane:H2O (18:2 5 mL) was added cesium carbonate (0.738 g, 2.264 mmol), 7-bromo-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.31 g, 0.916 mmol) and bis(triphenylphosphine)palladium(II) dichloride catalyst (0.027 g, 0.038 mmol) under an atmosphere of argon. The reaction was then sealed and stirred at 90 °C for 18 hours. The cooled reaction was then diluted with EtOAc (30 mL) and washed with water (30 mL) and brine (10 mL). The organic layer was then concentrated under reduced pressure and purified by flash column chromatography eluting from 50 -100% petroleum ether: EtOAc to afford the desired compound as a light brown solid (0.18 g, 68%). 1 H NMR (500 MHz, DMSO-d6) δ 12.01 (s, 1H), 10.54 (s, 1H), 8.40 (s, 1H), 8.35 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.4 Hz, 1H), 7.79 (s, 1H), 7.40 (dd, J = 5.4, 1.7 Hz, 1H), 5.72 (s, 2H), 2.14 (s, 3H). LRMS (ESI +ve): C14H12BrN5O Molecular Weight: 346.1880 found 346.0, 347.0 N-(4-(3-Amino-7-phenyl-1H-indazol-5-yl)pyridin-2-yl)acetamid e (Example 196) To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide (0.07 g, 0.02022 mmol) in a degassed dioxane:H 2 O (18:25 mL) was added cesium carbonate (0.1976 g, 0.6066 mmol), phenylboronic acid (0.1219 g, 0.02426 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.002022 mmol) under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a dark brown solid (0.058 g.84%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.74 (s, 1H), 10.52 (s, 1H), 8.48 (s, 1H), 8.36 (s, 1H), 8.19 (s, 1H), 7.83 – 7.71 (m, 2H), 7.64 – 7.45 (m, 5H), 5.63 (s, 2H), 2.14 (s, 3H). LRMS (ESI) m/z [M] + .For C 20 H 17 N 5 O Molecular Weight: 343.3900 found 344.3 N-(4-(3-Amino-7-(pyridin-4-yl)-1H-indazol-5-yl)pyridin-2-yl) acetamide (Example 197) To a solution of N-(4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)acetamide (0.07 g, 0.02022 mmol) in a degassed dioxane:H 2 O (18:25 mL) was added cesium carbonate (0.1976 g, 0.6066 mmol), 4-pyridylboronic acid (0.1219 g, 0.02426 mmol) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.002022 mmol) under an atmosphere of argon. The reaction was then sealed and heated at 90 °C for 18 hours. The cooled reaction was diluted with EtOAc and washed with water (20 mL) and brine (10 mL). The organic layer was concentrated under reduced pressure and purified by flash column chromatography utilising NH silica cartridges from Biotage eluting with 50-100% petroleum ether: EtOAc to afford the target compound as a yellow solid (0.034 g. 34%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.08 – 11.75 (m, 1H), 10.55 (s, 1H), 8.72 (s, 2H), 8.55 – 8.25 (m, 3H), 7.80 (s, 3H), 7.52 (s, 1H), 5.74 (s, 2H), 2.15 (s, 3H). LRMS (ESI +ve): Chemical Formula: C 19 H 16 N 6 O Molecular Weight: 344.3780 found 345.2 Example 306 Methyl (4-(3-amino-7-phenyl-1H-indazol-5-yl)pyridin-2-yl)carbamate SU1742 A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (1.1 g, 2.96 mmol, 1 Eq), phenylboronic acid (0.5 g, 4.44 mmol, 1.5 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II ) (322 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 80 ºC for 1 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as white solid (0.5 g, 1.4 mmol, 47%).1H NMR (500 MHz, DMSO) δ 11.75 (s, 1H), 10.22 (s, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.23 (d, J = 1.6 Hz, 1H), 8.20 (d, J = 1.7 Hz, 1H), 7.77 (d, J = 7.6 Hz, 2H), 7.63 (d, J = 1.6 Hz, 1H), 7.55 (t, J = 7.6 Hz, 2H), 7.48 – 7.42 (m, 2H), 5.63 (s, 2H), 3.72 (s, 3H). LC-MS: For C20H17N5O2 requires 359.39 found 360.3 (M+H). Example 307 Methyl (4-(3-amino-7-(4-(difluoromethyl)phenyl)-1H-indazol-5-yl)pyr idin-2-yl)carbamate A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (1.1 g, 2.96 mmol, 1 Eq), (4-(difluoromethyl)phenyl)boronic acid (0.76 g, 4.44 mmol, 1.5 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (322 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 80 ºC for 1 h. The reaction mixture was poured onto cold water (10 mL). The produced ppt was filtered, washed with water (5 mL), dried and purified using column chromatography (5% MeOH in EtOAc) to give the titled product as white solid (0.7 g, 1.7 mmol, 58%). 1H NMR (500 MHz, DMSO) δ 11.81 (s, 1H), 10.23 (s, 1H), 8.32 (d, J = 5.2 Hz, 1H), 8.24 (s, 2H), 7.91 (d, J = 7.8 Hz, 2H), 7.83 – 7.64 (m, 3H), 7.47 (d, J = 5.2 Hz, 1H), 7.15 (t, J = 55.9 Hz, 1H), 5.67 (s, 2H), 3.72 (s, 3H). LC-MS: For C21H17F2N5O2 requires 409.40 found 410.2 (M+H). Example 282 N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)oxazol-2-amine [00221] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), N-(4-chloropyridin-2-yl)oxazol-2-amine (0.34 g, 1.76 mmol, 1.2 Eq), cesium carbonate (1 g, 2.94 mmol, 2 Eq) and 1,1'-bis(di-tert- butylphosphino) ferrocene palladium chloride (144 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 4 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) followed by HPLC purification (60% MeCN in H2O) to give the titled product as yellow solid (186 mg, 0.5 mmol, 35%). 1 H NMR (500 MHz, DMSO-d6) δ 11.84 (s, 1H), 10.74 (s, 1H), 8.32 – 8.26 (m, 2H), 8.15 (d, J = 1.7 Hz, 1H), 7.73 (s, 1H), 7.53 (d, J = 1.7 Hz, 1H), 7.26 (d, J = 5.3 Hz, 1H), 7.13 – 7.09 (m, 1H), 5.64 (s, 2H), 1.38 (s, 9H). LRMS: Calculated for C21H20N6O requires 372.43 found 373.3 (M+H). Route to Example 282 N-(4-Chloropyridin-2-yl)oxazol-2-amine [00222] A mixture of palladium(II) acetate (67 mg, 0.3 mmol, 0.05 Eq) and xantphos (335 mg, 0.6 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (1.7 g, 8.92 mmol, 1.5 Eq), oxazol-2-amine (0.5 g, 5.95 mmol, 1 Eq) and Cs2CO3 (3.9 g, 11.9 mmol, 2 Eq) in toluene (2 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 30 h. The organic solvent was removed under reduced pressure. The crude residue was stirred in MeOH (10 mL) for 30 min., filtered and washed with MeOH (2 × 3 mL). The filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (20% EtOAc in petroleum ether) to give the tilted product as white solid (350 mg, 1.8 mmol, 30%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.06 – 7.12 (m, 2H), 7.75 (d, J = 1.0 Hz, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.25 (d, J = 5.4 Hz, 1H), 11.07 (s, 1H). LRMS: Calculated for C 8 H 6 ClN 3 O requires 195.61 found 196.1 (M+H). Example 283 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3,3,3-trifluoropropyl)a mino)pyridin-4-yl)-1H-indazol-3- amine [00223] 3,3-Dimethylbut-1-yne (204 mg, 0.3 mL, 2.48 mmol, 2 Eq) was added to a solution of 7-bromo-5-(2-((3,3,3-trifluoropropyl)amino)pyridin-4-yl)-1H- indazol-3-amine (0.5 g, 1.24 mmol, 1 Eq), copper(I) iodide (47 mg, 0.24 mmol, 0.2 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (91 mg, 0.13 mmol, 0.1 Eq) in anhydrous DMF (2 mL) and triethylamine (2 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 60 ºC for 18 h. The reaction mixture was extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (70% EtOAc in petroleum ether) followed by HPLC purification (60% MeCN in H2O) to give the titled product as white solid (80 mg, 0.2 mmol, 16%). 1 H NMR (500 MHz, DMSO) δ 1.37 (s, 9H), 2.56 (dt, J = 11.6, 7.0 Hz, 2H), 3.56 (q, J = 6.7 Hz, 2H), 5.58 (s, 2H), 6.70 (t, J = 5.8 Hz, 1H), 6.77 (d, J = 1.6 Hz, 1H), 6.85 (dd, J = 5.3, 1.6 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 8.05 (d, J = 5.4 Hz, 1H), 8.08 (d, J = 1.6 Hz, 1H), 11.77 (s, 1H). LRMS: Calculated for C21H22F3N5 requires 401.44 found 402.3 (M+H). Route to Example 283 4-Iodo-N-(3,3,3-trifluoropropyl)pyridin-2-amine [00224] A solution of 2-fluoro-4-iodopyridine (1 g, 4.49 mmol, 1 Eq), 3,3,3-trifluoropropan-1- amine (1 g, 0.8 mL, 8.98 mmol, 2 Eq) and triethylamine (1.4 g, 2 mL, 13.47 mmol, 3 Eq) in DMSO (5 mL) was stirred in a sealed vial (20 mL) at 100 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (3 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified through column chromatography (20% EtOAc in petroleum ether) to give the titled product as white solid (0.8 g, 2.5 mmol, 56%). 1 H NMR (500 MHz, DMSO) δ 2.45 – 2.56 (m, 2H), 3.47 (td, J = 7.0, 5.8 Hz, 2H), 6.84 – 6.92 (m, 2H), 6.94 (d, J = 1.4 Hz, 1H), 7.72 (d, J = 5.3 Hz, 1H). 7-Bromo-5-(2-((3,3,3-trifluoropropyl)amino)pyridin-4-yl)-1H- indazol-3-amine [00225] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (1 g, 2.96 mmol, 1 Eq), 4-iodo-N-(3,3,3-trifluoropropyl)pyridin-2-amine (0.94 g, 2.96 mmol, 1 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (312 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 80 ºC for 18 h. Cold water (10 mL) was added to the reaction mixture. The produced precipitate was filtered and washed with cold water (2 × 5 mL). The crude product was filtered through silica and dried to be used in the next step without further purification (0.5 g, 1.25 mmol, 42%). Example 284 7-(Cyclopropylethynyl)-5-(2-(oxetan-3-ylamino)pyridin-4-yl)- 1H-indazol-3-amine SU1719 [00226] To a solution of 7-(cyclopropylethynyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)- 1H-indazol-3-amine (70 mg, 0.216 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodo-N-(oxetan-3-yl)pyridin-2-amine (54.35 mg, 0.196 mmol, 1 Eq), cesium carbonate (191.58 mg, 0.588 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (14.74 mg, 0.021 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (135.39 mg, 0.39 mmol, 50%). 1 H NMR (500 MHz, DMSO-d6) δ 11.82 (s, 1H), 8.05 (d, J = 1.6 Hz, 1H), 8.00 (d, J = 5.4 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 6.3 Hz, 1H), 6.85 (dd, J = 5.4, 1.6 Hz, 1H), 6.73 (s, 1H), 5.56 (s, 2H), 4.96 (q, J = 6.6 Hz, 1H), 4.84 (t, J = 6.7 Hz, 2H), 4.47 (t, J = 6.2 Hz, 2H), 1.62 (tt, J = 7.9, 5.1 Hz, 1H), 0.95 – 0.90 (m, 4H) ppm. LRMS (ESI +ve): Calculated for C20H19N5O requires 345.41 found 346.2 (M+H). Route to Example 284 4-Iodo-N-(oxetan-3-yl)pyridin-2-amine [00227] In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 3 mL of DMSO. Then 3-aminooxetane (97.57 mg, 0.936 mL, 1.78 mmol, 1.5 Eq) and triethylamine (270.17mg, 0.372 mL, 2.67mmol, 3 Eq) were added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. [00228] The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (135.14 mg, 0.49 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.67 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 6.0 Hz, 1H), 6.95 – 6.83 (m, 2H), 4.88 – 4.80 (m, 1H), 4.77 (dd, J = 7.3, 5.8 Hz, 2H), 4.40 (t, J = 6.1 Hz, 2H). ppm. 7-(Cyclopropylethynyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-1H-indazol-3-amine [00229] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (1.00 g, 3.0 mmol, 1 Eq), copper (I) iodide (0.100 g, 0.5 mmol, 0.15 Eq) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol, 0.1 Eq) in 10 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of ethynylcyclopropane (1.01 mL, 12 mmol, 4 Eq). The reaction mixture was heated to 80 °C for 1.2h. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (60% EtOAc in petroleum ether) to give the product as a brown foam (0.563 g, 1.65 mmol, 55%). 1 H NMR (500 MHz, DMSO-d6): ^ 11.77 (s, 1H), 8.11 (s, 1H), 7.44 (s, 1H), 5.56 (s, 2H), 1.57 (ddd, J = 13.0, 8.1, 5.2 Hz, 1H), 1.29 (s, 12H), 0.90 – 0.85 (m, 4H) ppm. LRMS: Calculated for C 18 H 22 BN 3 O 2 requires 323.2 found 324.3 (M+1). Example 285 Methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)py ridin-2-yl)carbamate [00230] To a solution of 7-((tetrahydro-2H-pyran-4-yl)ethynyl)-5-(4,4,5,5-tetramethyl -1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (116.23 mg, 0.316 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added methyl (4-iodopyridin-2-yl)carbamate (80 mg, 0.287 mmol, 1 Eq), cesium carbonate (280.53 mg, 0.861 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (20.14 mg, 0.028 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a white solid (73.02 mg, 0.19 mmol, 65%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.90 (s, 1H), 10.22 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.18 (d, J = 1.6 Hz, 1H), 8.15 (s, 1H), 7.60 (d, J = 1.6 Hz, 1H), 7.37 (dd, J = 5.4, 1.8 Hz, 1H), 5.66 (s, 2H), 3.88 (dt, J = 11.6, 4.3 Hz, 2H), 3.72 (s, 3H), 3.49 (td, J = 9.0, 4.6 Hz, 2H), 2.99 (tt, J = 8.8, 4.1 Hz, 1H), 1.92 (dq, J = 12.4, 4.0 Hz, 2H), 1.76 (dtd, J = 12.9, 9.1, 3.7 Hz, 2H) ppm. LRMS (ESI +ve): Calculated for C 21 H 21 N 5 O 3 requires 391.43 found 392.2 (M+H). Route to Example 285 Methyl (4-iodopyridin-2-yl)carbamate [00231] To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise methyl chloroformate (257.71 mg, 0.21 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% EtOAc in petroleum ether) to give the titled product as a white solid (523.85 mg, 1.88 mmol, 83%). 1 H NMR (500 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.26 (d, J = 1.4 Hz, 1H), 7.98 (d, J = 5.2 Hz, 1H), 7.45 (dd, J = 5.2, 1.5 Hz, 1H), 3.68 (s, 3H) ppm. 7-((Tetrahydro-2H-pyran-4-yl)ethynyl)-5-(4,4,5,5-tetramethyl -1,3,2-dioxaborolan-2-yl)-1H- indazol-3-amine [00232] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (200 mg, 0.59 mmol, 1 Eq), copper (I) iodide (23 mg, 0.12 mmol, 0.2 Eq) and [1,1'- bis(diphenylphosphino)ferrocene]palladium(II) dichloride (43 mg, 0.06 mmol, 0.1 Eq) in 2 ml of N,N-dimethyformamide-triethylamine (1:1) was degassed in sealed tube followed by addition of 4-ethynyltetrahydro-2H-pyran (0.2 mL, 1.18 mmol, 2 Eq). The reaction mixture was heated to 80 °C for 2h. The reaction was then diluted with EtOAc (30 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (80% EtOAc in petroleum ether) to give the titled product as brown crystals (100 mg, 0.27 mmol, 46%). 1 H NMR (500 MHz, DMSO-d 6 ): ^ 1.30 (s, 12H), 1.72 (ddt, J = 13.7, 9.2, 4.5 Hz, 2H), 1.84 – 1.94 (m, 2H), 2.94 (tt, J = 8.7, 4.1 Hz, 1H), 3.48 (ddd, J = 11.6, 8.9, 2.9 Hz, 2H), 3.85 (dt, J = 11.5, 4.3 Hz, 2H), 5.61 (s, 2H), 7.50 (s, 1H), 8.16 (s, 1H), 11.81 (s, 1H). LRMS (ESI +ve): Calculated for C20H26BN3O3 requires 367.26 found 368.3 (M+H). Example 286 Methyl (4-(3-amino-7-((3-methyloxetan-3-yl)ethynyl)-1H-indazol-5-yl )pyridin-2- yl)carbamate [00233] 7-((3-Methyloxetan-3-yl)ethynyl)-5-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)-1H- indazol-3-amine (0.5 g, 1.4 mmol, 1 Eq), methyl (4-iodopyridin-2-yl)carbamate (0.47 g, 1.68 mmol, 1.2 Eq), cesium carbonate (1.4 g, 4.2 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (148 mg, 0.21 mmol, 0.15 Eq) were added to the crude residue. The mixture was dissolved in dioxane (4 mL) and water (1 mL) and stirred under nitrogen atmosphere at 80 ºC for 18 h. The reaction mixture was poured into ice-cold water (10 mL). The precipitate was filtered, washed with water (2 × 5 mL) and dried. The crude solid was purified by column chromatography (C18, 60% MeCN in water) to give the titled product as yellow solid (150 mg, 0.4 mmol, 28%).1H NMR (500 MHz, DMSO) δ 12.00 (s, 1H), 10.23 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.21 (d, J = 1.7 Hz, 1H), 8.16 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 1.7 Hz, 1H), 7.38 (dd, J = 5.3, 1.7 Hz, 1H), 5.69 (s, 2H), 4.93 (d, J = 5.4 Hz, 2H), 4.46 (d, J = 5.4 Hz, 2H), 3.72 (s, 3H), 1.73 (s, 3H). LRMS: For C20H19N5O3 requires 377.4 found 378.3 (M+H). Route to Example 286 7-((3-Methyloxetan-3-yl)ethynyl)-5-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)-1H- indazol-3-amine [00234] 3-Ethynyl-3-methyloxetane (114 mg, 0.15 mL, 1.18 mmol, 2 Eq) was added to a solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (200 mg, 0.59 mmol, 1 Eq), copper(I) iodide (23 mg, 0.12 mmol, 0.2 Eq) and [1,1'- bis(diphenylphosphino)ferrocene]palladium(II) dichloride (43 mg, 0.06 mmol, 0.1 Eq) in anhydrous DMF (1 mL) and triethylamine (1 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 80 ºC for 2 h. The reaction mixture was cooled, extracted between EtOAc (30 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate and removed under reduced pressure. The crude residue was loaded onto silica gel and purified by column chromatography (80% EtOAc in petroleum ether) to give the titled product as brown crystals (50 mg, 0.15 mmol, 25%). 1 H NMR (500 MHz, DMSO) δ 1.31 (s, 12H), 1.69 (s, 3H), 4.44 (d, J = 5.3 Hz, 2H), 4.88 (d, J = 5.3 Hz, 2H), 5.64 (s, 2H), 7.52 (s, 1H), 8.18 (s, 1H), 11.90 (s, 1H). LC-MS: For C19H24BN3O3 requires 353.23 found 354.2 (M+H). Example 287 4-(3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-7 -yl)-2-methylbut-3-yn-2-ol [00235] To a solution of 4-(3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazol- 7-yl)-2-methylbut-3-yn-2-ol (135.95 mg, 0.40 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodo-N-(oxetan-3-yl)pyridin-2-amine (100 mg, 0.36 mmol, 1 Eq), cesium carbonate (390.98 mg, 1.2 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (28.07 mg, 0.04 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (91.58 mg, 0.252 mmol, 70%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.78 (s, 1H), 8.10 (s, 1H), 8.00 (d, J = 5.4 Hz, 1H), 7.52 (s, 1H), 7.23 (d, J = 6.2 Hz, 1H), 6.86 (dd, J = 5.5, 1.6 Hz, 1H), 6.74 (d, J = 1.6 Hz, 1H), 5.61 (s, 2H), 5.43 (s, 1H), 4.94 (p, J = 6.7 Hz, 1H), 4.83 (t, J = 6.7 Hz, 2H), 4.46 (t, J = 6.2 Hz, 2H), 1.54 (s, 6H) ppm. LRMS (ESI +ve): Calculated for C 20 H 21 N 5 O 2 requires 363.42 found 364.3 (M+H). Route to Example 287 4-!odo-N-(oxetan-3-yl)pyridin-2-amine [00236] In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 3 mL of DMSO. Then 3-aminooxetane (97.57 mg, 0.936 mL, 1.78 mmol, 1.5 Eq) and triethylamine (270.17mg, 0.372 mL, 2.67mmol, 3 Eq) were added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. [00237] The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (135.14 mg, 0.49 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.67 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 6.0 Hz, 1H), 6.95 – 6.83 (m, 2H), 4.88 – 4.80 (m, 1H), 4.77 (dd, J = 7.3, 5.8 Hz, 2H), 4.40 (t, J = 6.1 Hz, 2H). ppm. 4-(3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazol-7-yl)-2-methylbut-3- yn-2-ol [00238] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (1.00 g, 3.0 mmol, 1 Eq), copper (I) iodide (0.100 g, 0.5 mmol, 0.15 Eq) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol, 0.1 Eq) in 10 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of 2- methylbut-3-yn-2-ol (1.16 mL, 12 mmol, 4 Eq). The reaction mixture was heated to 80 °C for 1.2h. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (70% EtOAc in petroleum ether) to give the product as a brown foam (0.563 g, 1.65 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ): ^ 11.75 (s, 1H), 8.15 (s, 1H), 7.48 (s, 1H), 5.62 (s, 2H), 5.35 (s, 1H), 1.51 (s, 6H), 1.30 (s, 12H) ppm. LRMS: Calculated for C18H24BN3O3 requires 341.2 found 342.2 (M+1).
Example 288 5-(2-(Oxetan-3-ylamino)pyridin-4-yl)-7-((tetrahydro-2H-pyran -4-yl)ethynyl)-1H-indazol-3- amine [00239] To a solution of 7-((tetrahydro-2H-pyran-4-yl)ethynyl)-5-(4,4,5,5-tetramethyl -1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (73.16 mg, 0.199 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added 4-iodo-N-(oxetan-3-yl)pyridin-2-amine (50 mg, 0.181 mmol, 1 Eq), cesium carbonate (176.92 mg, 0.543 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (12.63 mg, 0.018 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether, then 10% MeOH in EtOAc) followed by HPLC purification to afford the titled compound as a brown solid (31.72 mg, 0.08 mmol, 45%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.83 (s, 1H), 8.08 (d, J = 1.7 Hz, 1H), 7.99 (d, J = 5.3 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.23 (d, J = 6.2 Hz, 1H), 6.85 (dd, J = 5.5, 1.7 Hz, 1H), 6.74 (d, J = 1.6 Hz, 1H), 5.58 (s, 2H), 4.94 (p, J = 6.6 Hz, 1H), 4.83 (t, J = 6.6 Hz, 2H), 4.46 (t, J = 6.2 Hz, 2H), 3.86 (dt, J = 11.5, 4.2 Hz, 2H), 3.47 (ddd, J = 11.7, 9.1, 2.8 Hz, 3H), 2.96 (tt, J = 8.7, 4.0 Hz, 1H), 1.90 (dq, J = 12.5, 3.9 Hz, 2H), 1.73 (ddt, J = 13.8, 9.3, 4.6 Hz, 3H) ppm. LRMS (ESI +ve): Calculated for C22H23N5O2 requires 389.46 found 390.3 (M+H). Route to Example 288 4-Iodo-N-(oxetan-3-yl)pyridin-2-amine [00240] In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 3 mL of DMSO. Then 3-aminooxetane (97.57 mg, 0.936 mL, 1.78 mmol, 1.5 Eq) and triethylamine (270.17mg, 0.372 mL, 2.67mmol, 3 Eq) were added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. [00241] The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the titled product (135.14 mg, 0.49 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 7.67 (d, J = 5.3 Hz, 1H), 7.39 (d, J = 6.0 Hz, 1H), 6.95 – 6.83 (m, 2H), 4.88 – 4.80 (m, 1H), 4.77 (dd, J = 7.3, 5.8 Hz, 2H), 4.40 (t, J = 6.1 Hz, 2H). ppm. 7-((Tetrahydro-2H-pyran-4-yl)ethynyl)-5-(4,4,5,5-tetramethyl -1,3,2-dioxaborolan-2-yl)-1H- indazol-3-amine [00242] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (200 mg, 0.59 mmol, 1 Eq), copper (I) iodide (23 mg, 0.12 mmol, 0.2 Eq) and [1,1'- bis(diphenylphosphino)ferrocene]palladium(II) dichloride (43 mg, 0.06 mmol, 0.1 Eq) in 2 ml of N,N-dimethyformamide-triethylamine (1:1) was degassed in sealed tube followed by addition of 4-ethynyltetrahydro-2H-pyran (0.2 mL, 1.18 mmol, 2 Eq). The reaction mixture was heated to 80 °C for 2h. The reaction was then diluted with EtOAc (30 mL) and the organic layer was washed with water (2 X 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (80% EtOAc in petroleum ether) to give the titled product as brown crystals (100 mg, 0.27 mmol, 46%). 1 H NMR (500 MHz, DMSO-d6): ^ 1.30 (s, 12H), 1.72 (ddt, J = 13.7, 9.2, 4.5 Hz, 2H), 1.84 – 1.94 (m, 2H), 2.94 (tt, J = 8.7, 4.1 Hz, 1H), 3.48 (ddd, J = 11.6, 8.9, 2.9 Hz, 2H), 3.85 (dt, J = 11.5, 4.3 Hz, 2H), 5.61 (s, 2H), 7.50 (s, 1H), 8.16 (s, 1H), 11.81 (s, 1H). LRMS (ESI +ve): Calculated for C 20 H 26 BN 3 O 3 requires 367.26 found 368.3 (M+H). Example 289 N-(4-(3-Amino-7-(cyclopropylethynyl)-1H-indazol-5-yl)pyridin -2- yl)cyclopropanecarboxamide [00243] To a solution of 7-(cyclopropylethynyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)- 1H-indazol-3-amine (213.31 mg, 0.66 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(4-iodopyridin-2-yl)cyclopropanecarboxamide (151.84 mg, 0.60 mmol, 1 Eq), cesium carbonate (586.47 mg, 1.8 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (42.11 mg, 0.06 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (171.56 mg, 0.48 mmol, 80%). 1 H NMR (500 MHz, DMSO-d6) δ 11.85 (s, 1H), 10.82 (s, 1H), 8.40 (d, J = 1.6 Hz, 1H), 8.32 (d, J = 5.3 Hz, 1H), 8.13 (d, J = 1.6 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.37 (dd, J = 5.3, 1.8 Hz, 1H), 5.61 (s, 2H), 2.05 (tt, J = 7.8, 4.8 Hz, 1H), 1.61 (tt, J = 7.5, 5.6 Hz, 1H), 0.93 – 0.89 (m, 4H), 0.86 – 0.80 (m, 4H) ppm. LRMS (ESI +ve): Calculated for C21H19N5O requires 357.42 found 358.3 (M+H). Route to Example 289 N-(4-Iodopyridin-2-yl)cyclopropanecarboxamide [00244] To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise cyclopropanecarbonyl chloride (285.07 mg, 0.247 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (30% EtOAc in petroleum ether) to give the titled product (622 mg, 2.16 mmol, 95%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 10.90 (s, 1 H), 8.54 (d, J = 1.2 Hz, 1 H), 8.04 (d, J = 5.2 Hz, 1 H), 7.49 (dd, J = 5.2, 1.5 Hz, 1 H), 2.00 (quin, J = 6.2 Hz, 1 H), 0.84 (s, 2 H), 0.82 (s, 2 H) ppm. 7-(Cyclopropylethynyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxabor olan-2-yl)-1H-indazol-3-amine [00245] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (1.00 g, 3.0 mmol, 1 Eq), copper (I) iodide (0.100 g, 0.5 mmol, 0.15 Eq) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol, 0.1 Eq) in 10 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of ethynylcyclopropane (1.01 mL, 12 mmol, 4 Eq). The reaction mixture was heated to 80 °C for 1.2h. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (60% EtOAc in petroleum ether) to give the product as a brown foam (0.563 g, 1.65 mmol, 55%). 1 H NMR (500 MHz, DMSO-d6): ^ 11.77 (s, 1H), 8.11 (s, 1H), 7.44 (s, 1H), 5.56 (s, 2H), 1.57 (ddd, J = 13.0, 8.1, 5.2 Hz, 1H), 1.29 (s, 12H), 0.90 – 0.85 (m, 4H) ppm. LRMS: Calculated for C 18 H 22 BN 3 O 2 requires 323.2 found 324.3 (M+1). Example 290 N-(4-(3-Amino-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indazol -5-yl)pyridin-2- yl)cyclopropanecarboxamide [00246] To a solution of 4-(3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazol- 7-yl)-2-methylbut-3-yn-2-ol (260 mg, 0.76 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added N-(4-iodopyridin-2-yl)cyclopropanecarboxamide (199.56 mg, 0.69 mmol, 1 Eq), cesium carbonate (674.44 mg, 2.07 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (53.34 mg, 0.076 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. [00247] The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (194.28 mg, 0.517 mmol, 75%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.83 (s, 1H), 10.84 (s, 1H), 8.41 (d, J = 1.7 Hz, 1H), 8.33 (d, J = 5.2 Hz, 1H), 8.19 (d, J = 1.7 Hz, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.39 (dd, J = 5.3, 1.7 Hz, 1H), 5.67 (s, 2H), 5.45 (s, 1H), 2.05 (td, J = 7.8, 3.7 Hz, 1H), 0.83 (dtd, J = 12.7, 6.4, 3.9 Hz, 4H) ppm. LRMS (ESI +ve): Calculated for C21H21N5O2 requires 375.43 found 376.2 (M+H). Route to Example 290 N-(4-Iodopyridin-2-yl)cyclopropanecarboxamide [00248] To a solution of 4-iodopyridin-2-amine (500 mg, 2.27 mmol, 1 Eq) and triethylamine (1.38 g, 2 mL, 13.65 mmol, 1 Eq) in Dioxane (5 mL) was added dropwise cyclopropanecarbonyl chloride (285.07 mg, 0.247 mL, 2.73 mmol, 1.2 Eq) at 5 ºC. The reaction mixture was allowed to stir at room temperature overnight. The reaction was diluted with EtOAc (10 mL) and the organic layer was washed with water (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (30% EtOAc in petroleum ether) to give the titled product (622 mg, 2.16 mmol, 95%). 1 H NMR (500 MHz, DMSO-d6) δ 10.90 (s, 1 H), 8.54 (d, J = 1.2 Hz, 1 H), 8.04 (d, J = 5.2 Hz, 1 H), 7.49 (dd, J = 5.2, 1.5 Hz, 1 H), 2.00 (quin, J = 6.2 Hz, 1 H), 0.84 (s, 2 H), 0.82 (s, 2 H) ppm. 4-(3-Amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazol-7-yl)-2-methylbut-3- yn-2-ol [00249] A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3- amine (1.00 g, 3.0 mmol, 1 Eq), copper (I) iodide (0.100 g, 0.5 mmol, 0.15 Eq) and bis(triphenylphosphine) palladium(II) chloride (0.220 g, 0.3 mmol, 0.1 Eq) in 10 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of 2- methylbut-3-yn-2-ol (1.16 mL, 12 mmol, 4 Eq). The reaction mixture was heated to 80 °C for 1.2h. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was purified by column chromatography (70% EtOAc in petroleum ether) to give the product as a brown foam (0.563 g, 1.65 mmol, 55%). 1 H NMR (500 MHz, DMSO-d 6 ): ^ 11.75 (s, 1H), 8.15 (s, 1H), 7.48 (s, 1H), 5.62 (s, 2H), 5.35 (s, 1H), 1.51 (s, 6H), 1.30 (s, 12H) ppm. LRMS: Calculated for C18H24BN3O3 requires 341.2 found 342.2 (M+1). Example 291 Methyl (4-(3-amino-7-(5-morpholinopent-1-yn-1-yl)-1H-indazol-5-yl)p yridin-2-yl)carbamate [00250] A mixture of 7-(5-chloropent-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-diox aborolan-2-yl)- 1H-indazol-3-amine (0.5 g, 1.4 mmol, 1 Eq), morpholine (1.7 g, 1.7 mL, 19.6 mmol, 14 Eq) and potassium iodide (140 mg, 0.84 mmol, 0.6 Eq) in N,N-dimethylamide (2 mL) was stirred at 110 ºC for 2 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and NaHCO3 (5 mL). The organic layer was washed brine (3 × 10 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. Methyl (4-iodopyridin-2-yl)carbamate (0.5 g, 1.7 mmol, 1.2 Eq), cesium carbonate (1.4 g, 4.2 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (148 mg, 0.21 mmol, 0.15 Eq) were added to the crude residue. The mixture was dissolved in dioxane (4 mL) and water (1 mL) and stirred under nitrogen atmosphere at 80 ºC for 18 h. The reaction mixture was poured into ice-cold water (10 mL). The precipitate was filtered, washed with water (2 × 5 mL) and dried. The crude solid was purified by column chromatography (40% MeOH in EtOAc) followed by HPLC purification to give the titled product as yellow solid (182 mg, 0.42 mmol, 30%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.89 (s, 1H), 10.22 (s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.16 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.39 – 7.34 (m, 1H), 5.64 (s, 1H), 3.72 (s, 2H), 3.60 (t, J = 4.6 Hz, 3H), 2.65 (s, 4H), 2.44 (t, J = 7.1 Hz, 2H), 2.40 (s, 2H), 1.82 (q, J = 7.2 Hz, 4H). LRMS: Calculated for C 23 H 26 N 6 O 3 requires 434.50 found 435.3 (M+H). Route to Example 291 7-(5-Chloropent-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-diox aborolan-2-yl)-1H-indazol-3- amine [00251] 5-Chloropent-1-yne (121 mg, 0.15 mL, 1.18 mmol, 2 Eq) was added to a solution of 7- bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-ind azol-3-amine (200 mg, 0.59 mmol, 1 Eq), copper(I) iodide (23 mg, 0.12 mmol, 0.2 Eq) and [1,1'- bis(diphenylphosphino)ferrocene]palladium(II) dichloride (43 mg, 0.06 mmol, 0.1 Eq) in anhydrous DMF (1 mL) and triethylamine (1 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 80 ºC for 2 h. The reaction mixture was cooled, extracted between EtOAc (30 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous sodium sulfate and removed under reduced pressure. The crude residue was loaded onto silica gel and purified by column chromatography (70% EtOAc in petroleum ether) to give the titled product as brown crystals (100 mg, 0.28 mmol, 47%). 1 H NMR (500 MHz, DMSO-d6) δ 1.30 (s, 12H), 2.07 (p, J = 6.7 Hz, 2H), 2.65 (t, J = 6.9 Hz, 2H), 3.82 (t, J = 6.4 Hz, 2H), 5.62 (s, 2H), 7.52 (s, 1H), 8.17 (s, 1H), 11.85 (s, 1H). LRMS: Calculated for C18H23BClN3O2 requires 359.66 found 360.1 (M+H). Example 292 N-(4-(3-Amino-7-(3-hydroxy-3-methylbutyl)-1H-indazol-5-yl)py ridin-2- yl)cyclopropanecarboxamide [00252] To a solution of N-(4-(3-amino-7-(3-hydroxy-3-methylbut-1-yn-1-yl)-1H-indazol -5- yl)pyridin-2-yl)cyclopropanecarboxamide (SU1714) (50 mg, 0.133 mmol, 1 Eq) in dry MeOH (3 mL) was added 10% Pd/C (15 mg, 0.14 mmol, 1 Eq). The reaction mixture was allowed to stir under H2 atmosphere at room temperature overnight. [00253] The reaction was then diluted with MeOH, filtered through celite, concentrated under reduced pressure and the crude residue was purified by flash column chromatography (0% to 10% MeOH in EtOAc) followed by HPLC purification to afford the target compound (34.3 mg, 0.09 mmol, 68%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.57 (s, 1H), 10.79 (s, 1H), 8.42 (d, J = 1.7 Hz, 1H), 8.32 (d, J = 5.2 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.42 – 7.32 (m, 2H), 5.50 (s, 2H), 4.27 (s, 1H), 2.91 – 2.83 (m, 2H), 2.05 (td, J = 7.7, 3.9 Hz, 1H), 1.83 – 1.74 (m, 2H), 1.20 (s, 6H), 0.89 – 0.80 (m, 4H) ppm. LRMS: Calculated for C 21 H 25 N 5 O 2 requires 379.46 found 380.2 (M+H). Example 293 Methyl (4-(3-amino-7-(3,3-dimethylbutyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate [00254] To a solution of methyl (4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5- yl)pyridin-2-yl)carbamate (SU1680) (100 mg, 0.254 mmol, 1 Eq) in dry MeOH (3 mL) was added 10% Pd/C (53.21 mg, 0.05 mmol, 0.2 Eq). The reaction mixture was allowed to stir under H2 atmosphere at 40 °C overnight. [00255] The reaction was then diluted with MeOH, filtered through celite, concentrated under reduced pressure and the crude residue was purified by flash column chromatography (0% to 10% MeOH in EtOAc) followed by HPLC purification to afford the target compound as a pale orange solid (83 mg, 0.226 mmol, 89%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.63 (s, 1H), 10.16 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 8.14 (d, J = 1.7 Hz, 1H), 7.97 (d, J = 1.7 Hz, 1H), 7.36 (d, J = 1.6 Hz, 1H), 7.33 (dd, J = 5.3, 1.7 Hz, 1H), 5.49 (s, 2H), 3.70 (s, 3H), 2.82 – 2.75 (m, 2H), 1.62 – 1.56 (m, 2H), 1.00 (s, 9H) ppm. LRMS: Calculated for C 20 H 25 N 5 O 2 requires 367.45 found 368.3 (M+H). Example 302 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((1-methyl-1H-pyrazol-3-y l)amino)pyridin-4-yl)-1H- indazol-3-amine 4-Chloro-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine A mixture of palladium(II) acetate (30 mg, 0.12 mmol, 0.05 Eq) and xantphos (145 mg, 0.25 mmol, 0.1 Eq) in anhydrous toluene (2 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (750 mg, 4 mmol, 1.5 Eq), 1-methyl-1H-pyrazol-3-amine (250 mg, 2.5 mmol, 1 Eq) and Cs 2 CO 3 (1.6 g, 5 mmol, 2 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 30 h. The organic solvent was removed under reduced pressure. The crude residue was stirred in MeOH (10 mL) for 30 min., filtered and washed with MeOH (2 × 3 mL). The filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (50% EtOAc in petroleum ether) to give the tilted product as white solid (210 mg, 1 mmol, 40%). 1 H NMR (500 MHz, DMSO) δ 9.50 (s, 1H), 8.09 (d, J = 5.5 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H), 6.78 (dd, J = 5.5, 2.0 Hz, 1H), 6.24 (d, J = 2.3 Hz, 1H), 3.76 (s, 3H). LC-MS: For C9H9ClN4 requires 208.65 found 209.1 (M+H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((1-methyl-1H-pyrazol-3-y l)amino)pyridin-4-yl)-1H- indazol-3-amine A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)-1H- indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), 4-chloro-N-(1-methyl-1H-pyrazol-3-yl)pyridin-2-amine (0.31 g, 1.47 mmol, 1 Eq), cesium carbonate (1 g, 2.94 mmol, 2 Eq) and 1,1'-bis(di-tert- butylphosphino) ferrocene palladium chloride (144 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (10% MeOH in EtOAc) followed by trituration with MeOH (× 2) then MeCN (× 2) to give the titled product as white solid (113 mg, 0.3 mmol, 20%). 1 H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 9.18 (s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 8.11 (d, J = 1.6 Hz, 1H), 7.52 (d, J = 2.2 Hz, 2H), 7.48 (d, J = 1.7 Hz, 1H), 7.00 (dd, J = 5.3, 1.7 Hz, 1H), 6.39 (d, J = 2.2 Hz, 1H), 5.62 (s, 2H), 3.77 (s, 3H), 1.38 (s, 9H). LRMS: For C22H23N7 requires 385.48 found 386.3 (M+H). Example 303 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((1-methyl-1H-pyrazol-4-y l)amino)pyridin-4-yl)-1H- indazol-3-amine 4-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine A mixture of palladium(II) acetate (30 mg, 0.12 mmol, 0.05 Eq) and xantphos (145 mg, 0.25 mmol, 0.1 Eq) in anhydrous toluene (2 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (750 mg, 4 mmol, 1.5 Eq), 1-methyl-1H-pyrazol-4-amine (250 mg, 2.5 mmol, 1 Eq) and Cs2CO3 (1.6 g, 5 mmol, 2 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 30 h. The organic solvent was removed under reduced pressure. The crude residue was stirred in MeOH (10 mL) for 30 min., filtered and washed with MeOH (2 × 3 mL). The filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (70% EtOAc in petroleum ether) to give the tilted product as white solid (140 mg, 0.7 mmol, 27%). 1 H NMR (500 MHz, DMSO) δ 8.98 (s, 1H), 8.07 (d, J = 5.4 Hz, 1H), 7.94 (s, 1H), 7.44 (s, 1H), 6.72 – 6.65 (m, 2H), 3.81 (s, 3H). LC-MS: For C9H9ClN4 requires 208.65 found 209.2 (M+H). 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((1-methyl-1H-pyrazol-4-y l)amino)pyridin-4-yl)-1H- indazol-3-amine A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2-yl)-1H- indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), 4-chloro-N-(1-methyl-1H-pyrazol-4-yl)pyridin-2-amine (0.31 g, 1.47 mmol, 1 Eq), cesium carbonate (1 g, 2.94 mmol, 2 Eq) and 1,1'-bis(di-tert- butylphosphino) ferrocene palladium chloride (144 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (20% MeOH in EtOAc) followed by trituration with Et2O (× 5) to give the titled product as white solid (170 mg, 0.44 mmol, 30%). 1 H NMR (500 MHz, DMSO) δ 11.80 (s, 1H), 8.77 (s, 1H), 8.14 (d, J = 5.3 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.97 (s, 1H), 7.50 (d, J = 1.7 Hz, 1H), 7.43 (s, 1H), 6.96 – 6.90 (m, 2H), 5.60 (s, 2H), 3.82 (s, 3H), 1.38 (s, 9H). LRMS: For C22H23N7 requires 385.48 found 386.3 (M+H). Examples 304 and 305 Methyl (4-(3-amino-7-((1-hydroxycyclopentyl)ethynyl)-1H-indazol-5-y l)pyridin-2- yl)carbamate (Example 304) 1-((3-amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol- 7-yl)ethynyl)cyclopentan-1-ol (Example 305) 4-(3-Amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H-indazol-7- yl)ethynyl)cyclopentan-1-ol A solution of 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-i ndazol-3-amine (338 mg, 1 mmol, 1 Eq), 1-ethynylcyclopentan-1-ol (330 mg, 2 mmol, 3 Eq), copper (I) iodide (38 mg, 0.2 mmol, 0.2 Eq) and (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride (73 mg, 0.1 mmol, 0.1 Eq) in 6 ml of N,N-dimethyformamide-triethylamine (4:1) was degassed in sealed tube. The reaction mixture was heated to 80 °C for 1h the concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 1:0→0:1] afforded the title compound as a brown foam (240 mg, 0.65 mmol, 65%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.75 (br s, 1H, NH), 8.15 (s, 1H, Ar-H), 7.49 (s, 1H, Ar-H), 5.62 (br s, 2H, NH 2 ), 5.23 (s, 1H, OH), 1.96 – 1.64 (m, 8H, c Pent), 1.30 (s, 12H, BPin). LRMS: Calculated for C 20 H 26 BN 3 O 3 requires 367.26 found 286.3 (M+1– C 6 H 10 ). Methyl (4-(3-amino-7-((1-hydroxycyclopentyl)ethynyl)-1H-indazol-5-y l)pyridin-2- yl)carbamate (Example 304) To a microwave vial was added 4-(3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H- indazol-7-yl)ethynyl)cyclopentan-1-ol (125 mg, 0.340 mmol), methyl (4-iodopyridin-2- yl)carbamate (95 mg, 0.340 mmol), Pd(dtbpf)Cl2 (25 mg, 0.034 mmol), and caesium carbonate (222 mg, 0.681 mmol) under an argon atmosphere. To the vial was added dioxane:water (9:1) and the mixture was degassed then stirred at 80 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate:methanol 1:0:0→0:1:0→0:6:4] followed by flash column chromatography using basic silica [petrol:ethyl acetate:methanol 1:0:0→0:1:0→0:5:5] afforded the title compound as a dark yellow solid (16 mg, 12%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.84 (br s, 1H, NH), 10.23 (br s, 1H, NH), 8.29 (d, J = 5.2 Hz, 1H, Ar- H), 8.19 (s, 1H, Ar-H), 8.15 (s, 1H, Ar-H), 7.58 (s, 1H, Ar-H), 7.36 (d, J = 5.2 Hz, 1H, Ar-H), 5.67 (br s, 2H, NH 2 ), 5.32 (s, 1H, OH), 3.71 (s, 3H, CH 3 ), 2.09 – 1.88 (m, 4H, c Pent), 1.82 – 1.67 (m, 4H, c Pent). LRMS: Calculated for C 21 H 21 N 5 O 3 391.16 found 392.3 (M+1). 1-((3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol- 7-yl)ethynyl)cyclopentan-1-ol (Example 305) To a microwave vial was added 4-(3-amino-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1 H- indazol-7-yl)ethynyl)cyclopentan-1-ol (125 mg, 0.340 mmol), 4-iodo-N-(oxetan-3-yl)pyridin-2- amine (94 mg, 0.340 mmol), Pd(dtbpf)Cl2 (25 mg, 0.034 mmol), and caesium carbonate (222 mg, 0.681 mmol) under an argon atmosphere. To the vial was added dioxane:water (9:1) and the mixture was degassed then stirred at 80 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate:methanol 1:0:0→0:1:0→0:6:4] followed by trituration from diethyl ether and methanol afforded the title compound as a dark yellow solid (9 mg, 7%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.78 (br s, 1H, NH), 8.10 (s, 1H, Ar- H), 8.00 (d, J = 5.1 Hz, 1H, Ar-H), 7.53 (s, 1H, Ar-H), 7.23 (d, J = 5.1 Hz, 1H, Ar-H), 6.85 (d, J = 5.1 Hz, 1H, Ar-H), 6.74 (br s, 1H, NH), 5.61 (br s, 2H, NH 2 ), 5.29 (s, 1H, OH), 5.03 – 4.89 (m, 1H, CH), 4.83 (t, J = 6.0 Hz, 2H, CH 2 ), 4.46 (t, J = 6.0 Hz, 2H, CH 2 ), 2.11 – 1.87 (m, 4H, c Pent), 1.86 – 1.64 (m, 4H, c Pent). LRMS: Calculated for C 22 H 23 N 5 O 2 389.46 found 390.3 (M+1). Section 9 – compounds of the formula: Example 199 7-(Furan-3-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol- 3-amine A 2-5 mL MW tube was charged with a mixture of 7-chloro-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 4) (50 mg, 0.15 mmol, 1 eq.), furan-3-ylboronic acid (98 mg, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16 mg, 0.0075 mmol, 5mol%) in dioxane (oxygen-free, 1.4 mL) was heated to 50 °C under a gentle flow of nitrogen for 10 minutes, then 2 M aq. K2CO3 (oxygen-free, 0.6 mL, 0.9 mmol, 6 eq.) was added and the reaction mixture was heated to 110 °C for 16 hours. The reaction mixture was then cooled to room temperature, diluted water (10 mL), the mixture was extracted with EtOAc (3 x 20 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under reduced pressure. The resulting residue was purified by flash chromatography (Silica, 50 g, 1:1 pet ether: AcOEt to 100% EtOAc) to give the title compound as a pale yellow solid (33 mg, 70%). 1 H NMR (400 MHz, DMSO-D 6 ) δ 5.65 (s, 2H), 6.74 (dd, J = 3.5, 1.8 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.28 (d, J = 1.4 Hz, 1H), 7.54 – 7.55 (m, 1H), 7.84 ((dd, J = 3.5, 1.8 Hz, 1H), 8.15 (d, J = 1.5 Hz, 1H), 8.29 (d, J = 4.9 Hz, 1H), 8.44 (d, J = 1.8 Hz, 1H), 11.53 (s, 1H), 11.73 (s, 1H). LRMS: Calculated for C 18 H 13 N 5 O 315.11; Found: 316.0 Example 200 7-Ethynyl-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-ami ne A 2-5 mL MW tube was charged with a mixture of 5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-7- ((triisopropylsilyl)ethynyl)-1H-indazol-3-amine (300 mg, 0.7 mmol), and THF (5 mL) and placed under nitrogen, TBAF (3.8 mL, 1M in THF) was then added and the solution allowed to stir for 20 min at room temperature. The reaction was quenched with the addition of water (5 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under reduced pressure. The resulting residue was purified by flash chromatography (Silica, 50 g, 1:1 pet ether: AcOEt to 100% EtOAc) to give the desired product as a pale yellow solid (132 mg, 69%). 1 H NMR (400 MHz, DMSO-D 6 ) δ 4.54 (s, 1H), 5.66 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.54 – 7.55 (m, 1H), 7.75 ((d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.76 (s, 1H), 11.96 (s, 1H). LRMS: Calculated for C 16 H 11 N 5 273.1; Found: 274.1 Example 201 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4- yl)-1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-chloro-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 4) (43 mg, 0.15 mmol, 1 eq.), (3,3-dimethylbut-1-yn-1- yl)trifluoroborate (56 mg, 0.3 mmol, 2 eq.), XphosG2 (5.9 mg, 0.0075 mmol, 5mol%) in dioxane (oxygen-free, 1.4 mL) was heated to 50 °C under a gentle flow of nitrogen for 10 minutes, then 2 M aq. K2CO3 (oxygen-free, 0.45 mL, 0.9 mmol, 6 eq.) was added and the reaction mixture was heated to 110 °C for 11 hours. The reaction mixture was then cooled to room temperature, diluted water (10 mL), and filtered. The filtered solid was washed with water (10 mL x 3), and purified by flash chromatography (Silica, 50 g, 0-2% MeOH in AcOEt) to give the title compound as a light beige solid (33 mg, 0.100 mmol, 67%). 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.37 (s, 9H), 5.63 (s, 2H), 6.68 (dd, J = 3.5, 1.8 Hz, 1H), 7.19 (d, J = 4.9 Hz, 1H), 7.52 – 7.55 (m, 1H), 7.57 (d, J = 1.5 Hz, 1H), 8.17 (d, J = 1.5 Hz, 1H), 8.25 (d, J = 4.9 Hz, 1H), 11.74 (s, 1H), 11.80 (s, 1H). HRMS: Calculated for C 20 H 19 N 5 329.1640; Example 202 7-(Cyclopropylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), ethynylcyclopropane (30 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (11 mg, 26%). 1 H NMR (400 MHz, DMSO-D6) δ 0.91 (s, 4H), 1.62 (m, 1H), 5.60 (s, 2H), 6.68 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.54 – 7.55 (m, 1H), 7.61 (d, J = 1.8 Hz, 1H), 8.15 (d, J = 1.8 Hz, 1H), 8.25 (m, 2H), 11.73 (s, 1H), 11.82 (s, 1H). LRMS: Calculated for C19H15N5313.13; Found: 314.1 Example 203 7-(Cyclopentylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), ethynylcyclopentane (32 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (19 mg, 40 %). 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.24 (s, 1H), 1.6 (m, 2H), 1.77 (m, 4H), 2.01 (m, 2H), 5.60 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.54 – 7.55 (m, 1H), 7.60 (d, J = 1.8 Hz, 1H), 8.16 (d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.73 (s, 1H), 11.81 (s, 1H). LRMS: Calculated for C 21 H 19 N 5 341.16; Found: 342.2 Example 204 7-(Cyclohexylethynyl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-i ndazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), ethynylcyclohexane (33 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (26 mg, 46 %). Calculated for C 22 H 21 N 5 355.18; Found: 356.0 Example 205 3-(3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl )prop-2-yn-1-ol A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), prop-2-yn-1-ol (30 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (22 mg, 41 %) 1 H NMR (400 MHz, DMSO-D6) δ 4.2 (s, 2H), 5.44 s, 1H), 5.58 (s, 2H), 6.67 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.52 – 7.54 (m, 1H), 7.61 (d, J = 1.8 Hz, 1H), 8.16 (d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.73 (s, 1H), 11.81 (s, 1H) . LRMS: Calculated for C17H13N5O 303.11; Found: 304.1 Example 206 4-(3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl )-2-methylbut-3-yn-2-ol A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 2-methylbut-3-yn-2-ol (30 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (16 mg, 33 %) 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.54 (s, 2H), 5.46 (s, 1H), 5.68 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.52 – 7.54 (m, 1H), 7.62 (d, J = 1.8 Hz, 1H), 8.21 (d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.76 (s, 1H), 11.81 (s, 1H). LRMS: Calculated for C 19 H 17 N 5 O 331.14; Found: 332.1. Example 207 1-((3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-y l)ethynyl)cyclopentan-1-ol A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 1-ethynylcyclopentan-1-ol (30 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (22 mg, 41 %) 1 H NMR (400 MHz, DMSO-D6) δ 1.24 (s, 1H), 1.6 (m, 2H), 1.77 (m, 4H), 2.01 (m, 2H), 5.44 (s, 1H), 5.60 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.54 – 7.55 (m, 1H), 7.60 (d, J = 1.8 Hz, 1H), 8.16 (d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.73 (s, 1H), 11.81 (s, 1H). LRMS: Calculated for C21H19N5O 357.16; Found: 358.1. Example 208 1-((3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-y l)ethynyl)cyclohexan-1-ol A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 1-ethynylcyclohexan-1-ol (33 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (26 mg, 46 %). 1 H NMR (500 MHz, DMSO) δ 12.03 (s, 1H), 8.36 – 8.27 (m, 2H), 7.72 (d, J = 1.6 Hz, 1H), 7.64 (t, J = 2.9 Hz, 1H), 7.33 (d, J = 5.2 Hz, 1H), 6.78 (dd, J = 3.6, 1.7 Hz, 1H), 1.97 (dd, J = 11.7, 6.5 Hz, 2H), 1.72 – 1.53 (m, 6H), 1.51 – 1.40 (m, 1H), 1.29 (d, J = 13.9 Hz, 1H). δ LRMS: Calculated for C 22 H 21 N 5 O 371.17; Found: 372.2. Example 209 1-((3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-y l)ethynyl)cycloheptan-1-ol A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 1-ethynylcycloheptan-1-ol (35 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (26 mg, 46 %). 1 H NMR (500 MHz, DMSO) δ 11.76 (s, 1H), 8.37 – 8.15 (m, 1H), 7.64 (s, 1H), 7.56 (t, J = 3.1 Hz, 1H), 7.20 (d, J = 5.0 Hz, 1H), 6.69 (d, J = 2.8 Hz, 1H), 5.67 (s, 1H), 2.15 – 2.07 (m, 2H), 1.94 – 1.83 (m, 2H), 1.71 – 1.42 (m, 8H). LRMS: Calculated for C 23 H 23 N 5 O 385.2; Found: 386.2. Example 210 7-(5-Morpholinopent-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4 -yl)-1H-indazol-3-amine A 0.5-2 mL MW tube was charged with a mixture of 7-(5-chloropent-1-yn-1-yl)-5-(1H- pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amine (52 mg, 0.15 mol, 1 eq.) and morpholine (131 µL, 1.5 mmol, 10 eq.) in acetonitrile (1.4 mL) and sealed under nitrogen. The reaction mixture was heated to 100 °C for 6 hours and then cooled to room temperature and diluted with AcOEt (100 mL) and washed with 1 M aq. Na2CO3 (30 mL x 3), dried (MgSO4) and purified by flash chromatography (Silica, 50 g, 1-10%, MeOH in AcOEt containing 1% triethylamine) to give the title compound as a yellow solid (21 mg, 35%). 1 H NMR (400 MHz, DMSO) δ 1.77 – 1.87 (m, 2H), 2.35 – 2.47 (m, 6H), 2.53 – 2.57 (m, 2H), 3.58 (t, J = 4.7 Hz, 4H), 5.59 (s, 2H), 6.68 (dd, J = 3.5, 1.9 Hz, 1H), 7.18 (d, J = 5.0 Hz, 1H), 7.53 (dd, J = 3.5, 2.5 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.5 Hz, 1H), 8.25 (d, J = 5.0 Hz, 1H), 11.72 (s, 1H), 11.82 (s, 1H). Example 211 7-(4-(Piperidin-1-yl)but-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyri din-4-yl)-1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 1-(but-3-yn-1-yl)piperidine (33 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (26 mg, 46 %). 1 H NMR (400 MHz, DMSO-D6) δ 1.41 (m, 2H), 1.53 (m, 4H), 2.24 (m, 4H), 2.66 (m, 4H), 5.62 (s, 2H), 6.68 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.53 (m, 1H), 7.61 (d, J = 1.8 Hz, 1H), 8.17 (d, J = 1.8 Hz, 1H), 8.26 (m, 2H), 11.74 (s, 1H), 11.83 (s, 1H). LRMS: Calculated for C 23 H 24 N 6 384.21; Found: 385.2. Example 212 7-(5-(Piperidin-1-yl)pent-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyr idin-4-yl)-1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-(5-chloropent-1-yn-1-yl)-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-1H-indazol-3-amine (70 mg, 0.2 mL, 1 eq.) and piperidine (198 µL, 2 mmol, 10 eq.) in acetonitrile (1.8 mL) and sealed under nitrogen. The reaction mixture was heated to 100 °C for 6 hours and then cooled to room temperature and diluted with AcOEt (100 mL) and washed with 1 M aq. Na 2 CO 3 (50 mL x 3), dried (MgSO 4 ) and purified by flash chromatography (Silica, 50 g, 1-12%, MeOH in AcOEt containing 1% triethylamine) to give the title compound as a yellow solid (8 mg, 10%). 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.33 – 1.42 (m, 2H), 1.44 – 1.55 (m, 4H), 1.74 – 1.83 (m, 2H), 2.54 (d, J = 2.3 Hz, 4H), 5.62 (s, 2H), 6.68 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 4.9 Hz, 1H), 7.50 – 7.57 (m, 1H), 7.62 (d, J = 1.6 Hz, 1H), 8.16 (d, J = 1.6 Hz, 1H), 8.25 (d, J = 4.9 Hz, 1H), 11.75 (s, 1H), 11.84 (s, 1H). A CH 2 peak not observed due solvent peak. Example 213 7-(6-(Piperidin-1-yl)hex-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyri din-4-yl)-1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), 1-(hex-5-yn-1-yl)piperidine (33 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (14 mg, 20 %). 1 H NMR (400 MHz, DMSO-D 6 ) δ 1.66-1.95 (m, 10H), 2.70 (m, 6H), 3.7 (m, 2H), 5.71 (s, 2H), 6.70 (dd, J = 3.5, 1.8 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.25 (d, J = 1.5 Hz, 1H), 7.54 (m, 2H), 8.23 (d, J = 1.8 Hz, 1H), 8.29 (m, 1H), 11.72 (s, 1H), 11.79 (s, 1H). LRMS: Calculated for C 25 H 28 N 6 412.24; Found: 413.2. Example 214 6-(3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl )hex-5-ynoic acid A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), hex-5-ynoic acid (30 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (22 mg, 40 %). 1 H NMR (400 MHz, DMSO-D6) δ 0.97 (t, J = 7.0 Hz, 2H), 1.86 (q, J = 7.3 Hz, 2H), 2.44 (t, J = 7.3 Hz, 2H), 5.63 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.20 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 1.5 Hz, 1H), 7.64 (d, J = 1.5 Hz 2H), 8.18 (d, J = 1.8 Hz, 1H), 8.26 (m, 1H), 11.75 (s, 1H), 11.79 (s, 1H). LRMS: Calculated for C20H17N5O2359.14; Found: 360.2. Example 215 7-(3-Amino-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-7-yl )hept-6-ynoic acid A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), hept-6-ynoic acid (31 uL, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (18 mg, 33 %). 1 H NMR (400 MHz, DMSO-D6) δ 1.67 (m, 6H), 2.28 (t, J = 7.3 Hz, 2H), 5.63 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 7.18 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 1.5 Hz, 1H), 7.62 (d, J = 1.5 Hz 2H), 8.17 (d, J = 1.8 Hz, 1H), 8.26 (m, 1H), 11.75 (s, 1H), 11.79 (s, 1H). LRMS: Calculated for C21H19N5O2373.15; Found: 374.2. Example 216 7-(4-Phenoxybut-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl) -1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), (but-3-yn-1-yloxy)benzene (52 mg, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt 3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (28 mg, 46 %). 1 H NMR (400 MHz, DMSO-D 6 ) δ 3.01 (t, J = 7.3 Hz 2H), 4.29 (t, J = 7.3 Hz, 2H), 5.63 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 6.95 (t, J = 7.2 Hz, 1H), 7.03 (m, 1H) 7.19 (d, J = 1.5 Hz, 1H), 7.31 (m, 2H), 7.54 (t, J = 2.8 Hz, 1H), 7.65 (d, J = 1.5 Hz 2H), 8.20 (d, J = 1.8 Hz, 1H), 8.26 (m, 1H), 11.74 (s, 1H), 11.89 (s, 1H). LRMS: Calculated for C 24 H 19 N 5 O 393.16; Found: 394.1. Example 217 7-(6-Phenoxyhex-1-yn-1-yl)-5-(1H-pyrrolo[2,3-b]pyridin-4-yl) -1H-indazol-3-amine A 2-5 mL MW tube was charged with a mixture of 7-bromo-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine (Example 5) (50 mg, 0.15 mmol, 1 eq.), (hex-5-yn-1-yloxy)benzene (52 mg, 0.3 mmol, 2 eq.), 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) catalyst (16mg, 0.02 mmol, 15 mol%) and CuI (4.2 mg 0.02 mmol, 15 mol%) in DMF (1 mL) and NEt3 (1mL). The tube was then heated to 85 °C under nitrogen for 16 hrs. The reaction mixture was then cooled to room temperature, diluted with water (10 mL), the mixture was extracted with EtOAc (3 x 10 mL) and the organic fractions combined and dried over magnesium sulfate, filtered and the solvent removed under high vacuum. The resulting residue was purified by HPLC to give the desired product as a yellow solid (22 mg, 33 %). 1 H NMR (400 MHz, DMSO-D6) δ 1,80 (m, 2H), 1,91 (m, 2H), 2.61 (t, J = 7.3 Hz, 2H) 4.05 (t, J = 7.3 Hz, 2H), 5.63 (s, 2H), 6.69 (dd, J = 3.5, 1.8 Hz, 1H), 6.95 (m, 3H), 7.19 (d, J = 1.5 Hz, 1H), 7.36 (m, 2H), 7.53 (t, J = 2.8 Hz, 1H), 7.63 (d, J = 1.5 Hz 2H), 8.17 (d, J = 1.8 Hz, 1H), 8.26 (m, 1H), 11.75 (s, 1H), 11.87 (s, 1H). LRMS: Calculated for C25H21N5O 407.17; Found: 408.2. Section 10 – compounds of the formula: General procedure A: A suspension of the required 4-chloroazaindole substrate (1 eq.), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (1.2-1.5 eq.) and base (2 eq.) in 1:3 of solvent was deoxygenated with nitrogen in sealed tube. Then [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.05 eq.) was added then the tube was sealed and the mixture allowed to stirred at 90-100 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and water were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography. Example 218 4-Chloro-3-(cyclopropylethynyl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.12 g, 0.4 mmol), copper (I) iodide (0.004 g, 0.02 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.014 g, 0.02 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of ethynylcyclopropane (0.06 g, 0.7 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was diluted with EtOAc and extracted with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (25% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.8 g, 90%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.81-0.87 (m, 2 H) 0.89-0.95 (m, 2 H) 1.63 (tt, J=8.24, 5.04 Hz, 1 H).6.36 (br. s., 2 H) 6.66 (d, J=5.49 Hz, 1 H) 7.81 (d, J=5.34 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 0.50, 7.99, 67.38, 100.90, 103.76, 111.46, 143.07, 146.44, 146.43, 160.05. m/z (ESI-MS) [M] + 193.1. 4-Chloro-2-cyclopropyl-7-azaindole To a solution of 4-chloro-3-(cyclopropylethynyl)pyridin-2-amine (0.108 g, 0.56 mmol) in 1,4 dioxane (2 ml), potassium tert-butoxide (0.157 g, 1.4 mmol) and 18-crown-6 (0.014 g, 10%, 0.056 mmol) were added and the mixture was stirred at 110 °C for 18h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (96 mg, 88%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.82-0.91 (m, 2 H) 0.97-1.05 (m, 2 H) 2.05 (tt, J=8.40, 5.22 Hz, 1 H) 6.15 (s, 1 H) 7.09 (d, J=5.27 Hz, 1 H) 8.02 (d, J=4.83 Hz, 1 H) 11.87 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 9.24, 9.85, 70.20, 93.15, 115.73, 120.08, 132.48, 142.10, 145.62, 149.71. m/z (ESI-MS) [M] + 193.0. 5-(2-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3 -amine 4-Chloro-2-cyclopropyl -7-azaindole (0.074 g, 0.39 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.15 g, 0.58 mmol), 1M potassium phosphate solution (0.78 ml, 0.78 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.012 g, 0.195 mmol) in 2.3 ml ethanol were reacted as described in General procedure A and chromatographic purification (60% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as white solid (84 mg, 74%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.85-0.91 (m, 2 H) 0.95-1.04 (m, 2 H) 2.07 (tt, J= 8.35, 5.27 Hz, 1 H) 5.52 (s, 2 H) 6.38 (d, J=1.76 Hz, 1 H) 7.10 (d, J= 4.83 Hz, 1 H) 7.36 (d, J=8.35 Hz, 1 H) 7.63 (dd, J=8.57, 1.54 Hz, 1 H) 8.10-8.14 (m, 2 H) 11.52 (m, 2 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 10.01, 14.66, 21.33, 95.04, 110.34, 114.50, 115.11, 118.70, 120.64, 127.18, 128.68, 140.04, 141.61, 141.93,143.98, 149.97, 150.37. m/z (ESI-HRMS) calculated for C 19 H 21 N 6 = 333.1822 found=333.1820. Example 219 2-Cyclohexyl-7-azaindole To a stirred solution of 2(Boc-amino)-3-methyl-pyridine (1.04 g, 4.7 mmol) in anhydrous THF (20 ml) at -4 °C, 2M n-butyllithium (5.8 ml, 11.7 mmol) was added slowly over 15 min, then 2- cyclohexyl-N-methoxy-N-methylcarboxamide (0.9 g, 5.2 mmol) was added slowly and the reaction mixture allowed to stirred for 2 h. Thereafter, hydrochloric acid (5M, 50 ml) was added and the reaction was heated to 60° C and stirred for 2 h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (15% EtOAc in petroleum ether 60-80%) to give the product as white solid (188 mg, 18%) 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.12-1.56 (m, 6 H) 1.70-2.02 (m, 4 H) 2.59-2.79 (m, 1 H) 6.11 (d, J=1.32 Hz, 1 H) 6.96 (dd, J=7.91, 4.83 Hz, 1 H) 7.72-7.83 (m, 1 H) 8.09 (dd, J=4.61, 1.54 Hz, 1 H) 11.45 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.20, 26.36, 32.65, 37.43, 95.11, 115.69, 120.88, 127.30, 141.66, 146.86, 149.20. m/z (ESI-MS) [M] + 201.1. 2-Cyclohexyl-7-oxide-7-azaindole To an ice cooled solution of 2-cyclohexyl-7-azaindole (0.18 g, 0.9 mmol) in EtOAc, meta- chloroperoxybenzoic acid (0.25 g, 1.4 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.15 g, 83%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.13-1.40 (m, 6 H) 1.59-1.62 (m, 4 H) 2.60 (m, 1 H) 6.27 (s, 1 H) 7.05 (dd, J=7.91, 6.15 Hz, 1 H) 7.50 (d, J=7.91 Hz, 1 H) 8.04 (d, J=6.15 Hz, 1 H) 11.90 (br. s., 1 H). m/z (ESI-MS) [M] + 217. 2-Cyclohexyl-4-chloro-7-azaindole In sealed tube, 2-cyclohexyl-7-oxide-7-azaindole (0.15 g, 0.7 mmol) was dissolved in phosphoryl chloride (0.2 ml, 2 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured in to water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate, concentrated and purified using column chromatography (30% EtOAc in petroleum ether 60-80%) to afford the titled compound as white solid (92 mg, 60%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.07-1.31 (m,6 H) 1.68-2.03 (m, 4 H) 2.66-2.82 (m, 1H) 6.18 (d, J=1.32 Hz, 1 H) 7.11 (d, J=5.27 Hz, 1 H) 8.06 (d, J=5.27 Hz, 1 H) 11.89 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.12, 26.30, 32.49, 37.39, 93.39, 115.60, 119.72, 131.21. 5-(2-Cyclohexyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3- amine 2-Cyclohexyl-4-chloro-7-azaindole (0.023 g, 0.1 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.04 g, 0.15 mmol), 1M potassium phosphate solution (0.2 ml, 0.2 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.0012 g, 0.005 mmol) in 0.6 ml ethanol were reacted as described in General procedure A and chromatographic purification (70% EtOAc in petroleum ether 60-80%), gave the titled compound as yellow solid (13.6 mg, 41%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.18-1.38 (m, 4 H) 1.52-1.54 (m, 2 H) 1.71-1.81 (m, 4 H) 2.68-2.81 (m, 1 H) 5.52 (s, 2 H) 6.39 (d, J=1.76 Hz, 1 H) 7.10 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.57, 1.54 Hz, 1 H) 8.08-8.17 (m, 2 H) 11.54 (m, 2 H). 13 C NMR (100 MHz, DMSO-d 6 ) 26.21, 26.42, 32.69, 37.58, 94.80, 110.36, 114.39, 115.12, 118.36, 120.65, 127.23, 128.73, 140.64, 141.63, 142.18, 146.92, 149.95, 150.36. m/z (ESI-HRMS) calculated for C 20 H 22 N 5 = 332.1870 found= 332.1867. Example 220 2-Neopentyl-7-azaindole To a stirred solution of 2(Boc-amino)-3-methyl-pyridine (2.3 g, 10.5 mmol) in anhydrous THF (50 ml) at -4 °C, 2M n-butyllithium (13.1 ml, 26.25 mmol) was added slowly over 15 min, then N-methoxy-N,3,3-trimethylbutanamide (2 g, 12.5 mmol) was added slowly and the reaction mixture stirred for 2 h. Thereafter, hydrochloric acid (5M, 50 ml) was added and the reaction was heated to 60° C and stirred for 2h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (15% EtOAc in petroleum ether 60-80%) to give the product as white solid (1 g, 50%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.94 (s, 9 H) 2.59 (s, 2 H) 6.11 (d, J=1.76 Hz, 1 H) 6.97 (dd, J=7.91, 4.83 Hz, 1 H) 7.80 (dd, J=7.69, 1.54 Hz, 1 H) 8.10 (dd, J=4.83, 1.76 Hz, 1 H) 11.41 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 29.80, 31.94, 42.38, 99.13, 115.63, 121.04, 127.04, 139.10, 141.51, 148.80. m/z (ESI-MS) [M] + 189.1. 2-Neopentyl-7-oxide-7-azaindole To an ice-cooled solution of 2-neopentyl-7-azaindole (0.85 g, 4.5 mmol) in EtOAc, meta- chloroperoxybenzoic acid (1.2 g, 7.2 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.95 g, 99%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.91 (s, 9 H) 2.63 (s, 2 H) 6.27 (s, 1 H) 7.02 (dd, J=8.13, 6.37 Hz, 1 H) 7.54 (d, J=7.91 Hz, 1 H) 8.05 (d, J=6.15 Hz, 1 H) 12.35 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 29.64, 41.55, 60.38, 101.29, 116.38, 119.07, 125.12, 130.58, 138.37, 140.05. m/z (ESI-MS) [M] + 205.2. 2-Neopentyl-4-chloro-7-azaindole In sealed tube, 2-neopentyl-7-oxide-7-azaindole (0.9 g, 4.4 mmol) was dissolved in phosphoryl chloride (1.2 ml, 13.2 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured in to water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate, concentrated and triturated EtOAc in petroleum ether to afford the titled compound as brown solid (270 mg, 27%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.94 (s, 9 H) 2.62 (s, 2 H) 6.18 (d, J=1.76 Hz, 1 H) 7.12 (d, J=5.27 Hz, 1 H) 8.07 (d, J=5.27 Hz, 1 H) 11.83 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 29.77, 31.97, 42.23, 97.23, 115.56, 119.81, 132.83, 140.56, 142.30, 149.33. m/z (ESI-MS) [M] + 223.1. 5-(2-Neopentyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-a mine 4-Chloro-2-neopentyl-7-azaindole (0.08 g, 0.36 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.14 g, 0.54 mmol), 1M potassium phosphate solution (0.72 ml, 0.72 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.011 g, 0.018 mmol) in 2.16 ml ethanol were reacted as described in general procedure and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as white solid (89.8 mg, 86%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.95 (s, 9 H) 2.63 (s, 2 H) 5.51 (s, 2 H) 6.39 (s, 1 H) 7.12 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.57, 1.54 Hz, 1 H) 8.13 (s, 1 H) 8.16 (d, J= 5.27 Hz, 1 H) 11.51 (s, 1 H) 11.55 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 29.88, 32.00, 42.47, 98.80, 110.27, 114.36, 115.07, 118.56, 120.59, 127.12, 128.71, 139.18, 140.38, 141.56, 142.05, 149.57, 150.26. m/z (ESI-HRMS) calculated for C19H22N5 = 320.1870 found=320.1867. Example 221 2-(Cyclohexylmethyl)-7-azaindole To a stirred solution of 2(Boc-amino)-3-methyl-pyridine (1.77 g, 7.97 mmol) in anhydrous THF (40 ml) at -4°C, 2M n-butyllithium (10 ml, 20 mmol) was added slowly over 15 min. Then, 2- cyclohexyl-N-methoxy-N-methylacetamide (1.5 g, 8.7 mmol) was added slowly and the reaction mixture was stirred for 2 h. Thereafter, hydrochloric acid (5M, 50 ml) was added and the reaction was heated to 60°C and stirred for 2 h. The organic layer was separated and the aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate, and evaporated. The crude product was then purified using column chromatography (15% EtOAc in petroleum ether 60-80%) to give the product as a white solid (1.1 g, 69%).1H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.88-1.02 (m, 2 H) 1.09-1.25 (m, 3 H) 1.55-1.68 (m, 6 H) 2.59 (d, J=7.03 Hz, 2 H) 6.11 (d, J=1.76 Hz, 1 H) 6.96 (dd, J=7.91, 4.83 Hz, 1 H) 7.77 (dd, J=7.91, 1.32 Hz, 1 H) 8.07 (dd, J=4.83, 1.76 Hz, 1 H) 11.41 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.20, 26.54, 33.19, 36.19, 37.90, 98.12, 115.72, 121.16, 127.04, 140.41, 141.53, 149.22. m/z (ESI-MS) [M] + 215.1. 2-(Cyclohexylmethyl)-7-oxide-7-azaindole To an ice-cooled solution of 2-(cyclohexylmethyl)-7-azaindole (0.83 g, 4.18 mmol) in EtOAc, meta-chloroperoxybenzoic acid (1.1 g, 6.7 mmol) was added slowly. Then, the reaction was warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated, with 1M sodium carbonate solution, and extracted with EtOAc. The residue was then concentrated under vacuum to give the product as a yellow solid. (0.81 g, 89%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.83-0.98 (m, 2 H) 1.03-1.16 (m, 3 H) 1.59-1.62 (m, 6 H) 2.60 (d, J=6.59 Hz, 2 H) 6.26 (s, 1 H) 7.01 (dd, J=7.91, 6.15 Hz, 1 H) 7.51 (d, J=7.91 Hz, 1 H) 8.04 (d, J=6.15 Hz, 1 H) 12.41 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.17, 26.48, 33.02, 35.63, 37.97, 100.36, 116.51, 119.12, 125.28, 130.64, 138.74, 141.40. m/z (ESI-MS) [M] + 231.2. 2-(Cyclohexylmethyl)-4-chloro-7-azaindole In a sealed tube, 2-(cyclohexylmethyl)-7-oxide-7-azaindole (0.8 g, 3.7 mmol) was dissolved in phosphoryl chloride (1.04 ml, 11.2 mmol). Next, the reaction mixture was heated to 90°C and stirred for 18 h. Then, the reaction mixture was warmed to room temperature, poured into water, neutralized with saturated sodium carbonate solution, and extracted with EtOAc. The collected organic layer was dried over magnesium sulfate, concentrated and purified using column chromatography (30% EtOAc in petroleum ether 60-80%) to afford the titled compound as a white solid. (0.56 g, 64%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.85-1.03 (m, 2 H) 1.05- 1.28 (m, 3 H) 1.53-1.78 (m, 6 H) 2.62 (d, J=7.03 Hz, 2 H) 6.19 (s, 1 H) 7.11 (d, J=5.27 Hz, 1 H) 8.05 (d, J=5.27 Hz, 1 H) 11.83 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.17, 26.50, 33.14, 35.63, 37.84, 96.30, 115.64, 119.95, 132.82, 141.92, 142.32, 149.75. m/z (ESI-MS) [M] + 249.1 5-(2-(Cyclohexylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-in dazol-3-amine 2-(Cyclohexylmethyl)-4-chloro-7-azaindole (0.08 g, 0.34 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.13 g, 0.51 mmol), 1M potassium phosphate solution (0.6 ml, 0.6 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.004 g, 0.017 mmol) in 2 ml ethanol were reacted as described in General procedure A and chromatographic purification (70% EtOAc in petroleum ether 60-80%), gave the titled compound as yellow solid (71.8 mg, 61%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.88-1.04 (m, 2 H) 1.08-1.27 (m, 3 H) 1.54-1.75 (m, 6 H) 2.63 (d, J=6.59 Hz, 2 H) 5.52 (s, 2 H) 6.41 (d, J=1.76 Hz, 1 H) 7.11 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.79, 1.32 Hz, 1 H) 8.08-8.17 (m, 2 H) 11.52 (s, 1 H) 11.54 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 26.22, 26.54, 33.24, 36.31, 38.03, 97.86, 110.34, 114.40, 115.14, 118.66, 120.67, 127.22, 128.73, 140.34, 140.52, 141.63, 142.06, 149.98, 150.37. m/z (ESI-HRMS) calculated for C 21 H 24 N 5 = 346.2026 found= 346.2028. Example 222 2-Cyclohexylpropyl-7-azaindole To a stirred solution of 2(Boc-amino)-3-methyl-pyridine (0.87 g, 4.1 mmol) in anhydrous THF (30 ml) at -4 °C, 2M n-butyllithium (5.1 ml, 10.25 mmol) was added slowly over 15 min, then 3- cyclohexyl-N-methoxy-N-methylpropanamide (1 g, 5 mmol) was added slowly and the reaction mixture allowed to stirred for 2h. Thereafter, hydrochloric acid (5M, 30 ml) was added and the reaction was heated to 60° C and stirred for 2 h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (15% EtOAc in petroleum ether 60-80%) to give the product as white solid (0.38 g, 40%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.87-.99 (m, 2 H) 1.08-1.23 (m, 4 H) 1.23- 1.31 (m, 1 H) 1.54-163 (m, 2 H) 1.63-1.71 (m, 2 H) 1.75 (d, J=12.97 Hz, 2 H) 2.73 (t, J=7.86 Hz, 2 H) 6.06-6.19 (m, 1 H) 6.97 (dd, J=7.78, 473 Hz, 1 H) 7.67-7.88 (m, 1 H) 8.08 (dd, J=4.73, 1.53 Hz, 1 H) 11.41 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 25.62, 26.23, 26.63, 33.10, 36.45, 37.03, 96.98, 115.62, 121.06, 126.98, 141.47, 141.99, 149.18. m/z (ESI-MS) [M] + 229.1. 2-Cyclohexylethyl-7-oxide-7-azaindole To an ice-cool solution of 2-cyclohexylethyl-7-azaindole (0.34 g, 1.5 mmol) in EtOAc, meta- chloroperoxybenzoic acid (0.41 g, 2.5 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.4 g, 99%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.86-.99 (m, 2 H) 1.10-1.28 (m, 4 H) 1.55-1.63 (m, 4 H) 1.67 (d, J=12.05 Hz, 2 H) 1.73 (d, J=12.82 Hz, 2 H) 2.74 (t, J=7.78 Hz, 1 H) 6.28 (s, 1 H) 7.00 (dd, J=7.86, 6.18 Hz, 1 H) 7.49 (d, J=7.78 Hz, 1 H) 8.01 (d, J=6.26 Hz, 1 H) 12.27 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ 25.25, 26.20, 26.62, 33.05, 36.43, 36.69, 99.28, 116.41, 118.82, 125.11, 130.56, 142.91, 157.14. ,m/z (ESI-MS) [M] + 245.1. 4-Chloro-2-(2-cyclohexylethyl)-7-azaindole In sealed tube, 2-cyclohexylethyl-7-oxide-7-azaindole (0.4 g, 1.6 mmol) was dissolved in phosphoryl chloride (0.45 ml, 4.9 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured in to water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate, concentrated and triturated EtOAc in petroleum ether to afford the titled compound as brown solid (307 mg, 73%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.88- .98 (m, 2 H) 1.10-1.31 (m, 4 H) 1.56-1.71 (m, 5 H) 1.75 (d, J=12.66 Hz, 2 H) 2.72-2.78 (m, 2 H) 6.19-6.23 (m, 1 H) 7.11 (d, J=5.19 Hz, 1 H) 8.06 (d, J=5.19 Hz, 1 H) 11.85 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 25.59, 26.21, 26.62, 33.06, 36.31, 37.06, 95.19, 115.55, 119.86, 132.78, 142.25, 143.53, 149.71. m/z (ESI-MS) [M] + 263.1. 5-(2-(2-Cyclohexylethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-i ndazol-3-amine 4-Chloro-2-cyclohexylethyl-7-azaindole (0.075 g, 0.25 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.1 g, 0.41 mmol), 1M potassium phosphate solution (0.5 ml, 0.5 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.008 g, 0.012 mmol) in 1.5 ml ethanol were reacted as described in general procedure and chromatographic purification (60% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as white solid (60 mg,66%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.87-0.98 (m, 2 H) 1.10-1.32 (m, 5 H) 1.56-1.70 (m, 4 H) 1.76 (d, J= 12.51 Hz, 2 H) 2.72-2.81 (m, 2 H) 5.50 (s, 2 H) 6.39-6.45 (m, 1 H) 7.11 (d, J= 5.04 Hz, 1 H) 7.38 (d, J=8.70 Hz, 1 H) 7.65 (dd, J=8.70, 1.53 Hz, 1 H) 8.10-8.17 (m, 2 H) 11.53 (m, 2 H). 13 C NMR (100 MHz, DMSO- d 6 ) δ ppm 25.80, 26.22, 26.63, 37.19, 33.10, 36.59, 96.96, 110.24, 114.33, 115.05, 118.56, 120.57, 127.10, 128.64, 140.3, 1141.55, 141.99, 142.09, 149.95, 150.26. m/z (ESI-HRMS) calculated for C 21 H 25 N 6 = 361.2135 found=361.2132. Example 223 4-Chloro-3-(3-phenylprop-1-yn-1-yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by addition of prop-2-yn-1-ylbenzene (0.1 ml, 0.88 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was diluted with EtOAc and washed with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (5- 15% EtOAc in petroleum ether 60-80%) to give the product as yellow solid (0.095 g, 64 %),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 4.00 (s, 2 H) 6.52 (br. s., 2 H) 6.69 (d, J=5.71 Hz, 1 H) 7.31- 7.35 (m, 2 H) 7.35-7.39 (m, 1 H) 7.42-7748 (m, 2 H) 7.85 (d, J=5.71 Hz, 1 H). m/z (ESI-MS) [M] + 243.1. 2-Benzyl-4-chloro-7-azaindole To a solution of 4-chloro-3-(3-phenylprop-1-yn-1-yl)pyridin-2-amine (0.087 g, 0.36 mmol) in 1,4 dioxane (2 ml), potassium tert-butoxide (0.12 g, 1 mmol) and 18-crown-6 (0.009 g, 10%, 0.036 mmol) were added and the mixture was stirred at 110 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (76.7 mg, 88%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 4.10 (s, 2 H) 6.18 (s, 1 H) 7.12 (d, J=5.27 Hz, 1 H) 7.20-7.27 (m, 1 H) 7.31-7.37 (m, 4 H) 8.07 (d, J=5.27 Hz, 1 H) 12.10 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 34.45, 96.39, 115.78, 119.87, 126.99, 129.03, 129.31, 133.24, 139.22, 142.08, 142.79, 149.93. m/z (ESI-MS) [M] + 243.0. 5-(2-Benzyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-indazol-3-amin e 2-Benzyl-4-chloro-7-azaindole (0.02 g, 0.08 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)-1H-indazol-3-amine (0.031 g, 0.12 mmol), 1M potassium phosphate solution (0.16 ml, 0.16 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.002 g, 0.004 mmol) in 0.5 ml ethanol were reacted as described in General procedure A and HPLC purification gave the titled compound as yellow solid (22 mg, 48%),. 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 4.20 (s, 2 H) 6.62 (s, 1H) 7.25-7.30 (m, 1 H) 7.31 (d, J= 5.19 Hz, 1 H) 7.37 (t, J=7.63 Hz, 2 H) 7.40 (d, J=7.02, 2 H) 7.52 (d, J= 8.85 Hz, 1 H) 7.81 (d, J= 8.70 Hz, 1 H) 8.29- 8.33 (m, 2 H) 12.10 (br. s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 34.44, 98.56, 110.98, 114.56, 115.44, 119.84, 121.40, 126.49, 126.83, 128.89, 128.91, 129.11, 136.09, 139.40, 141.34, 141.89, 144.31, 151.35, 152.76. m/z (ESI-HRMS) calculated for C 21 H 18 N 5 = 340.1550 found=340.1557. Example 224 4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-d]pyridin-2-yl)me thanol 4-(Chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)methanol (0.11 g, 0.60 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.258 g, 1.00 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.040 g, 0.06 mmol) in EtOH (3.0 mL, degassed under nitrogen) was added K 3 PO 4 (1M, 1.2 mL) and the reaction mixture was heated to 100 ^C for 20 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with water and brine. The organics were concentrated under reduced pressure, diluted into EtOAc, and filtered through a pad of celite. The solution was then concentrated under reduced pressure and the resulting residue was dissolved in DMF (1.5 mL) and passed through a pad of cotton wool prior to being purified by HPLC. Purification of 0.02 g of crude material by HPLC (tR = 6 min) afforded the title compound as the double TFA salt (0.0052 g, 16.9%). 1 H NMR (DMSO-d 6 ): ^ 4.67 (s, 2H), 6.68 (s, 1H), 7.29 (d, J = 5.2 Hz, 1H), 7.47 (d, J = 8.8 Hz, 1H), 7.77 (dd, J = 1.6, 8.8 Hz, 1H), 8.27 (m, 2H), 11.97 (br s, 1H). HRMS: For C15H14ON5 requires 280.1190 found 280.1193. Analytical LCMS @ 254 nm tR = 8.88 min; 87.9%; MS (ESI) m/z (M+H) + . Example 225 2-(4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl )propan-2-ol 2-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)propan-2-ol (0.105 g, 0.5 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.194 g, 0.75 mmol) and [1,1′-bis(di- tert-butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.016 g, 0.025 mmol) in EtOH (3.0 mL, degassed under nitrogen) was added K 3 PO 4 (1M, 1.2 mL) and the reaction mixture was heated to 100 ^C for 22 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with water and brine. The organics were concentrated under reduced pressure, diluted into EtOAc, and filtered through a pad of celite. The solution was then concentrated under reduced pressure and the resulting residue was dissolved in DMF (1.5 mL) and passed through a pad of cotton wool prior to being purified by HPLC to afford the title compound as the double TFA salt (0.0551 g, 20%). Example 226 3-(4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-d]pyridin-2-yl )pentan-3-ol 3-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)pentan-3-ol (0.105 g, 0.44 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.21 g, 0.80 mmol) and [1,1′-bis(di- tert-butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.029 g, 0.044 mmol) in EtOH (3.0 mL, degassed under nitrogen) was added K 3 PO 4 (1M, 1.2 mL) and the reaction mixture was heated to 100 ^C for 22 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, washed with water and brine. The organics were concentrated under reduced pressure, diluted into EtOAc, and filtered through a pad of celite. The solution was then concentrated under reduced pressure and the resulting residue was dissolved in DMF (1.5 mL) and passed through a pad of cotton wool prior to being purified by HPLC. Purification by HPLC (tR = 11 min) afforded the title compound as the double TFA salt (0.0451 g, 18.2%). 1 H NMR (DMSO-d 6 ): ^ 0.73 (m, 6H), 1.83 (m, 4H), 6.61 (d, J = 2.0 Hz, 1H), 7.29 (d, J = 5.6 Hz, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.80 (dd, J = 1.6, 8.8 Hz, 1H), 8.27 (m, 2H), 11.90 (br s, 1H). HRMS: For C19H22ON5 requires 336.1819 found 336.1813. Example 227 2-tert-Butoxymethy-4-chloro-7-azaindole To a solution of 3-(3-(tert-butoxy)prop-1-yn-1-yl)-4-chloropyridin-2-amine (0.6 g, 0.25 mmol) in 1,4 dioxane (2 ml), potassium tert-butoxide (0.07 g, 0.63 mmol) and 18-crown-6 (0.006 g, 10 %, 0.0025 mmol) were added and the mixture was stirred at 110 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (31.7 mg, 96%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.24 (s, 9 H) 4.54 (s, 2 H) 6.38 (s, 1 H) 7.15 (d, J=5.19 Hz, 1 H) 8.12 (d, J=5.19 Hz, 1 H) 11.98 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 27.83, 40.27, 57.64, 96.45, 115.72, 115.68, 119.34, 140.50, 143.20, 143.19. m/z (ESI-MS) 5-(2-(tert-Butoxymethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-i ndazol-3-amine 4-Chloro-2-tert-butoxymethyl-7-azaindole (0.03 g, 0.12 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.05 g, 0.19 mmol), 1M potassium phosphate solution (0.25 ml, 0.25 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.004 g, 0.006 mmol) in 0.7 ml ethanol were reacted as described in General procedure A and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as white solid (22 mg, 52%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.26 (s, 9 H) 4.55 (s, 2 H) 5.51 (s, 2 H) 6.59 (s, 1 H) 7.15 (d, J= 5.04 Hz, 1 H) 7.38 (d, J=8.70 Hz, 1 H) 7.65 (dd, J=8.62, 1.6 Hz, 1 H) 8.15 (s, 1 H) 8.21 (d, J= 5.04 Hz, 1 H) 11.53 (s, 1 H) 11.66 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 27.88, 40.27, 57.85, 98.37, 110.29, 114.46, 115.05, 118.03, 120.69, 127.12, 128.45, 138.98, 141.34, 141.59, 143.00, 150.01, 150.29. m/z (ESI-HRMS) calculated for C 19 H 22 ON 5 = 336.1819 found=336.1815. Example 228 2-((Tetrahydro-2H-pyran-4-yl)-7-azaindole To stirred solution of 2(Boc-amino)-3-methyl-pyridine (0.55 g, 2.6 mmol) in anhydrous THF (20 ml) at -4 °C, 2M n-butyllithium (3.2 ml, 6.5 mmol) was added slowly over 15 min, then N- methoxy-N-methyl-2-(tetrahydro-2H-pyran-4-yl)carboxamamide (0.5 g, 2.9 mmol) was added slowly and the reaction mixture allowed to stirred for 2h. Therafter, hydrochloric acid (5M, 19 ml) was added and the reaction was heated to 60° C and stirred for 2h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated to give the product as white solid (0.51 g, 84%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.64-1.79 (m, 2 H) 1.87-1.97 (m, 2 H) 2.97 (tt, J=11.75, 3.63 Hz, 1 H) 3.45 (td, J=11.64, 2.20 Hz, 2 H) 3.94 (dd, J=11.42, 2.64 Hz, 2 H) 6.11-6.19 (m, 1 H) 6.98 (dd, J=7.91, 4.83 Hz, 1 H) 7.81 (dd, J=7.91, 1.32 Hz, 1 H) 8.11 (dd, J=4.83, 1.76 Hz, 1 H) 11.53 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 32.28, 34.58, 67.34, 95.46, 115.72, 120.69, 127.43, 141.86, 145.23, 149.20. m/z (ESI- MS) [M] + 203.1. 2-(Tetrahydro-2H-pyran-4-yl)-7-oxide-7-azaindole To an ice-cooled solution of 2-((tetrahydro-2H-pyran-4-yl)-7-azaindole (0.55 g, 2.4 mmol) in EtOAc, meta-chloroperoxybenzoic acid (0.68 g, 3.9 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1 M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.4 g, 76%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.64-1.77 (m, 2 H) 1.89-1.96 (m, 2 H) 2.99 (tt, J=11.75, 3.63 Hz, 1 H) 3.42 (td, J=11.64, 1.76 Hz, 2 H) 3.93(dd, J=11.42, 3.08 Hz, 2 H) 6.31 (s, 1 H) 7.02 (dd, J=7.91, 6.15 Hz, 1 H) 7.53 (d, J=7.91 Hz, 1 H) 8.05 (d, J=6.15 Hz, 1 H) 12.35 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 32.19, 34.40, 67.32, 97.81, 116.51, 119.27, 124.81, 130.91, 138.86, 146.15. m/z (ESI-MS) [M] + 219.1. 2-(Tetrahydro-2H-pyran-4-yl)-4-chloro-7-azaindole In sealed tube, 2-(tetrahydro-2H-pyran-4-yl)-7-oxide-7-azaindole (0.35 g, 1.6 mmol) was dissolved in phosphoryl chloride (0.4 ml, 4.8 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured into water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (40-60% EtOAc in petroleum ether 60-80%) to give the product as white solid (68.6 mg, 18%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 11.69-1.80 (m, 2 H) 1.94 (dd, J= 12.82, 1.83 Hz, 2 H) 3.01 (tt, J=11.67, 3.74 Hz, 1 H) 3.46 (td, J=11.67, 1.83 Hz, 2 H) 3.95 (dd, J=10.83, 3.20 Hz, 2 H) 6.24 (d, J=1.53 Hz, 1 H) 7.13 (d, J=5.19 Hz, 1 H) 8.10 (d, J=5.34 Hz, 1 H) 11.93 (br. s., 1 H).. 13 C NMR (100 MHz, DMSO-d6) δ ppm 32.09, 34.58, 67.28, 93.73, 115.63, 119.52, 133.26, 142.64, 146.57, 149.75. m/z (ESI-MS) [M] + 237.1. 5-(2-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-b]pyridin-4-y l)-1H-indazol-3-amine 4-Chloro-2-(tetrahydro-2H-pyran-4yl)-7-azaindole (0.048 g, 0.2 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.08 g, 0.3 mmol), 1M potassium phosphate solution (0.4 ml, 0.4 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.006 g, 0.012 mmol) in 1.2 ml ethanol were reacted as described in General procedure A and chromatographic purification (18% methanol in EtOAc and 1% triethylamine), gave the titled compound as brown solid (56.5 mg, 84%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.72-1.85 (m, 2 H) 1.91-2.01 (m, 2 H) 3.02 (tt, J=11.65, 3.68 Hz, 1 H) 3.47 (td, J= 11.63, 1.60 Hz, 2 H) 3.96 (dd, J=11.22, 2.98 Hz, 2 H) 5.51 (s, 2 H) 6.44 (d, J=1.53 Hz, 1 H) 7.13 (d, J= 5.04 Hz, 1 H) 7.38 (d, J=8.70 Hz, 1 H) 7.65 (dd, J=8.54, 1.53 Hz, 1 H) 8.14 (s, 1 H) 8.17 (d, J= 5.04 Hz, 1 H) 11.53 (s, 1 H) 11.62 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 32.30, 34.73, 67.39, 95.17, 110.29, 114.39, 115.05, 118.18, 120.59, 127.12, 128.55, 140.77, 141.56, 142.36, 145.25, 149.98, 150.27.m/z (ESI-HRMS) calculated for C 19 H 20 ON 5 = 334.1662 found=334.1659. Example 229 2-((Tetrahydro-2H-pyran-2-yl)-7-azaindole To stirred solution of 2(Boc-amino)-3-methyl-pyridine (0.55 g, 2.6 mmol) in anhydrous THF (20 ml) at -4 °C, 2M n-butyllithium (3.2 ml, 6.5 mmol) was added slowly over 15 min, then N- methoxy-N-methyl-2-(tetrahydro-2H-pyran-4-yl)carboxamamide (0.5 g, 2.9 mmol) was added slowly and the reaction mixture allowed to stirred for 2h. Thereafter, hydrochloric acid (5M, 19 ml) was added and the reaction was heated to 60° C and stirred for 2 h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated to give the product as white solid (0.54 g, 84%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.75 (m, 3 H) 1.86- 1.98 (m, 2 H) 3.52-3.62 (m, 1 H) 3.97-4.03 (m, 1 H) 4.52 (dd, J=10.76, 2.21 Hz, 1 H) 6.31 (s, 1 H) 7.02 (dd, J=7.78, 4.73 Hz, 1 H) 7.87 (dd, J=7.78, 1.68 Hz, 1 H) 8.16 (dd, J=4.65, 1.60 Hz, 1 H) 11.59 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 23.36, 25.91, 31.40, 68.26, 73.80, 96.65, 115.83, 120.19, 128.10, 141.77, 142.53, 148.99. m/z (ESI-MS) [M] + 203.1. 2-(Tetrahydro-2H-pyran-2-yl)-7-oxide-7-azaindole To an ice-cooled solution of 2-((tetrahydro-2H-pyran-2-yl)-7-azaindole (0.5 g, 2.4 mmol) in EtOAc, meta-chloroperoxybenzoic acid (0.68 g, 4 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1 M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.5 g, 95%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.57 (d, J=7.28 Hz, 3 H) 1.84-1.92 (m, 1 H) 1.92-2.02 (m, 1 H) 3.65 (t, J=6.78 Hz, 1 H) 3.93-4.04 (m, 2 H) 4.51 (dd, J=10.79, 2.01 Hz, 1 H) 6.44 (s, 1 H) 7.06 (s, 1 H) 7.56 (s, 1 H) 8.08 (s, 1 H) 12.44 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 22.89, 25.29, 31.11, 67.87, 72.97, 98.31, 116.13, 119.25, 123.90, 127.59, 130.86, 142.25. m/z (ESI-MS) [M] + 219.1. 2-(Tetrahydro-2H-pyran-2-yl)-4-chloro-7-azaindole In sealed tube, 2-(tetrahydro-2H-pyran-2-yl)-7-oxide-7-azaindole (0.35 g, 1.6 mmol) was dissolved in phosphoryl chloride (0.4 ml, 4.8 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured in to water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (40-60% EtOAc in petroleum ether 60-80%) to give the product as white solid (41 mg, 7.5%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.57-1.80 (m, 3 H) 1.84-189 (m, 1 H) 1.90-3.05 (m, 2 H) 3.46-3.61 (m, 1 H) 3.95 (d, J=10.99 Hz, 1 H) 4.50 (dd, J=10.98, 2.06 Hz, 1 H) 6.24 (d, J=1.53 Hz, 1 H) 7.13 (d, J=5.19 Hz, 1 H) 8.09 (d, J=5.34 Hz, 1 H) 11.93 (br. s., 1 H).m/z (ESI-MS) [M] + 237.1. 5-(2-(Tetrahydro-2H-pyran-2-yl)-1H-pyrrolo[2,3-b]pyridin-4-y l)-1H-indazol-3-amine 4-Chloro-2-(tetrahydro-2H-pyran-2yl)-7-azaindole (0.033 g, 0.14 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.054 g, 0.21 mmol), 1M potassium phosphate solution (0.28 ml, 0.28 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.004 g, 0.007 mmol) in 0.84 ml ethanol were reacted as described in General procedure A and chromatographic purification (18% methanol in EtOAc and 1% triethylamine), gave the titled compound as brown solid (28.3 mg, 60%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.53-1.71 (m, 3 H) 1.73-1.84 (m, 1 H) 1.87-2.01 (m, 2 H) 3.54-3.61 (m, 1 H) 4.01 (d, J=10.99, 1 H) 4.55 (dd, J=10.91, 2.06 Hz, 1 H) 5.52 (s, 2 H) 6.54 (d, J=1.53 Hz, 1 H) 7.15 (d, J= 5.04 Hz, 1 H) 7.38 (d, J=8.54 Hz, 1 H) 7.64 (dd, J=8.62, 1.60 Hz, 1 H) 8.15 (s, 1 H) 8.21 (d, J= 4.88 Hz, 1 H) 11.53 (s, 1 H) 11.69 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 23.41, 25.91, 31.47, 68.30, 73.96, 96.38, 110.30, 114.48, 115.05, 117.76, 120.67, 127.14, 128.41, 141.45, 141.60, 141.82, 143.01, 149.77, 150.29. m/z (ESI-HRMS) calculated for C 19 H 20 ON 5 = 334.1662 found=334.1660. Example 230 2-((Tetrahydro-2H-pyran-4-yl)methyl)-7-azaindole To stirred solution of 2-(Boc-amino)-3-methyl-pyridine (1.5 g, 7.3 mmol) in anhydrous THF (40 ml) at -4 °C, 2M n-butyllithium (9.1 ml, 18.25 mmol) was added slowly over 15 min, then N- methoxy-N-methyl-2-(tetrahydro-2H-pyran-4-yl)acetamide (1.5 g, 8 mmol) was added slowly and the reaction mixture allowed to stirred for 2 h. Thereafter, hydrochloric acid (5M, 50 ml) was added and the reaction was heated to 60° C and stirred for 2 h. The organic layer was separated and aqueous layer was neutralized and extracted with EtOAc. The collected organic layer was washed with brine, dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (40-60% EtOAc in petroleum ether 60-80%) to give the product as white solid (0.8 g, 50%), . 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.19-1.29 (m, 2 H) 1.53 (dd, J=12.89, 1.75 Hz, 2 H) 1.94 (ttt, J=11.25, 11.25, 7.44, 7.44, 3.74, 3.74 Hz, 1 H) 2.66 (d, J=7.17 Hz, 2 H) 3.26 (td, J=7.67, 1.98 Hz, 2 H) 3.83 (dd, J=11.44, 2.44 Hz, 2 H) 6.16 (d, J=1.83 Hz, 1 H) 6.97 (dd, J=7.71, 4.65 Hz, 1 H) 7.79 (dd, J=7.78, 1.07 Hz, 1 H) 8.09 (dd, J=4.65, 1.60 Hz, 1 H) 11.43 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 33.05, 35.16, 35.56, 67.39, 98.23, 115.68, 121.02, 127.05, 139.51, 141.58, 149.14. m/z (ESI-MS) [M] + 217.1. 2-((Tetrahydro-2H-pyran-4-yl)methyl)-7-oxide-7-azaindole To an ice-cooled solution of 2-((tetrahydro-2H-pyran-4-yl)methyl)-7-azaindole (0.35 g, 1.6 mmol) in EtOAc, meta-chloroperoxybenzoic acid (0.45 g, 2.6 mmol) was added slowly then the reaction warmed to room temperature and stirred to 1 h. After the reaction was completed, the solvent was evaporated, treated with 1M sodium carbonate solution and extracted with EtOAc. The residue then concentrated under vacuum to give the product as a yellow solid (0.35 g, 94%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.13-1.27 (m, 2 H) 1.48 (dd, J=12.80, 1.76 Hz, 2 H) 1.84- 1.97 (m, 1 H) 2.66 (d, J=7.28 Hz, 2 H) 3.15-3.25 (m, 2 H) 3.80 (dd, J=11.29, 2.51 Hz, 2 H) 6.30 (s, 1 H) 7.02 (dd, J=8.13, 6.37 Hz, 1 H) 7.54 (d, J=7.91 Hz, 1 H) 8.05 (d, J=6.15 Hz, 1 H) 12.35 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 32.38, 34.51, 34.71, 66.84, 100.00, 115.96, 118.60, 124.63, 130.16, 138.21, 139.99. m/z (ESI-MS) [M] + 233.1. 2-((Tetrahydro-2H-pyran-4-yl)methyl)-4-chloro-7-azaindole In sealed tube, 2-((tetrahydro-2H-pyran-4-yl)methyl)-7-oxide-7-azaindole (0.35 g, 1.5 mmol) was dissolved in phosphoryl chloride (0.4 ml, 4.5 mmol) and the reaction heated to 90 °C and stirred to 18 h. The reaction mixture then warmed to room temperature and poured in to water and neutralized with saturated sodium carbonate solution and extract with EtOAc. The collected organic layer dried over magnesium sulfate and concentrated. The crude then purified using column chromatography (40-60% EtOAc in petroleum ether 60-80%) to give the product as white solid (82.7 mg, 22%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.18-1.31 (m, 2 H) 1.46-1.58 (m, 2 H) 1.95 (dtt, J= 11.25, 7.51, 7.51, 3.72, 3.72 Hz, 1 H) 2.68 (d, J=7.32 Hz, 2 H) 3.21-3.31 (m, 2 H) 3.83 (dd, J=11.37, 2.82 Hz, 2 H) 6.24 (d, J=1.83 Hz, 1 H) 7.12 (d, J=5.19 Hz, 1 H) 8.07 (d, J=5.19 Hz, 1 H) 11.86 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 32.98, 35.08, 35.43, 67.35, 96.41, 115.60, 119.84, 132.84, 141.02, 142.36, 149.67. m/z (ESI-MS) [M] + 251.1. 5-(2-((tetrahydro-2H-pyran-4-yl)methyl)-1H-pyrrolo[2,3-b]pyr idin-4-yl)-1H-indazol-3-amine 4-Chloro-2((tetrahydro-2H-pyran-4yl)methyl)-7-azaindole (0.065 g, 0.25 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.1 g, 0.38 mmol), 1M potassium phosphate solution (0.5 ml, 0.5 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.008 g, 0.012 mmol) in 1.5 ml ethanol were reacted as described in general procedure and chromatographic purification (18% methanol in EtOAc and 1% triethylamine), gave the titled compound as brown solid (71.2 mg, 81%), . 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.20-1.30 (m, 2 H) 1.50-1.58 (m, 2 H) 1.91-2.01 (m, 1 H) 2.70 (d, J= 7.17 Hz, 2 H) 3.23-3.29 (m, 2 H) 3.82 (dd, J=11.37, 2.67 Hz, 2 H) 5.50 (s, 2 H) 6.40-6.48 (m, 1 H) 7.12 (d, J= 5.04 Hz, 1 H) 7.38 (d, J=8.70 Hz, 1 H) 7.65 (dd, J=8.70, 1.53 Hz, 1 H) 8.14 (s, 1 H) 8.16 (d, J= 4.88 Hz, 1 H) 11.54 (br. s., 2 H). 13 C NMR (100 MHz, DMSO- d6) δ ppm 33.07, 35.27, 35.68, 67.39, 97.97, , 110.27, 114.35, 115.07, 118.55, 120.59, 127.12, 128.61, 139.60, 140.38, 141.57, 142.10, 149.91, 150.28. m/z (ESI-HRMS) calculated for C20H22ON5 = 348.1819 found=348.1814. Example 231 Methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carb oxylate A 2–5 mL MW vial was charged with methyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (0.210 g, 1mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (0.337 g, 1.3 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.054 g, 0.208 mmol, 8%mol) and K2CO3 (0.248 g, 1.8 mmol, anhydrous). The vial was sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, and purged with nitrogen. The vial was then charged with MeOH (5 mL, anhydrous O2-free) and the mixture was stirred at 45 °C and purged with N2 for 15 min. The resulting mixture was then stirred to 70 °C for 13 hours. The reaction was then diluted with EtOAc (200 mL) and washed with H2O (30 mL × 3). The organic phase was then dried (MgSO 4 ), filtered, absorbed onto silica and purified by flash chromatography (Biotage SP4, 50 g SiO 4 , 0-3% MeOH in EtOAc) to afford the title compound as a green solid (0.045 g, 0.146 mmol, 15%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 3.89 (s, 3H), 5.59 (s, 2H), 7.28 (d, J = 4.9 Hz, 1H), 7.35 – 7.45 (m, 2H), 7.67 (d, J = 8.7 Hz, 1H), 8.22 (s, 1H), 8.45 (d, J = 4.9 Hz, 1H), 11.60 (s, 1H), 12.62 (s, 1H). HRMS: Calculated for C 16 H 14 O 2 N 5 (M+H + ) = 308.1142; Found: 308.1142 Example 232 Ethyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carb oxylate Ethyl 4-chloro-1H-pyrrolo[2,3-b]pyridin-2-carboxylate (0.11 g, 0.5 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.150 g, 0.58 mmol) and [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.038 g, 0.058 mmol) in EtOH (3.0 mL, degassed under nitrogen) was added K3PO4 (1M, 1.2 mL) and the reaction mixture was heated to 80 ^C for 24 h. The reaction mixture was cooled to room temperature and the reaction mixture was diluted with EtOAc, washed with water, aqueous saturated NaHCO 3 and brine. Organics were concentrated under reduced pressure and purified by column chromatography (100% Hexane – 2/1 Hexane/EtOAc – 100% EtOAc – 10% MeOH/EtOAc) and triturated with MeOH and Hexane to afford the title compound as an off-white solid (0.004 g, 0.013 mmol, 3%). 1 H NMR (DMSO-d6): ^ 1.34 (t, J = 7.2 Hz, 3H), 4.33 (q, J = 7.2 Hz, 2H), 5.59 (br s, 2H), 7.27 (d, J = 4.8 Hz, 1H), 7.35 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.65 (dd, J = 1.6, 8.4 Hz, 1H), 8.21 (s, 1H), 8.45 d, J = 5.2 Hz, 1H), 11.61 (br s, 1H), 12.59 (br s, 1H). HRMS: For C 17 H 16 O 2 N 5 requires 322.1299 found 322.1293. Example 233 3-(2-Amino-4-chloropyridin-3-yl)propiolamide A solution of 4-chloro-3-iodopyridin-2-amine (1.00 g, 3.9 mmol), copper (I) iodide (0.38 g, 0.2 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.28 g, 0.4 mmol) in 16 ml of N,N- dimethyformamide-triethylamine (4:1) was degassed in sealed tube followed by addition of propiolamide (1.00 g, 14.5 mmol). The reaction mixture was heated to 80 °C for 10 hours. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and filtrated through silica (petroleum ether 60-80%/acetone 7:3) to give the crude product as a brown solid. (0.36 g, 47%) which was used without further purification. 1 H NMR (400 MHz, (CD3)2CO): ^ 6.31 (br s, 2H), 6.74 (d, J = 5.4 Hz, 1H), 7.98 (d, J = 5.4 Hz, 1H), 2 protons missing. LRMS: Calculated for C 8 H 6 ClN 3 O 195.0 found 196.0 (M+1). 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carb oxamide A solution of 3-(2-amino-4-chloropyridin-3-yl)propiolamide (0.50 g, 2.6 mmol), K 3 PO 4 (4.10 g, 19.2 mmol), Sphos (113 mg, 0.26 mmol), bis(triphenylphosphine) palladium(II) chloride (58 mg, 0.26 mmol) and 2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz onitrile (1.58 g, 6.4 mmol) in 16.6 ml of dioxane-water (5:1) was degassed in sealed tube and submitted to reaction. The reaction mixture was heated to 80 °C, o/n. The resulting mixture was diluted with EtOAc, filtered through silica, concentrated under reduced pressure and the residue was filtered through silica (petroleum ether 60-80%/acetone 4:6) to provide a brown solid (0.11 g) which was used as followed without further purification. To a solution of 3-(2-amino-4-(3-cyano-4-fluorophenyl)pyridin-3-yl)propiolami de (60 mg, 0.22 mmol) in 0.3 ml of EtOH was added hydrazine (0.86 mL, 1 Mol solution in EtOH). The reaction was stirred at 80 °C, o/n. The resulting mixture was diluted with EtOAc, washed with water, concentrated under reduced pressure and the residue purified by HPLC to give the product as a yellow solid. (5 mg, 8%) 1 H NMR (400 MHz, DMSO-d6): ^ 5.54 (br s, 2H), 7.22 (d, J = 4.9 Hz, 1H), 7.40 (d, J = 8.6 Hz, 1H), 7.46 (s, 1H), 7.67 (dd, J = 8.6, 1.6 Hz, 1H), 8.07 (br s, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.36 (d, J = 4.9 Hz, 1H), 11.59 (br s, 1H), 12.12 (br s, 1H). LRMS: Calculated for C 15 H 12 N 6 O 292.1 found 293.1 (M+1). Example 234 (4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)( pyrrolidin-1-yl)methanone A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), pyrrolidine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N 2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.007 g, 0.0122 mmol, 33%).. 1 H NMR (400 MHz, DMSO-d6) δ 1.76 – 2.05 (m, 4H), 3.55 (t, J = 6.6 Hz, 2H), 3.80 (t, J = 6.5 Hz, 2H), 7.13 (s, 1H), 7.28 (d, J = 4.5 Hz, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.80 (dd, J = 8.7, 1.7 Hz, 1H), 8.30 (s, 1H), 8.42 (s, 1H), 12.29 (s, 1H). HRMS: Calculated for C 19 H 19 ON 6 (M+H + ) = 347.1615; Found: 347.1613 Example 235 4-(3-Amino-1H-indazol-5-yl)-N-cyclopentyl-1H-pyrrolo[2,3-b]p yridine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), cyclopentanamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N 2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0058 g, 0.00986 mmol, 26%).. 1 H NMR (400 MHz, DMSO-d6) δ 1.47 – 1.59 (m, 4H), 1.63 – 1.74 (m, 2H), 1.85 – 1.97 (m, 2H), 4.18 – 4.31 (m, 1H), 7.24 (d, J = 5.0 Hz, 1H), 7.42 (s, 1H), 7.50 (d, J = 8.7 Hz, 1H), 7.77 (d, J = 8.3 Hz, 1H), 8.26 (s, 1H), 8.36 (d, J = 7.2 Hz, 1H), 8.38 (d, J = 5.0 Hz, 1H), 12.25 (s, 1H). HRMS: Calculated for C 20 H 21 ON 6 (M+H + ) = 361.1771; Found: 361.1776 Example 236 4-(3-Amino-1H-indazol-5-yl)-N-cyclohexyl-1H-pyrrolo[2,3-b]py ridine-2-carboxamide Ethyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridine-2-carb oxylate (Example 232) (0.060 g, 0.187 mmol), cyclohexylamine ( 0.5 mL, 4.36 mmol) and a magnetic stirrer bar were added in a 0.5 - 2 mL Biotage microwave vial which was sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum. Then MeOH (0.1 mL) was added and the vial was subjected to microwave irradiation for 90 min at 190 ºC. After cooling, the solvent was evaporated and the mixture was suspended in 0.1 M NaOH (aquous solution, 5 mL) and extracted with EtOAc (3 x 8 mL), the organic layer was dried under MgSO4 and the solvent evaporated in vacuo. The residue was purified by flash chromatography (SiO2, dichloromethane - dichlorormethane:MeOH 95:5) to obtain the title compound as brown solid (0.010 g, 0.027 mmol, 15%). 1 H NMR (400 MHz, DMSO-d6) δ 1.25 – 1.39 (m, 5H), 1.58 - 1.63 (m, 2H), 1.72 - 1.78 (m, 2H), 1.82 - 1.88 (m, 2H), 5.54 (s, 2H), 7.19 (d, J = 4.7 Hz, 1H), 7.39 – 7.42 (m, 2H), 7.66 (d, J = 8.4 Hz, 1H), 8.16 (s, 1H), 8.25 (d, J = 8.4 Hz, 1H), 8.35 (d, J = 4.7 Hz, 1H), 11.58 (s, 1H), 12.09 (s, 1H). HRMS found 375.19 (M+H) + calculated for C21H23ON6375.19 Example 237 4-(3-Amino-1H-indazol-5-yl)-N-isopentyl-1H-pyrrolo[2,3-b]pyr idine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.026 g, 0.0809 mmol, 1 eq.), i-pentylamine (94 μL, 0.810 mmol, 10eq.) EtOH (500 μL, anhydrous). The vial was sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N 2 and heated to 170 °C under microwave irradiation for 90 minutes. The resulting solution was evaporated to give a yellow solid that was checked by NMR showing the presence of product and starting material. The solid was dissolved with EtOH (300 uL, anhydrous) and i-pentylamine (282 μL, 30 eq.), purged with N 2 and heated to 170 °C under mw irradiation for additional 2 hours. The resulting solution was evaporated to give a yellow solid that was purified by HPLC to afford the title compound as a yellow solid (0.0187 g, 0.0317 mmol, 39%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 0.92 (d, J = 6.6 Hz, 6H), 1.06 (t, J = 7.0 Hz, 1H), 1.40 – 1.49 (m, 2H), 1.61 – 1.66 (m, 1H), 3.28 – 3.35 (m, 2H), 7.23 (d, J = 5.0 Hz, 1H), 7.38 (s, 1H), 7.45 (d, J = 8.5 Hz, 1H), 7.72 (d, J = 8.5 Hz, 1H), 8.22 (s, 1H), 8.37 (d, J = 4.9 Hz, 1H), 8.43 – 8.50 (m, 1H), 12.18 (s, 1H).HRMS: Calculated for C 20 H 23 ON 6 (M+H + ) = 363.1928; Found: 363.1931 Example 238 4-(3-Amino-1H-indazol-5-yl)-N-phenethyl-1H-pyrrolo[2,3-b]pyr idine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), 2-phenylethanamine (0.183 mL, dried on MS3A) and EtOH (0.367 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0066 g, 28%). 1 H NMR (400 MHz, DMSO-d6) δ 2.87 (t, J = 7.4 Hz, 2H), 3.52 (app q, J = 6.8 Hz, 2H), 7.15 – 7.34 (m, 6H), 7.39 (s, 1H), 7.46 (d, J = 8.6 Hz, 1H), 7.73 (d, J = 8.7 Hz, 1H), 8.22 (s, 1H), 8.39 (s, 1H), 8.65 (t, J = 5.8 Hz, 1H), 12.22 (s, 1H). HRMS: Calculated for C23H21ON6 (M+H + ) = 397.1771; Found: 397.1766 Example 239 4-(3-Amino-1H-indazol-5-yl)-N-(3-phenylpropyl)-1H-pyrrolo[2, 3-b]pyridine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), 3-phenylpropan-1-amine (0.183 mL, dried on MS3A) and MeOH (0.367 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 160 °C under microwave irradiation for 8 hours. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0059 g, 0.00924 mmol, 25%).. 1 H NMR (400 MHz, DMSO-d6) δ 1.78 – 1.92 (m, 2H), 2.60 – 2.70 (m, 2H), 3.31 (app q, J = 6.9 Hz, 2H), 7.14 – 7.34 (m, 6H), 7.40 (s, 1H), 7.47 (d, J = 8.7 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 8.24 (s, 1H), 8.38 (d, J = 4.9 Hz, 1H), 8.56 (t, J = 5.4 Hz, 1H), 12.25 (s, 1H). HRMS: Calculated for C24H23ON6 (M+H + ) = 411.1928; Found: 411.1930 Example 240 4-(3-Amino-1H-indazol-5-yl)-N-(2-methoxyethyl)-1H-pyrrolo[2, 3-b]pyridine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.015 g, 0.0488 mmol), 2-methoxyethanamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 5 hours. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0106 g, 0.0183 mmol, 38%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 3.28 (s, 3H), 3.42 – 3.50 (m, 4H), 7.26 (d, J = 5.0 Hz, 1H), 7.46 (s, 1H), 7.51 (d, J = 8.7 Hz, 1H), 7.80 (d, J = 8.6 Hz, 1H), 8.29 (s, 1H), 8.40 (d, J = 5.0 Hz, 1H), 8.61 – 8.66 (m, 1H), 12.30 (s, 1H). HRMS: Calculated for C 18 H 19 O 2 N 6 (M+H + ) = 351.1564; Found: 351.1567 Example 241 4-(3-Amino-1H-indazol-5-yl)-N-(2-aminoethyl)-1H-pyrrolo[2,3- b]pyridine-2-carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), ethane-1,2-diamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0077 g, 0.0114 mmol, 30%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 2.99 (app q, J = 5.8 Hz, 2H), 3.52 (app q, J = 6.0 Hz, 2H), 7.24 (d, J = 5.0 Hz, 1H), 7.38 (s, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.78 (bs, 3H), 8.20 (s, 1H), 8.40 (d, J = 5.0 Hz, 1H), 8.68 (t, J = 5.7 Hz, 1H), 11.81 (s, 0H), 12.27 (s, 1H). HRMS: Calculated for C17H18ON7 (M+H + ) = 420.2506; Found: 336.1563 Example 242 4-(3-Amino-1H-indazol-5-yl)-N-(2-(dimethylamino)ethyl)-1H-py rrolo[2,3-b]pyridine-2- carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), N1,N1-dimethylethane-1,2- diamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 5 hours. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0075 g, 0.0106, 29%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 2.85 (d, J = 4.6 Hz, 6H), 3.27 (app q, J = 5.9 Hz, 2H), 3.64 (app q, J = 6.0 Hz, 2H), 7.25 (d, J = 5.0 Hz, 1H), 7.40 (s, 1H), 7.46 (d, J = 8.7 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 8.21 (s, 1H), 8.40 (d, J = 4.9 Hz, 1H), 8.77 (t, J = 5.8 Hz, 1H), 9.39 (s, 1H), 11.85 (bs, 1H), 12.30 (s, 1H). HRMS: Calculated for C 19 H 22 ON 7 (M+H + ) = 364.1880; Found: 364.1880 Example 243 (4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)( 4-methylpiperazin-1- yl)methanone A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), 1-methylpiperazine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 200 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0052 g, 0.0725 mmol, 19%). 1 H NMR (400 MHz, DMSO-d6) δ 2.85 (s, 3H), 3.02 – 3.15 (m, 2H), 3.29 – 3.53 (m, 2H), 4.43 – 4.65 (m, 2H), 7.04 (s, 1H), 7.27 (d, J = 4.9 Hz, 1H), 7.41 (d, J = 8.7 Hz, 1H), 7.71 (d, J = 8.5 Hz, 1H), 8.22 (s, 1H), 8.40 (d, J = 4.8 Hz, 1H), 9.82 (bs, 1H), 11.72 (bs, 1H), 12.34 (s, 1H). HRMS: Calculated for C20H22ON7 (M+H + ) = 376.1880; Found: 376.1876 Example 244 4-(3-Amino-1H-indazol-5-yl)-N-(2-(piperidin-1-yl)ethyl)-1H-p yrrolo[2,3-b]pyridine-2- carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), 2-(piperidin-1-yl)ethanamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0061 g, 0.00818, 22%).. 1 H NMR (400 MHz, DMSO-d 6 ) δ 1.31 – 1.44 (m, 1H), 1.53 – 1.75 (m, 3H), 1.77 – 1.89 (m, 2H), 2.87 – 3.02 (m, 2H), 3.15 – 3.29 (m, 2H), 7.23 (d, J = 4.9 Hz, 1H), 7.38 (d, J = 1.7 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.66 – 7.71 (m, 1H), 8.18 (s, 1H), 8.39 (d, J = 4.9 Hz, 1H), 8.77 (t, J = 5.9 Hz, 1H), 9.00 (bs, 1H), 11.73 (s, 1H), 12.30 (s, 1H). HRMS: Calculated for C 22 H 26 ON 7 (M+H + ) = 404.2193; Found: 404.2197 Example 245 4-(3-Amino-1H-indazol-5-yl)-N-(2-(butyl(ethyl)amino)ethyl)-1 H-pyrrolo[2,3-b]pyridine-2- carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), N1-butyl-N1-ethylethane-1,2- diamine (0.183 mL, dried on MS3A) and EtOH (0.367 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0079 g, 0.0103 mmol, 28%). 1 H NMR (400 MHz, DMSO-d6) δ 0.90 (t, J = 7.4 Hz, 3H), 1.22 (t, J = 7.1 Hz, 3H), 1.27 – 1.39 (m, 2H), 1.50 – 1.68 (m, 2H), 3.06 – 3.19 (m, 2H), 3.19 – 3.34 (m, 4H), 3.64 (app q, J = 6.1 Hz, 2H), 7.24 (d, J = 4.8 Hz, 1H), 7.37 (s, 1H), 7.43 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 8.8 Hz, 1H), 8.18 (s, 1H), 8.40 (s, 1H), 8.78 (t, J = 5.7 Hz, 1H), 9.17 (bs, 1H), 11.72 (s, 1H), 12.30 (s, 1H). HRMS: Calculated for C23H30ON7 (M+H + ) = 420.2506; Found: 420.2501 Example 246 4-(3-Amino-1H-indazol-5-yl)-N-(2-(diisopropylamino)ethyl)-1H -pyrrolo[2,3-b]pyridine-2- carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), N1,N1-diisopropylethane-1,2- diamine (0.183 mL, dried on MS3A) and EtOH (0.367 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N2 and heated to 190 °C under microwave irradiation for 90 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0070 g, 0.0092 mmol, 25%). 1 H NMR (400 MHz, DMSO-d6) δ 1.31 (d, J = 6.4 Hz, 12H), 3.16 – 3.26 (m, 2H), 3.54 – 3.63 (m, 2H), 3.65 – 3.77 (m, 2H), 7.24 (d, J = 4.9 Hz, 1H), 7.36 (s, 1H), 7.44 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 8.7 Hz, 1H), 8.18 (s, 1H), 8.40 (d, J = 5.0 Hz, 1H), 8.62 (s, 1H), 8.84 (t, J = 5.2 Hz, 1H), 11.74 (bs, 1H), 12.33 (s, 1H). HRMS: Calculated for C23H30ON7 (M+H + ) = 420.2506; Found: 420.2503 Example 247 4-(3-Amino-1H-indazol-5-yl)-N-(3-(dimethylamino)propyl)-1H-p yrrolo[2,3-b]pyridine-2- carboxamide A 0.5-2 mL MW vial was charged with methyl 4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3- b]pyridine-2-carboxylate (Example 231) (0.012 g, 0.0373 mmol), N1,N1-dimethylpropane-1,3- diamine (0.5 mL, dried on MS3A) and MeOH (0.1 mL, dried on MS3A), sealed with an aluminium crimp cap fitted with a disposable PTFE/silicon septum, purged with N 2 and heated to 190 °C under mw irradiation for 15 minutes. The reaction mixture was then evaporated in vacuo and purified by HPLC to afford the title compound as a yellow solid (0.0071 g, 0.00987 mmol, 26%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 1.89 (m, 2H), 2.78 (d, J = 4.8 Hz, 6H), 3.06 – 3.16 (m, 2H), 3.36 (app q, J = 6.1 Hz, 2H), 7.24 (d, J = 4.9 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.45 (d, J = 8.7 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 8.21 (s, 1H), 8.39 (d, J = 4.8 Hz, 1H), 8.69 (t, J = 6.0 Hz, 1H), 9.34 (bs, 1H), 12.23 (s, 1H). HRMS: Calculated for C 20 H 24 ON 7 (M+H + ) = 378.2037; Found: 378.2038 Section 11 – compounds of the formula: where Q is -L 1 -Y 1 -L 2 -Q 1 and Y 1 is N(R y1 )_or Q 1 is heterocyclyl. 4-Chloro-1-(methoxymethyl)-7-azaindole-2-carbaldehyde A solution of 4-chloro-1-(methoxymethyl)-7-azaindole (0.66 g, 3.3 mmol) in anhydrous THF (20 ml) was added slowly at -75°C to freshly prepare lithium diisopropylamide solution (5 mmol, prepared by slowly adding 2M n-butyllithium (2.5 ml) to 0.7 ml diisopropylamine in 20 ml of anhydrous THF). Then, the reaction mixture was aged for 30 min in -75 °C. Thereafter, the reaction was quenched by addition of dimethylformamide (0.77 ml, 10 mmol) and stirred for 1 h at -75°C. The mixture was then treated with sulphuric acid (2M, 10 ml), diluted with diethyl ether, and extracted. The separated organic layer was washed with water, dried over magnesium sulfate, and evaporated to afford the desired compound as a yellow solid (0.68 g, 92%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 3.20 (s, 3 H) 5.94 (s, 2 H) 7.50 (d, J=4.83 Hz, 1 H) 7.67 (s, 1 H) 8.54 (d, J=4.83 Hz, 1 H) 10.03 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 56.65, 73.53, 113.78, 118.27, 118.65, 136.02, 138.49, 149.76, 150.92, 184.57. m/z (ESI-MS) [M-OCH 3 ] + 193.0. 4-Chloro-7-azaindole-2-carbaldehyde To a cooled solution of 4-chloro-1-(methoxymethyl)-7-azaindole-2-carbaldehyde in anhydrous dichloromethane (5 ml) at 0 °C, bromo-catecolborane (0.28 g, 1.3 mmol) was added and the mixture was stirred for 1.5 h. To the thick suspension, potassium acetate (3.2 g, 30 mmol) and ethanol (10 ml) were added and the reaction was stirred for 24 h at room temperature. Then, the solvent was evaporated and the residue was triturated with water for 3 h. The suspension was then filtrated under vacuum and washed with saturated sodium bicarbonate solution to give 4-chloro-7-azaindole-2-carbaldehyde as a creamy solid (0.15 g, 80%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.37 (d, J= 4.83 Hz, 1 H) 7.49 (d, J= 2.20 Hz, 1 H) 8.44 (d, J=4.83 Hz, 1 H) 9.93 (s, 1 H) 12.96 (br. s., 1 H) . 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 110.39, 117.46, 118.84, 137.06, 138.02, 149.37, 150.54, 184.25. m/z (ESI-MS) [M]-179.0. General procedure A: The appropriate aldehyde (1 eq.) and required amine (1.3 eq.) were allowed to react in the presence of sodium triacetoxyborohydride (1.5 eq.) and acetic acid (1.3 eq.) in dimethylacetamide (2 ml) at room temperature for 48 h. The reaction mixture then poured into 1M sodium carbonate solution and stirred in ice path for 3 h then filtered. The solid was then collected and purified by column chromatography. General procedure B: A suspension of the required 4-chloroazaindole substrate (1 eq.), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (1.2-1.5 eq.) and base (2 eq.) in 1:3 of solvent was deoxygenated with nitrogen in sealed tube. Then [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.05 eq.) was added then the tube was sealed and the mixture allowed to stirred at 90-100 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and water were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography. Example 248 N-((4-Chloro-7-azaindole)methyl)-N-(tert-butyl)amine 4-Chloro-7-azaindole -2-carbaldehyde (0.08 g, 0.44 mmol) was reacted with tert-butylamine (0.06 ml, 0.57 mmol), sodium triacetoxyborohydride (0.14 g, 0.66 mmol) and acetic acid (0.03 ml, 0.66 mmol) as described in general procedure A to afford the desired compound as a yellow solid (90 mg, 86%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.09 (s, 9 H) 3.82 (s, 2 H) 6.35 (s, 1 H) 7.12 (d, J= 4.83 Hz, 1 H) 8.07 (d, J=4.83 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 29.33, 49.15, 50.79, 95.51, 115.63, 119.69, 133.22, 142.61, 143.58, 149.72. m/z (ESI-MS) [M-tBu-amine] + 165.1 (100%) [M] + 238.1 (20%) 5-(2-((tert-Butylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-y l)-1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-N-(tert-butyl)amine (0.034 g, 0.14 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.055 g, 0.215 mmol), 1M potassium phosphate solution (0.28 ml, 0.28 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.004 g, 0.007 mmol) in 0.84 ml ethanol were reacted as described in general procedure B and chromatographic purification (0- 10% methanol in EtOAc and 1% triethylamine), gave the titled compound as a white solid ( 33 mg, 70%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.10 (s, 9 H) 3.85 (s, 2 H) 5.51 (s, 2 H) 6.55 (s, 1 H) 7.12 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (d, J=8.79, 1 H) 8.14 (s, 1 H) 8.16 (d, J=5.27 Hz, 1 H) 11.54 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 29.16, 48.94, 50.77, 96.52, 110.24, 114.38, 115.05, 118.30, 120.63, 127.12, 128.57, 139.01, 141.29, 141.63, 142.46, 149.83, 150.01. m/z (ESI-HRMS) calculated for C19H23N6= 335.1979 found= 335.1981. Example 249 N-((4-Chloro-7-azaindole)methyl)-N-isopentylamine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with isopentylamine (0.1 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as brown solid (125.6 mg, 75%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.84 (d, J=6.15 Hz, 6 H) 1.21-1.38 (m, 2 H) 1.53-1.66 (m, 1 H) 3.82 (s, 2 H) 6.35 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 8.08 (d, J=4.39 Hz, 1 H) . 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 23.20, 26.02, 39.20, 46.77, 47.24, 96.17, 115.70, 119.66, 133.33, 142.39, 142.79, 149.78 m/z (ESI-MS) [M] + 252.1. 5-(2-((Isopentylamino)methyl)-1H-pyrrolo[2,3-b]pyridine-4-yl )-1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-N-isopentylamine (0.08 g, 0.32 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.12 g, 0.48 mmol), 1M potassium phosphate solution (0.64 ml, 0.64 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.01 g, 0.016 mmol) in 1.9 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-15% methanol in EtOAc and 1% triethylamine), gave the titled compound as reddish solid ( 47.1 mg, 42%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.83 (d, J= 56.59 Hz, 6 H) 1.32 (q, J=7.03 Hz, 2 H) 1.61 (m, 1 H) 3.38 (t, J=7.03 Hz, 2 H) 3.85 (s, 2 H) 5.51 ( s, 2 H) 6.56 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.35 Hz, 1 H) 7.63-7.67 (m, 1 H) 8.13-8.15 (m, 1 H) 8.17 (d, J=5.27 Hz, 1 H) 11.54 ( br. s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 23.21, 26.04, 39.22, 47.03, 47.26, 94.88, 110.33, 114.46, 115.14, 118.33, 120.74, 127.20, 128.62, 140.78, 140.91, 141.64, 142.57, 150.02, 150.37. m/z (ESI-HRMS) calculated for C20H25N6= 349.2135 found= 349.2132. Example 250 tert-Butyl 2-((2-amino-4-chloropyridin-3-yl)ethynyl)piperidine-1-carbox ylate To a solution of 4-chloro-3-iodo-pyridine-2-amine (0.064 g, 0.255 mmol), copper (I) iodide (0.002 g, 0.012 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.008 g, 0.012 mmol) in 2 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by tert-butyl 2-ethynylpiperidine-1-carboxylate (0.064 g, 0.3 mmol). The reaction mixture was stirred at 80 °C for 4 h. After reaction completed, the reaction mixture was diluted with EtOAc and extract with 1M sodium carbonate. Extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60- 80%) to give the product as yellow oil (0.042 g, 40%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.39 (s, 9 H) 1.40 (d, J=5.19 Hz, 1 H) 1.41-1.45 (m, 4 H) 2.42 (m., 4 H) 6.65 (br. s., 2 H) 7.18 (d, J=5.49 Hz, 1 H) 8.12 (d, J=5.49 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 19.81, 25.16, 28.29, 28.50, 40.27, 66.82,70.27, 95.83, 115.87, 119.57, 133.31, 141.73, 143.04, 152.64, 169.32. m/z (ESI-MS) [M] + 336.1. Tert-butyl 2-(4-chloro-7-azaindol-2-yl)piperdine-1-carboxylate To a solution of tert-butyl 2-((2-amino-4-chloropyridin-3-yl)ethynyl)piperidine-1-carbox ylate (0.04 g, 0.12 mmol) in 1,4 dioxane (1 ml), potassium tert-butoxide (0.033 g, 0.3 mmol) and 18- crown-6 (0.003 g, 10%, 0.012 mmol) were added and the mixture was stirred at 110 °C for 18h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (38.8 mg, 96%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.41 (s, 9 H) 1.51-1.64 (m, 3 H) 1.75 (d, J=3.08 Hz, 1 H) 1.81 (d, J=1.32 Hz, 1 H) 1.30-2.40 (m, 1 H) 2.86-2.99 (m, 1 H) 3.96 (d, J=12.74 Hz, 1 H) 5.41-5.46 (m, 1 H) 6.14 (s, 1 H) 7.17 (d, J=5.27 Hz, 1 H) 8.12 (d, J=5.27 Hz, 1 H) 11.98 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 19.81, 25.16, 28.29, 28.50, 40.27, 66.82,70.27, 95.83, 115.87, 119.57, 133.31, 141.73, 143.04, 152.64, 169.32. m/z (ESI-MS) [M] + 336.1. 4-Chloro-2-(piperdin-2yl)-7-azaindole Trifloroacetic acid (0.03 ml) was added to a solution of tert-butyl 2-(4-chloro-7-azaindol-2- yl)piperdine-1-carboxylate ( 0.03 g, 0.09 mmol) in dicloromethane (1ml) and the reaction was stirred at room temperature for 3 h. The reaction mixture was diluted with EtOAc, washed with 1 M sodium carbonate, dried over magnesium sulfate and concentrated under vacuum under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a yellow solid (18 mg, 85%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.58-1.72 (m, 3 H) 1.78-1.95 (m, 4 H) 2.22 (d, J=14.94 Hz, 1 H) 4.11 (q, J=5.27 Hz, 1 H) 4.44 (dd, J=10.33, 1.10 Hz, 1 H) 6.62 (s, 1 H) 7.26 (d, J=5.27 Hz, 1 H) 8.22 (d, J=5.27 Hz, 1 H) 12.20 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 19.81, 25.16, 28.29, 77.21, 79.60, 95.83, 115.87, 119.57, 113.31, 143.04, 143.03, 154.91. m/z (ESI-MS) [M] + 236.1. 5-(2-(Piperidin-2-yl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-ind azol-3-amine 4-Chloro-2-(piperidin-2-yl)-7-azaindole (0.03 g, 0.12 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.05 g, 0.19 mmol), 1M potassium phosphate solution (0.25 ml, 0.25 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.0016 g, 0.006 mmol) in 0.7 ml ethanol were reacted as described in general procedure B and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60- 80%), gave the titled compound as white solid (10.5 mg, 79%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.41-1.52 (m, 2 H) 1.59 (d, J= 11.86 Hz, 2 H) 1.79-1.89 (m, 1 H) 1.99 (d, J=10.55 Hz, 1 H) 2.66-2.75 (m, 1 H) 3.07(d, J= 11.86 Hz, 1 H) 3.80-3.89 (m, 1 H) 5.52 (s, 2 H) 6.55 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.57, 1.54 Hz, 1 H) 8.13 (s, 1 H) 8.18 (d, J= 5.27 Hz, 1 H) 11.54 (br. s., 1 H) 11.58 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 24.57, 25.59, 32.38, 46.66, 55.04, 95.97, 110.24, 114.43, 115.07, 117.98, 120.63, 127.09, 128.47, 141.13, 141.58, 142.75, 142.91, 149.71, 150.26. m/z (ESI-HRMS) calculated for C 19 H 21 N 6 = 333.1822 found=333.1820. Example 251 N-((4-Chloro-7-azaindole)methyl)-N-cyclohexylamine 4-Chloro-7-azaindole -2-carbaldehyde (0.1 g, 0.55 mmol) was reacted with cyclohexylamine (0.1 ml, 0.72 mmol), sodium triacetoxyborohydride (0.17 g, 0.82 mmol) and acetic acid (0.04 ml, 0.72 mmol) as described in general procedure A and chromatographic purification (30- 100% EtOAc in petroleum ether 60-80%) afforded the desired compound as a yellow solid (40.9 mg, 41%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.98-1.10 (m, 2 H) 1.14 (m, 2 H) 1.53 (m, 2 H) 1.61-1.71 (m, 2 H) 1.81 (m, 2 H) 2.30-2.39 (m, 1 H) 3.87 (s, 2 H) 6.35 (s, 1 H) 7.12 (d, J= 4.83 Hz, 1 H) 8.07 (d, J=5.27 Hz, 1 H) 11.91 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 24.87, 26.44, 33.29, 43.62, 55.40, 96.06, 115.70, 119.67, 120.07, 130.97, 142.80, 150.56. m/z (ESI-MS) [M- cyclohexylamine] + 165.1 (100%) [M] + 264.2 (40%). 5-(2-((cyclohexylamino)methyl)-1H-pyrrolo[2,3-b]339yridine-4 -yl)-1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-N- cyclohexylamine (0.04 g, 0.15 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.06 g, 0.22 mmol), 1M potassium phosphate solution (0.3 ml, 0.3 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.005 g, 0.007 mmol) in 0.9 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-18% methanol in EtOAc and 1% triethylamine), gave the titled compound as brown solid ( 26.6 mg, 49%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.00-1.09 (m, 2 H) 1.15-1.21 (m, 2 H) 1.47-1.55 (m, 2 H) 1.58-1.69 (m, 2 H) 1.83 (m, 2 H) 2.37 (m, 1 H) 3.89 (s, 2 H) 5.51 ( s, 2 H) 6.55 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.65 (d, J=7.03 Hz, 1 H) 8.14 (s, 1 H) 8.17 (d, J=4.83 Hz, 1 H) 11.54 ( br. s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 24.77, 26.31, 33.09, 43.74, 55.41, 97.78, 110.27, 111.54, 114.40, 118.26, 120.66, 127.12, 128.52, 135.65, 140.90, 142.19, 142.50, 149.90, 150.28. m/z (ESI-HRMS) calculated for C 21 H 25 N 6 = 361.2135 found= 361.2138. Example 252 N-((4-Chloro-7-azaindole)methyl)-aniline 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with aniline (0.08 ml, 0.86 mmol), sodium triacetoxyborohydride (0.21 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afford the desired compound as a white solid (0.07 g, 41%), (LC-MS purity = 93%). 1 H NMR (400 MHz, CDCl3) δ δ 4.43 (d, J=5.71 Hz, 2 H) 6.53 (t, J=7.03 Hz, 1 H) 6.65 (d, J=7.91 Hz, 1 H) 7.07 (t, J=7.47 Hz, 1 H) 7.11-7.17 (m, 1 H) 7.26-7.34 (m, 2 H) 7.42-7.50 (m, 1 H) 8.12 (s, 1 H) 8.09 (d, J=5.27 Hz, 1 H) 11.55 (s, 1 H) 11.67 (s, 1 H).. 13 C NMR (100 MHz, CDCl3) δ ppm 41.05, 96.11, 113.06, 115.83, 116.89, 121.59, 129.44, 133.43, 141.36, 142.97, 146.86,148.91. m/z (ESI-MS) [M]- 256.1. 5-(2-((Phenylamino)methyl)-1H-pyrrolo[2,3-b]340yridine-4-yl) -1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-aniline 0.039 g, 0.15 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.059 g, 0.22 mmol), 1M potassium phosphate solution (0.3 ml, 0.3 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.0018 g, 0.007 mmol) in 0.9 ml ethanol were reacted as described in general procedure B and chromatographic purification (80% EtOAc and 1% triethylamine in petroleum ether 60- 80%), gave the titled compound as white solid (32 mg, 60%),. 1 H NMR (400 MHz, DMSO-d6) δ 4.42 (d, J=5.71 Hz, 2 H) 5.50 (s, 2 H) 6.03 (t, J=5.93 Hz, 1 H) 6.53 (t, J=7.69 Hz, 1 H) 6.59- 6.69 (m, 3 H) 7.01 - 7.08 (m, 2 H) 7.13 (d, J=5.27 Hz, 1 H) 7.36 (d, J=8.35 Hz, 1 H) 7.62 (d, J=8.79 Hz, 1 H) 8.12 (s, 1 H) 8.18 (d, J=5.27 Hz, 1 H) 11.55 (s, 1 H) 11.67 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 41.41, 97.89, 110.34, 113.11, 114.60, 115.16, 116.80, 118.42, 120.75, 127.16, 128.56, 129.38, 139.63, 141.09, 141.63, 142.77, 149.03, 149.94, 150.35. m/z (ESI- HRMS) calculated for C 21 H 19 N 6 = 355.1666 found= 355.1665. Example 253 2-(Benzyloxy)-N-((4-chloro-1-(methoxymethyl)-7-azaindol-2-yl )methyl)aniline 4-Chloro-1-(methoxymethyl)-7-azaindole-2-carbaldehyde (0.3 g, 1.3 mmol) was reacted 2- (benzoxy)aniline (0.34 ml, 1.7 mmol), sodium triacetoxyborohydride (0.41 g, 1.95 mmol) and acetic acid (0.11 ml, 1.95 mmol) as described in general procedure A to afforded the desired compound as a white solid (209 mg, 40 %).. 1 H NMR (400 MHz, DMSO-d6) δ ppm 3.18 (s, 3 H) 4.65 (d, J= 6.10 Hz, 2 H) 5.17 (s, 2 H) 5.64 (t, J= 6.18 Hz, 1 H) 5.74 (s, 2 H) 6.42 (s, 1 H) 6.52- 6.58 (m, 1 H) 6.64 (d, J= 7.78 Hz, 1 H) 6.74 (t, J= 7.63 Hz, 1 H) 6.94 (d, J= 8.09 Hz, 1 H) 7.25 (d, J= 5.19 Hz, 1 H) 7.30-7.35 (m, 1 H) 7.40 (t, J= 7.40 Hz, 2 H) 7.53 (d, J= 5.32 Hz, 2 H) 8.20 (d, J=5.19 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 56.31, 63.44, 69.96, 72.67, 97.60, 110.75, 112.22, 116.74, 116.99, 119.01, 121.80, 128.08, 128.93, 134.02, 137.95, 138.22, 141.99, 143.38, 146.05, 150.01. m/z (ESI-MS) [M-OCH 3 ] + 376.0 5-(2-(((2-(Benzyloxy)phenyl)amino)methyl)-1-(methoxymethyl)- 7-azainol-4-yl)-1H-indazol- 3-amine 2-(Benzyloxy)-N-((4-chloro-1-(methoxymethyl)-7-azaindol-2-yl )methyl)aniline (0.05 g, 0.12 mmol) 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (0.05 g, 0.19 mmol), 1M potassium phosphate solution (0.24 ml, 0.24 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.004 g, 0.006 mmol) in 0.72 ml ethanol were reacted as described in general procedure and chromatographic purification (60- 100% EtOAc in petroleum ether 60-80%), gave the titled compound as white solid (55.6 mg, 91%).. 1 H NMR (400 MHz, DMSO-d6) δ ppm 3.19 (s, 3 H) 4.64 (d, J= 5.71 Hz, 2 H) 5.12 (s, 2 H) 5.64-5.57 (m, 3 H) 5.77 (s, 2 H) 6.48-6.55 (m, 1 H) 6.69 (s, 2 H) 6.71 (d, J= 7.47 Hz, 1 H) 6.88 (d, J= 7.47 Hz, 1 H) 7.22 (d, J= 4.83 Hz, 1 H) 7.24-7.37 (m, 4 H) 7.47 (d, J= 7.03 Hz, 2 H) 7.58 (dd, J= 8.57, 1.54 Hz, 1 H) 8.10 (s, 1 H) 8.28 (d, J=4.83 Hz, 1 H) 11.57 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 56.21, 60.32, 69.97, 72.35, 99.77, 110.44, 110.85, 112.06, 115.17, 115.89, 116.78, 117.70, 120.99, 121.77, 127.09, 128.05, 128.25, 128.91, 137.88, 138.35, 140.04, 141.66141.89, 143.16, 146.11, 150.22, 150.39. m/z (ESI-MS) [M] + 505.1 5-(2-(((2-(Benzyloxy)phenyl)amino)methyl)-1H-pyrrolo[2,3-b]3 42yridine-4-yl)-1H-indazol- 3-amine To a cool solution of 5-(2-(((2-(Benzyloxy)phenyl)amino)methyl)-1-(methoxymethyl)- 7-azainol- 4-yl)-1H-indazol-3-amine (0.1 g, 0.25 mmol) in anhydrous dichloromethane (5 ml), a solution of bromo-catecolborane (0.065 g, 0.33 mmol) in anhydrous dichloromethane (5 ml) was added and the mixture was stirred for 1.5h. To the thick suspension, potassium acetate (0.73 g, 7.5 mmol) and ethanol (10 ml) were added and the reaction allowed to stir for 24h at room temperature. Then the solvent was evaporated and residue triturated with water for 30 min. The suspension then filtered under vacuum and washed with saturated sodium bicarbonate solution. The filtrate then purified using column chromatography (30% EtOAc in petroleum ether 60-80%) to give the product as a yellow solid (40.1 mg, 34%).. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 4.14 (s, 2 H) 4.30 (s, 2 H) 5.45 (t, J= 6.18 Hz, 1 H) 5.51 (br. s, 2 H) 6.57 (s, 1 H) 6.59-6.70 (m, 2 H) 6.75-6.79 (m, 1 H) 6.80-6.88 (m, 1 H) 6.97 (d, J= 6.96 Hz, 1 H) 7.14 (d, J= 5.13 Hz, 1 H) 7.21-7.23 (m, 4 H) 7.34-7.39 (m, 1 H) 7.62 (dd, J= 8.79, 1.46 Hz, 1 H) 8.12 (s, 1 H) 8.20 (d, J=5.13 Hz, 1 H) 11.83 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 48.69, 74.94, 95.95, 99.51, 112.39, 115.34, 118.62, 119.40, 126.53, 126.71, 128.01, 128.57, 128.63, 128.83, 132.79, 136.53, 138.74, 140.94, 141.58, 142.34, 144.21, 147.61, 149.44, 153.13, 161.00. m/z (ESI-MS) [M] + 461.1 Example 254 N-((4-Chloro-7-azaindole)methyl)-N-(2-methoxyethyl)amine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with 2- methoxyethylamine (0.07 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as yellow oil (55 mg, 34%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.65 (t, J=5.49 Hz, 2 H) 3.23 (s, 3 H) 3.40 (t, J=5.49 Hz, 2 H) 3.85 (s, 2 H) 6.35 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 8.09 (d, J=5.27 Hz, 1 H) 11.87 (br. S., 1 H) . 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 46.60, 48.31, 58.55, 72.28, 96.28, 115.73, 119.63, 133.39, 142.12, 142.86, 149.80 m/z (ESI-MS) [M] + 240.1. 5-(2-(((2-Methoxyethyl)amino)methyl)-1H-pyrrolo[2,3-b]343yri dine-4-yl)-1H-indazol-3- amine N-((4-Chloro-7-azaindole)methyl)-N-(2-methoxyethyl)amine (0.025 g, 0.1 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.04 g, 0.15 mmol), 1M potassium phosphate solution (0.2 ml, 0.2 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.001 g, 0.005 mmol) in 0.6 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-18% methanol in EtOAc and 1% triethylamine), gave the titled compound as yellow solid ( 22.1 mg, 65%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.67 (t, J= 5.71 Hz, 2 H) 3.22 (s, 3 H) 3.40 (t, J=5.71 Hz, 2 H) 3.87 (s, 2 H) 5.51 ( s, 2 H) 6.56 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.79 Hz, 1 H) 8.14 (s, 1 H) 8.17 (d, J=5.27 Hz, 1 H) 11.50- 11.59 (m, 2 H). 13 C NMR (100 MHz, DMSO-d 6 ) 46.86, 48.33, 58.54, 72.26, 98.00, 110.35, 114.49, 115.14, 118.30, 120.75, 127.22, 128.11, 138.84, 140.98, 141.91, 142.65, 150.04, 150.37. m/z (ESI-HRMS) calculated for C 18 H 21 ON 6 = 337.1771 found= 337.1769. Example 255 N 1 -((4-Chloro-7-azaindole)methyl)- N 2 ,N 2 -dimethyl-1,2-ethanediamine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with N 1 ,N 1 dimethyl- 1,2ethanediamine (0.09 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A and chromatographic purification (18 % methanol in EtOAc and 1% triethylamine to afforded the desired compound as yellow solid (30.7 mg, 18%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.11 (s, 6 H) 2.32 (t, J= 6.27 Hz, 2 H) 2.59 (t, J= 6.40 Hz, 2 H) 2.86 (s, 2 H) 6.35 (s, 1 H) 7.13 (d, J= 5.02 Hz, 1 H) 8.09 (d, J= 5.02 Hz, 1 H). m/z (ESI-MS) [M] + 253.1. N 1 -((4-(3-Amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridi n-2-yl)methyl)-N2,N2- dimethylethane-1,2-diamine N 1 -((4-Chloro-7-azaindole)methyl)- N 2 ,N 2 -dimethyl-1,2-ethanediamine (0.03 g, 0.12 mmol), 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.046 g, 0.18 mmol), 1M potassium phosphate solution (0.24 ml, 0.24 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0015 g, 0.006 mmol) in 0.7 ml ethanol were reacted as described in general procedure B and chromatographic purification (2% triethylamine in ethanol), gave the titled compound as yellow solid (19.1 mg, 45%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.08 (s, 6 H) 2.31 (t, J= 6.37 Hz, 2 H) 2.54-2.62 (m, 2 H), 3.86 (s., 2 H) 5.51 (s, 2 H) 6.55 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.57,1.54 Hz, 1 H) 8.14 (s, 1 H) 8.17 (d, J=4.83 Hz, 1 H) 11.60 ( br. s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 45.72, 46.65, 46.82, 59.29, 97.78, 110.24, 114.37, 115.06, 118.23, 120.63, 127.11, 128.54, 138.78, 140.62, 141.58, 142.51, 149.97, 150.27. m/z (ESI-HRMS) calculated for C 19 H 24 N 7 = 350.2088 found= 350.2086. Example 256 N-((4-Chloro-7-azaindole)methyl)-N-(2-methoxypropyl)amine 4-Chloro-7-azaindole -2-carbaldehyde (100) (0.12 g, 0.66 mmol) was reacted with 2- methoxypropylamine (0.08 ml, 0.8 mmol), sodium triacetoxyborohydride (0.21 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as a brown oil (0.14 g, 83%). 1 H NMR (400 MHz, CDCl3) δ 1.60-1.70 (m, 2 H), 2.53-2.58 (m, 2 H), 3.19 (s, 3 H) 3.36 (br. s., 2 H) 3.85 (s, 2 H) 6.36 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 8.08 (d, J=4.83 Hz, 1 H). 13 C NMR (100 MHz, CDCl3) δ ppm 29.91, 46.50, 46.08, 58.40, 69.68, 96.39, 115.71, 119.63, 133.37, 141.86, 142.86, 145.05. m/z (ESI-MS) [M] + 254.1. 5-(2-(((3-methoxypropyl)amino)methyl)-1H-pyrrolo[2,3-b]pyrid ine-4-yl)-1H-indazol-3- amine N-((4-chloro-7-azaindole)methyl)-N-(2-methoxypropyl)amine (0.09 g, 0.35 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.138 g, 0.53 mmol), 1M potassium phosphate solution (0.71 ml, 0.71 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.004 g, 0.017 mmol) in 2.1 ml ethanol were reacted as described in general procedure B and chromatographic purification (10-15% methanol in EtOAc and 1% triethylamine), gave the titled compound as white solid (10.4 mg, 8%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.68 (quin, J=6.70 Hz 2 H), 2.55-2.66 (m, 2 H), 3.19 (s, 3 H) 3.36 (m, 2 H) 3.93 (m, 2 H) 5.51 ( s, 2 H) 6.61 (s, 1 H) 7.15 (d, J= 5.27 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.79, 1.76 Hz, 1 H) 8.12-8.16 (m, 1 H) 8.20 (d, J=4.83 Hz, 1 H) 11.57 (s, 1 H) 11.55 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 29.48, 46.01, 46.44, 58.40, 70.62, 96.44, 110.37, 114.58, 115.15, 118.28, 120.79, 127.19, 128.51, 140.74, 141.18, 141.66, 142.93, 149.97, 150.38. m/z (ESI-HRMS) calculated for C19H23ON6 = 351.1928 found= 351.1927. Example 257 N-((4-Chloro-7-azaindole)methyl)-N-(3-isoprpoxypropyl)amine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with isoprpoxypropylamine (0.12 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A and chromatographic purification (30-100% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afforded the desired compound as white solid (77.4 mg, 41%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.04 (d, J=6.02 Hz, 6 H) 1.62 (quin, J=6.65 Hz, 2 H) 2.56 (t, J=6.90 Hz, 2 H) 3.40 (t, J=6.40 Hz, 2 H) 3.48 (dt, J= 12.11, 6.12 Hz, 1 H) 3.84 (s, 2 H) 6.36 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 8.09 (d, J=5.02 Hz, 1 H) 11.85 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 22.54, 30.56, 46.23, 46.57, 66.04, 70.94, 96.10, 115.61, 119.58, 133.25, 142.13, 142.70,149.68. m/z (ESI-MS) [M] + 282.1. 5-(2-(((3-Isopropoxypropyl)amino)methyl)-1H-pyrrolo[2,3-b]34 6yridine-4-yl)-1H-indazol-3- amine N-((4-Chloro-7-azaindole)methyl)- N-(3-isoprpoxypropyl)amine (0.05 g, 0.13 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.07 g, 0.27 mmol), 1M potassium phosphate solution (0.64 ml, 0.64 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.006 mmol) in 1.9 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-10% methanol in EtOAc and 1% triethylamine), gave the titled compound as yellow solid (10.6 mg, 21%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.02 (d, J= 6.27 Hz, 6 H) 1.62 (quin, J= 6.59 Hz, 2 H) 2.54-2.61 (m, 2 H), 3.39 (t, J= 6.53 Hz, 2 H) 3.42-3.51 (m, 1 H) 3.86 (s, 2 H) 5.49 ( s, 2 H) 6.56 (s, 1 H) 7.13 (d, J= 5.02 Hz, 1 H) 7.38 (d, J=8.78 Hz, 1 H) 7.66 (dd, J=8.66,1.63 Hz, 1 H) 8.14 (s, 1 H) 8.18 (d, J=5.02 Hz, 1 H) 11.48-1154 (m, 2 H). 13 C NMR (100 MHz, DMSO-d6) 22.52, 30.51, 46.25, 46.77, 66.07, 70.93, 96.49, 110.22, 114.39, 115.42, 119.29, 120.63, 127.09, 128.65, 138.77, 139.80, 140.09, 140.19, 149.92, 151.80. m/z (ESI-HRMS) calculated for C 21 H 27 ON 6 = 379.2241 found= 379.2243. Example 258 N 1 -((4-chloro-7-azaindole)methyl)-N 2 ,N 2 -dimethyl-1,2-propanediamine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with N 1 ,N 1 dimethyl- 1,2propanediamine (0.1 ml, 0.08 mmol), sodium triacetoxyborohydride (0.21g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as a whit solid (0.08 g, 45%), 1 H NMR (400 MHz, CDCl 3 ) δ 1.47-1.60 (m, 2 H), 1.85 (s, 6 H), 2.20-2.25 (m, 2 H) 3.17 (s, 2 H) 3.83 (s, 2 H) 6.35 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 8.08 (d, J=5.27 Hz, 1 H) 11.49 (s, 1 H). m/z (ESI-MS) [M] + 267.1. N 1 -((4-(3-amino-1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridi n-2-yl)methyl)-N 3 ,N 3 - dimethylpropane-1,3-diamine N 1 -((4-Chloro-7-azaindole)methyl)-N 2 ,N 2 -dimethyl-1,2-propanediamine (0.05 g, 0.18 mmol), 5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-a mine (0.073 g, 0.28 mmol), 1M potassium phosphate solution (0.36 ml, 0.36 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.009 mmol) in 1.08 ml ethanol were reacted as described in general procedure B and chromatographic purification (100% ethanol and 1% triethylamine, further purification by HPLC gave the titled compound as yellow solid (27.5 mg, 32%),. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.96-2.07 (m, 2 H), 2.77 (s, 6 H), 3.04 (br. s, 2 H) 3.13 (t, J=7.53 Hz, 2 H) 4.40 (br. s., 2 H) 6.91(s, 1 H) 7.26 (d, J=5.02 Hz, 1 H) 7.43 (d, J= 8.53 Hz, 1 H) 7.71 (dd, J=8.66, 1.63 Hz, 1 H) 8.19 (s, 1 H) 8.34 (d, J=5.02 Hz, 1 H) 11.88 (br. s., 2 H). m/z (ESI-HRMS) calculated for C20H26N7 = 364.2244 found= 364.2243. Example 259 N-((4-Chloro-7-azaindole)methyl)-N-isopropyl-N-methylamine 4-Chloro-7-azaindole -2-carbaldehyde (0.1 g, 0.55 mmol) was reacted with isopropylmethylamine (0.07 ml, 0.72 mmol), sodium triacetoxyborohydride (0.17 g, 0.82 mmol) and acetic acid (0.05 ml, 0.83 mmol) as described in general procedure A to afford the desired compound as a yellow solid (110 g, 84%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.02 (d, J=6.59 Hz, 6 H) 2.13 (s, 3 H) 2.81-2.90 (m, 2 H) 3.65 (s, 2 H) 6.34 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 8.09 (d, J=5.27 Hz, 1 H) 11.88 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 18.19, 36.96, 51.09, 52.93, 96.95, 115.71, 119.32, 131.29, 141.14, 142.89, 149.82. m/z (ESI-MS) [M- dialkylamine] + 165.1 (100%) [M] + 238.1 (20%). 5-(2-((Isopropyl(methyl)amino)methyl)-1H-pyrrolo[2,3-b]pyrid ine-4-yl)-1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-N-isopropyl-N-methylamine (0.05 g, 0.21 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.08 g, 0.315 mmol), 1M potassium phosphate solution (0.42 ml, 0.42 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.006 g, 0.01 mmol) in 1.2 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-18% methanol in EtOAc and 1% triethylamine), gave the titled compound as brown solid ( 46.1 mg, 65%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.01 (d, J=6.59 Hz, 6 H), 2.13 (s, 3 H) 2.43 (q, J=7.03 Hz, 1 H) 3.67 (s, 2 H) 5.52 ( br. s, 2 H) 6.54 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.35, 1.32 Hz, 1 H) 8.13 (s, 1 H) 8.18 (d, J=4.83 Hz, 1 H) 11.56 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 18.07, 36.73, 51.32, 52.72, 98.49, 110.29, 114.37, 115.04, 118.25, 120.63, 127.14, 128.54, 139.55, 140.81, 141.57, 142.53, 149.93, 150.27. m/z (ESI-HRMS) calculated for C 19 H 23 N 6 = 335.1979 found= 335.1981. Example 260 N-((4-Chloro-7-azaindole)methyl)-piperdine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with piperidine (0.08 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A and chromatographic purification (30-100% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afforded the desired compound as white solid (77.2 mg, 47%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (m, 2 H) 1.50 (q, J=5.49 Hz, 4 H) 2.38 (br. s., 4 H) 3.59 (s, 2 H) 6.33 (d, J= 1.76 Hz, 1 H) 7.14 (d, J= 4.83 Hz, 1 H) 8.10 (d, J=5.27 Hz, 1 H) 11.96 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 24.43, 26.06, 54.40, 56.11, 97.58, 115.76, 119.53, 133.47, 139.32, 143.03, 149.74. m/z (ESI-MS) [M] + 250.2. 5-(2-(Piperidin-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)- 1H-indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-piperdine (0.043 g, 0.17 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.067 g, 0.26 mmol), 1M potassium phosphate solution (0.34 ml, 0.34 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.002 g, 0.008 mmol) in 1.0 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-10% methanol in EtOAc and 1% triethylamine), gave the titled compound as white solid (30.0 mg, 51%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.31-1.41 (m, 2 H), 1.44-1.53 (m, 4 H), 2.38 (br. s., 4 H) 3.60 (s, 2 H) 5.53 ( s, 2 H) 6.53 (d, J=1.76 Hz, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.57,1.54 Hz, 1 H) 8.14 (s, 1 H) 8.19 (d, J=4.83 Hz, 1 H) 11.55 ( br. s, 1 H) 11.67 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 24.48, 26.06, 54.44, 56.45, 99.28, 110.39, 114.49, 115.14, 118.25, 120.77, 127.24, 128.57, 137.88, 141.03, 141.65, 142.78, 149.95, 150.39. m/z (ESI-HRMS) calculated for C20H23N6= 347.1979 found= 347.1976. Example 261 N-((4-Chloro-7-azaindole)methyl)-4,4-difluoropiperidine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with 4,4- difluoropiperidine hydrochloride (0.12 gm, 1.0 mmol), sodium triacetoxyborohydride (0.21 g, 0.99 mmol) and triethylamine (0.14 ml, 1 mmol) as described in general A procedure to afforded the desired compound as a white solid (0.043 g, 22%). 1 H NMR (400 MHz, CDCl 3 ) δ 1.92 -2.03 (m, 4 H), 2.55 (t, J=5.27 Hz, 4 H), 3.74 (s, 2 H) 6.39 (d, J=1.76 Hz,, 1 H) 7.16 (d, J= 5.27 Hz, 1 H) 8.12 (d, J=5.27 Hz, 1 H) 12.00 (br. s., 1 H). 13 C NMR (100 MHz, CDCl 3 ) δ ppm 33.97, 49.83, 54.21, 97.74, 100.44, 115.86, 119.54, 133.65, 138.77, 143.24, 149.75. 19 F NMR (DMSO-d 6 ) -95.77. m/z (ESI-MS) [M] + 286.1. 5-(2-((4,4-Difluoropiperidin-1-yl)methyl)-1H-pyrrolo[2,3-b]p yridine-4-yl)-1H-indazol-3- amine N-((4-Chloro-7-azaindole)methyl)-4,4-difluoropiperidine (0.027 g, 0.09 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.036 g, 0.14 mmol), 1M potassium phosphate solution (0.18 ml, 0.18 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.001 g, 0.0045 mmol) in 0.54 ml ethanol were reacted as described in general procedure B and chromatographic purification (5- 10% methanol in EtOAc and 1% triethylamine), gave the titled compound as reddish solid (14.3 mg, 41%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.92 -2.03 (m, 4 H), 2.57 (br. s., 4 H), 3.75 (s, 2 H) 5.51 ( s, 2 H) 6.59 (s, 1 H) 7.15 (d, J= 5.06 Hz, 1 H) 7.39 (d, J=8.36 Hz, 1 H) 7.66 (d, J=6.82 Hz, 1 H) 8.15 (s, 1 H) 8.21 (d, J=5.06 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 33.41, 49.26, 53.95, 98.85, 101.35, 109.80, 113.99, 114.57, 117.67, 120.18, 126.63, 127.94, 136.73, 140.63, 141.09, 142.39, 149.39, 149.57. 19 F NMR (DMSO-d 6 ) -95.77. m/z (ESI-HRMS) calculated for C20H21N6 F2= 383.1790 found= 383.1795. Example 262 N-((4-Chloro-7-azaindole)methyl)-morpholine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with morpholine (0.07 ml, 0.86 mmol), sodium triacetoxyborohydride (0.21 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afford the desired compound as a white solid (116 mg, 70%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.38-2.44 (m, 4 H) 3.56-4.61 (m, 4 H) 3.64 (s, 2 H) 6.37 (s, 1 H) 7.15 (d, J= 5.27 Hz, 1 H) 8.11 (d, J=5.27 Hz, 1 H) 12.03 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 53.65, 55.64, 66.70, 97.84, 115.80, 119.50, 133.58,138.58, 143.19, 149.78. m/z (ESI-MS) [M]- 250.1. 5-(2-(Morpholinomethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H-i ndazol-3-amine N-((4-Chloro-7-azaindole)methyl)-morpholine (0.055 g, 0.22 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.085 g, 0.33 mmol), 1M potassium phosphate solution (0.43 ml, 0.43 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.007 g, 0.01 mmol) in 1.3 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-15% methanol in EtOAc and 1% triethylamine), gave the titled compound as a reddish solid ( 42.8 mg, 56%) 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (br. s., 4 H), 3.58 (t, J=4.39 Hz, 4 H) 3.65 (s, 2 H) 5.53 ( s, 2 H) 6.57 (d, J=1.76 Hz, 1 H) 7.14 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.57,1.54 Hz, 1 H) 8.14 (s, 1 H) 8.20 (d, J=4.83 Hz, 1 H) 11.54 ( br. s, 1 H) 11.67 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 53.62, 55.92, 66.61, 99.48, 110.30, 114.45, 115.06, 118.14, 120.68, 127.14, 128.46, 136.99, 141.07, 142.68, 142.84, 149.85, 150.29. m/z (ESI-HRMS) calculated for C19H21ON6= 349.1771 found= 349.1774. Example 263 1-((4-Chloro-7-azaindole)methyl)-4-methylpiperazine 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with 4-methylpiperazine (0.09 ml, 0.86 mmol), sodium triacetoxyborohydride (0.22 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A and chromatographic purification (30- 100% EtOAc and 1% triethylamine in petroleum ether 60-80%) to afforded the desired compound as white solid (107.13 mg, 61%). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.77 (s, 8 H) 2.15 (s, 3 H) 3.62 (s, 2 H) 6.35 (s, 1 H) 7.14 (d, J= 5.27 Hz, 1 H) 8.10 (d, J= 4.83 Hz, 1 H) 11.89 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 21.72, 46.21, 55.18, 97.73, 115.79, 119.51, 132.57, 138.39, 143.13, 150.75 m/z (ESI-MS) [M] + 265.1. 5-(2-((4-Methylpiperazin-1-yl)methyl)-1H-pyrrolo[2,3-b]pyrid ine-4-yl)-1H-indazol-3-amine 1-((4-Chloro-7-azaindole)methyl)-4-methylpiperazine (0.05 g, 0.19 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.07 g, 0.28 mmol), 1M potassium phosphate solution (0.4 ml, 0.4 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.002 g, 0.01 mmol) in 1.2 ml ethanol were reacted as described in general procedure B and chromatographic purification (2% triethylamine in ethanol), gave the titled compound as white solid (40.4 mg, 61%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.74 (s, 8 H) 2.14 (s, 3 H) 3.64 (s, 2 H) 5.50 ( s, 2 H) 6.56 (s, 1 H) 7.14 (d, J= 5.02 Hz, 1 H) 7.39 (d, J=8.53 Hz, 1 H) 7.65 (dd, J=8.53,1.51 Hz, 1 H) 8.13-8.16 (m, 1 H) 8.20 (d, J= 5.02 Hz, 1 H) 11.66 ( br. s, 2 H). 13 C NMR (100 MHz, DMSO-d 6 ) 46.20, 53.05, 55.12, 55.58, 99.31, 110.33, 114.41, 115.03, 118.15, 120.66, 127.10, 128.45, 137.49, 141.03, 141.61, 142.75, 149.90, 150.25 m/z (ESI-HRMS) calculated for C 20 H 24 N 7 = 362.2088 found= 362.2085. Example 264 1-((4-Chloro-7-azaindole)methyl)-4-(tert-butyl)piperazine 4-Chloro-7-azaindole-2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with N-(tert- butyl)piperazine (0.122 ml, 0.86 mmol), sodium triacetoxyborohydride (0.21 g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as a white solid (130 mg, 76%),. 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.98 (s, 9 H) 2.42 ( br. s., 4 H) 3.61 (s, 2 H) 6.33 (s, 1 H) 7.14 (d, J= 5.27 Hz, 1 H) 8.10 (d, J=4.83 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.65, 45.07, 52.92, 53.41, 54.71, 97.03, 115.17, 118.94, 132.92, 138.46, 142.48, 149.14. m/z (ESI-MS) [M] + 307.1. 5-(2-((4-(tert-Butyl)piperazin-1-yl)methyl)-1H-pyrrolo[2,3-b ]pyridin-4-yl)-1H-indazol-3- amine 1-((4-Chloro-7-azaindole)methyl)-4-(tert-butyl)piperazine (0.05 g, 0.16 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.063 g, 0.24 mmol), 1M potassium phosphate solution (0.32 ml, 0.32 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.006 g, 0.008 mmol) in 1 ml ethanol were reacted as described in general procedure and chromatographic purification (1% triethylamine in EtOAc), gave the titled compound as white solid (56 mg, 86 %), 1 H NMR (400 MHz, DMSO-d6) δ ppm 0.97 (s, 9 H) 2.43 (br. s., 4 H) 3.62 (s, 2 H) 5.53 (s, 2 H) 6.54 (s, 1 H) 7.13 (d, J= 4.83 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (d, J=10.11, 1 H) 8.14 (s, 1 H) 8.19 (d, J=4.83 Hz, 1 H) 11.55 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.64, 45.07, 52.94, 53.45, 55.05, 98.73, 109.79, 113.92, 114.56, 117.66, 120.16, 126.64, 127.99, 136.99, 140.49, 141.08, 142.23, 149.37, 149.78. m/z (ESI-HRMS) calculated for C 23 H 30 N 7 = 404.2557 found=404.2562. Example 265 N-((4-Chloro-7-azaindole)methyl)-azapane 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with azapane (0.07 ml, 0.86 mmol), sodium triacetoxyborohydride (0.21g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as a white solid (0.09 g, 51%), 1 H NMR (400 MHz, CDCl3) δ 1.57 (br. s., 8 H), 2.57-2.66 (m, 4 H), 3.76 (s, 2 H) 6.31 (s, 1 H) 7.14 (d, J= 4.03 Hz, 1 H) 8.09 (d, J=5.49 Hz, 1 H) 11.93 (br. s., 1 H). 13 C NMR (100 MHz, CDCl3) δ ppm 27.02, 28.39, 55.41, 55.48, 97.07, 115.73, 119.60, 133.42, 140.63, 142.93, 149.75. m/z (ESI-MS) [M] + 264.1. 5-(2-(Azepan-1-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-4-yl)-1H- indazol-3-amine N-((4-Chloro-7-azaindole)methyl)-azapane (0.066 g, 0.25 mmol), 5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (0.097 g, 0.37 mmol), 1M potassium phosphate solution (0.5 ml, 0.5 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.003 g, 0.012 mmol) in 1.5 ml ethanol were reacted as described in general procedure B and chromatographic purification (0-5% methanol in EtOAc and 1% triethylamine), gave the titled compound as white solid (39.1 mg, 43%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.56 (br. s., 8 H), 2.57-2.66 (m, 4 H), 3.77 (s, 2 H) 5.52 ( s, 2 H) 6.54 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 7.38 (d, J=8.35 Hz, 1 H) 7.65 (dd, J=8.57, 1.10 Hz, 1 H) 8.14 (s, 1 H) 8.18 (d, J=4.83 Hz, 1 H) 11.54 (s, 1 H) 11.58 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 27.04, 28.34, 55.46, 55.69, 98.80, 110.38, 114,49, 115.14, 118.31. 120.76, 127.23, 128.61, 139.13, 140.98, 141.65, 142.69, 149.98, 150.39. m/z (ESI-HRMS) calculated for C 21 H 25 N 6 = 361.2135 found= 361.2135. Example 266 1-((4-Chloro-7-azaindole)methyl)-4-methyl-1,4-diazapane 4-Chloro-7-azaindole -2-carbaldehyde (0.12 g, 0.66 mmol) was reacted with 4-methylazapane (0.09 ml, 0.86 mmol), sodium triacetoxyborohydride (0.21g, 0.99 mmol) and acetic acid (0.06 ml, 0.99 mmol) as described in general procedure A to afforded the desired compound as a white solid (0.05 g, 27%), 1 H NMR (400 MHz, CDCl 3 ) δ 1.65-1.74 (m., 2 H), 1.85 (s, 4 H), 2.23 (s, 3 H) 2.61-2.74 (m, 4 H) 3.77 (s, 2 H) 6.35 (s, 1 H) 7.15 (d, J= 4.03 Hz, 1 H) 8.08 (d, J=5.49 Hz, 1 H) 11.92 (br. s., 1 H) 11.97 (s, 1 H). 13 C NMR (100 MHz, CDCl 3 ) δ ppm 27.48, 47.13, 54.27, 54.72, 55.28, 56.72, 57.70, 97.22, 115.76, 119.58, 133.46, 140.31, 142.99, 149.91. m/z (ESI-MS) [M] + 279.1. 5-(2-((4-Methyl-1,4-diazepan-1-yl)methyl)-1H-pyrrolo[2,3-b]p yridin-4-yl)-1H-indazol-3- amine 1-((4-Chloro-7-azaindole)methyl)-4-methyl-1,4diazapane (0.038 g, 0.13 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.053 g, 0.2 mmol), 1M potassium phosphate solution (0.26 ml, 0.26 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0016 g, 0.065 mmol) in 0.78 ml ethanol were reacted as described in general procedure B and chromatographic purification (18% methanol in EtOAc and 1% triethylamine), gave the titled compound as white solid (48 mg, 98%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.65-1.74 (m., 2 H), 1.85 (s, 4 H), 2.23 (s, 3 H) 2.61-2.74 (m, 4 H) 3.77 (s, 2 H) 5.52 (br. s., 2 H) 6.55 (s, 1 H) 7.13 (d, J= 5.27 Hz, 1 H) 7.38 (d, J=8.79 Hz, 1 H) 7.65 (dd, J=8.57, 1.54 Hz, 1 H) 8.14 (s, 1 H) 8.19 (d, J=5.27 Hz, 1 H) 11.61 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 27.42, 47.10, 54.28, 54.63 55.55, 56.74, 58.21, 98.98, 110.39, 114.49, 115.14, 118.29, 120.76, 127,23, 128.58, 138.81, 141.01, 141.66, 142.75, 150.01, 150.37. m/z (ESI-HRMS) calculated for C21H26N7 = 376.2244 found= 376.2245. Example 267 4-Chloro-3-(4-(piperidin-1-yl)but-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 4 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in a sealed tube followed by addition of 4-(but-3-yn-1-yl)piperidine (0.12 ml, 0.88 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was diluted with EtOAc and extracted with 1M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.063 g, 40%), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.39 (d, J=5.19 Hz, 2 H) 1.52 (quin, J=5.57 Hz, 4 H) 2.39 (br. s., 4 H) 2.52-2.55 (m, 2 H) 2.64-2.72 (m, 2 H) 6.65 (d, J=5.34 Hz, 3 H) 6.83 (d, J=5.49 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 18.07, 24.52, 25.83, 54.08, 57.34, 74.94, 101.20, 102.19, 112.47, 143.22, 148.05, 161.96. m/z (ESI-MS) [M] + 264.0. 4-(2-(4-Chloro-7-azaindole-2-yl)ethyl)piperidine To a solution of 4-chloro-3-(4-piperidin-1-yl)but-1-yn-1yl)pyridin-2-amine (128) (0.057 g, 0.19 mmol) in 1,4 dioxane (1 ml), potassium tert-butoxide (0.05 g, 0.4 mmol) and 18-crown-6 (0.005 g, 10%, 0.02 mmol) were added and the mixture was stirred at 120 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (52.6 mg, 93%), 1H NMR (400 MHz, DMSO-d6) δ ppm 1.31-1.45 (m, 2 H) 1.45-154 (m, 4 H) 2.40 (br. s., 4 H) 2.63 (t, J=7.69 Hz, 2 H) 2.89 (t, J=7.69 Hz, 2 H) 6.26 (s, 1 H) 7.11 (d, J=5.27 Hz, 1 H) 8.06 (d, J=5.27 Hz, 1 H) 11.90 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 24.66, 26.17, 54.37, 58.26, 70.06, 95.83, 115.66, 119.92, 132.95, 141.84, 142.43, 149.70. m/z (ESI-MS) [M] + 264.1. 5-(2-(2-(Piperidin-1-yl)ethyl)-1H-pyrrolo[2,3-b]pyridine-4-y l)-1H-indazol-3-amine 4-(2-(4-Chloro-7-azaindole-2-yl)ethyl)piperidine (0.045 g, 0.17 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.06 g, 0.25 mmol), 1M potassium phosphate solution (0.3 ml, 0.3 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.002 g, 0.008 mmol) in 1.0 ml ethanol were reacted as described in general procedure B and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60-80%), gave the titled compound as white solid (38 mg, 62%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.32-1.45 (m, 2 H) 1.45-1.60 (m, 4 H) 2.43 (br. s., 4 H) 2.68 (br. s., 2 H) 2.92 (t, J=6.59 Hz, 2 H) 5.51 (s, 2 H) 6.47 (s, 1 H) 7.12 (d, J= 4.83 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.79, 1.76 Hz, 1 H) 8.02-8.26 (m, 2 H) 11.51-11.66 (m, 2 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 25.95, 53.71, 58.17, 66.76, 97.50, 110.34, 114.46, 115.14, 118.61, 120.70, 127.20, 128.66, 139.99, 140.55, 141.63, 142.28, 149.96, 150.38. m/z (ESI-HRMS) calculated for C21H25N6 = 361.2135 found=361.2132. Example 268 4-Chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.02 g, 0.03 mmol) in 4 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in a sealed tube followed by addition of 4-(but-3-yn-1-yl)morpholine (0.12 ml, 0.88 mmol) and stirred at 80 °C for 3 h. The reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as yellow oil (0.139 g, 89%), 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (br. s., 4 H) 2.56 (t, J=6.81 Hz, 2 H) 3.70 (t, J=6.81 Hz, 2 H) 3.59 (t, J=4.61 Hz, 4 H) 6.51-6.78 (m, 3 H) 6.84 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.85, 53.45, 57.05, 66.58, 75.05, 101.03, 102.25, 112.61, 143.38, 148.20, 162.01. m/z (ESI-MS) [M] + 266.0. 4-(2-(4-Chloro-7-azaindole-2-yl)ethyl)morpholine To a solution of 4-chloro-3-(4-morpholinobut-1-yn-1yl)pyridin-2-amine (0.1 g, 0.37 mmol) in 1,4 dioxane (1 ml), potassium tert-butoxide (0.1 g, 0.94 mmol) and 18-crown-6 (0.009 g, 10%, 0.037 mmol) were added and the mixture was stirred at 120 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (89.9 mg, 91%), 1H NMR (400 MHz, DMSO-d6) δ ppm 2.43 (br. s., 4 H) 2.67 (t, J=7.69 Hz, 2 H) 2.92 (t, J=7.47 Hz, 2 H) 3.55-3.60 (m, 4 H) 6.28 (s, 1 H) 7.12 (d, J=5.27 Hz, 1 H) 8.06 (d, J=5.27 Hz, 1 H) 11.95 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.75, 53.68, 57.85, 66.75, 95.93, 115.67, 119.92, 132.98, 141.56, 142.48, 149.72. m/z (ESI-MS) [M] + 266.1. 5-(2-(2-Morpholinoethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-i ndazol-3-amine 4-(2-(4-Chloro-7-azaindole-2-yl)ethyl)morpholine (0.06 g, 0.22 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.08 g, 0.34 mmol), 1M potassium phosphate solution (0.4 ml, 0.4 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.002 g, 0.01 mmol) in 1.3 ml ethanol were reacted as described in general procedure B and chromatographic purification (90% EtOAc and 1% triethylamine in petroleum ether 60- 80%), gave the titled compound as white solid (68.8 mg, 86%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.44 (br. s., 4 H) 2.69 (t, J=7.47 Hz, 2 H) 2.88-2.97 (m, 2 H) 3.58 (t, J=4.39 Hz, 4 H) 5.52 (s, 2 H) 6.48 (s, 1 H) 7.12 (d, J= 5.27 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.79, 0.88 Hz, 1 H) 8.13 (s, 1 H) 8.15 (d, J= 4.83 Hz, 1 H) 11.54 (s, 1 H) 11.56 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 25.95, 53.71, 58.17, 66.76, 97.50, 110.34, 114.46, 115.14, 118.61, 120.70, 127.20, 128.66, 139.99, 140.55, 141.63, 142.28, 149.96, 150.38. m/z (ESI-HRMS) calculated for C20H23ON6 = 363.1928 found= 363.1924. Example 269 4-Chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine A solution of 4-chloro-3-iodo-pyridine-2-amine (0.15 g, 0.6 mmol), copper (I) iodide (0.005 g, 0.03 mmol) and bis(triphenylphosphine) palladium(II) chloride(0.02 g, 0.03 mmol) in 4 ml of tetrahydrofuran – triethylamine (1:4) was degassed in a sealed tube followed by the addition of 5-chloro-1-pentyne (0.1 ml, 0.9 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was diluted with EtOAc and extracted with water. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The crude then purified using column chromatography (10% EtOAc in petroleum ether 60-80%) to give the product as yellow oil (0.102 g, 75%) 1H NMR (400 MHz, DMSO-d6) δ ppm 2.03 (quin, J=6.70 Hz, 2 H) 2.67 (t, J=6.81 Hz, 2 H) 3.79 (t, J=6.59 Hz, 2 H) 6.48 (br.s., 2 H) 6.67 (d, J=5.27 Hz, 1 H) 6.84 (d, J=4.83 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.48, 31.37, 44.58, 74.36, 100.42, 102.02, 112.80, 144.48, 148.25, 161.55. m/z (ESI-MS) [M] + 229.0. 4-Chloro-3-(5-piperdinopent-1-yn-1yl)pyridin-2-amine In sealed tube, a mixture of 4-chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.4 mmol), piperdine (0.5 ml) and potassium iodide (0.04 g, 0.22 mmol) in N,N-dimethylamide (1.5 ml) was heated to 110 °C for 50 min. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow oil (0.1 g, 90 %), 1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (d, J=5.49 Hz, 2 H) 1.48 (quin, J=5.49 Hz, 4 H) 2.03 (quin, J=7.05 Hz, 2 H) 2.31 (br. s., 4 H) 2.36 (t, J=7.14 Hz, 2 H) 2.67 (t, J=4.61 Hz, 2 H) 6.41 (br. s., 2 H) 6.66 (dd, J=5.49, 2.93 Hz, 1 H) 7.83 (d, J=5.49 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 16.88, 25.58, 30.77, 44.24, 54.10, 57.43, 73.76, 101.61, 102.30, 112.19, 143.70, 147.65, 160.95. m/z (ESI-MS) [M] + 292.1. 4-(3-(4-Chloro-7-azaindole-2-yl)propyl)piperidine To a solution of 4-chloro-3-(5-piperdinopent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.36 mmol) in toluene (1 ml), potassium tert-butoxide (0.1 g, 0.9 mmol) and 18-crown-6 (0.0095 g, 10%, 0.036 mmol) were added and the mixture was stirred at 110 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (30 mg, 45%), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.38 (d, J=5.27 Hz, 2 H) 1.43-1.57 (m, 4 H) 1.76-1.92 (m, 2 H) 2.21-2.40 (m, 6 H) 2.75 (t, J=7.69 Hz, 2 H) 6.22 (s, 1 H) 7.10 (d, J=4.83 Hz, 1 H) 8.05 (d, J=5.27 Hz, 1 H) 11.97 (br. s.1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 9.22, 24.75, 26.17, 54.63, 58.63, 70.28, 95.40, 115.73, 119.95, 132.89, 142.38, 143.28, 149.84. m/z (ESI-MS) [M] + 278.2. 5-(2-(3-(Piperidin-1-yl)propyl)-1H-pyrrolo[2,3-b]pyridin-4-y l)-1H-indazol-3-amine 4-(3-(4-chloro-7-azaindole-2-yl)propyl)piperidine (0.05 g, 0.22 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.085 g, 0.33 mmol), 1M potassium phosphate solution (0.44 ml, 0.44 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.007 g, 0.011 mmol) in 0.45 ml ethanol were reacted as described in general procedure B and purified using HPLC to give the titled compound as yellow solid (0.058 mg, 70%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.48-1.76 (m, 6 H) 2.02-2.18 (m, 2 H) 2.77-2.95 (m, 4 H) 3.01-3.15 (m, 2 H) 3.45 (d, J=11.86 Hz, 2 H) 6.56 (s, 1 H) 7.22 (d, J= 5.27 Hz, 1 H) 7.44 (d, J=8.79 Hz, 1 H) 7.73 (dd, J=8.79, 1.32 Hz, 1 H) 8.23 (d, J=6.59 Hz, 2 H) 11.54 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 24.64, 26.02, 26.56, 31.27, 54.57, 58.69, 96.98, 110.34, 114.41, 115.12, 118.62, 120.68, 127.20, 128.69, 140.44, 141.62, 141.71, 142.17, 150.08, 150.37. m/z (ESI-HRMS) calculated for C22H27N6 = 375.2292 found= 375.2290. Example 270 4-Chloro-3-(5-(cyclohexylamino)pent-1-yn-1yl)pyridin-2-amine In sealed tube, a mixture of 4-chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.4 mmol), cyclohexylamine (0.5 ml) and potassium iodide (0.04 g, 0.22 mmol) in N,N- dimethylamide (1.5 ml) was heated to 110 °C for 50 min. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow oil (119 mg, 93 %), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.54 (d, J=10.99 Hz, 2 H) 1.60-1.73 (m, 6 H) 1.81 (d, J=10.99 Hz, 4 H) 2.31-2.43 (m, 1 H) 2.56 (t, J=7.03 Hz, 2 H) 2.68 (t, J=6.81 Hz, 2 H) 6.42 (br. s., 2 H) 6.66 (d, J=5.27 Hz, 1 H) 7.82 (d, J=5.71 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.85, 21.99, 26.43, 29.22, 33.38, 45.67, 56.65, 73.75, 102.26, 102.36, 112.80, 144.25, 148.03, 161.52. m/z (ESI-MS) [M] + 292.1. 5-(2-(3-(Cyclohexylamino)propyl)-1H-pyrrolo[2,3-b]pyridin-4- yl)-1H-indazol-3-amine 4-(3-(4-Chloro-7-azaindole-2-yl)propyl)cyclohexylamine (0.041 g, 0.14 mmol), 5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.054 g, 0.21 mmol), 1M potassium phosphate solution (0.28 ml, 0.28 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.0018 g, 0.007 mmol) in 0.86 ml ethanol were reacted as described in general procedure B and chromatographic purification (18% methanol in EtOAc and 1% triethylamine) gave the titled compound as white solid (38 mg, 69%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.94-1.05 (m, 2 H) 1.07-1.24 (m, 4 H) 1.53 (dd, J=11.64, 4.17 Hz, 1 H) 1.59-1.69 (m, 2 H) 1.74-1.89 (m, 4 H) 2.31-2.39 (m, 1H) 2.59 (t, J=6.81 Hz, 2 H) 2.79 (t, J=7.47 Hz, 2 H) 5.51 (s, 2 H) 6.43 (s, 1 H) 7.11 (d, J= 5.27 Hz, 1 H) 7.36 (d, J=8.35 Hz, 1 H) 7.64 (dd, J=8.57, 1.54 Hz, 1 H) 8.08-8.19 (m, 2 H) 11.53 (br. s., 1 H) 11.62 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.01, 26.45, 26.50, 29.77, 33.45, 46.37, 56.66, 96.94, 110.31, 114.40, 115.14, 118.64, 120.67, 127.19, 128.71, 140.41, 141.63, 141.87, 142.12, 150.05, 150.36. m/z (ESI-HRMS) calculated for C 22 H 27 N 7 = 389.2322 found= 389.2319. Example 271 4-Chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine In sealed tube, a mixture of 4-chloro-3-(5-chloropent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.4 mmol), morpholine (0.5 ml) and potassium iodide (0.04 g, 0.22 mmol) in N,N-dimethylamide (1.5 ml) was heated to 110 °C for 50 min. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow oil (115 mg, 90 %), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.73 (quin, J=7.14 Hz, 2 H) 2.35 (br. s., 4 H) 3.41 (t, J=7.03 Hz, 2 H) 2.52-2.56 (m, 2 H) 3.57 (t, J=4.61 Hz, 4 H) 6.42 (br. s., 2 H) 6.66 (d, J=5.71 Hz, 1 H) 7.82 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 17.77, 25.57, 53.95, 57.69, 66.77, 79.36, 100.30, 102.30, 112.82, 144.29, 148.05, 161.50. m/z (ESI- MS) [M] + 280.1. 4-(3-(4-Chloro-7-azaindole-2-yl)propyl)morpholine To a solution of 4-chloro-3-(5-morpholinopent-1-yn-1yl)pyridin-2-amine (0.1 g, 0.36 mmol) in dioxane (1 ml), potassium tert-butoxide (0.1 g, 0.89 mmol) and 18-crown-6 (0.01 g, 10%, 0.036 mmol) were added and the mixture was stirred at 120 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid to give the product as yellow solid (100 mg, 99%), 1H NMR (400 MHz, DMSO-d6) δ ppm 1.73 (quin, J=7.40 Hz, 2 H) 2.34 (m, 6 H) 2.77 (d, J=7.63 Hz, 2 H) 3.58 (t, J=4.58 Hz, 4 H) 6.24 (s, 1 H) 7.12 (d, J=5.19 Hz, 1 H) 8.07 (d, J=5.19 Hz, 1 H) 11.95 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 25.66, 26.12, 53.79, 58.11, 69.97, 95.35, 115.55, 119.83, 132.81, 142.32, 143.08, 149.74. m/z (ESI-MS) [M] + 280.1. 5-(2-(3-Morpholinopropyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine 4-(3-(4-Chloro-7-azaindole-2-yl)propyl)morpholine (0.09 g, 0.32 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.12 g, 0.48 mmol), 1M potassium phosphate solution (0.64 ml, 0.64 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.004 g, 0.016 mmol) in 1.9 ml ethanol were reacted as described in general procedure B and chromatographic purification (90% EtOAc in petroleum ether 60-80%), gave the titled compound as white solid (96.6 mg, 80%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.88 (quin, J=7.36 Hz, 2 H) 2.27-2.42 (m, 6 H) 2.78 (t, J=7.69 Hz, 2 H) 3.57 (t, J=4.61 Hz, 4 H) 5.50 (s, 2 H) 6.39-6.51 (m, 1 H) 7.11 (d, J= 4.83 Hz, 1 H) 7.37 (d, J=8.79 Hz, 1 H) 7.64 (dd, J=8.57, 1.54 Hz, 1 H) 8.08-8.23 (m, 2 H) 11.53 (s, 1 H) 11.58 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.98, 26.40, 53.91, 58.34, 66.77, 97.01, 110.35, 114.43, 115.14, 118.6, 120.68, 127.20, 128.69, 140.46, 141.63, 141.68, 142.18, 150.09, 150.37. m/z (ESI-HRMS) calculated for C 21 H 25 ON 6 = 377.2084 found= 377.2082. Example 272 Tert-butyl 4-((2-amino-4-chloropyridin-3-yl)ethynyl)methyl)piperidine-1 -carboxylate A solution of 4-chloro-3-iodo-pyridine-2-amine (0.12 g, 0.48 mmol), copper (I) iodide (0.004 g, 0.024 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.016 g, 0.024 mmol) in 3 ml of N,N-dimethyformamide-triethylamine (1:4) was degassed in a sealed tube followed by addition of tert-butyl 4-(prop-2-yn-1-yl)piperidine-1-carboxylate (0.13 g, 0.58 mmol). The reaction mixture was stirred at 80 °C for 4 h. The reaction mixture was diluted with EtOAc and extracted with 1 M sodium carbonate. The extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (20% EtOAc in petroleum ether 60-80%) to give the product as yellow oil (0.13 g, 77%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.11-1.28 (m, 4 H) 1.39 (s, 9 H) 1.43-1.45 (m, 1 H) 1.74 (d, J=9.67 Hz, 4 H) 3.96 (d, J=12.30 Hz, 2 H) 6.41 (br. s., 2 H) 6.67 (d, J=5.71 Hz, 1 H) 7.82 (d, J=5.27 Hz, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 26.62, 28.66, 31.33, 35.35, 36.34, 74.92, 79.02, 100.39, 102.25, 112.84, 144.39, 148.11, 154.42, 161.47. m/z (ESI-MS) [M-tert-butyl] + 294.0. Tert-butyl 4-((4-chloro-7-azaindol-2-yl)methyl) piperdine-1-carboxylate To a solution of tert-butyl 4-((2-amino-4-chloropyridin-3-yl)ethynyl)methyl)piperidine-1 - carboxylate (0.1 g, 0.28 mmol) in 1,4 dioxane (2 ml), potassium tert-butoxide (0.08 g, 0.7 mmol) and 18-crown-6 (0.007 g, 10%, 0.028 mmol) were added and the mixture was stirred at 110 °C for 18h. After the reaction was cooled to room temperature, EtOAc and 1 M sodium carbonate solution were added. The extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give the product as yellow solid (70 mg, 71%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.95-1.14 (m, 2 H) 1.38 (s, 9 H) 1.59 (d, J=12.74 Hz, 2 H) 1.74 (d, J=12.74 Hz, 2 H) 1.80-1.95 (m, 1 H) 2.67 (d, J=7.03 Hz, 2 H) 3.91 (d, J=13.62 Hz, 2 H) 6.24 (s, 1 H) 7.12 (d, J=5.27 Hz, 1 H) 8.06 (d, J=5.27 Hz, 1 H) 11.87 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 28.66, 32.10, 35.07, 36.05, 70.30, 79.01, 96.55, 115.71, 119.92, 132.95, 141.21, 142.48, 154.41. m/z (ESI-MS) [M-tert-butyl] + 294.0. 2-(Piperdin-4ylmethyl)-4-chloro-7-azaindole Trifloroacetic acid (0.07 ml) was added to a solution of tert-butyl 4-((4-chloro-7-azaindol-2- yl)methyl)piperdine-1-carboxylate (0.064 g, 0.18 mmol) in dicloromethane (2 ml) and the reaction was stirred at room temperature for 3 h. The reaction mixture was diluted with EtOAc, washed with 1M sodium carbonate, dried over magnesium sulfate and concentrated under vacuum under reduced pressure and the residue purified by column chromatography (80% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the product as a yellow solid (30 mg, 66%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.90-1.14 (m, 2 H) 1.60 (d, J=12.74 Hz, 2 H) 1.74 (d, J=12.74 Hz, 2 H) 1.80-1.95 (m, 1 H) 2.67 (d, J=7.03 Hz, 2 H) 3.91 (d, J=13.62 Hz, 2 H) 6.62 (s, 1 H) 7.20 (d, J=5.27 Hz, 1 H) 8.18 (d, J=5.27 Hz, 1 H) 12.13 (br. s., 1 H). m/z (ESI- MS) [M] + 250. 5-(2-(Piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-1 H-indazol-3-amine 4-Chloro-2-(piperidin-2-ylmethyl)-7-azaindole (0.03 g, 0.086 mmol), 5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.033 g, 0.13 mmol), 1M potassium phosphate solution (0.17 ml, 0.17 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.003 g, 0.004 mmol) in 0.5 ml ethanol were reacted as described in general procedure B and HPLC purification gave the titled compound as yellow solid (13.5 mg, 22%), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.32-1.45 (m, 2 H) 1.79 (d, J= 13.28 Hz, 2 H) 2.01 (ddd, J=10.76, 7.17, 3.74 Hz, 1 H) 2.77 (d, J=6.87 Hz, 2 H) 2.79-2.89 (m, 2 H) 3.25 (d, J= 12.36 Hz, 2 H) 6.59 (s, 1 H) 7.28 (d, J= 5.34 Hz, 1 H) 7.49 (d, J= 8.70 Hz, 1 H) 7.79 (d, J= 8.70 Hz, 1 H) 8.27 (d, J=5.34 Hz, 1 H) 8.29 (s, 1 H) 8.60 (d, J= 9.31 Hz, 1 H) 12.02 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 28.68, 33.94, 34.53, 43.62, 98.85, 111.50, 114.49, 115.48, 119.58, 121.50, 128.67, 128.89, 139.97, 140.19, 141.85, 141.89, 158.57, 158.85. m/z (ESI- HRMS) calculated for C 20 H 23 N 6 = 347.1979 found=347.1977. Example 273 5-(2-((1-benzylpiperidin-4-yl)methyl)-1H-pyrrolo[2,3-b]pyrid in-4-yl)-1H-indazol-3-amine To a solution of 5-(2-(piperdin-4-ylmethyl)-7-azaindol-4-yl)-1H-indazol-3-ami ne (0.012 g, 0.034mmol) and potassium carbonate (0.0046g , 0.034 mmol) in a N,N-dimethylformamide (1 ml) at 100 °C, chloromethylbenzene (0.0048 ml, 0.038 mmol) was added and the reaction mixture allowed to stirred for 2 h. then, the reaction mixture concentrated and the residue purified by HPLC to give the title compound as yellow solid (0.84 mg, 8 %), 1 H NMR (400 MHz, DMSO-d6) δ ppm 1.37-1.50 (m, 2 H) 1.79-1.88 (m, 2 H) 1.89-2.00 (m, 1 H) 2.73 (d, J=6.59 Hz, 2 H) 3.33 (d, J= 10.99 Hz, 4 H) 4.26 (d, J= 4.39 Hz, 2 H) 6.49 (s, 1 H) 7.19 (d, J= 5.27 Hz, 1 H) 7.41 (d, J= 8.79 Hz, 1 H) 7.46 (s, 5 H) 7.70 (dd, J=8.79, 1.32 Hz, 1 H) 8.18 (s, 1 H) 8.21 (d, J= 5.27 Hz, 1 H) 11.78 (br. s., 1 H). m/z (ESI-HRMS) calculated for C27H29N6 = 437.2448 found=437.2453. Section 12 – compounds of the formula: 3-Chloro-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)benzonitrile Preparation of stock solution: [Ir(OMe)cod]2 ([(1,5-cyclooctadiene) (methoxy) iridium (I) dimer]) (104 mg, 0.312 mmol), dtbpy (di-tert-butyl-2,2′dipyridyl) (84 mg, 0.312 mmol) and B2pin2 (bis (pinacolato) diboron) (2644 mg, 10.4 mmol) were mixed in volumetric flask and diluted up to 25 ml with MTBE (tert-butyl-methylether). Then 12.6 ml of stock solution was added to 3-chloro-2- fluorobenzonitrile (0.85 g, 5.5 mmol) in microwave vial under nitrogen. The reaction vial then deoxygenated, sealed and heated to 80 °C for 30 min in microwave. Thereafter, the solvent was evaporated and residue purified by column chromatography (0-20% EtOAc in petroleum ether 60-80%) to give the title compound as a white solid (1.3 g, 84%). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.31 (s, 12 H) 7.99-8.07 (m, 2 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.05, 85.32, 102.93, 113.26, 121.36, 136.54, 138.60, 141.51, 159.40. 7-Chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- indazol-3-amine To a solution of 3-chloro-2-fluoro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl) benzonitrile (187) (0.4 g, 1.4 mmol) in ethanol (20 ml), hydrazine hydrate (0.22 ml, 2.47 g, 6.8 mmol, 50- 60 %) was added and the reaction refluxed for 18 h. The solvent was evaporated and the residue was triturated with 12 ml EtOAc and petroleum ether (1:1) and then filtrated under vacuum and washed with water and petroleum ether 60-80% to give the desired compound as a yellow solid (320 mg, 78 %). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.31 (s, 12 H) 5.68 (s, 2 H) 7.45 (s, 1 H) 8.15 (s, 1 H) 12.02 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) δ ppm 25.17, 84.07, 102.89, 116.70, 119.82, 125.89, 128.07, 130.59, 146.33. 3-(3,3-Dimethylbut-1-yn-1-yl)-2-fluorobenzonitrile To a solution of 3-bromo-2-fluorobenzonitrile (1 g, 5 mmol), copper (I) iodide (0.047 g, 0.25 mmol) and bis(triphenylphosphine) palladium(II) chloride (0.175 g, 0.25 mmol) in 15 ml of N,N- dimethyformamide-triethylamine (1:4) was degassed in sealed tube followed by 3,3- dimethylbut-1-yne (0.61 g, 7.5 mmol). The reaction mixture was stirred at 80 °C for 3 h. After reaction completed, the reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. Extracted organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography (5 % EtOAc in petroleum ether 60-80%) to give the product as yellow solid (1 g, 99%). 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 01.31 (s, 9 H) 7.38 (t, J=7.69 Hz, 1 H) 7.80 (td, J=7.58, 1.54 Hz, 1 H) 7.90 (ddd, J=7.80, 6.26, 1.76 Hz, 1 H). Potassium (phenyleth-1-yn-1-yl) trifluoroborate To a solution of ethynylbenzene (1.6 ml, 15 mmol) in tetrahydrofuran (30 ml) at -78 °C, n- butyllithium (6 ml, 15 mmol, 2.5 M) was added gradually and the solution was stirred for 1 h at this temperature. Then, trimethylborate (2.5 ml, 22.5 mmol) was added and the reaction mixture allowed to stirred at -78 °C for 1 h and then warm to -20 °C and stirred for another hour. Saturated aqueous solution of potassium hydrogen difluoride (7 g, 90 mmol) was added and reaction mixture allowed to warm to room temperature and stirred for 18 h. The solvent then evaporated and the residue washed with acetone and filtered. The organic layer then concentrated and the residue dissolved in hot acetone and precipitated with diethyl ether. The solid then collected to give the title compound as white solid (2.8 g, 90%). 1 H NMR (400 MHz, DMSO-d6) δ ppm 7.28 (m, 3 H) 7.28-7.29 (m, 2 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 125.53, 126.67, 128.22, 130.90. General procedure A: A suspension of required chloroaryl (1 eq.), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H- indazol-3-amine (1.2-1.5 eq.), base (2 eq.) in 1:3 of solvent was deoxygenated with nitrogen in sealed tube. Then [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.05 eq.) was added then the tube was sealed and the mixture allowed to stirred at 90-100 °C for 18 h. After the reaction was cooled to room temperature, EtOAc and water were added. Extracted organic layer was dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by column chromatography. Example 274 4-(3-Amino-7-chloro-1H-indazol-5-yl)-N-(2-(piperidin-1-yl)et hyl)-1H-pyrrolo[2,3-b]pyridine- 2-carboxamide A 2-5 mL Biotage MW tube was charged with 4-chloro-N-(2-(piperidin-1-yl)ethyl)-1H- pyrrolo[2,3-b]pyridine-2-carboxamide (100 mg, 0.3 mmol), 7-chloro-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (111 mg, 0.4 mmol, 1.3 eq.), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (9.8 mg, 0.015 mmol, 5 mol%) and dioxane (1.8 mL). The resulting suspension was purged with nitrogen for 5 minutes before adding 1 M aq. K3PO4 (1.8 mL). The reaction mixture was heated to 110 °C for 16 hrs. The reaction mixture was then allowed to cool to room temperature, diluted with water (10 mL) and extracted with EtOAc (3 x 20 mL). The combined organic fractions were then dried over magnesium carbonate filtered and the solvent removed under reduced pressure and the crude product was then purified by HPLC to give the desired product as a pale yellow solid (54 mg). 1 H NMR (500 MHz, DMSO-D6) δ 1.36-1.48 (m, 7H), 2.36-2.53 (m, 5H) 3.39 (s, 2H), 5.70 (s, 2H), 7.23 (d, J = 5.05 Hz, 1H), 7.33 (d, J = 1.7 Hz, 1H), 7.69 (s, 1H), 8.12 (s, 1H), 8.37 (d, J = 5.00 Hz, 1H), 8.47 (bs, 1H), 12.07 (s, 1H), 12.18 (s, 1H). LRMS: Calculated for C22H24ClN7O 437.17; Found:438.20 Example 275 7-Chloro-5-(2-(cyclohexylmethyl)-1H-pyrrolo[2,3-b]pyridin-4- yl)-1H-indazol-3-amine 4-Chloro-2-(cyclohexylmethyl)-7-azaindole (0.08 g, 0.34 mmol), 7-chloro-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.15 g, 0.51 mmol), 1M potassium phosphate solution (0.68 ml, 0.68 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.007 g, 0.01 mmol) in 2 ml ethanol were reacted as described in General procedure A and purified by column chromatography (60% EtOAc and 1% triethylamnie in petroleum ether 60-80%) to give the titled compound as white solid (81 mg, 63%), 1 H NMR (400 MHz, DMSO- d 6 ) δ ppm 0.92-1.03 (m, 2 H) 1.10-1.18 (m, 4 H) 1.16 (d, J=9.46 Hz,1 H) 1.66 (d, J=10.83 Hz, 4 H) 2.65 (d, J=7.02 Hz, 2 H) 5.69 (s, 2 H) 6.40 (s, 1 H) 7.14 (d, J= 4.88 Hz, 1 H) 7.67 (s, 1 H) 8.14 (d, J=1.37 Hz, 1 H) 8.16 (d, J=4.88 Hz, 1 H) 11.56 (s, 1 H) 12.03 (s, 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 26.10, 26.44, 33.12, 36.18, 37.93, 97.45, 111.92, 114.42, 116.92, 118.46, 119.71, 125.97, 128.73, 129.89, 138.75, 140.89, 141.98, 149.89, 151.16. m/z (ESI-HRMS) calculated for C 21 H 23 N 5 Cl= 380.1636 found= 380.1641. Example 276 7-Chloro-5-(2-(morpholinomethyl)-1H-pyrrolo[2,3-b]pyridin-4- yl)-1H-indazol-3-amine 4-((4-Chloro-7-azaindole-2-yl)methyl)morpholine (0.1 g, 0.36 mmol), 7-chloro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.16 g, 0.53 mmol), 1M potassium phosphate solution (0.72 ml, 0.72 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.008 g, 0.01 mmol) in 2.2 ml ethanol were reacted as described in General procedure A and purified by column chromatography (90% EtOAc and 1% triethylamine in petroleum ether 60-80%) to give the titled compound as white solid (65 mg, 47%), 1 H NMR (400 MHz, DMSO-d6) δ ppm 2.42 (br. s., 4 H) 3.58 (t, J=4.17 Hz, 4 H) 3.66 (s, 2 H) 5.75 (br. s., 2 H) 6.57 (d, J= 1.76 Hz, 1 H) 7.17 (d, J= 4.83 Hz, 1 H) 7.68 (d, J=1.32 Hz, 1 H) 8.15 (d, J= 0.88 Hz, 1 H) 8.21 (d, J= 4.83 Hz, 1 H) 11.77 (s, 1 H) 12.08 (s, 1 H). 13 C NMR (100 MHz, DMSO-d6) 46.20, 53.61, 66.59, 99.19, 113.17, 114.61, 116.90, 118.04, 118.50, 119.84, 122.96, 126.00, 129.67, 139.61, 142.89, 147.45, 149.92. m/z (ESI-MS) [M] + 383.2. Example 277 7-Chloro-5-(2-(2-morpholinoethyl)-1H-pyrrolo[2,3-b]pyridin-4 -yl)-1H-indazol-3-amine 4-(2-(4-Chloro-7-azaindole-2-yl)ethyl)morpholine (0.1 g, 0.37 mmol), 7-chloro-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (0.16 g, 0.56 mmol), 1M potassium phosphate solution (0.74 ml, 0.74 mmol), [1,1′-bis(di-tert- butylphosphino)ferrocene]dichloropalladium(II) catalyst (0.008 g, 0.01 mmol) in 2.2 ml ethanol were reacted as described in general procedure and purified by column chromatography (90% EtOAc and 1% triethylamnie in petroleum ether 60-80%) to give the titled compound as white solid (63.3 mg, 43 %), 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 2.45 (br. s., 4 H) 2.70 (t, J=7.71 Hz, 2 H) 2.94 (t, J=7.63 Hz, 2 H) 3.59 (t, J=4.58 Hz, 4 H) 5.69 (br. s., 2 H) 6.38-6.54 (m, 1 H) 7.15 (d, J= 5.04 Hz, 1 H) 7.68 (d, J=1.22 Hz, 1 H) 8.11-8.21 (m, 2 H) 11.61 (s, 1 H) 12.03 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d 6 ) 25.84, 53.60, 58.02, 66.68, 97.14, 110.82, 114.46, 116.17, 118.42, 119.73, 125.96, 126.99, 129.81, 138.95, 140.37, 142.18, 149.86, 150.58. m/z (ESI-HRMS) calculated for C 20 H 22 ON 6 Cl= 397.1538 found= 397.1542. Example 278 5-(2-(Cyclohexylmethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3, 3-dimethylbut-1-yn-1-yl)-1H- indazol-3-amine A solution of 7-chloro-5-(2-(cyclohexylmethyl)-7-azaindol-4-yl)-1H-indazol -3-amine (0.03 g, 0.08 mmol), chloro (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl) [2-(2′-amino-1,1′- biphenyl)]palladium(II) (0.003 g, 0.004 mmol), 2 M potassium carbonate (0.23 ml, 0.4 mmol) and potassium (3,3-dimethylbut-1-yn-1-yl) trifluoroborate (0.03 g, 0.158 mmol) in 0.7 ml of 1,4 dioxane was degassed in a sealed tube and stirred at 110 °C for 18 h. Thereafter, the reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. The extracted organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by HPLC to give the product as yellow solid (13.3 mg, 26 %), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 0.93-1.04 (m, 2 H) 1.07-1.32 (m, 4 H) 1.38 (s, 9 H) 1.67 (d, J=11.80 Hz, 4 H) 1.74 (td, J=6.40, 3.51 Hz, 1 H) 2.68 (d, J=7.03 Hz, 2 H) 6.49 (s, 1 H) 7.27 (d, J=5.02 Hz, 1 H) 7.62 (d, J=1.25 Hz, 1 H) 8.20 (m, 2 H) 11.88 (br. s., 1 H) 12.01 (br. s., 1 H). m/z (ESI-HRMS) calculated for C 27 H 32 N 5 = 426.2652 found= 426.2657. Example 279 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(morpholinomethyl)-1H-pyr rolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine A solution of 7-chloro-5-((2-morpholinomethyl)-7-azaindol-4-yl)-1H-indazol -3-amine (0.03 g, 0.07 mmol), chloro (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl) [2-(2′-amino-1,1′- biphenyl)]palladium (II) (0.005 g, 0.007 mmol), 2 M potassium carbonate (0.21 ml, 0.42 mmol) and potassium (3,3-dimethylbut-1-yn-1-yl) trifluoroborate (0.03 g, 0.157 mmol) in 0.7 ml of dioxane was degassed in a sealed tube and stirred at 110 °C for 18 h. Thereafter, the reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. The extracted organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by HPLC to give the product as yellow solid (10.7 mg, 23 %), 1H NMR (400 MHz, DMSO-d6) δ ppm 1.37 (s, 9 H) 3.15 (br. s., 2 H) 3.38 (br. s., 2 H) 3.64 (br. s., 2 H) 3.95 (br. s., 2 H) 4.53 (br. s., 2 H) 6.90 (s, 1 H) 7.27 (d, J=4.83 Hz, 1 H) 7.59 (d, J=1.32 Hz, 1 H) 8.16 (d, J=1.32 Hz, 1 H) 8.35 (d, J=4.83 Hz, 1 H) 11.92 (br. s., 1 H) 12.00 (br. s., 1 H). 13 C NMR (100 MHz, DMSO-d6) δ ppm 31.20, 31.24, 51.63, 53.13, 63.94, 74.86, 95.67, 98.45, 103.99, 106.08, 115.35, 117.88, 121.11, 121.27, 128.25, 129.42, 138.56, 141.97, 142.67, 149.71, 150.81. m/z (ESI-MS) [M] + 429.1. Example 280 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(2-morpholinoethyl)-1H-py rrolo[2,3-b]pyridin-4-yl)-1H- indazol-3-amine A solution of 7-chloro-5-(2-(2-morpholinoethyl)-7-azaindol-4-yl)-1H-indazo l-3-amine (0.03 g, 0.075 mmol), chloro (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl) [2-(2′-amino- 1,1′-biphenyl)]palladium(II) (0.006 g, 0.007 mmol), 2 M potassium carbonate (0.22 ml, 0.45 mmol) and potassium (3,3-dimethylbut-1-yn-1-yl) trifluoroborate (0.03 g, 0.151 mmol) in 0.7 ml of 1,4 dioxane was degassed in a sealed tube and stirred at 110 °C for 18 h. Thereafter, the reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. The extracted organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by HPLC to give the product as yellow solid (10.4 mg, 17 %), 1H NMR (400 MHz, DMSO-d 6 ) δ ppm 1.38 (s, 9 H) 3.16 (br. s., 2 H) 3.25 (t, J=7.78 Hz, 2 H) 3.45-3.60 (m, 4 H) 3.67 (t, J=11.29 Hz, 2 H) 4.02 (d, J=12.05 Hz, 2 H) 6.58 (s, 1 H) 7.20 (d, J=5.02 Hz, 1 H) 7.57 (d, J=1.51 Hz, 1 H) 8.13 (d, J=1.51 Hz, 1 H) 8.24 (d, J=5.02 Hz, 1 H) 11.79-11.97 (m, 2 H). m/z (ESI-HRMS) calculated for C 26 H 31 ON 6 = 443.2554 found= 443.2557. Example 281 5-(2-(2-Morpholinoethyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(p henylethynyl)-1H-indazol-3- amine A solution of 7-chloro-5-(2-(2-morpholinoethyl)-7-azaindol-4-yl)-1H-indazo l-3-amine (0.03 g, 0.075 mmol), chloro (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′- biphenyl) [2-(2′-amino- 1,1′-biphenyl)]palladium(II) (0.006 g, 0.007 mmol), 2 M potassium carbonate solution (0.22 ml, 0.45 mmol) and potassium (phenyleth-1-yn-1-yl) trifluoroborate (193) (0.03 g, 0.151 mmol) in 0.7 ml of 1,4 dioxane was degassed in a sealed tube and stirred at 110°C for 18 h. Thereafter, the reaction mixture was diluted with EtOAc and extract with 1 M sodium carbonate. The extracted organic layer was washed with brine, dried over magnesium sulfate and concentrated under reduced pressure and the residue purified by HPLC to give the product as yellow solid (17 mg, 16 %), 1H NMR (400 MHz, DMSO-d6) δ ppm 3.15 (br. s., 2 H) 3.27 (t, J=7.91 Hz, 2 H) 3.42-3.61 (m, 4 H) 3.68 (t, J=10.92 Hz, 2 H) 3.90-4.09 (m, 2 H) 6.64 (s, 1 H) 7.27 (d, J=5.27 Hz, 1 H) 7.44-7.51 (m, 3 H) 7.72-7.76 (m, 2 H) 7.82 (d, J=1.51 Hz, 1 H) 8.25 (d, J=1.51 Hz, 1 H) 8.28 (d, J=5.02 Hz, 1 H) 11.95 (br. s., 1 H). m/z (ESI-HRMS) calculated for C28H27ON6 = 463.2241 found= 463.2245. Example 294 5-(2-Cyclopropyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dimet hylbut-1-yn-1-yl)-1H-indazol- 3-amine [00256] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (94.6 mg, 0.279 mmol), 4-chloro-2-cyclopropyl- 1H-pyrrolo[2,3-b]pyridine (53.7 mg, 0.279 mmol), Pd(dtbpf)Cl2 (18.2 mg, 0.028 mmol), and caesium carbonate (273 mg, 0.836 mmol) under an argon atmosphere. To the vial was added dioxane:water (9:1) and the mixture was degassed the stirred at 80 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→100%] followed by preparative HPLC purification afforded the title compound as an orange solid (11.8 mg, 11%). 1 H NMR (400 MHz, DMSO-d6) δ 11.76 (br s, 1H, Ar-NH), 11.49 (br s, 1H, Ar-NH), 8.14 – 8.06 (m, 2H, 2xAr-H), 7.53 (d, J = 1.4 Hz, 1H, Ar-H), 7.09 (d, J = 4.9 Hz, 1H, Ar- H), 6.36 (d, J = 1.8 Hz, 1H, Ar-H), 5.61 (br s, 2H, NH2), 2.13 – 2.03 (m, 1H, c Pr-CH), 1.37 (s, 9H, t Bu), 1.03 – 0.95 (m, 2H, c Pr-CH2), 0.92 – 0.85 (m, 2H, c Pr-CH2). LRMS: Calculated for C23H23N5369.20 found 370.3 (M+1). Route to Example 294 4-Chloro-3-(cyclopropylethynyl)pyridin-2-amine [00257] To a degassed solution of 4-chloro-3-iodopyridin-2-amine (300 mg, 1.18 mmol), Pd2Cl2(PPh3)2 (82.8 mg, 0.118 mmol), and copper(I) iodide (44.9 mg, 0.236 mmol) in 1:1 N,N- dimethylformamide: triethylamine (0.3 mM) was added cyclopropylacetylene (162 μL, 2.36 mmol) and the mixture was stirred at 60 °C for 16 hours. The mixture was cooled to room temperature, filtered over celite, diluted with ethyl acetate and brine, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→30%] afforded the title compound as an orange oil that solidified upon standing (216 mg, 1.12 mmol, 95%). 1 H NMR (400 MHz, CDCl 3 ) δ 7.82 (d, J = 5.5 Hz, 1H, Ar-H), 6.66 (d, J = 5.5 Hz, 1H, Ar-H), 5.10 (br s, 2H, NH 2 ), 1.59–1.50 (m, 1H, c Pr-CH), 0.98–0.90 (m, 2H, c Pr-CH 2 ), 0.90–0.84 (m, 2H, c Pr-CH 2 ). LRMS: Calculated for C 10 H 9 35 ClN 2 192.05 found 193.1 (M+1). 4-Chloro-2-cyclopropyl-1H-pyrrolo[2,3-b]pyridine [00258] To a solution of 4-chloro-3-(cyclopropylethynyl)pyridin-2-amine (151 mg, 0.783 mmol) and 18-crown-6 (20.7 mg, 0.0783 mmol) in dry toluene (65 mM) was added potassium tert- butoxide (862 μL, 1.72 mmol, 2M in tetrahydrofuran) and the mixture was stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→40%] afforded the title compound as pale yellow solid (22.8 mg, 0.118 mmol, 15%). 1 H NMR (500 MHz, CDCl 3 ) δ 11.14 (br s, 1H, NH), 8.12 (d, J = 5.3 Hz, 1H, Ar-H), 7.06 (d, J = 5.3 Hz, 1H, Ar-H), 6.25 (d, J = 1.5 Hz, 1H, Ar-H), 2.13–2.06 (m, 1H, c Pr-CH), 1.13– 1.09 (m, 2H, c Pr-CH 2 ), 0.98–0.93 (m, 2H, c Pr-CH 2 ). LRMS: Calculated for C 10 H 9 35 ClN 2 192.05 found 193.1 (M+1).
Example 295 5-(2-Cyclopentyl-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dimet hylbut-1-yn-1-yl)-1H-indazol-3- amine [00259] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (88.6 mg, 0.261 mmol), 4-chloro-2-cyclopentyl-1H- pyrrolo[2,3-b]pyridine (57.6 mg, 0.261 mmol), Pd(dtbpf)Cl2 (17.0 mg, 0.026 mmol), and caesium carbonate (255 mg, 0.783 mmol) under an argon atmosphere. To the vial was added dioxane:water (9:1) and the mixture was degassed the stirred at 80 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→100%] followed by preparative HPLC purification afforded the title compound as a brown solid (10.7 mg, 10%). 1 H NMR (400 MHz, DMSO-d6) δ 11.78 (br s, 1H, Ar-NH), 11.58 (br s, 1H, Ar-NH), 8.14 (d, J = 5.0 Hz, 1H, Ar-H), 8.12 (d, J = 1.4 Hz, 1H, Ar-H), 7.53 (d, J = 1.4 Hz, 1H, Ar-H), 7.10 (d, J = 5.0 Hz, 1H, Ar-H), 6.38 (d, J = 1.4 Hz, 1H, Ar-H), 5.62 (br s, 2H, NH2), 3.19 (pent., J = 8.0 Hz, 1H, c Pent-CH), 2.14 – 2.03 (m, 2H, c Pent-CH2), 1.83 – 1.60 (m, 6H, c Pent- CH2), 1.36 (s, 9H, t Bu). LRMS: Calculated for C25H27N5397.23 found 398.3 (M+1). Route to Example 295 4-Chloro-3-(cyclopentylethynyl)pyridin-2-amine [00260] To a degassed solution of 4-chloro-3-iodopyridin-2-amine (300 mg, 1.18 mmol), Pd 2 Cl 2 (PPh 3 ) 2 (82.8 mg, 0.118 mmol), and copper(I) iodide (44.9 mg, 0.236 mmol) in 1:1 N,N- dimethylformamide: triethylamine (0.3 mM) was added cyclopentylacetylene (284 μL, 2.36 mmol) and the mixture was stirred at 60 °C for 16 hours. The mixture was cooled to room temperature, filtered over celite, diluted with ethyl acetate and brine, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→20%] afforded the title compound as an orange oil that solidified upon standing (255 mg, 1.16 mmol, 98%). 1 H NMR (500 MHz, CDCl 3 ) δ 7.78 (d, J = 5.5 Hz, 1H, Ar-H), 6.63 (d, J = 5.6 Hz, 1H, Ar-H), 5.28 (br s, 2H, NH 2 ), 2.96–2.86 (m, 1H, CH), 2.01–1.95 (m, 2H, CH 2 ), 1.82–1.68 (m, 6H, CH 2 ), 1.65–1.55 (m, 2H, CH 2 ). LRMS: Calculated for C 12 H 13 35 ClN 2 220.08 found 221.2 (M+1). 4-Chloro-2-cyclopentyl-1H-pyrrolo[2,3-b]pyridine [00261] To a solution of 4-chloro-3-(cyclopentylethynyl)pyridin-2-amine (230 mg, 1.04 mmol) in dioxane (4 mL) was added potassium tert-butoxide (293 mg, 2.61 mmol) and 18-crown-6 (27.6 mg, 0.104 mmol) and the mixture was stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Trituration from 1:2 diethyl ether:petroleum ether afforded the title compound as a pale brown solid (61.0 mg, 0.276 mmol, 27%). The filtrate was resubjected to the above conditions using 18-crown-6 (15 mg, 0.0567 mmol) and potassium tert-butoxide (700 μL, 1.40 mmol, 2M in tetrahydrofuran) under microwave irradiation at 130 °C for 30 minutes. Flash column chromatography of the combined filtrand and resubjected filtrate [petrol:ethyl acetate 0→40%] afforded the title compound as a pale yellow solid (92.6 mg, 0.420 mmol, 40%). 1 H NMR (500 MHz, CDCl 3 ) δ 10.86 (br s, 1H, NH), 8.09 (d, J = 5.3 Hz, 1H, Ar-H), 7.07 (d, J = 5.3 Hz, 1H, Ar- H), 6.32 (d, J = 1.6 Hz, 1H, Ar-H), 3.34–3.21 (m, 1H, CH), 2.25–2.13 (m, 2H, CH2), 1.92–1.70 (m, 6H, CH 2 ). LRMS: Calculated for C 12 H 13 35 ClN 2 220.08 found 221.2 (M+1). Example 296 5-(2-(tert-Butyl)-1H-pyrrolo[2,3-b]pyridin-4-yl)-7-(3,3-dime thylbut-1-yn-1-yl)-1H-indazol-3- amine [00262] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (93.3 mg, 0.275 mmol), 2-(tert-butyl)-4-chloro-1H- pyrrolo[2,3-b]pyridine (52.2 mg, 0.250 mmol), Pd(dtbpf)Cl2 (16.3 mg, 0.025 mmol), and caesium carbonate (163 mg, 0.500 mmol) under an argon atmosphere. To the vial was added DMF:water (4:1) and the mixture was degassed the stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was washed with lithium chloride solution (10 w/v %) five times, dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→100%] followed by preparative HPLC purification afforded the title compound as a white solid (13.5 mg, 14%). 1 H NMR (400 MHz, DMSO-d6) δ 11.78 (br s, 1H, NH), 11.63 (br s, 1H, NH), 8.16 (d, J = 5.0 Hz, 1H, Ar-H), 8.13 (s, 1H, Ar-H), 7.54 (s, 1H, Ar-H), 7.10 (d, J = 5.0 Hz, 1H, Ar-H), 6.32 (s, 1H, Ar-H), 5.63 (br s, 2H, NH2), 1.38 (s, 9H, t Bu), 1.36 (s, 9H, t Bu). LRMS: Calculated for C24H27N5385.23 found 386.3 (M+1). Route to Example 296 4-Chloro-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-amine [00263] To a degassed solution of 4-chloro-3-iodopyridin-2-amine (300 mg, 1.18 mmol), Pd 2 Cl 2 (PPh 3 ) 2 (82.8 mg, 0.118 mmol), and copper(I) iodide (44.9 mg, 0.236 mmol) in 1:1 N,N- dimethylformamide: triethylamine (0.3 mM) was added 3,3-dimethyl-1-butyne (290 μL, 2.36 mmol) and the mixture was stirred at 60 °C for 16 hours. The mixture was cooled to room temperature, filtered over celite, diluted with ethyl acetate and brine, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→30%] afforded the title compound as a yellow solid (246 mg, 1.18 mmol, quant). 1 H NMR (500 MHz, CDCl 3 ) δ 7.83 (d, J = 5.4 Hz, 1H, Ar-H), 6.67 (d, J = 5.4 Hz, 1H, Ar-H), 5.07 (br s, 2H, NH 2 ), 1.36 (s, 9H, t Bu). LRMS: Calculated for C 11 H 13 35 ClN 2 208.08 found 209.2 (M+1). 2-(tert-Butyl)-4-chloro-1H-pyrrolo[2,3-b]pyridine [00264] To a solution of 4-chloro-3-(3,3-dimethylbut-1-yn-1-yl)pyridin-2-amine (236 mg, 1.13 mmol) and 18-crown-6 (29.9 mg, 0.113 mmol) in dry toluene (65 mM) was added potassium tert-butoxide (1.25 mL, 2.49 mmol, 2M in tetrahydrofuran) and the mixture was stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→40%] afforded the title compound as a pale yellow solid (65.3 mg, 0.313 mmol, 28%). 1 H NMR (500 MHz, CDCl3) δ 10.99 (br s, 1H, NH), 8.15 (d, J = 5.3 Hz, 1H, Ar-H), 7.08 (d, J = 5.3 Hz, 1H, Ar-H), 6.32 (d, J = 2.3 Hz, 1H, Ar-H), 1.48 (s, 9H, t Bu). LRMS: Calculated for C11H13ClN2208.08 found 209.2 (M+1).
Example 297 (4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-1 H-pyrrolo[2,3-b]pyridin-2- yl)methanol [00265] To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (56.72 mg, 0.167 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (3 mL), were added (4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)methanol (27.77 mg, 0.152 mmol, 1 Eq), cesium carbonate (148.57 mg, 0.456 mmol, 3 Eq) and 1,1'- bis(di-tert-butylphosphino) ferrocene palladium chloride (9.90 mg, 0.0152 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. [00266] The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a white solid (41 mg, 0.114 mmol, 75%). 1 H NMR (500 MHz, DMSO-d6) δ 11.78 (s, 1H), 11.60 (s, 1H), 8.18 (d, J = 5.0 Hz, 1H), 8.13 (d, J = 1.7 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.14 (d, J = 5.0 Hz, 1H), 6.54 (d, J = 2.0 Hz, 1H), 5.60 (s, 2H), 5.27 (t, J = 5.6 Hz, 1H), 4.65 (d, J = 5.7 Hz, 2H), 1.37 (s, 9H) ppm. LRMS: Calculated for C21H21N5O requires 359.43 found 360.3 (M+H). Route to Example 297 (4-Chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)methanol [00267] To a solution of methyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (300 mg, 1.42 mmol, 1 Eq) in 2 mL of tetrahydrofuran was added dropwise lithium aluminium hydride 1M solution in THF (0.5 mL, 5.68 mmol, 4 Eq) at room temperature under argon atmosphere. The resulting reaction mixture was heated to 70 °C for 3h. [00268] The reaction was then cooled to 0 °C, EtOAc (10 mL) and water (10 mL) were added sequentially, and the resulting suspension was filtered through celite. The filtrate was washed with EtOAc (10 mL) and the organic and aqueous layers were separated. The aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic layer was washed with water (2 x 10 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure to obtain the titled compound (129.65 mg, 0.71 mmol, 50%) which was sufficiently pure for the next step. 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.91 (s, 1H), 8.12 – 8.06 (m, 1H), 7.16 – 7.11 (m, 1H), 6.36 (s, 1H), 5.36 (t, J = 5.5 Hz, 1H), 4.62 (d, J = 4.6 Hz, 2H) ppm. LRMS (ESI +ve): Calculated for C 8 H 7 ClN 2 O requires 182.6 found 183.1 (M+H). Example 298 2-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) -1H-pyrrolo[2,3-b]pyridin-2- yl)propan-2-ol [00269] To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (56.04 mg, 0.165 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (3 mL), were added 2-(4-chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)propan- 2-ol (32 mg, 0.150 mmol, 1 Eq), cesium carbonate (146.61 mg, 0.45 mmol, 3 Eq) and 1,1'- bis(di-tert-butylphosphino) ferrocene palladium chloride (9.77 mg, 0.0150 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. [00270] The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a white solid (30 mg, 0.114 mmol, 55%). [00271] 1 H NMR (500 MHz, DMSO-d6) δ 11.77 (s, 1H), 11.52 (br. s, 1H), 8.17 (d, J = 5.0 Hz, 1H), 8.11 (d, J = 1.6 Hz, 1H), 7.54 (d, J = 1.5 Hz, 1H), 7.11 (d, J = 5.0 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 5.61 (s, 2H), 5.20 (s, 1H), 1.56 (s, 6H), 1.37 (s, 9H) ppm. LRMS: Calculated for C 23 H 25 N 5 O requires 387.49 found 388.3 (M+H). Route to Example 298 2-(4-Chloro-1H-pyrrolo[2,3-b]pyridin-2-yl)propan-2-ol [00272] To a solution of methyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2-carboxylate (300 mg, 1.42 mmol, 1 Eq) in 1.5 mL of tetrahydrofuran was added dropwise a solution of 2.5M methylmagnesium bromide in diethyl ether (1.14 mL, 2.84 mmol, 2 Eq) at 0 °C under argon atmosphere. The resulting reaction mixture was then allowed to stir at 40 °C overnight. [00273] The reaction was poured slowly into an ice-cooled saturated solution of NH4Cl and extracted with EtOAc (10 mL). The combined organic layer was washed with brine (2 x 10 mL), dried over anhydrous sodium sulphate, filtered and evaporated under reduced pressure. The residue was purified by flash column chromatography (60% EtOAc in petroleum ether) to afford the titled compound (269.22 mg, 1.28 mmol, 90%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.84 (s, 1H), 8.09 (d, J = 5.2 Hz, 1H), 7.12 (d, J = 5.2 Hz, 1H), 6.30 (d, J = 1.8 Hz, 1H), 5.29 (s, 1H), 3.32 (s, 1H), 1.54 (s, 6H) ppm. LRMS (ESI +ve): Calculated for C10H11ClN2O requires 210.6 found 211.2 (M+H). Example 299 Methyl 4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl)-1H -pyrrolo[2,3- [00274] To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (354.14 mg, 1.044 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (5 mL), were added methyl 4-chloro-1H-pyrrolo[2,3-b]pyridine-2- carboxylate (200 mg, 0.949 mmol, 1 Eq), cesium carbonate (927.61 mg, 2.847 mmol, 3 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (61.85 mg, 0.0949 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. [00275] The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a white solid (73.53 mg, 0.189 mmol, 20%). [00276] 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.63 (s, 1H), 11.84 (s, 1H), 8.44 (d, J = 4.8 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.35 (d, J = 2.1 Hz, 1H), 7.29 (d, J = 4.9 Hz, 1H), 5.69 (br. s, 2H), 3.90 (s, 3H), 1.37 (s, 9H) ppm. LRMS: Calculated for C 22 H 21 N 5 O 2 requires 387.44 found 388.1 (M+H). Section 13 - Imidazopyridines Example 300 5-(2-(Difluoromethyl)-3H-imidazo[4,5-b]pyridin-7-yl)-7-(3,3- dimethylbut-1-yn-1-yl)-1H- indazol-3-amine [00277] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (125 mg, 0.368 mmol), 7-chloro-2- (difluoromethyl)-3H-imidazo[4,5-b]pyridine (75.0 mg, 0.368 mmol), Pd(dtbpf)Cl 2 (24.0 mg, 0.0368 mmol), and caesium carbonate (360 mg, 1.11 mmol) under an argon atmosphere. To the vial was added DMF:water (9:1) and the mixture was degassed the stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium bicarbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was washed with lithium chloride solution (10 w/v %) five times, dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→100%] followed by preparative HPLC purification afforded the title compound as a yellow solid (11.7 mg, 8%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.91 (br s, 1H, NH), 11.78 (br s, 1H, NH), 8.53 (d, J = 1.5 Hz, 1H, Ar-H), 8.42 (d, J = 1.5 Hz, 1H, Ar-H), 8.25 (d, J = 5.2 Hz, 1H, Ar-H), 7.44 (d, J = 5.2 Hz, 1H, Ar-H), 5.58 (br s, 2H, NH 2 ), 3.79 (p, J = 8.7 Hz, 1H, c Bu-CH), 2.48 – 2.31 (m, 4H, c Bu-CH 2 ), 2.14 – 2.02 (m, 1H, c Bu-CH 2 ), 2.02 – 1.88 (m, 1H, c Bu-CH 2 ), 1.37 (s, 9H, t Bu). LRMS: Calculated for C 20 H 18 F 2 N 6 380.16 found 381.3 (M+1). Route to Example 300 7-Chloro-2-(difluoromethyl)-3H-imidazo[4,5-b]pyridine [00278] A solution of 4-chloropyridine-2,3-diamine (144 mg, 1.00 mmol) and carboxylic acid (70 μL, 1.1 mmol) in polyphosphoric acid (4 mL) was stirred at 100 °C for 18 hours in a sealed microwave vial. The mixture was cooled to room temperature, diluted with a water and ice, and adjusted to pH7 (NaOH pellets followed by 2M NaOH solution). The mixture was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo to afford the title compound as a pale brown solid (166 mg, 81%), which was used without further purification. 1 H NMR (400 MHz, DMSO-d 6 ) δ 14.38 (br s, 1H, NH), 8.41 (d, J = 5.2 Hz, 1H, Ar-H), 7.51 (d, J = 5.2 Hz, 1H, Ar-H), 7.32 (t, J = 52.9 Hz, 1H, CF2H). LRMS: Calculated for C7H4 35 ClF2N3203.01 found 204.1 (M+1). Example 301 5-(2-Cyclobutyl-3H-imidazo[4,5-b]pyridin-7-yl)-7-(3,3-dimeth ylbut-1-yn-1-yl)-1H-indazol-3- amine [00279] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (97.1 mg, 0.286 mmol), 7-chloro-2-cyclobutyl-3H- imidazo[4,5-b]pyridine (65.4 mg, 0.315 mmol), Pd(dtbpf)Cl 2 (25.0 mg, 0.0384 mmol), and caesium carbonate (280 mg, 0.859 mmol) under an argon atmosphere. To the vial was added DMF:water (9:1) and the mixture was degassed the stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was washed with lithium chloride solution (10 w/v %) five times, dried (magnesium sulfate), filtered, and concentrated in vacuo. Flash column chromatography [petrol:ethyl acetate 0→100%] followed by preparative HPLC purification afforded the title compound as a white solid with a ca.15% impurity (5.5 mg, 5%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 12.91 (br s, 1H, NH), 11.78 (br s, 1H, NH), 8.53 (d, J = 1.5 Hz, 1H, Ar-H), 8.42 (d, J = 1.5 Hz, 1H, Ar-H), 8.25 (d, J = 5.2 Hz, 1H, Ar-H), 7.44 (d, J = 5.2 Hz, 1H, Ar-H), 5.58 (br s, 2H, NH 2 ), 3.79 (p, J = 8.7 Hz, 1H, c Bu-CH), 2.48 – 2.31 (m, 4H, c Bu-CH 2 ), 2.14 – 2.02 (m, 1H, c Bu-CH2), 2.02 – 1.88 (m, 1H, c Bu-CH2), 1.37 (s, 9H, t Bu). LRMS: Calculated for C23H24N6384.21 found 385.4 (M+1). Route to Example 301 [00280] 7-Chloro-2-cyclobutyl-3H-imidazo[4,5-b]pyridine [00281] A solution of 4-chloropyridine-2,3-diamine (144 mg, 1.00 mmol) and carboxylic acid (105 μL, 1.1 mmol) in polyphosphoric acid (4 mL) was stirred at 130 °C for 18 hours in a sealed microwave vial. The mixture was cooled to room temperature, diluted with a water and ice, and adjusted to pH7 (NaOH pellets followed by 2M NaOH solution). The title compound was collected via vacuum filtration as a black solid (211 mg, 100%), which was used without further purification. 1 H NMR (500 MHz, DMSO-d6) δ 13.15 (br s, 1H, NH), 8.16 (d, J = 5.3 Hz, 1H, Ar- H), 7.27 (d, J = 5.3 Hz, 1H, Ar-H), 3.74 (p, J = 8.6 Hz, 1H, c Bu-CH), 2.47 – 2.39 (m, 2H, c Bu- CH2), 2.38 – 2.30 (m, 2H, c Bu-CH2), 2.12 – 2.01 (m, 1H, c Bu-CH2), 1.96 – 1.88 (m, 1H, c Bu- CH2). LRMS: Calculated for C10H10 35 ClN3207.06 found 208.2 (M+1). Example 308 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-(trifluoromethyl)-3H-imid azo[4,5-b]pyridin-7-yl)-1H- indazol-3-amine Route to Example 308 7-Chloro-2-(trifluoromethyl)-3H-imidazo[4,5-b]pyridine [00282] A solution of 4-chloropyridine-2,3-diamine (144 mg, 1.00 mmol) and trifluoroacetic acid (80 μL, 1 mmol) in polyphosphoric acid (4 mL) was stirred at 100 °C for 18 hours in a sealed microwave vial. The mixture was cooled to room temperature, diluted with a water and ice, and adjusted to pH7 (NaOH pellets followed by 2M NaOH solution). The mixture was extracted with ethyl acetate three times and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo to afford the title compound as a pale brown solid (187 mg, 85%), which was used without further purification. 1 H NMR (500 MHz, DMSO-d6) δ 15.09 (br s, 1H, NH), 8.50 (d, J = 5.3 Hz, 1H, Ar-H), 7.60 (d, J = 5.3 Hz, 1H, Ar-H). LRMS: Calculated for C 7 H 3 ClF 3 N 3 221.57 found 222.1 (M+1). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(trifluoromethyl)-3H-imid azo[4,5-b]pyridin-7-yl)-1H-indazol-3- amine SU1737 [00283] To a microwave vial was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (123 mg, 0.361 mmol), 7-chloro-2- (trifluoromethyl)-3H-imidazo[4,5-b]pyridine (80 mg, 0.361 mmol), Pd(dtbpf)Cl2 (24 mg, 0.036 mmol), and caesium carbonate (353 mg, 1.08 mmol) under an argon atmosphere. To the vial was added DMF:water (9:1) and the mixture was degassed the stirred at 100 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium bicarbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was washed with lithium chloride solution (10 w/v %) five times, dried (magnesium sulfate), filtered, and concentrated in vacuo. Preparative HPLC purification followed by recrystallisation from ethyl acetate afforded the title compound as a yellow solid (47 mg, 33%). 1 H NMR (500 MHz, DMSO-d6) δ 14.78 (br s, 1H, NH), 11.90 (br s, 1H, NH), 8.58 (s, 1H, Ar-H), 8.52 (d, J = 4.8 Hz, 1H, Ar-H), 8.32 (s, 1H, Ar-H), 7.66 (d, J = 4.8 Hz, 1H, Ar-H), 5.66 (br s, 2H, NH 2 ), 1.38 (s, 9H, t Bu). LRMS: Calculated for C 20 H 17 F 3 N 6 398.4 found 399.3 (M+1). Additional Examples General Procedures General procedure 1: Suzuki coupling [00284] To a microwave vial was added aryl chloride (1 – 1.1 equiv.), aryl BPin (1 – 1.1 equiv.), Palladium catalyst [10 mol%], and cesium carbonate (2 – 3 equiv.) under an argon atmosphere. To the vial was added dioxane:water or DMF:water (9:1 – 4:1) and the mixture was degassed the stirred at 80 °C for 18 hours or 120 °C for 90 minutes under microwave irradiation. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, if DMF was used, the organic phase was extracted with LiCl 10% w/v solution five times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. General procedure 2: Buchwald coupling [00285] To a microwave vial under inert atmosphere was added Pd(OAc)2 [2 – 5 mol%] and Xantphos [3 – 10 mol%], followed by dry solvent which was stirred at r.t. – 80 °C for 10 minutes to afford the catalyst solution. To a separate microwave vial under inert atmosphere was added aryl halide (1 equiv.), amine (1 – 1.5 equiv.), and base (1 – 2 equiv.), followed by solvent and catalyst solution. The mixture was degassed and stirred at 60–110 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and saturated sodium carbonate solution, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. General procedure 3: tetrahydropyran protection [00286] To a round bottomed flask was added amine (1 equiv.) and PTSA [10 mol%] under an inert atmosphere. Dry THF followed by 3,4-dihydro-2H-pyran (2 equiv.) was added and the reaction was stirred at 65 °C for 18 hours. The mixture was cooled to room temperature, diluted with ethyl acetate and water, and the organic phase separated. The aqueous phase was extracted with ethyl acetate three times, and the combined organic phase was dried (magnesium sulfate), filtered, and concentrated in vacuo. General procedure 4: Nitro reduction [00287] To a round bottomed flask was added nitro compound (1 equiv.) and palladium on carbon (10%, wet) [10 mol%] in methanol. The flask was purged with hydrogen gas for 5 minutes, then stirred at room temperature for 5 hours. The mixture was allowed to cool and concentrated in vacuo. Example 309 - N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2- yl)cyanamide SU1770 Route to SU1770 N'-Hydroxy-N-(4-iodopyridin-2-yl)formimidamide [00288] N,N-Dimethylformamide dimethyl acetal (1.6 g, 1.8 mL, 13.64 mmol, 3 Eq) was added to a solution of 4-iodopyridin-2-amine (1 g, 4.55 mmol, 1 Eq) in 2-propanol (10 mL). The reaction mixture was refluxed for 2 h under a nitrogen. The reaction mixture was cooled to 50 °C and hydroxylamine hydrochloride (0.6 g, 9.1 mmol, 2 Eq) was added and the reaction mixture was allowed to stir at 50 °C for 18 h under nitrogen. The reaction mixture was concentrated under reduced pressure and the residue was allowed to stir in a mixture DCM (20 mL) and NaOH aqueous solution (2N, 5 mL) for 30 min. The organic layer was dried over anhydrous sodium sulfate and removed under reduced pressure. The crude residue was purified using column chromatography (50% EtOAc in petroleum ether) to afford the titled compound as white solid (0.42 g, 1.6 mmol, 35%). [00289] 1 H NMR (500 MHz, DMSO) δ 10.20 (s, 1H), 9.43 (d, J = 9.9 Hz, 1H), 7.85 (d, J = 5.3 Hz, 1H), 7.81 (d, J = 9.8 Hz, 1H), 7.53 (s, 1H), 7.21 (d, J = 5.3 Hz, 1H). N-(4-Iodopyridin-2-yl)cyanamide [00290] POCl 3 (0.7 g, 0.4 mL, 4.56 mmol, 1.2 Eq) was added dropwise to a solution of N'- hydroxy-N-(4-iodopyridin-2-yl)formimidamide (1 g, 3.8 mmol, 1 Eq) in anhydrous DMA (5 mL) at 0 °C while purged with nitrogen. The reaction mixture was allowed to stir under nitrogen at rt for 2 h. The reaction mixture was extracted between EtOAc (20 mL) and NaOH aqueous solution (1N, 5 mL). The organic layer was dried over anhydrous sodium sulfate and removed under reduced pressure. The crude residue was purified using column chromatography (5% MeOH in EtOAc) to afford the titled compound as white solid (0.47 g, 1.9 mmol, 50%). [00291] 1 H NMR (500 MHz, DMSO) δ 4.11 (s, 1H), 6.60 (dd, J = 5.2, 1.5 Hz, 1H), 6.73 (d, J = 1.6 Hz, 1H), 7.53 (d, J = 5.3 Hz, 1H). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)cyanamide SU1770 [00292] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (66 mg, 0.2 mmol, 1.2 Eq), N-(4-iodopyridin-2-yl)cyanamide (40 mg, 0.16 mmol, 1 Eq), cesium carbonate (156 mg, 0.48 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (17 mg, 0.03 mmol, 0.15 Eq) in dioxane (2 mL) and water (0.5 mL) was stirred under nitrogen atmosphere at 80 ºC for 18 h. The solvents were removed under reduced pressure. The crude residue was purified using column chromatography (10% MeOH in EtOAc) followed by trituration using MeOH to give the titled product as yellow solid (10 mg, 0.03 mmol, 20%). 1 H NMR (500 MHz, DMSO) δ 11.96 (s, 1H), 8.28 (s, 1H), 7.82 (d, J = 6.4 Hz, 1H), 7.59 (s, 1H), 7.17 (s, 1H), 7.05 (d, J = 6.7 Hz, 1H), 5.74 (s, 2H), 1.38 (s, 9H). LCMS: For C19H18N6 requires 330.40 found 331.3 (M+H). Example 310 - 5-(2-((1H-Pyrazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbu t-1-yn-1-yl)-1H- indazol-3-amine SU1759 Route to SU1759 3-Nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole [00293] General procedure 3 was followed using 3-nitro-1H-pyrazole (113.1 mg, 1 mmol), PTSA (17.2 mg, 0.1 mmol), and dihydropyran (183 μL, 2 mmol). Flash column chromatography [petrol:ethyl acetate 0→30%] afforded the title compound (197 mg, quant). 1 H NMR (500 MHz, DMSO-d6) δ 8.19 (d, J = 2.6 Hz, 1H), 7.09 (d, J = 2.6 Hz, 1H), 5.57 (dd, J = 9.6, 2.5 Hz, 1H), 3.97 – 3.89 (m, 1H), 3.71 – 3.63 (m, 1H), 2.12 – 2.02 (m, 1H), 2.01 – 1.89 (m, 2H), 1.74 – 1.62 (m, 2H), 1.60 – 1.49 (m, 2H). 13 C NMR (101 MHz, DMSO-d6) δ 155.16, 132.77, 102.85, 87.63, 66.92, 29.26, 24.31, 21.32. LCMS C3H2N3O2 – requires [M–THP] – , 112.02. Observed: [M–THP] – , 122.2. 1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine [00294] General procedure 4 was followed using 3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazole (197.2 mg, 1 mmol) and Pd/C (5.3 mg, 0.05 mmol) to afford the title compound which was used without further purification (167 mg, quant). 1 H NMR (500 MHz, DMSO-d6) δ 7.43 (d, J = 2.3 Hz, 1H), 5.46 (d, J = 2.3 Hz, 1H), 5.04 (dd, J = 10.2, 2.3 Hz, 1H), 4.59 (br s, 2H), 3.89 – 3.83 (m, 1H), 3.57 – 3.48 (m, 1H), 2.04 – 1.95 (m, 1H), 1.93 – 1.87 (m, 1H), 1.81 – 1.75 (m, 1H), 1.65 – 1.55 (m, 1H), 1.50 – 1.40 (m, 2H). 13 C NMR (101 MHz, DMSO-d6) δ 155.18, 129.39, 93.26, 86.09, 66.55, 29.59, 24.75, 22.36. 4-Chloro-N-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyr idin-2-amine [00295] General procedure 2 was followed using 2-bromo-4-chloropyridine (925 mg, 4.81 mmol), 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine (804 mg, 4.81 mmol), Pd(OAc)2 (54.1 mg, 0.241 mmol), Xantphos (278.3 mg, 0.481 mmol), and Cs2CO3 (1.568 g, 4.81 mmol) in toluene at 90 °C for 18 hours. Flash column chromatography [petrol:ethyl acetate 0→100%] afforded the title compound (358 mg, 27%). 1 H NMR (500 MHz, DMSO-d6) δ 9.59 (s, 1H), 8.09 (d, J = 5.4 Hz, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.41 (d, J = 0.8 Hz, 1H), 6.80 (dd, J = 5.4, 0.8 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 5.28 (dd, J = 10.5, 2.1 Hz, 1H), 3.92 (d, J = 10.5 Hz, 1H), 3.67 – 3.56 (m, 1H), 2.13 – 2.02 (m, 1H), 1.98 – 1.87 (m, 2H), 1.70 – 1.62 (m, 1H), 1.55 – 1.48 (m, 2H). 13 C NMR (101 MHz, DMSO-d6) δ 156.02, 149.23, 149.01, 143.13, 129.31, 114.02, 108.43, 96.54, 86.35, 66.66, 29.62, 24.69, 22.10. LCMS C13H15 39 ClN4O requires [M+H] + 278.09, observed [M+H] + 279.2. 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((1-(tetrahydro-2H-pyran- 2-yl)-1H-pyrazol-3- yl)amino)pyridin-4-yl)-1H-indazol-3-amine [00296] General procedure 1 was followed using 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (118.7 mg, 0.35 mmol), 4-chloro-N-(1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)pyridin-2-amine (68.1 mg, 0.244 mmol), Pd(dtbpf)Cl2 (22.8 mg, 0.035 mmol), and Cs2CO3 (228 mg, 0.7 mmol) in 9:1 dioxane:water at 120 °C for 6 hours under MW irradiation. Flash column chromatography [petrol:ethyl acetate 0→100%] using basic silica afforded the title compound (76.1 mg, 71%). 1 H NMR (400 MHz, DMSO-d6) δ 11.80 (br s, 1H), 9.29 (br s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 8.12 (d, J = 1.5 Hz, 1H), 7.71 (d, J = 2.4 Hz, 1H), 7.65 (d, J = 0.7 Hz, 1H), 7.51 (d, J = 1.5 Hz, 1H), 7.03 (dd, J = 5.3, 0.7 Hz, 1H), 6.40 (d, J = 2.4 Hz, 1H), 5.59 (br s, 2H), 5.30 (dd, J = 9.5, 2.5 Hz, 1H), 3.95 – 3.86 (m, 1H), 3.66 – 3.56 (m, 1H), 2.22 – 2.08 (m, 1H), 2.02 – 1.90 (m, 2H), 1.75 – 1.61 (m, 1H), 1.58 – 1.49 (m, 2H), 1.37 (s, 9H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 155.81, 150.53, 149.70, 148.52, 148.12, 141.37, 129.27, 127.87, 127.32, 119.04, 114.93, 111.84, 106.12, 105.50, 103.20, 96.47, 86.08, 74.43, 66.34, 30.69, 29.49, 27.90, 24.76, 22.00. LCMS C 26 H 29 N 7 O requires [M–THP+H] + 372.19, observed [M–THP+H] + 372.3. 5-(2-((1H-Pyrazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbu t-1-yn-1-yl)-1H-indazol-3- amine SU1759 [00297] To a round bottomed flask was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-yl)amino)pyridin-4-y l)-1H-indazol-3-amine (66.4 mg, 0.148 mmol) and 1:1 TFA:DCM (5 mL) and the mixture was stirred at room temperature for 18 hours. The mixture was diluted with saturated aqueous NaHCO3 solution, and the resultant precipitate was collected by vacuum filtration. Reverse phase flash column chromatography afforded the title compound (28.5 mg, 53%) [00298] 1 H NMR (400 MHz, DMSO-d6) δ 12.12 (br s, 1H), 11.80 (br s, 1H), 9.20 (br s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.58 (br s, 1H), 7.56 (d, J = 0.5 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 7.00 (dd, J = 5.3, 0.5 Hz, 1H), 6.30 (br s, 1H), 5.60 (br s, 2H), 1.37 (s, 9H). [00299] 13 C NMR (101 MHz, DMSO-d 6 ) δ 156.00, 150.50, 148.66, 148.07, 141.34, 128.08, 127.45, 119.08, 114.91, 111.80, 105.99, 105.43, 103.30, 74.48, 30.70, 27.91. Three C not observed. [00300] LCMS C 21 H 21 N 7 requires [M+H] + 372.19, observed [M+H] + 372.2. Example 311 - 5-(2-((1H-Pyrazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbu t-1-yn-1-yl)-1H- indazol-3-amine SU1760 Route to SU1760 4-Nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole [00301] General procedure 3 was followed using 4-nitro-1H-pyrazole (113.1 mg, 1 mmol), PTSA (17.2 mg, 0.1 mmol), and dihydropyran (183 μL, 2 mmol). Flash column chromatography [petrol:ethyl acetate 0→25%] afforded the title compound (197 mg, quant). 1 H NMR (500 MHz, DMSO-d6) δ 9.02 (s, 1H), 8.30 (s, 1H), 5.50 (dd, J = 9.7, 2.4 Hz, 1H), 3.98 – 3.91 (m, 1H), 3.69 – 3.61 (m, 1H), 2.15 – 2.05 (m, 1H), 1.98 – 1.88 (m, 2H), 1.73 – 1.61 (m, 1H), 1.59 – 1.50 (m, 2H). 13 C NMR (101 MHz, DMSO-d6) δ 135.37, 129.47, 87.47, 66.94, 29.15, 24.31, 21.38. One C not observed. LCMS C3H2N3O2 – requires [M–THP] – , 112.02. Observed: [M–THP] – , 122.2. 1-(Tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-amine [00302] General procedure 4 was followed using 4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H- pyrazole (197.2 mg, 1 mmol) and Pd/C (5.3 mg, 0.05 mmol) to afford the title compound which was used without further purification (167 mg, quant). 1 H NMR (500 MHz, DMSO-d6) δ 7.10 (s, 1H), 6.96 (s, 1H), 5.16 (dd, J = 9.9, 2.3 Hz, 1H), 3.85 (br s, 2H), 3.60 – 3.50 (m, 1H), 2.02 – 1.93 (m, 1H), 1.93 – 1.87 (m, 1H), 1.84 – 1.77 (m, 1H), 1.67 – 1.56 (m, 1H), 1.54 – 1.43 (m, 3H). 13 C NMR (101 MHz, DMSO-d6) δ 131.30, 129.97, 114.35, 86.71, 66.55, 29.72, 24.69, 22.18. 4-Chloro-N-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyr idin-2-amine [00303] General procedure 2 was followed using 2-bromo-4-chloropyridine (385 mg, 2 mmol), 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-amine (334 mg, 2 mmol), Pd(OAc)2 (9 mg, 0.04 mmol), Xantphos (34.7 mg, 0.06 mmol), and Cs2CO3 (658 mg, 2 mmol) in toluene at 60 °C for 18 hours. Flash column chromatography [petrol:ethyl acetate 0→50%] afforded the title compound (422 mg, 76% 1 H NMR (500 MHz, DMSO-d 6 ) δ 9.06 (s, 1H), 8.11 – 8.07 (m, 2H), 7.48 (s, 1H), 6.73 – 6.68 (m, 2H), 5.34 (dd, J = 9.9, 2.1 Hz, 1H), 3.91 (d, J = 12.1 Hz, 1H), 3.66 – 3.57 (m, 1H), 2.10 – 2.01 (m, 1H), 2.00 – 1.86 (m, 1H), 1.69 – 1.62 (m, 1H), 1.55 – 1.47 (m, 2H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 156.58, 149.27, 142.59, 130.74, 123.61, 118.47, 112.96, 108.07, 86.90, 66.71, 29.74, 24.63, 22.06. LCMS C 13 H 15 39 ClN 4 O requires [M+H] + 278.09, observed [M+H] + 279.2. 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((1-(tetrahydro-2H-pyran- 2-yl)-1H-pyrazol-4- yl)amino)pyridin-4-yl)-1H-indazol-3-amine [00304] General procedure 1 was followed using 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (118.7 mg, 0.35 mmol), 4-chloro-N-(1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)pyridin-2-amine (97.6 mg, 0.35 mmol), Pd(dtbpf)Cl2 (22.8 mg, 0.035 mmol), and Cs2CO3 (228 mg, 0.7 mmol) in 9:1 dioxane:water at 120 °C for 6 hours under MW irradiation. Flash column chromatography [petrol:ethyl acetate 0→100%] using basic silica afforded the title compound (94.9 mg, 60%). [00305] 1 H NMR (500 MHz, DMSO-d6) δ 11.80 (br s, 1H), 8.86 (br s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 7.50 (s, 2H), 6.97 – 6.91 (m, 2H), 5.59 (br s, 2H), 5.35 (d, J = 10.4 Hz, 1H), 3.92 (d, J = 11.5 Hz, 1H), 3.66 – 3.60 (m, 1H), 2.15 – 2.03 (m, 1H), 1.96 – 1.88 (m, 2H), 1.72 – 1.61 (m, 1H), 1.59 – 1.52 (m, 2H), 1.36 (s, 9H). 13 C NMR not obtained. LCMS C 26 H 29 N 7 O requires [M+H] + 445.24, observed [M–THP+H] + 456.3. 5-(2-((1H-Pyrazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylbu t-1-yn-1-yl)-1H-indazol-3- amine SU1760 [00306] To a round bottomed flask was added 7-(3,3-dimethylbut-1-yn-1-yl)-5-(2-((1- (tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)amino)pyridin-4-y l)-1H-indazol-3-amine (85.2 mg, 0.187 mmol) and 1:1 TFA:DCM (5 mL) and the mixture was stirred at room temperature for 18 hours. The mixture was diluted with saturated aqueous NaHCO3 solution, and the resultant precipitate was collected by vacuum filtration. Reverse phase flash column chromatography afforded the title compound (35 mg, 51%) 1 H NMR (400 MHz, DMSO-d6) δ 12.44 (br s, 1H), 11.80 (br s, 1H), 8.72 (br s, 1H), 8.13 (d, J = 6.0 Hz, 1H), 8.09 (d, J = 1.5 Hz, 1H), 7.75 (br s, 2H), 7.49 (d, J = 1.5 Hz, 1H), 6.94 – 6.90 (m, 2H), 5.60 (br s, 2H), 1.36 (s, 9H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 156.77, 150.48, 148.20, 147.98, 141.31, 127.81, 127.42, 123.52, 118.86, 114.90, 110.64, 105.46, 105.37, 103.21, 74.47, 30.70, 27.90. Example 312 – 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((5-methyl-1H-pyrazol-3- yl)amino)pyridin-4-yl)-1H-indazol-3-amine SU1745 Route to SU1745 5-Methyl-3-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole [00307] 3,4-Dihydro-2H-pyran (1.3 g, 1.5 mL, 15.8 mmol, 2 Eq) was added to a solution of 5- methyl-3-nitro-1H-pyrazole (1 g, 7.9 mmol, 1 Eq) and p-toluenesulfonic acid monohydrate (150 mg, 0.8 mmol, 0.1 Eq) in anhydrous THF (5 mL). The reaction mixture was stirred under nitrogen atmosphere at 65 ºC for 3 h. The organic solvent was evaporated under reduced pressure. The crude mixture was extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (50% EtOAc in petroleum ether) to give the titled product as white solid (1.2 g, 5.7 mmol, 72%). [00308] 1 H NMR (500 MHz, DMSO) δ 6.89 (s, 1H), 5.59 (dd, J = 9.5, 2.7 Hz, 1H), 3.93 – 3.86 (m, 1H), 3.69 (dtd, J = 8.9, 6.6, 4.6 Hz, 1H), 2.39 (s, 3H), 2.20 (dddd, J = 13.3, 11.8, 9.4, 4.1 Hz, 1H), 2.01 (dtd, J = 13.3, 4.2, 1.6 Hz, 1H), 1.93 (dt, J = 13.2, 3.5 Hz, 1H), 1.76 – 1.63 (m, 1H), 1.56 (dq, J = 10.2, 5.9, 4.8 Hz, 2H). 5-Methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine [00309] Pd/C 10% (0.1 g, 0.02 Eq) was added to a solution of 5-methyl-3-nitro-1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazole (1 g, 4.7 mmol, 1 Eq) in MeOH (10 mL). The reaction mixture was allowed to stir under H 2 gas at rt for 4 h. The reaction mixture was filtered through a pad of Celite and evaporated under reduced pressure to give the titled product as green oil (0.8 g, 4.4 mmol, 94 %). [00310] 1 H NMR (500 MHz, DMSO) δ 5.31 (s, 1H), 5.08 (dd, J = 10.0, 2.4 Hz, 1H), 4.50 (s, 2H), 3.86 (ddd, J = 11.0, 4.1, 2.1 Hz, 1H), 3.56 (td, J = 10.9, 3.8 Hz, 1H), 2.27 – 2.14 (m, 1H), 2.14 (s, 3H), 2.00 – 1.90 (m, 1H), 1.75 (dq, J = 13.3, 3.4 Hz, 1H), 1.62 (tdd, J = 12.8, 10.4, 4.5 Hz, 1H), 1.48 (p, J = 4.2 Hz, 2H). 4-Chloro-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol -3-yl)pyridin-2-amine [00311] A mixture of palladium(II) acetate (62 mg, 0.28 mmol, 0.05 Eq) and xantphos (319 mg, 0.55 mmol, 0.1 Eq) in anhydrous toluene (2 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (1.6 g, 8.3 mmol, 1.5 Eq), 5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3-amine (1 g, 5.5 mmol, 1 Eq) and Cs2CO3 (3.6 g, 11 mmol, 2 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (50% EtOAc in petroleum ether) to give the titled product as white solid (0.5 g, 1.7 mmol, 31%). [00312] 1 H NMR (500 MHz, DMSO) δ 9.52 (s, 1H), 8.09 (d, J = 5.4 Hz, 1H), 7.41 (d, J = 1.9 Hz, 1H), 6.79 (dd, J = 5.4, 1.9 Hz, 1H), 6.18 (s, 1H), 5.29 (dd, J = 9.7, 2.5 Hz, 1H), 3.92 – 3.86 (m, 1H), 3.67 – 3.58 (m, 1H), 2.27 (s, 3H), 2.27 – 2.19 (m, 1H), 2.02 (dt, J = 12.8, 4.2 Hz, 1H), 1.87 (dq, J = 13.3, 3.4 Hz, 1H), 1.69 (tq, J = 12.7, 4.4 Hz, 1H), 1.60 – 1.47 (m, 2H). 4-Chloro-N-(5-methyl-1H-pyrazol-3-yl)pyridin-2-amine [00313] Trifluoroacetic acid (7.5 g, 5 mL, 65.8 mmol, 40 Eq) was added to a solution of 4- chloro-N-(5-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-3 -yl)pyridin-2-amine (0.5 g, 1.7 mmol, 1 Eq) in DCM (5 mL) at 0 ºC. The reaction mixture was stirred at rt for 5 h. The reaction was quenched with saturated solution of NaHCO3 (5 mL). The produced ppt was filtered, washed with water (5 mL) then DCM (2 mL) and dried to give the titled product as white solid (300 mg, 1.4 mmol, 85%). [00314] 1 H NMR (500 MHz, DMSO) δ 11.84 (s, 1H), 9.37 (s, 1H), 8.07 (d, J = 5.5 Hz, 1H), 7.47 (s, 1H), 6.77 (dd, J = 5.4, 2.0 Hz, 1H), 6.00 (s, 1H), 2.20 (s, 3H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((5-methyl-1H-pyrazol-3-y l)amino)pyridin-4-yl)-1H- indazol-3-amine SU1745 [00315] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), 4-chloro-N-(5-methyl-1H-pyrazol-3-yl)pyridin- 2-amine (0.31 g, 1.47 mmol, 1 Eq), cesium carbonate (1 g, 2.94 mmol, 2 Eq) and 1,1'-bis(di- tert-butylphosphino) ferrocene palladium chloride (144 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was stirred at 120 ºC for 4 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (5% MeOH in EtOAc) followed by HPLC purification (50% MeCN in H2O) to give the titled product as white solid (260 mg, 0.67 mmol, 46%). [00316] 1 H NMR (500 MHz, DMSO) δ 11.80 (s, 1H), 9.07 (s, 1H), 8.14 (d, J = 5.3 Hz, 1H), 8.09 (d, J = 1.7 Hz, 1H), 7.61 (s, 1H), 7.49 (d, J = 1.7 Hz, 1H), 6.99 (d, J = 5.5 Hz, 1H), 6.07 (s, 1H), 5.60 (s, 2H), 2.21 (s, 3H), 1.38 (s, 9H). [00317] LCMS: For C22H23N7 requires 385.48 found 386.3 (M+H). Example 313 – 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3-methyl-1H-pyrazol-4- yl)amino)pyridin-4-yl)-1H-indazol-3-amine SU1750 Route to SU1750 3-Methyl-4-nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole [00318] 3,4-Dihydro-2H-pyran (2.0 g, 2.2 mL, 23.6 mmol, 2 Eq) was added to a solution of 3- methyl-4-nitro-1H-pyrazole (1.5 g, 11.8 mmol, 1 Eq) and p-toluenesulfonic acid monohydrate (225 mg, 1.18 mmol, 0.1 Eq) in anhydrous THF (10 mL). The reaction mixture was stirred under nitrogen atmosphere at 65 ºC for 3 h. The organic solvent was concentrated under reduced pressure. The crude mixture was extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (50% EtOAc in petroleum ether) to give the titled product as yellow oil (2.4 g, 11.36 mmol, 96%). [00319] 1 H NMR (500 MHz, DMSO) δ 8.92 (s, 1H), 5.42 (dd, J = 9.9, 2.3 Hz, 1H), 3.99 – 3.94 (m, 1H), 3.64 (ddd, J = 11.5, 8.6, 6.7 Hz, 1H), 2.67 (s, 1H), 2.44 (s, 3H), 2.14 – 2.04 (m, 1H), 1.97 – 1.86 (m, 2H), 1.66 (dtd, J = 15.3, 11.4, 11.0, 6.5 Hz, 1H), 1.55 (q, J = 3.7 Hz, 2H). 3-Methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-amine [00320] Pd/C 10% (0.24 g, 0.02 Eq) was added to a solution of 3-methyl-4-nitro-1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazole (2.4 g, 11.36 mmol, 1 Eq) in MeOH (10 mL). The reaction mixture was allowed to stir under H2 gas at rt for 4 h. The reaction mixture was filtered through a pad of Celite and evaporated under educed pressure to give the titled product as yellow solid (1.8 g, 9.9 mmol, 87 %). [00321] 1 H NMR (500 MHz, DMSO) δ 7.05 (s, 1H), 5.08 (dd, J = 10.1, 2.5 Hz, 1H), 3.90 – 3.81 (m, 1H), 3.66 (s, 2H), 3.63 – 3.50 (m, 1H), 2.12 (s, 1H), 2.01 (s, 3H), 2.00 – 1.95 (m, 1H), 1.95 – 1.88 (m, 1H), 1.79 (dt, J = 12.7, 3.2 Hz, 1H), 1.62 (dq, J = 11.4, 3.8 Hz, 1H), 1.49 (dd, J = 7.5, 3.8 Hz, 1H). 4-Chloro-N-(3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol -4-yl)pyridin-2-amine [00322] A mixture of palladium(II) acetate (97 mg, 0.43 mmol, 0.05 Eq) and xantphos (498 mg, 0.86 mmol, 0.1 Eq) in anhydrous toluene (3 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (1.3 g, 6.88 mmol, 0.8 Eq), 3-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-amine (1.56 g, 8.6 mmol, 1 Eq) and Cs2CO3 (2.8 g, 8.6 mmol, 1 Eq) in toluene (6 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 90 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (40 mL) and water (15 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (60% EtOAc in petroleum ether) to give the titled product as yellow oil (400 mg, 1.4 mmol, 20 %). 1 H NMR (500 MHz, DMSO) δ 8.39 (s, 1H), 8.06 (d, J = 4.9 Hz, 2H), 6.75 (d, J = 1.9 Hz, 1H), 6.70 (dd, J = 5.5, 1.8 Hz, 1H), 5.25 (dd, J = 10.2, 2.4 Hz, 1H), 3.98 – 3.85 (m, 1H), 3.60 (ddd, J = 11.5, 8.2, 5.9 Hz, 1H), 2.13 (s, 3H), 2.06 (tdd, J = 12.6, 10.1, 4.0 Hz, 1H), 1.94 (dtd, J = 9.5, 3.9, 2.0 Hz, 1H), 1.87 (dt, J = 12.8, 3.2 Hz, 1H), 1.65 (dtdd, J = 16.2, 12.4, 9.2, 3.8 Hz, 1H), 1.58 – 1.48 (m, 2H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3-methyl-1-(tetrahydro- 2H-pyran-2-yl)-1H-pyrazol-4- yl)amino)pyridin-4-yl)-1H-indazol-3-amine [00323] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.38 g, 1.1 mmol, 1.2 Eq), 4-chloro-N-(3-methyl-1-(tetrahydro-2H- pyran-2-yl)-1H-pyrazol-4-yl)pyridin-2-amine (0.27 g, 0.92 mmol, 1 Eq), cesium carbonate (0.6 g, 1.84 mmol, 2 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (150 mg, 0.23 mmol, 0.25 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as yellow solid (300 mg, 64 mmol, 70%). 1 H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 8.21 (s, 1H), 8.18 – 8.10 (m, 3H), 7.52 (d, J = 1.7 Hz, 1H), 7.11 – 7.07 (m, 1H), 6.96 (dd, J = 5.4, 1.7 Hz, 1H), 5.60 (s, 2H), 5.27 (dd, J = 10.2, 2.4 Hz, 1H), 3.92 (d, J = 12.1 Hz, 1H), 3.67 – 3.56 (m, 1H), 2.23 (s, 1H), 2.19 (s, 3H), 2.13 – 2.02 (m, 1H), 1.98 – 1.86 (m, 1H), 1.72 – 1.60 (m, 1H), 1.53 (td, J = 8.6, 7.2, 3.9 Hz, 2H), 1.37 (s, 9H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((3-methyl-1H-pyrazol-4-y l)amino)pyridin-4-yl)-1H- indazol-3-amine SU1750 [00324] Trifluoroacetic acid (2.9 g, 2 mL, 25.6 mmol, 40 Eq) was added to a solution of 7-(3,3- dimethylbut-1-yn-1-yl)-5-(2-((3-methyl-1-(tetrahydro-2H-pyra n-2-yl)-1H-pyrazol-4- yl)amino)pyridin-4-yl)-1H-indazol-3-amine (0.3 g, 0.64 mmol, 1 Eq) in DCM (3 mL) at 0 ºC. The reaction mixture was stirred at rt for 5 h. The reaction was quenched with saturated solution of NaHCO3 (5 mL). The reaction mixture was extracted between EtOAc (20 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using reversed-phase column chromatography (50% MeCN in H2O) to give the titled product as yellow solid (100 mg, 0.26 mmol, 40%). 1 H NMR (500 MHz, DMSO) δ 11.79 (s, 1H), 8.08 (d, J = 5.5 Hz, 2H), 8.01 (s, 1H), 7.48 (s, 1H), 6.90 (d, J = 5.4 Hz, 2H), 5.60 (s, 2H), 2.17 (s, 3H), 1.37 (s, 9H). LC-MS: For C22H23N7 requires 385.48 found 386.4 (M+H). Example 314 – N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2- yl)thiazol-2-amine SU1762 Route to SU1762 N-(4-Chloropyridin-2-yl)thiazol-2-amine [00325] A mixture of palladium(II) acetate (56 mg, 0.25 mmol, 0.05 Eq) and xantphos (289 mg, 0.5 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (1.4 g, 7.5 mmol, 1.5 Eq), thiazol-2-amine (0.5 g, 4.99 mmol, 1 Eq) and Cs 2 CO 3 (3 g, 10 mmol, 2 Eq) in toluene (2 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 18 h. The organic solvent was removed under reduced pressure. The crude residue was stirred in MeOH (10 mL) for 30 min., filtered and washed with MeOH (2 × 3 mL). The filtrate was concentrated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the tilted product as yellow solid (315 mg, 1.49 mmol, 30%). 1 H NMR (500 MHz, DMSO) δ 11.40 (s, 1H), 8.29 (d, J = 5.5 Hz, 1H), 7.42 (d, J = 3.6 Hz, 1H), 7.16 (d, J = 1.8 Hz, 1H), 7.07 (d, J = 3.6 Hz, 1H), 7.02 (dd, J = 5.5, 1.8 Hz, 1H). LCMS: For C 8 H 6 ClN 3 S requires 211.67 found 212.3 (M+H). N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)thiazol-2-amine SU1762 [00326] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (309 mg, 0.9 mmol, 1.2 Eq), N-(4-chloropyridin-2-yl)thiazol-2-amine (160 mg, 0.76 mmol, 1 Eq), cesium carbonate (0.5 g, 1.52 mmol, 2 Eq) and 1,1'-bis(di-tert- butylphosphino) ferrocene palladium chloride (124 mg, 0.19 mmol, 0.15 Eq) in dioxane (3 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) followed by HPLC purification (50% MeCN in water) to give the titled product as white solid (23 mg, 0.06 mmol, 8%). 1 H NMR (500 MHz, DMSO) δ 11.87 (s, 1H), 11.19 (s, 1H), 8.33 (d, J = 5.4 Hz, 1H), 8.15 (d, J = 1.7 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 3.6 Hz, 1H), 7.34 (d, J = 1.7 Hz, 1H), 7.23 (dd, J = 5.4, 1.6 Hz, 1H), 7.02 (d, J = 3.6 Hz, 1H), 5.64 (s, 2H), 1.38 (s, 9H). LCMS: For C 21 H 20 N 6 S requires 388.49 found 389.2 (M+H). Example 315 – N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-4- methyloxazol-2-amine SU1746 Route to SU1746 N-(4-Chloropyridin-2-yl)-4-methyloxazol-2-amine [00327] General procedure 2 was followed using 2-bromo-4-chloropyridine (192.4 mg, 1 mmol), 4-methyloxazol-2-amine (98.1 mg, 1 mmol), Pd(OAc) 2 (11.3 mg, 0.05 mmol), Xantphos (57.9 mg, 0.1 mmol), and Cs2CO3 (651.6 mg, 2 mmol) in toluene at 110 °C for 18 hours. Flash column chromatography [petrol:ethyl acetate 0→30%] afforded the title compound (63.6 mg, 30%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 10.95 (br s, 1H), 8.22 (d, J = 5.4 Hz, 1H), 8.17 (s, 1H), 7.42 (d, J = 1.3 Hz, 1H), 7.07 (dd, J = 5.4, 1.3 Hz, 1H), 2.07 (d, J = 0.9 Hz, 3H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 154.87, 153.44, 149.48, 144.05, 135.08, 128.74, 116.92, 109.47, 11.72. LCMS C 9 H 8 35 ClN 3 O requires [M+H] + , 209.04. Observed: [M+H] + , 210.2. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-4-methyloxazol- 2-amine SU1746 [00328] General procedure 1 was followed using 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3-amine (118.7 mg, 0.35 mmol), N-(4- chloropyridin-2-yl)-4-methyloxazol-2-amine (73.4 mg, 0.35 mmol), Pd(dtbpf)Cl2 (22.8 mg, 0.035 mmol), and Cs2CO3 (228.1 mg, 0.7 mmol) in 9:1 dioxane:water at 120 °C for 2.5 hours. Flash column chromatography [petrol:ethyl acetate:methanol 0→100%→20%] afforded the title compound (55.8 mg, 41%). 1 H NMR (500 MHz, DMSO-d6) δ 11.84 (br s, 1H), 10.59 (br s, 1H), 8.32 – 8.22 (m, 2H), 8.14 (s, 1H), 7.55 (s, 1H), 7.42 (s, 1H), 7.24 (d, J = 4.7 Hz, 1H), 5.62 (br s, 2H), 2.08 (s, 3H), 1.37 (s, 9H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 155.56, 153.14, 150.55, 149.50, 148.37, 141.35, 135.04, 128.47, 127.73, 127.58, 119.32, 114.94, 114.70, 107.01, 105.57, 103.36, 74.46, 30.67, 27.90, 11.77. LCMS C 22 H 22 N 6 O requires [M+H] + , 386.19. Observed: [M+H] + , 387.3. Example 316 – N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-4- (trifluoromethyl)oxazol-2-amine SU1753 Route to SU1753 N-(4-Chloropyridin-2-yl)-4-(trifluoromethyl)oxazol-2-amine [00329] A mixture of palladium(II) acetate (37 mg, 0.17 mmol, 0.05 Eq) and xantphos (191 mg, 0.33 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (940 mg, 4.9 mmol, 1.5 Eq), 4-(trifluoromethyl)oxazol-2-amine (0.5 g, 3.3 mmol, 1 Eq) and Cs 2 CO 3 (2 g, 6.6 mmol, 2 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 18 h. The reaction mixture was cooled and extracted with EtOAc (20 mL) and water (30 mL). The organic layer was washed with brine (2 × 20 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (40% EtOAc in petroleum ether) to give the tilted product as yellow solid (300 mg, 1.1 mmol, 34 %). 1 H NMR (500 MHz, DMSO) δ 11.55 (s, 1H), 8.51 (d, J = 1.9 Hz, 1H), 8.28 (d, J = 5.4 Hz, 1H), 7.99 (d, J = 1.8 Hz, 1H), 7.16 (dd, J = 5.4, 1.8 Hz, 1H). 13 C NMR (126 MHz, DMSO) δ 162.92, 157.08, 153.15, 149.98, 144.77,134.84, 130.01, 129.70, 122.35, 118.32, 110.59. N-(4-(3-Amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-4- (trifluoromethyl)oxazol-2-amine SU1753 [00330] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (309 mg, 0.9 mmol, 1.2 Eq), N-(4-chloropyridin-2-yl)-4- (trifluoromethyl)oxazol-2-amine (200 mg, 0.76 mmol, 1 Eq), cesium carbonate (0.5 g, 1.52 mmol, 2 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (124 mg, 0.19 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (70% EtOAc in petroleum ether) followed by HPLC purification (50% MeCN in water) to give the titled product as yellow solid (150 mg, 0.34 mmol, 45%). 1 H NMR (500 MHz, DMSO) δ 11.89 (s, 1H), 11.22 (s, 1H), 8.51 (t, J = 1.9 Hz, 1H), 8.33 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.6 Hz, 1H), 8.17 (s, 1H), 7.59 (d, J = 1.7 Hz, 1H), 7.35 (dd, J = 5.3, 1.7 Hz, 1H), 5.63 (s, 2H), 1.37 (s, 9H). Example 317 – N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)- 3,5-dimethylisoxazol-4-amine SU1764 Route to SU1764 N-(4-Chloropyridin-2-yl)-3,5-dimethylisoxazol-4-amine [00331] A mixture of palladium(II) acetate (20 mg, 0.09 mmol, 0.05 Eq) and xantphos (154.50 mg, 0.27 mmol, 0.15 Eq) in anhydrous toluene (1 mL) was stirred under argon atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (513.81 mg, 2.7 mmol, 1.5 Eq), 3,5-dimethylisoxazol-4-amine (200 mg, 1.78 mmol, 1 Eq) and Cs 2 CO 3 (1,160 g, 3.56 mmol, 2 Eq) in toluene (4 mL) under argon atmosphere. The reaction mixture was allowed to stir at 60 ºC for 18 h. [00332] The reaction was then diluted with EtOAc (20 mL) and the organic layer was washed with water (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (50% EtOAc in petroleum ether) to give the tilted product as a solid (259 mg, 1.16 mmol, 65%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.27 (s, 1H), 7.97 (d, J = 5.5 Hz, 1H), 6.74 (dd, J = 5.5, 1.8 Hz, 1H), 6.58 (d, J = 1.1 Hz, 1H), 2.24 (s, 3H), 2.04 (s, 3H) ppm. 13 C NMR (126 MHz, DMSO-d 6 ) δ 62.8, 158.5, 158.3, 149.4, 143.3, 115.9, 113.7, 107.1, 10.6, 9.6 ppm. N-(4-(3-amino-7-(3,3-dimethylbut-1-yn-1-yl)-1H-indazol-5-yl) pyridin-2-yl)-3,5- dimethylisoxazol-4-amine SU1764 [00333] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (183.20 mg, 0.54 mmol, 1.2 Eq), N-(4-chloropyridin-2-yl)-3,5- dimethylisoxazol-4-amine (100 mg, 0.45 mmol, 1 Eq), cesium carbonate (293.24 mg, 0.9 mmol, 2 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (45.62 mg, 0.07 mmol, 0.15 Eq) in dioxane (3 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction was then diluted with EtOAc (20 mL) and the organic layer was washed with water (2 × 10 mL) and brine (1 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. [00334] The crude residue was purified using column chromatography (40% to 90% EtOAc in petroleum ether) followed by HPLC purification to give the titled product as a solid (131.56 mg, 0.33 mmol, 73%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.79 (s, 1H), 8.07 (s, 1H), 8.04 – 7.99 (m, 2H), 7.49 (d, J = 1.2 Hz, 1H), 6.81 (s, 1H), 6.60 (d, J = 4.5 Hz, 1H), 5.60 (s, 2H), 2.28 (s, 3H), 2.08 (s, 3H), 1.36 (s, 9H) ppm. LCMS (ESI +ve): Calculated for C 23 H 24 N 6 O requires 400.49 found 401.3 (M+H). Example 318 – 5-(2-((1H-Imidazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylb ut-1-yn-1-yl)- 1H-indazol-3-amine SU1769 Route to SU1769 4-Nitro-1-(tetrahydro-2H-pyran-2-yl)-1H-imidazole [00335] 3,4-Dihydro-2H-pyran (1.85 g, 2.0 mL, 22.1 mmol, 2.5 Eq) was added to a solution of 4-nitro-1H-imidazole (1 g, 8.85 mmol, 1 Eq) and p-toluenesulfonic acid monohydrate (150 mg, 0.9 mmol, 0.1 Eq) in anhydrous THF (10 mL) and DMSO (1 mL). The reaction mixture was stirred under nitrogen atmosphere at 65 ºC for 3 h. The organic solvent was concentrated under reduced pressure. The crude mixture was extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) to give the titled product as yellow oil (1.7 g, 8.85 mmol, 100%). 1 H NMR (500 MHz, DMSO) δ 8.51 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 1.6 Hz, 1H), 5.50 – 5.44 (m, 1H), 3.97 (dtd, J = 11.7, 3.7, 2.0 Hz, 1H), 3.64 (ddd, J = 11.6, 7.5, 5.2 Hz, 1H), 1.98 (ddd, J = 10.8, 8.7, 4.1 Hz, 2H), 1.89 (dtd, J = 13.4, 3.9, 1.9 Hz, 1H), 1.70 – 1.58 (m, 1H), 1.54 (ddt, J = 9.1, 6.0, 3.9 Hz, 2H). 1-(Tetrahydro-2H-pyran-2-yl)-1H-imidazol-4-amine [00336] Pd/C 10% (0.2 g, 0.02 Eq) was added to a solution of 4-nitro-1-(tetrahydro-2H-pyran- 2-yl)-1H-imidazole (1.7 g, 8.85 mmol, 1 Eq) in MeOH (10 mL). The reaction mixture was allowed to stir under H 2 gas at rt for 6 h. The reaction mixture was filtered through a pad of Celite and evaporated under educed pressure to give the titled product as brown oil (1.3 g, 7.78 mmol, 88 %). 1 H NMR (500 MHz, DMSO) δ 7.32 (d, J = 1.6 Hz, 1H), 6.24 (d, J = 1.6 Hz, 1H), 5.11 (dd, J = 7.4, 5.1 Hz, 1H), 3.91 (dp, J = 11.4, 2.4 Hz, 1H), 3.56 (ddd, J = 14.1, 7.5, 5.1 Hz, 1H), 1.88 – 1.76 (m, 3H), 1.69 – 1.54 (m, 1H), 1.50 (tp, J = 8.3, 4.8, 4.1 Hz, 2H). 4-Chloro-N-(1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-4-yl)py ridin-2-amine [00337] A mixture of palladium(II) acetate (47 mg, 0.21 mmol, 0.05 Eq) and xantphos (243 mg, 0.42 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (0.8 g, 4.2 mmol, 1 Eq), 1-(tetrahydro-2H-pyran-2-yl)-1H-imidazol-4-amine (0.7 g, 4.2 mmol, 1 Eq) and Cs2CO3 (2 g, 6.3 mmol, 1.5 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 80 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (80% EtOAc in petroleum ether) to give the titled product as yellow solid (0.4 g, 1.4 mmol, 34%). 1 H NMR (500 MHz, DMSO) δ 9.46 (s, 1H), 8.12 (d, J = 5.5 Hz, 1H), 7.62 (d, J = 1.6 Hz, 1H), 7.38 (d, J = 1.6 Hz, 1H), 6.97 (d, J = 1.9 Hz, 1H), 6.72 (dd, J = 5.5, 1.9 Hz, 1H), 5.33 – 5.24 (m, 1H), 3.96 (ddd, J = 12.2, 4.4, 2.4 Hz, 1H), 3.68 – 3.56 (m, 1H), 1.92 (ddt, J = 11.5, 7.7, 3.8 Hz, 3H), 1.65 (tt, J = 11.7, 4.0 Hz, 1H), 1.55 (ddt, J = 12.0, 8.1, 3.6 Hz, 2H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((1-(tetrahydro-2H-pyran- 2-yl)-1H-imidazol-4- yl)amino)pyridin-4-yl)-1H-indazol-3-amine [00338] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.44 g, 1.3 mmol, 1.2 Eq), 4-chloro-N-(1-(tetrahydro-2H-pyran-2-yl)-1H- imidazol-4-yl)pyridin-2-amine (0.3 g, 1.1 mmol, 1 Eq), cesium carbonate (0.7 g, 2.2 mmol, 2 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (179 mg, 0.28 mmol,0.25 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was poured onto ice-cold water (15 mL) and filtered, washed with water (2 × 5 mL) and dried. The crude solid was purified using column chromatography (90% EtOAc in petroleum ether) followed by HPLC (60% MeCN in water) to give the titled product as white solid (100 mg, 0.2 mmol, 20%). 1 H NMR (500 MHz, DMSO) δ 11.80 (s, 1H), 9.16 (s, 1H), 8.18 (d, J = 5.4 Hz, 1H), 8.08 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.45 (d, J = 1.7 Hz, 1H), 7.17 (d, J = 1.7 Hz, 1H), 6.95 (dd, J = 5.5, 1.7 Hz, 1H), 5.60 (s, 2H), 5.29 (dd, J = 7.1, 5.1 Hz, 1H), 4.01 – 3.93 (m, 1H), 3.68 – 3.59 (m, 1H), 1.98 – 1.88 (m, 3H), 1.66 (td, J = 8.3, 3.8 Hz, 1H), 1.62 – 1.50 (m, 2H), 1.38 (s, 9H). LC-MS: For C 26 H 29 N 7 O requires 455.57 found 456.3 (M+H). 5-(2-((1H-Imidazol-4-yl)amino)pyridin-4-yl)-7-(3,3-dimethylb ut-1-yn-1-yl)-1H-indazol-3- amine SU1769 [00339] Hydrochloric acid (2N, 2.2 mL, 4.4 mmol, 10 Eq) was added to a solution of 7-(3,3- dimethylbut-1-yn-1-yl)-5-(2-((1-(tetrahydro-2H-pyran-2-yl)-1 H-imidazol-4-yl)amino)pyridin-4-yl)- 1H-indazol-3-amine (SU1768, 0.1 g, 0.22 mmol, 1 Eq) in EtOH (10 mL). The reaction mixture was allowed to stir under reflux for 2 h. The reaction mixture was cooled, quenched with saturated solution of sodium carbonate solution (10 mL) and extracted between EtOAc (30 mL) and water (10 mL). The organic layer was washed with brine (3 × 5 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude residue was purified through HPLC (60% MeCN in water) to give the titled product as yellow solid (57 mg, 0.15 mmol, 70%). 1 H NMR (500 MHz, DMSO) δ 11.79 (s, 1H), 11.68 (s, 1H), 9.04 (s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 8.07 (d, J = 1.6 Hz, 1H), 7.48 (d, J = 1.7 Hz, 1H), 7.43 (d, J = 1.5 Hz, 1H), 7.26 (d, J = 1.5 Hz, 1H), 7.18 (d, J = 1.7 Hz, 1H), 6.92 (dd, J = 5.5, 1.7 Hz, 1H), 5.59 (s, 2H), 1.38 (s, 9H). LCMS: For C21H21N7 requires 371.45 found 372.3 (M+H). Example 319 – 5-(2-((4H-1,2,4-Triazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dime thylbut-1-yn-1- yl)-1H-indazol-3-amine SU1751 Route to SU1751 3-Nitro-4-(tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazole [00340] 3,4-Dihydro-2H-pyran (2.2 g, 2.5 mL, 26.3 mmol, 2 Eq) was added to a solution of 3- nitro-4H-1,2,4-triazole (1.5 g, 13.15 mmol, 1 Eq) and p-toluenesulfonic acid monohydrate (250 mg, 1.32 mmol, 0.1 Eq) in anhydrous THF (10 mL). The reaction mixture was stirred under nitrogen atmosphere at 65 ºC for 3 h. The organic solvent was concentrated under reduced pressure. The crude mixture was extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (60% EtOAc in petroleum ether) to give the titled product as yellow oil (2.6 g, 13.12 mmol, 100%). 1 H NMR (500 MHz, DMSO) δ 9.08 (s, 1H), 5.75 (dd, J = 8.1, 3.9 Hz, 1H), 3.95 (dt, J = 11.0, 3.8 Hz, 1H), 3.71 (ddd, J = 11.4, 8.5, 4.7 Hz, 1H), 2.08 (ddd, J = 10.1, 8.6, 4.3 Hz, 2H), 1.94 (dt, J = 13.6, 4.6 Hz, 1H), 1.70 (ddq, J = 19.4, 9.9, 5.1 Hz, 1H), 1.64 – 1.51 (m, 2H). 4-(Tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazol-3-amine [00341] Pd/C 10% (0.27 g, 0.02 Eq) was added to a solution of 3-nitro-4-(tetrahydro-2H-pyran- 2-yl)-4H-1,2,4-triazole (2.5 g, 12.6 mmol, 1 Eq) in MeOH (10 mL). The reaction mixture was allowed to stir under H 2 gas at rt for 4 h. The reaction mixture was filtered through a pad of Celite and evaporated under educed pressure to give the titled product as yellow solid (2 g, 11.9 mmol, 94 %). 1 H NMR (500 MHz, DMSO) δ 8.13 (s, 1H), 5.31 (s, 2H), 5.24 (dd, J = 9.9, 2.6 Hz, 1H), 3.90 (dd, J = 11.9, 3.7 Hz, 1H), 3.57 (ddd, J = 11.3, 8.9, 4.7 Hz, 1H), 2.00 (dtd, J = 12.9, 9.8, 9.2, 4.9 Hz, 1H), 1.88 (ddt, J = 28.2, 12.9, 3.8 Hz, 2H), 1.60 (td, J = 10.4, 8.2, 5.3 Hz, 1H), 1.51 (dd, J = 8.3, 4.1 Hz, 2H). 4-Chloro-N-(4-(tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazol-3- yl)pyridin-2-amine [00342] A mixture of palladium(II) acetate (67 mg, 0.3 mmol, 0.05 Eq) and xantphos (344 mg, 0.6 mmol, 0.1 Eq) in anhydrous toluene (2 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (1.7 g, 8.9 mmol, 1.5 Eq), 4-(tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazol-3-amine (1 g, 6.0 mmol, 1 Eq) and Cs 2 CO 3 (3.9 g, 11.9 mmol, 2 Eq) in toluene (5 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 110 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (2 × 10 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (40% EtOAc in petroleum ether) to give the titled product as white solid (0.65 g, 2.3 mmol, 39%). 1 H NMR (500 MHz, DMSO) δ 10.10 (s, 1H), 8.57 (s, 1H), 8.18 (d, J = 5.4 Hz, 1H), 7.96 (d, J = 1.9 Hz, 1H), 6.95 (dd, J = 5.4, 1.9 Hz, 1H), 5.49 (dd, J = 9.8, 2.3 Hz, 1H), 3.99 – 3.91 (m, 1H), 3.66 (ddd, J = 13.7, 7.1, 5.0 Hz, 1H), 2.14 – 2.03 (m, 1H), 1.96 (dp, J = 11.3, 3.9 Hz, 2H), 1.68 (dtd, J = 12.7, 9.1, 8.7, 5.8 Hz, 1H), 1.55 (dq, J = 9.7, 5.4, 4.5 Hz, 2H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((4-(tetrahydro-2H-pyran- 2-yl)-4H-1,2,4-triazol-3- yl)amino)pyridin-4-yl)-1H-indazol-3-amine [00343] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.15 g, 0.43 mmol, 1.2 Eq), 4-chloro-N-(4-(tetrahydro-2H-pyran-2-yl)- 4H-1,2,4-triazol-3-yl)pyridin-2-amine (0.1 g, 0.36 mmol, 1 Eq), cesium carbonate (0.24 g, 0.72 mmol, 2 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (59 mg, 0.09 mmol, 0.25 Eq) in dioxane (4 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was used in the next step without further purification (0.3 g). 5-(2-((4H-1,2,4-Triazol-3-yl)amino)pyridin-4-yl)-7-(3,3-dime thylbut-1-yn-1-yl)-1H-indazol-3- amine SU1751 [00344] Trifluoroacetic acid (3 g, 2 mL, 26.3 mmol, 40 Eq) was added to a solution of 7-(3,3- dimethylbut-1-yn-1-yl)-5-(2-((4-(tetrahydro-2H-pyran-2-yl)-4 H-1,2,4-triazol-3-yl)amino)pyridin-4- yl)-1H-indazol-3-amine (0.3 g, 0.66 mmol, 1 Eq) in DCM (3 mL) at 0 ºC. The reaction mixture was stirred at rt for 5 h. The reaction was quenched with saturated solution of NaHCO 3 (5 mL). The reaction mixture was extracted between EtOAc (20 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na 2 SO 4 and evaporated under reduced pressure. The crude residue was purified using reversed-phase column chromatography (40% MeCN in H2O) followed by HPLC purification (40% MeCN in H2O) to give the titled product as yellow solid (5 mg, 0.02 mmol, 3%). 1 H NMR (500 MHz, DMSO) δ 13.14 (s, 1H), 11.85 (s, 1H), 10.59 (s, 1H), 8.27 (s, 1H), 8.13 (d, J = 1.6 Hz, 1H), 7.68 (s, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.26 (d, J = 39.9 Hz, 2H), 5.63 (s, 2H), 1.38 (s, 9H). LCMS: For C20H20N8 requires 372.44 found 372.9 (M+H). Example 320 – 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((2-methyl-2H-tetrazol-5- yl)amino)pyridin-4-yl)-1H-indazol-3-amine SU1766 Route to SU1766 4-Chloro-N-(2-methyl-2H-tetrazol-5-yl)pyridin-2-amine [00345] A mixture of palladium(II) acetate (113 mg, 0.5 mmol, 0.05 Eq) and xantphos (584 mg, 1.0 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (2.3 g, 12.12 mmol, 1.5 Eq), 2-methyl-2H-tetrazol-5-amine (1 g, 10.1 mmol, 1 Eq) and Cs 2 CO 3 (5 g, 15.2 mmol, 1.5 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 80 ºC for 18 h. The resulted precipitate was filtered, washed with water (3 × 10 mL) and petroleum ether (3 × 10 mL) and dried under vacuum to give the tilted product as brown solid and used in the next step without further purification. 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((2-methyl-2H-tetrazol-5- yl)amino)pyridin-4-yl)-1H- indazol-3-amine SU1766 [00346] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (770 mg, 2.3 mmol, 1.2 Eq), 4-chloro-N-(2-methyl-2H-tetrazol-5- yl)pyridin-2-amine (400 mg, 1.9 mmol, 1 Eq), cesium carbonate (1 g, 3.8 mmol, 2 Eq) and 1,1'- bis(di-tert-butylphosphino) ferrocene palladium chloride (300 mg, 0.5 mmol, 0.15 Eq) in dioxane (3 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled, filtered through celite and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (90% EtOAc in petroleum ether) followed trituration using MeOH (5 × 3 mL) to give the titled product as white solid (220 mg, 0.57 mmol, 30%). 1 H NMR (500 MHz, DMSO) δ 11.84 (s, 1H), 10.28 (s, 1H), 8.27 (d, J = 5.3 Hz, 1H), 8.14 (d, J = 1.6 Hz, 1H), 7.93 – 7.89 (m, 1H), 7.55 (d, J = 1.6 Hz, 1H), 7.23 (dd, J = 5.3, 1.6 Hz, 1H), 5.63 (s, 2H), 4.32 (s, 3H), 1.38 (s, 9H). 13 C NMR (126 MHz, DMSO) δ 163.10, 154.67, 151.05, 150.00, 148.97, 141.88, 128.13, 128.03, 119.76, 115.44, 114.73, 106.91, 106.06, 103.91, 74.90, 31.18, 28.41. LCMS: For C 20 H 21 N 9 requires 387.45 found 388.3 (M+H). Example 321 – 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(pyrimidin-2-ylamino)pyri din-4-yl)-1H- indazol-3-amine SU1767 Route to SU1767 N-(4-Chloropyridin-2-yl)pyrimidin-2-amine [00347] A mixture of palladium(II) acetate (118 mg, 0.5 mmol, 0.05 Eq) and xantphos (608 mg, 1.1 mmol, 0.1 Eq) in anhydrous toluene (1 mL) was stirred under nitrogen atmosphere for 15 min. The resulting mixture was added to a mixture of 2-bromo-4-chloropyridine (2.4 g, 12.6 mmol, 1.5 Eq), pyrimidin-2-amine (1 g, 10.5 mmol, 1 Eq) and Cs 2 CO 3 (5 g, 15.8 mmol, 1.5 Eq) in toluene (4 mL) under nitrogen atmosphere. The reaction mixture was allowed to stir at 80 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (20 mL) and water (10 mL). The organic layer was washed with brine (3 × 10 mL) dried over anhydrous sodium sulfate and evaporated under reduced pressure. The crude residue was purified by column chromatography (30% EtOAc in petroleum ether) to give the tilted product as yellow solid (0.9 g, 4.2 mmol, 40%). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-(pyrimidin-2-ylamino)pyri din-4-yl)-1H-indazol-3-amine SU1767 [00348] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (770 mg, 2.3 mmol, 1.2 Eq), N-(4-chloropyridin-2-yl)pyrimidin-2-amine (400 mg, 1.9 mmol, 1 Eq), cesium carbonate (1 g, 3.8 mmol, 2 Eq) and 1,1'-bis(di-tert- butylphosphino) ferrocene palladium chloride (300 mg, 0.5 mmol, 0.15 Eq) in dioxane (3 mL) and water (1 mL) was heated in the microwave at 120 ºC for 3 h. The reaction mixture was cooled, poured onto ice-cold water (10 mL), filtered, washed with water (2 × 5 mL) and dried. The crude ppt was purified by column chromatography (90% EtOAc in petroleum ether) followed by HPLC purification (60% MeCN in water) to give the titled product as white solid (290 mg, 0.76 mmol, 40%). [00349] 1 H NMR (500 MHz, DMSO) δ 11.84 (s, 1H), 9.92 (s, 1H), 8.62 (d, J = 4.8 Hz, 2H), 8.55 (d, J = 1.7 Hz, 1H), 8.34 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 1.7 Hz, 1H), 7.58 (d, J = 1.6 Hz, 1H), 7.31 (dd, J = 5.2, 1.7 Hz, 1H), 6.99 (t, J = 4.8 Hz, 1H), 5.65 (s, 2H), 1.38 (s, 9H). [00350] LCMS: For C 22 H 21 N 7 requires 383.46 found 384.3 (M+H). Example 322 – 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((tetrahydrofuran-3-yl)am ino)pyridin-4- yl)-1H-indazol-3-amine SU1763 Route to SU1763 4-Iodo-N-(tetrahydrofuran-3-yl)pyridin-2-amine [00351] In a sealed 10 mL microwave vial, 2-fluoro-4-iodopyridine (200 mg, 0.89 mmol, 1 Eq) was dissolved in 3 mL of DMSO. Then tetrahydrofuran-3-amine (93.22 mg, 0.092 mL, 1.07 mmol, 1.2 Eq) and triethylamine (134.58 mg, 0.185 mL, 1.33 mmol, 1.5 Eq) were added and the resulting reaction mixture was heated at 100 ºC under microwave irradiation for 4 hours. [00352] The reaction was then diluted with EtOAc (10 mL) and the organic layer was washed with brine (2 X 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified by column chromatography (20% EtOAc in petroleum ether) to give the titled product (194 mg, 0.67 mmol, 75%). 1 H NMR (500 MHz, DMSO-d6) δ 7.68 (d, J = 5.3 Hz, 1H), 6.92 (s, 1H), 6.89 (d, J = 6.1 Hz, 1H), 6.83 (d, J = 5.1 Hz, 1H), 4.31 (dd, J = 9.8, 6.6 Hz, 1H), 3.81 (dt, J = 14.7, 6.8 Hz, 2H), 3.70 (dt, J = 13.9, 7.0 Hz, 1H), 3.48 (dd, J = 8.8, 3.7 Hz, 1H), 2.14 (td, J = 15.0, 7.5 Hz, 1H), 1.74 (dt, J = 12.3, 5.5 Hz, 1H) ppm. 13 C NMR (126 MHz, DMSO-d6) δ 158.8, 148.3, 120.0, 116.9, 105.7, 72.8, 66.3, 51.1, 32.4 ppm. LCMS (ESI +ve): Calculated for C9H11IN2O requires 290.10 found 291.1 (M+H). 7-(3,3-Dimethylbut-1-yn-1-yl)-5-(2-((tetrahydrofuran-3-yl)am ino)pyridin-4-yl)-1H-indazol-3- amine SU1763 [00353] To a solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (142.48 mg, 0.42 mmol, 1.1 Eq) in a degassed 9:1 solution of dioxane/water (8 mL), were added 4-iodo-N-(tetrahydrofuran-3-yl)pyridin-2-amine (110 mg, 0.38 mmol, 1 Eq), cesium carbonate (371.43 mg, 1.14 mmol, 3 Eq) and bis(triphenylphosphine)palladium chloride (26.67 mg, 0.038 mmol, 0.1 Eq) under argon atmosphere. The resulting reaction mixture was allowed to stir at 70 ºC overnight. [00354] The cooled reaction was diluted with EtOAc (20 mL) and washed with water (10 mL) and brine (2 x 10 mL). The organic layer was concentrated under reduced pressure and the crude was purified by flash column chromatography (0% to 100% EtOAc in petroleum ether) followed by HPLC purification to afford the titled compound as a solid (103 mg, 0.27 mmol, 72%). 1 H NMR (500 MHz, DMSO-d6) δ 11.77 (s, 1H), 8.06 (s, 1H), 8.01 (d, J = 5.3 Hz, 1H), 7.47 (s, 1H), 6.81 (d, J = 5.3 Hz, 1H), 6.76 (s, 1H), 6.70 (d, J = 6.2 Hz, 1H), 5.57 (s, 2H), 4.42 (d, J = 5.1 Hz, 1H), 3.91 – 3.82 (m, 2H), 3.73 (dd, J = 13.9, 7.9 Hz, 1H), 3.53 (dd, J = 8.7, 3.8 Hz, 1H), 2.18 (dd, J = 12.6, 7.3 Hz, 1H), 1.81 (dt, J = 11.5, 5.8 Hz, 1H), 1.36 (s, 9H) ppm. LCMS (ESI +ve): Calculated for C 22 H 25 N 5 O requires 375.48 found 376.3 (M+H). Example 323 – Methyl (4-(3-Amino-7-(4-hydroxyphenyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1744 [00355] A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (1.1 g, 2.96 mmol, 1 Eq), (4-hydroxyphenyl)boronic acid (0.61 g, 4.44 mmol, 1.5 Eq), cesium carbonate (2.9 g, 8.88 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (322 mg, 0.44 mmol, 0.15 Eq) in dioxane (8 mL) and water (2 mL) was stirred under nitrogen atmosphere at 80 ºC for 1 h. The reaction mixture was poured onto cold water (10 mL). The produced ppt was filtered, washed with water (5 mL), dried, purified using column chromatography (20% MeOH in EtOAc) and followed by trituration with MeOH (× 1) and Et 2 O (× 2) to give the titled product as white solid (0.4 g, 1.1 mmol, 37%). 1 H NMR (500 MHz, DMSO) δ 11.63 (s, 1H), 10.20 (s, 1H), 9.63 (s, 1H), 8.31 (d, J = 5.2 Hz, 1H), 8.21 (s, 1H), 8.11 (s, 1H), 7.58 (d, J = 8.2 Hz, 2H), 7.54 (d, J = 1.5 Hz, 1H), 7.43 (dd, J = 5.3, 1.6 Hz, 1H), 6.93 (d, J = 8.2 Hz, 2H), 5.58 (s, 2H), 3.72 (s, 3H). LCMS: For C 20 H 17 N 5 O 3 requires 375.39 found 376.3 (M+H). Example 324 – 4-(3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-7 -yl)phenol SU1749 Route to SU1749 7-Bromo-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-3-am ine [00356] General procedure 1 was followed using 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (67.6 mg, 0.2 mmol), 4-iodo-N-(oxetan-3-yl)pyridin-2- amine (55.2 mg, 0.2 mmol), Pd 2 Cl 2 (PPh 3 ) 2 (14 mg, 0.02 mmol), and Cs 2 CO 3 (195.2 mg, 0.6 mmol) in 9:1 dioxane:water at 90 °C for 18 hours. Trituration from DCM afforded the title compound (29.0 mg, 40%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.94 (br s, 1H), 8.12 (d, J = 1.0 Hz, 1H), 8.01 (d, J = 5.4 Hz, 1H), 7.74 (d, J = 1.0 Hz, 1H), 7.26 (br d, J = 6.2 Hz, 1H), 6.86 (d, J = 5.4 Hz, 1H), 6.74 (s, 1H), 5.66 (br s, 2H), 5.00 – 4.90 (m, 1H), 4.83 (app. t, J = 6.4 Hz, 2H), 4.47 (app. t, J = 6.4 Hz, 2H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 158.36, 150.70, 148.24, 147.62, 140.07, 129.22, 127.03, 118.28, 116.04, 110.55, 104.91, 102.67, 77.95, 46.02. LCMS C 15 H 14 79 BrN 5 O requires [M+H] + , 359.04. Observed: [M+H] + , 360.1. 4-(3-Amino-5-(2-(oxetan-3-ylamino)pyridin-4-yl)-1H-indazol-7 -yl)phenol SU1749 [00357] General procedure 1 was followed using 7-bromo-5-(2-(oxetan-3-ylamino)pyridin-4-yl)- 1H-indazol-3-amine (102 mg, 0.283 mmol), (4-hydroxyphenyl)boronic acid (78.1 mg, 0.566 mmol), Pd2(dppf)Cl2 (20.7 mg, 0.028 mmol), and Cs2CO3 (276.8 mg, 0.849 mmol) in 9:1 dioxane:water at 90 °C for 1 hour. Flash column chromatography [petrol:ethyl acetate:methanol 0→100%→50%] followed by reverse phase flash column chromatography [water:acetonitrile 0→50%] afforded the title compound (32.0 mg, 30%). [00358] 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.65 (br s, 1H), 8.06 (s, 1H), 7.65 (d, J = 6.2 Hz, 1H), 7.55 (d, J = 8.5 Hz, 2H), 7.46 (s, 1H), 6.90 (d, J = 8.5 Hz, 2H), 6.76 (br s, 1H), 6.46 (d, J = 6.2 Hz, 1H), 5.55 (br s, 2H), 4.26 – 4.12 (m, 1H), 4.06 – 3.95 (m, 1H), 3.56 – 3.50 (m, 1H), 3.44 – 3.35 (m, 1H). [00359] 13 C NMR (101 MHz, DMSO-d 6 ) δ 157.62, 156.96, 150.35, 150.25, 139.42, 135.64, 129.12, 127.66, 127.22, 124.12, 123.07, 117.36, 115.84, 115.52, 106.57, 104.04, 64.01, 51.63. [00360] LCMS C 21 H 19 N 5 O 2 requires [M+H] + , 373.15. Observed: [M+H] + , 374.3. Example 325 – Methyl (4-(3-amino-7-(4-aminophenyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1755 Route to SU1755 Methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate [00361] General procedure 1 was followed using 7-bromo-5-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)-1H-indazol-3-amine (507 mg, 1.5 mmol), methyl (4-iodopyridin-2- yl)carbamate (417 mg, 1.5 mmol), Pd 2 Cl 2 (PPh 3 ) 2 (105 mg, 0.15 mmol), and Cs2CO3 (1.466 g, 4.5 mmol) in 9:1 dioxane:water at 70 °C for 18 hours. Flash column chromatography [DCM;MeOH 0→100%] on basic silica afforded the title compound (202 mg, 37%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.00 (br s, 1H), 10.23 (br s, 1H), 8.30 (d, J = 5.3 Hz, 1H), 8.20 (d, J = 1.3 Hz, 1H), 8.14 (d, J = 1.1 Hz, 1H), 7.79 (d, J = 1.3 Hz, 1H), 7.36 (dd, J = 5.3, 1.1 Hz, 1H), 5.71 (br s, 2H), 3.71 (s, 3H). 13 C NMR (101 MHz, DMSO-d 6 ) δ Compound previously characterised. LCMS C 14 H 12 79 BrN 5 O 2 requires [M+H] + , 361.02. Observed: [M+H] + , 362.0. Methyl (4-(3-amino-7-(4-aminophenyl)-1H-indazol-5-yl)pyridin-2-yl)c arbamate SU1755 [00362] General procedure 1 was followed using methyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (74.7 mg, 0.206 mmol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)aniline (67.7 mg, 0.309 mmol), Pd 2 (dppf)Cl 2 (14.6 mg, 0.02 mmol), and Cs2CO3 (195.5 mg, 0.6 mmol) in 9:1 dioxane:water at 90 °C for 16 hours. Flash column chromatography [petrol:ethyl acetate:methanol 0→100%→100%] using basic silica followed by reverse phase flash column chromatography [water:acetonitrile 0→50%] afforded the title compound (48.4 mg, 62%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.55 (br s, 1H), 10.17 (br s, 1H), 8.29 (d, J = 5.2 Hz, 1H), 8.19 (s, 1H), 8.03 (s, 1H), 7.49 (s, 1H), 7.44 – 7.39 (m, 3H), 6.71 (d, J = 8.4 Hz, 2H), 5.52 (br s, 2H), 5.30 (br s, 2H), 3.70 (s, 3H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 154.19, 152.88, 150.29, 148.59, 148.23, 139.32, 128.58, 128.05, 124.94, 124.52, 122.83, 116.72, 116.38, 115.68, 114.20, 109.08, 51.82. One C not observed. LCMS C20H18N6O2 requires [M+H] + , 374.15. Observed: [M+H] + , 375.1. Example 326 – Methyl (4-(7-(4-acetamidophenyl)-3-amino-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1756 [00363] General procedure 1 was followed using methyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (72.4 mg, 0.2 mmol), N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)acetamide (78.3 mg, 0.3 mmol), Pd 2 (dppf)Cl 2 (14.6 mg, 0.02 mmol), and Cs2CO3 (195.5 mg, 0.6 mmol) in 9:1 dioxane:water at 90 °C for 16 hours. Reverse phase flash column chromatography [water:methanol 5→30%] followed by trituration from methanol afforded the title compound (13.0 mg, 16%). 1 H NMR (500 MHz, DMSO-d 6 ) δ 11.69 (br s, 1H), 10.19 (br s, 1H), 10.08 (br s, 1H), 8.30 (d, J = 4.8 Hz, 1H), 8.20 (s, 1H), 8.14 (s, 1H), 7.74 (d, J = 8.0 Hz, 2H), 7.68 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.43 (d, J = 4.8 Hz, 1H), 5.60 (br s, 2H), 3.70 (s, 3H), 2.09 (s, 3H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 168.42, 154.21, 152.92, 150.44, 150.04, 148.29, 139.19, 138.98, 131.88, 128.31, 128.07, 123.95, 123.76, 119.34, 118.03, 116.44, 109.13, 51.84, 24.07. One C not observed. LCMS C22H20N6O3 requires [M+H] + , 416.16. Observed: [M+H] + , 417.2. Example 327 – Methyl (4-(3-amino-7-(4-carbamoylphenyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1752 [00364] A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.15 g, 0.4 mmol, 1 Eq), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.15 g, 0.6 mmol, 1.5 Eq), cesium carbonate (0.4 g, 1.2 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (44 mg, 0.06 mmol, 0.15 Eq) in dioxane (2 mL) and water (0.5 mL) was stirred under nitrogen atmosphere at 80 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (2 mL). The organic layer was dried over anhydrous sodium sulphate and evaporated. The crude residue was purified using reversed-phase column chromatography (50% MeCN in H 2 O) followed by HPLC purification (50% MeCN in H 2 O) to give the titled product as yellow solid (2 mg, 0.02 mmol, 5%). 1 H NMR (500 MHz, DMSO) δ 10.31 (s, 1H), 8.36 (d, J = 5.2 Hz, 1H), 8.17 (d, J = 1.6 Hz, 1H), 8.13 (s, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.46 (s, 1H), 7.42 (dd, J = 5.3, 1.7 Hz, 1H), 3.71 (s, 3H). Example 328 – Methyl (4-(3-amino-7-(4-(morpholinomethyl)phenyl)-1H-indazol-5- yl)pyridin-2-yl)carbamate SU1757 [00365] General procedure 1 was followed using methyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (72.4 mg, 0.2 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)benzyl)morpholine (90.9 mg, 0.3 mmol), Pd2(dppf)Cl2 (14.6 mg, 0.02 mmol), and Cs2CO3 (195.5 mg, 0.6 mmol) in 9:1 dioxane:water at 90 °C for 16 hours. Flash column chromatography [petrol:ethyl acetate:methanol 0→100%→100%] using basic silica afforded the title compound (47.0 mg, 34%). 1 H NMR (400 MHz, DMSO-d6) δ 11.71 (br s, 1H), 10.20 (br s, 1H), 8.30 (d, J = 5.2 Hz, 1H), 8.21 (d, J = 1.3 Hz, 1H), 8.17 (d, J = 1.3 Hz, 1H), 7.71 (d, J = 8.2 Hz, 2H), 7.61 (d, J = 1.7 Hz, 1H), 7.46 (d, J = 8.2 Hz, 2H), 7.44 (dd, J = 5.2, 1.7 Hz, 1H), 5.61 (br s, 2H), 3.70 (s, 3H), 3.65 – 3.58 (m, 4H), 2.46 – 2.38 (m, 4H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 154.19, 152.92, 150.40, 149.94, 148.28, 139.27, 137.43, 136.07, 129.52, 127.99, 127.82, 124.24, 123.86, 118.33, 116.37, 115.89, 109.07, 66.23, 62.17, 53.22, 51.82. LCMS C 25 H 26 N 6 O 3 requires [M+H] + , 458.21. Observed: [M+H] + , 459.2. Example 329 – 5-(2-Aminopyridin-4-yl)-7-(4-(2-morpholinoethyl)phenyl)-1H-i ndazol-3- amine SU1772 Route to SU1772 tert-Butyl (4-(3-amino-7-(4-(2-morpholinoethyl)phenyl)-1H-indazol-5-yl) pyridin-2- yl)carbamate [00366] General procedure 1 was followed using tert-butyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (121.3 mg, 0.3 mmol), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenethyl)morpholine (142.8 mg, 0.45 mmol), Pd 2 (dppf)Cl 2 (21.9 mg, 0.03 mmol), and Cs2CO3 (293.2 mg, 0.9 mmol) in 9:1 dioxane:water at 90 °C for 16 hours. Flash column chromatography [petrol:ethyl acetate:methanol 0→100%→80%] using basic silica followed afforded the title compound (90.4 mg, 59%). 1 H NMR (400 MHz, DMSO-d6) δ 11.69 (br s, 1H), 9.77 (br s, 1H), 8.28 (d, J = 5.3 Hz, 1H), 8.15 (app. s, 2H), 7.67 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 1.5 Hz, 1H), 7.42 – 7.38 (m, 2H), 7.38 (s, 1H), 5.61 (br s, 2H), 3.63 – 3.55 (m, 4H), 2.86 – 2.78 (m, 2H), 2.62 – 2.54 (m, 2H), 2.48 – 2.43 (s, 4H), 1.49 (s, 9H). 13 C NMR (101 MHz, DMSO-d6) δ 153.10, 152.82, 150.40, 149.93, 148.21, 140.00, 139.20, 135.00, 129.27, 128.19, 127.87, 124.23, 123.91, 118.17, 116.21, 115.90, 109.16, 79.58, 66.19, 59.95, 53.27, 32.08, 28.06. LCMS C29H34N6O3 requires [M+H] + , 514.63. Observed: [M+H] + , 515.3. 5-(2-Aminopyridin-4-yl)-7-(4-(2-morpholinoethyl)phenyl)-1H-i ndazol-3-amine SU1772 [00367] To a suspension of tert-butyl (4-(3-amino-7-(4-(2-morpholinoethyl)phenyl)-1H-indazol- 5-yl)pyridin-2-yl)carbamate (35 mg, 0.068 mmol) in DCM (3 mL) was added TFA (3 mL) and the mixture was stirred at room temperature for 1 hour. Excess saturated sodium carbonate solution was added, and the mixture was stirred at room temperature for 30 minutes. The mixture was diluted with DCM and water and the organic phase was separated. The aqueous layer was extracted with DCM three times and the combined organic layer was discarded. The precipitate in the aqueous layer was collected via vacuum filtration to afford the title compound (10.0 mg, 35%). 1 H NMR (500 MHz, DMSO-d6) δ 11.62 (br s, 1H), 8.06 (s, 1H), 7.95 (d, J = 5.1 Hz, 1H), 7.66 (d, J = 7.9 Hz, 2H), 7.54 (s, 1H), 7.38 (d, J = 7.9 Hz, 2H), 6.87 (d, J = 5.1 Hz, 1H), 6.79 (s, 1H), 5.88 (br s, 2H), 5.53 (br s, 2H), 3.63 – 3.56 (m, 4H), 2.85 – 2.78 (m, 2H), 2.61 – 2.55 (m, 2H), 2.46 (app. br s, 4H). 13 C NMR (101 MHz, DMSO-d6) δ 160.42, 150.28, 148.81, 148.25, 139.94, 139.09, 135.14, 129.26, 128.73, 127.81, 124.08, 123.66, 117.59, 115.85, 110.12, 104.69, 66.21, 59.98, 53.29, 32.09. LCMS C24H26N6O requires [M+H] + , 414.51. Observed: [M+H] + , 415.3. Example 330 – Methyl (4-(3-amino-7-(4-(2-morpholinoethyl)phenyl)-1H-indazol-5- yl)pyridin-2-yl)carbamate SU1773 [00368] General procedure 1 was followed using methyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (0.5 g, 1.38 mmol, 1eq), 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan- 2-yl)phenethyl)morpholine (0.48g, 1.52 mmol, 1.1eq) Pd-DPPF (0.051 g, 0.069 mmol, 5 mol%) and cesium carbonate (1.35 g 4.14 mmol, 3.0 eq) in a sealed tube flushed with argon in a freshly degassed mixture of dioxane:water (9:1, 10 mL) and the resultant mixture stirred at 80 °C for 18 hours. The reaction was then cooled and partitioned between ethyl acetate and water. The aqueous layer was extracted (3x20 mL) and the combined organic layers concentrated under reduced pressure and then purified by automated reverse phase flash column chromatography eluting with a gradient of 0 to 70% acetonitrile in water to afford the target product as a light brown solid (0.042 g, 6%) 1 H NMR (400 MHz, DMSO) δ 11.71 (s, 1H), 10.20 (s, 1H), 8.31 (d, J = 5.3 Hz, 1H), 8.22 (s, 1H), 8.17 (s, 1H), 7.67 (d, J = 7.8 Hz, 2H), 7.60 (s, 1H), 7.44 (d, J = 5.5 Hz, 1H), 7.40 (d, J = 7.7 Hz, 2H), 5.61 (s, 2H), 3.71 (s, 3H), 3.61 (t, J = 4.6 Hz, 4H), 2.82 (d, J = 7.8 Hz, 2H), 2.59 (t, J = 7.8 Hz, 2H), 2.47 (s, 4H). 13 C NMR (101 MHz, DMSO) δ 154.2, 152.9, 149.9, 148.3, 140.0, 135.0, 129.3, 128.0, 127.8, 124.2, 116.3, 109.1, 66.2, 59.9, 53.2, 51.8, 32.1. LCMS (ESI+, m/z) expected for Chemical Formula: C26H28N6O3 is 472.5 found 473.3 (M+H), 471.3 (M-H) Example 331 – Methyl (4-(3-amino-7-(4-(methylsulfonyl)phenyl)-1H-indazol-5-yl)pyr idin-2- yl)carbamate SU1758 [00369] A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.15 g, 0.4 mmol, 1 Eq), (4-(methylsulfonyl)phenyl)boronic acid (0.12 g, 0.6 mmol, 1.5 Eq), cesium carbonate (0.4 g, 1.2 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (74 mg, 0.1 mmol, 0.25 Eq) in dioxane (2 mL) and water (0.5 mL) was stirred under nitrogen atmosphere at 80 ºC for 2 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (2 mL). The organic layer was dried over anhydrous sodium sulphate and evaporated. The crude residue was purified using reversed-phase column chromatography (30% MeCN in H 2 O) followed by HPLC purification (50% MeCN in H 2 O) to give the titled product as yellow solid (10 mg, 0.02 mmol, 6%). 1 H NMR (500 MHz, DMSO) δ 11.88 (s, 1H), 10.22 (s, 1H), 8.33 (d, J = 5.3 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.23 (d, J = 1.7 Hz, 1H), 8.06 (q, J = 8.2 Hz, 4H), 7.73 (d, J = 1.7 Hz, 1H), 7.48 (dd, J = 5.2, 1.7 Hz, 1H), 5.71 (s, 2H), 3.71 (s, 3H), 3.31 (s, 3H).. LCMS: For C 21 H 19 N 5 O 4 S requires 437.47 found 438.1 (M+H). Example 332 – Methyl (4-(3-amino-7-(3-hydroxyphenyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1748 [00370] A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.5 g, 1.38 mmol, 1 Eq), (3-hydroxyphenyl)boronic acid (0.29 g, 2.07 mmol, 1.5 Eq), cesium carbonate (1.4 g, 4.14 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (152 mg, 0.21 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was stirred under nitrogen atmosphere at 80 ºC for 2 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (2 mL). The organic layer was dried over anhydrous sodium sulphate and evaporated. The crude residue was purified using reversed-phase column chromatography (40% MeCN in H2O) to give the titled product as white solid (50 mg, 0.13 mmol, 10%). 1 H NMR (500 MHz, DMSO) δ 11.66 (s, 1H), 10.21 (s, 1H), 9.73 (s, 1H), 8.31 (d, J = 5.3 Hz, 1H), 8.20 (dd, J = 9.2, 1.6 Hz, 2H), 7.56 (d, J = 1.7 Hz, 1H), 7.43 (dd, J = 5.3, 1.7 Hz, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.25 (d, J = 7.5 Hz, 1H), 7.20 – 7.12 (m, 1H), 6.91 – 6.85 (m, 1H), 5.61 (s, 2H), 3.71 (s, 3H). LC-MS: For C20H17N5O3 requires 375.39 found 376.3 (M+H). Example 333 – Methyl (4-(3-amino-7-(3-carbamoylphenyl)-1H-indazol-5-yl)pyridin-2- yl)carbamate SU1754 [00371] A solution of methyl (4-(3-amino-7-bromo-1H-indazol-5-yl)pyridin-2-yl)carbamate (0.15 g, 0.4 mmol, 1 Eq), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (0.15 g, 0.6 mmol, 1.5 Eq), cesium carbonate (0.4 g, 1.2 mmol, 3 Eq) and [1,1′- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (74 mg, 0.1 mmol, 0.25 Eq) in dioxane (2 mL) and water (0.5 mL) was stirred under nitrogen atmosphere at 80 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (2 mL). The organic layer was dried over anhydrous sodium sulphate and evaporated. The crude residue was purified using reversed-phase column chromatography (40% MeCN in H 2 O) followed by HPLC purification (50% MeCN in H 2 O) to give the titled product as yellow solid (30 mg, 0.07 mmol, 18%). 1 H NMR (500 MHz, DMSO) δ 11.82 (s, 1H), 10.20 (s, 1H), 8.32 (d, J = 5.2 Hz, 1H), 8.21 (t, J = 1.7 Hz, 2H), 8.19 – 8.12 (m, 2H), 7.90 (dd, J = 7.6, 1.7 Hz, 2H), 7.68 (d, J = 1.7 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.48 – 7.43 (m, 2H), 5.66 (s, 2H), 3.71 (s, 3H). LCMS: For C 21 H 18 N 6 O 3 requires 402.41 found 403.3 (M+H). Example 334 – Methyl (4-(3-amino-7-(3-(morpholinomethyl)phenyl)-1H-indazol-5- yl)pyridin-2-yl)carbamate SU1765 [00372] General procedure 1 was followed using methyl (4-(3-amino-7-bromo-1H-indazol-5- yl)pyridin-2-yl)carbamate (36.2 mg, 0.1 mmol), (3-(morpholinomethyl)phenyl)boronic acid (44.2 mg, 0.2 mmol), Pd 2 (dppf)Cl 2 (7.3 mg, 0.01 mmol), and Cs2CO3 (97.7 mg, 0.3 mmol) in 9:1 dioxane:water at 100 °C for 16 hours. Flash column chromatography [petrol:THF 0→100%] using basic silica followed by trituration from methanol afforded the title compound (7 mg, 15%). 1 H NMR (400 MHz, DMSO-d 6 ) δ 11.72 (br s, 1H), 10.21 (br s, 1H), 8.31 (d, J = 5.3 Hz, 1H), 8.22 (d, J = 1.2 Hz, 1H), 8.19 (d, J = 1.5 Hz, 1H), 7.67 (s, 1H), 7.64 (app. d, J = 7.7 Hz, 1H), 7.61 (d, J = 1.5 Hz, 1H), 7.49 (app. t, J = 7.7 Hz, 1H), 7.44 (dd, J = 5.3, 1.2 Hz, 1H), 7.38 (app. d, J = 7.7 Hz, 1H), 5.63 (br s, 2H), 3.70 (s, 3H), 3.63 – 3.53 (m, 7H), 2.46 – 2.33 (m, 5H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 154.19, 152.92, 150.47, 149.93, 148.30, 139.20, 138.69, 137.22, 128.88, 128.50, 128.27, 128.03, 124.35, 123.98, 118.41, 116.37, 115.93, 109.08, 66.21, 62.36, 53.25, 51.80. LCMS C25H26N6O3 requires [M+H] + , 458.21. Observed: [M+H] + , 459.3. Example 335 – N-(4-(3-Amino-1H-indazol-5-yl)pyridin-2-yl)-2-cyclohexylacet amide SU1340 [00373] To a suspension of N-(4-chloropyridin-2-yl)-2-cyclohexylacetamide (0.307 g, 1.2 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-3 -amine (0.362 g, 1.4 mmol) and [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladi um(II) catalyst (0.063 g, 0.097 mmol) in EtOH (3.0 mL, degassed under nitrogen) was added K 3 PO 4 (1M, 1.2 mL) and the reaction mixture was heated to 80 ^C for 24 h. The reaction mixture was cooled to room temperature and diluted with EtOAc, washed with water, aqueous saturated NaHCO 3 and brine. The organics were concentrated under reduced pressure and the resulting residue and purified by column chromatography (100% Hexane – 1/1 Hexane/EtOAc – 100% EtOAc) to afford the title compound as an off-white solid (0.061 g, 0.17 mmol, 42%). 1 H NMR (DMSO-d6): ^ 0.99 (m, 2H), 1.22 (m, 3H), 1.62 (m, 2H), 1.69 (m, 4H), 1.79 (m, 1H), 2.30 (d, J = 5.6 Hz, 2H), 7.35 (d, J = 7.2 Hz, 1H), 7.37 (dd, J = 1.2, 4.0 Hz, 1H), 7.59 (dd, J = 1.2, 6.8 Hz, 1H), 8.16 (s, 1H), 8.31 (d, J = 4.4 Hz, 1H), 8.46 (s, 1H), 10.41 (br s, 1H), 11.56 (br s, 1H). HRMS: For C 20 H 24 ON 5 requires 350.1975 found 350.1795. (M+H) + [00374] A solution of 7-(3,3-dimethylbut-1-yn-1-yl)-5-(4,4,5,5-tetramethyl-1,3,2-d ioxaborolan-2- yl)-1H-indazol-3-amine (0.5 g, 1.47 mmol, 1 Eq), 6-amino-4-chloronicotinonitrile (0.23 g, 1.47 mmol, 1 Eq), cesium carbonate (1.4 g, 4.41 mmol, 3 Eq) and 1,1'-bis(di-tert-butylphosphino) ferrocene palladium chloride (144 mg, 0.22 mmol, 0.15 Eq) in dioxane (4 mL) and water (1 mL) was stirred under nitrogen atmosphere at 70 ºC for 18 h. The reaction mixture was cooled and extracted between EtOAc (10 mL) and water (5 mL). The organic layer was washed with brine (2 × 5 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was purified using column chromatography (80% EtOAc in petroleum ether) to give the titled product as yellow solid (0.4 g, 1.2 mmol, 82%). 1 H NMR (500 MHz, DMSO) δ 1.37 (s, 9H), 5.64 (s, 2H), 6.54 (s, 1H), 7.05 (s, 2H), 7.35 (d, J = 1.7 Hz, 1H), 7.93 (d, J = 1.7 Hz, 1H), 8.40 (s, 1H), 11.89 (s, 1H). LCMS: For C19H18N6 requires 330.4 found 331.3 (M+H).
Biological Assays IKK Assays IKKα and IKKβ inhibitory activity was determined using three different assays: a dissociation enhanced ligand fluorescent immunoassay (DELFIA) based on the protocol of HTScan™ IKKβ Kinase Assay (Cell Signaling Technology, USA); an Adapta IKKα assay (performed by Life Technologies); a Z′-LYTE™ IKKβ assay (performed by Life Technologies). The DELFIA assay Recombinant IKKα or IKKβ, 37 nM, (Millipore, Dundee, UK) was incubated with IκB-α (Ser32) (New England Biolabs, Hitchin, UK) biotinylated peptide substrate (0.375 µM) and 40 μM ATP in assay buffer (40 mM Tris-HCl (pH 7.5), 20 mM MgCl 2 , EDTA 1 mM, DTT 2 mM and BSA 0.01 mg/ml) in a V-well 96-well plate in the presence and absence of test compound. The assay plate was incubated for 60 minutes at 30 °C after which the kinase reaction was quenched by the addition of 50mM EDTA, pH8. The resulting mixture was transferred to a streptavidin coated 96-well plate (Perkin Elmer, Beaconsfield, UK) and incubated for 1 hour at 30 °C to immobilise the substrate peptide. After three washes with wash buffer (0.01 M phosphate buffered saline (PBS), 0.05% Tween -20, pH 7.4) a primary antibody against the phosphorylated substrate (phospho-IκB-α) (Ser32/36) (5A5) Mouse mAb (New England Biolabs, Hitchin, UK) (1:1000 dilution with 1% bovine serum albumin (BSA) in wash buffer) was added and incubated at 37 °C for 2 h. After a further three washes, a secondary europiated antibody (Eu-N1 labelled anti-mouse IgG, (Perkin Elmer, Beaconsfield, UK) diluted 1:500 in 1% BSA/ wash buffer) was added and incubated at 30 °C for 30 minutes. After a further five washes, DELFIA enhancement solution - (Perkin Elmer, Beaconsfield UK) was added and allowed to incubate for 10 min at room temperature, protected from light, to facilitate the chemifluorescent detection.The relative fluorescence units (RFU) signal were measured on a Wallac Victor 1420 multilabel counter (Perkin Elmer, Beaconsfield, UK ), in time-resolved fluorescence mode. The counter was set at an excitation wavelength of 340 nm with a 400 μs delay before detecting emitted light at 615 nm. The apparent Ki of the phosphorylated substrate was calculated for each compound using the Cheng-Prusoff Equation. Adapta IKKα assay The reaction was performed in low-volume white 384–well plates (Corning model 4512). The test compounds were screened in 1% DMSO (final) in the well. For 10 point titrations, 3- fold serial dilutions were conducted from the starting concentration of 50mM. The 2X CHUK (IKK alpha) kinase was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ–35, 10 mM MgCl 2 and 1 mM EGTA. The final 10 μL kinase mixture consisted of 50–250 ng CHUK (IKK alpha) in 32.5 mM HEPES pH 7.5, 0.005% BRIJ–35, 5 mM MgCl 2 and 0.5 mM EGTA. No substrate was required, as the assay measures the ability of a compound to inhibit the kinase's intrinsic ATPase activity. 5 μL of 2X Kinase mixture was incubated with 2.5 μL of ATP solution diluted to a 4X working concentration in water, in the presence of 100nL of 100X test compound in 100% DMSO and 2.4 μL of 30 mM HEPES buffer. After 30–second plate shake and 1–minute centrifuge at 1000 x g, the resulting kinase reaction was allowed to incubate for 1 hour at room temperature before 5 μL of Detection Mix was added. The Detection Mix, previously prepared in TR–FRET Dilution Buffer, consisted of EDTA (30 mM), Eu-anti-ADP antibody (6 nM) and an Alexa Fluor™ 647 labelled ADP tracer. The Detection Mix contained the EC60 concentration of tracer for 5–150 μM ATP. After 30–second plate shake and 1–minute centrifuge at 1000 x g, the Detection Mix was allowed to equilibrate at room temperature for 1 hour. Then the plate was read using a fluorescence plate reader configured for Adapta™ TR–FRET and the data analysed. ADP formation was determined by calculating the emission ratio from the assay well. Therefore, the emission ratio was calculated by dividing the intensity of the tracer (acceptor) emission by the intensity of the Eu (donor) emission at 615 nm as shown in the equation below. Z′-LYTE™ IKKβ assay The reaction was performed in low volume NBS, black 384–well plates (Corning model 4514). The test compounds were screened in 1% DMSO (final) in the well. For 10 point titrations, 3– fold serial dilutions were conducted from the starting concentration of 50mM. The 2X IKBKB (IKKβ)/Ser/Thr 05 mixture was prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ– 35, 10 mM MgCl2, 1 mM EGTA. The final 10μL Kinase Reaction consisted of 0.62–4 ng IKBKB (IKKβ) and 2 μM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ–35, 10 mM MgCl2, 1mM EGTA. 5 μL of 2X Kinase reaction was incubated with 2.5 μL of ATP solution diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ–35, 10 mM MgCl 2 , 1 mM EGTA) in the presence of 100nL of 100X test compound in 100% DMSO and 2.4 μL of Kinase buffer. The resulting kinase reaction was allowed to incubate for 1 hour at room temperature before 5 μL of a 1:64 dilution of Development Reagent B was added and the resulting Development Reaction was incubated for another hour at room temperature. Then the plate was read on a fluorescence plate reader and the data analysed. A ratiometric method, which calculated the Emission Ratio of donor emission (i.e. coumarin) to acceptor emission (i.e. fluorescein) after excitation of the donor fluorophore at 400nm, was used to quantitate reaction progress, as shown in the equation below. Biological data Ex 99 10 10 10 10 10 10 10 10 10 109 SU1413 5-(2-aminopyridin-4-yl)-7-(3-methoxyphenyl)- 55 587 1H-indazol-3-amine 110 SU1424 (3-(3-amino-5-(2-aminopyridin-4-yl)-1H- 29 290 indazol-7-yl)phenyl)methanol 111 SU1423 3-(3-amino-5-(2-aminopyridin-4-yl)-1H- 12 100 indazol-7-yl)benzaldehyde 112 SU1422 ethyl 3-(3-amino-5-(2-aminopyridin-4-yl)-1H- 152 1467 indazol-7-yl)benzoate 113 SU1445 3-(3-amino-5-(2-aminopyridin-4-yl)-1H- 43 840 indazol-7-yl)benzamide The IKK ^ ^and IKK ^ figures quoted in non-italicised form are from the DELFIA assay described above. The IKK ^ ^and IKKb figures quoted in italicised form are from the Adapta assay described above. Target engagement studies in cells with exemplars from the series Cell culture [00375] PC3M cells were grown in RPMI 1640 media which was supplemented with 10% (v/v) foetal calf serum (FCS), L-glutamine (27mg/ml) and penicillin/streptomycin (250 units/ml; 100 μg/ml). All cells were incubated in a humidified atmosphere at 37 o C and 5% (v/v) CO2. Cells were cultured as a monolayer in 10 ml media in 75 cm 3 vented flasks and grown until subculture was required. Sub-culturing of cells [00376] Cells were grown as a monolayer until approximately 70-85% confluent, the media was then aspirated, and the cells washed twice with 1.5 ml sterile 5% (w/v) trypsin solution. The trypsin was aspirated, and the flasks were given a gentle tap to ensure cells were fully detached. The flask was then washed with 10 ml media to re-suspend the recovered cells for passage into flasks and plates with fresh media as appropriate. Treatment of prostate cancer PC3M cell lines with SU compounds [00377] Determination of effects of inhibitors on the non-canonical NF-κB pathway: PC3M cells were grown in 12-well plates until approximately 85% confluent and serum starved for 24 h prior to stimulation. After serum starvation, cells were pre-treated with vehicle (V; < 0.05% (v/v) DMSO) or increasing concentrations (0.01 to 10 mM) of Example compound (SU inhibitor SU1XXX) for 1 hour prior to exposure to lymphotoxin (LT 1a2b ) (20 ng/ml) for 4 hours prior to preparation of whole cell extracts. Determination of effects of inhibitors on the canonical NF-κB pathway: PC3M cells were grown in 12-well plates until approximately 85% confluent and serum starved for 24 h prior to stimulation. After serum starvation, cells were pre-treated with vehicle (V; < 0.05% (v/v) DMSO) or increasing concentrations (0.01 to 10 mM) of Example compound (SU inhibitor - SUXXXX) for 1 hour prior to exposure to TNFα (10ng/ml) for 0.5 h prior to preparation of whole cell extracts. Sample preparation (whole cell extracts (WCEs) and Western blotting Sample preparation [00378] Whole cell extracts were prepared using a 1x sample buffer as detailed by Laemmli (1970: Nature, 227, 680-5) (63 mM Tris/HCl [pH 6.8], 2 mM Na4P2O7, 5 mM EDTA, 10% (v/v) glycerol, 2% (w/v) SDS,0.007% (w/v) bromophenol blue and 50mM DTT; termed DTT-SB). The bathing medium was firstly aspirated, and the cells were washed once with 1 ml of cold PBS. 250 μl of DTT-SB was added to each well to lyse the cells and cellular material was recovered using a cell scraper. Samples were passed through a 21 g needle 3-5 times to shear genomic DNA. Samples were then placed in eppendorfs boiled for 5 min (to denature the protein polypeptides). Samples were either used immediately or frozen at -20 ºC for future use. SDS-Polyacrylamide gel electrophoresis [00379] Prepared protein samples were separated based on their electrophoretic mobility using SDS-polyacrylamide gel electrophoresis (SDS-PAGE). Resolving gel, were prepared using N-methylenebis-acrylamide (30:0.8) to final differing percentages of 10% (v/v) or 7.5% (v/v) acrylamide containing 0.375 M Tris (pH 8.8), 0.1% (w/v) SDS and 10% (w/v) ammonium persulfate (APS) and 10% (v/v) glycerol. The acrylamide gel polymerised at room temperature following the addition of N,N,N,N-tetramethylethylenediamine (TEMED) 0.05% (v/v). The solution was poured between two glass plates with 0.05 cm spacing (Biorad Protean III setup) and this was assembled in a vertical slab orientation, leaving a 1-1.5 cm space and overlayed with 0.1% (w/v) SDS until polymerisation had taken place. After the gel had polymerised, the 0.1% (w/v) SDS was removed, and a stacking gel added. The stacking gel was composed of 10% (v/v) acrylamide: N -methylenebis-acrylamide (30:0.8) in 125 mM Tris, (pH 6.8) 0.1% (w/v) SDS, 0.05% (w/v) APS and 0.05% (v/v) TEMED. Immediately following the addition of the stacking gel, a teflon comb (10 or 15 wells) was inserted prior to polymerisation (~10-15 mins) to form the wells for loading. After polymerisation, the combs were removed from the wells, gels assembled in a Protean III™ (Bio-Rad) electrophoresis tank (Bio-Rad) and filled with electrophoresis running buffer (25 mM Tris, pH 7.5, 129 mM glycine, 0.1% (w/v) SDS). Using a Hamilton TM micro-syringe, a volume (2-5 μl) of pre-stained molecular weight (MW) markers of known molecular weights was loaded into a well in parallel to prepared cell lysates. Samples were electrophoresed at a constant voltage of 130 V until the bromophenol dye present in the sample buffer migrated beyond the bottom of the gel. Electrophoretic transfer of proteins to a nitrocellulose membrane [00380] Following gel electrophoresis, gels containing separated protein polypeptides were transferred onto nitrocellulose membranes by electrophoretic blotting. Each gel was placed firmly onto a nitrocellulose sheet between two 3 mm sheets of blotting paper and two outer sponges and assembled in a transfer cassette. This was submerged in transblot buffer (25 M Tris, 19 mM glycine, 20% (v/v) methanol) in a Bio-Rad Mini Trans-Blot TM tank with the nitrocellulose facing towards the anode. A constant current of 300 mA was applied for 1.75 h whilst cooled by the addition of an ice pack to the transfer tank. Immunological detection of protein using antisera [00381] Following transfer of the proteins to the nitrocellulose membrane, the membrane was then ‘blocked’ for non-specific binding by incubation in 5% (w/v) bovine serum albumin (BSA) in Tris-buffered saline, 0.1% Tween (TBST) buffer blocking solution (150 mM NaCl, 20 mM Tris, pH7.4, 0.1% (v/v) Tween-20) and gently rocked back and forth on a platform shaker for 2 h. The 5% (w/v) BSA blocking buffer was then discarded and replaced with 0.5% (w/v) BSA TBST pH 7.4 solution containing an appropriate concentration of antisera (primary antibody) specific to the target protein. This was left overnight on a roller at 4 o C in the cold room. The next day, the membranes were washed every 5 minutes in TBST for 15 minutes on a platform shaker. After this wash cycle, the membranes were incubated with a secondary antibody, an IgG antibody (conjugated with horseradish peroxidase) raised against the species of the primary antibody. This was added (1:10,000) to 0.5% (w/v) BSA in TBST buffer (pH 7.4) and left on the platform shaker at room temperature for 1.5 h . Following this, the membrane was then washed every 5 min for 15 min with TBST as described before. After this second wash cycle, the membrane was then developed using enhanced chemi-luminescence (ECL) reagents. The TBST buffer from the final wash was discarded and 5 ml of both ECL solution 1 (2.5 mM Luminol, 1.2 mM coumaric acid and 100 mM Tris/HCl solution [pH 8.5]) and 5 ml ECL solution 2 (100 mM Tris/HCl solution [pH 8.5] and 6.27 mM H2O2) were added and washed over the membrane for 2 min. The membranes were then blotted on tissue (to remove an excess ECL solution) before placed in an exposure cassette and covered with cling film. Lastly, the membranes were developed in the dark room where Kodak X-OMAT LS film was exposed to the membranes for an appropriate amount of time, dependent on the sensitivity of the antibody used. The film was developed by a Kodak M35-M-X-OMAT processor. The films were then scanned and quantified by densitometry using Scion image software (Scion Corp, Maryland, USA). Results - Figures 2 – 9 [00382] Whole cell lysates were prepared for separation using SDS-PAGE and analysed by Western blotting (see above) using specific antibodies for proteins relevant to the non- canonical and canonical NF-κB signalling pathways. GAPDH was used as a loading control. Blots from at least three independent experiments were quantified by scanning densitometry, each normalised to GAPDH expression and calculated as mean ± S.E.M relative to the stimulated sample (LT1a2b plus vehicle (4h; for non-canonical NF-kB markers) or TNFa plus vehicle (30 min; for canonical NF-kB markers)). Following curve fitting, IC 50 values were determined. Figure 2 - Effect of compound Example 164 (SU1644) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with SU16441 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS-PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC50 was determined. Figure 3. Effect of compound Example 190 (SU1680) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 190 (SU1680) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC50 was determined. Figure 4. Effect of compound Example 186 (SU1686) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 186 (SU1686) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC50 was determined. Figure 5. Effect of compound Example 167 (SU1688) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 167 (SU1688) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC 50 was determined. Figure 6. Effect of compound Example 155 (SU1699) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 155 (SU1699) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC 50 was determined. Figure 7. Effect of compound Example 180 (SU1703) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 180 (SU1703) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH and the IC 50 was determined. Figure 8. Effect of compound Example 137 (SU1433) on lymphotoxin-stimulated p100 phosphorylation in PC3M cells. Cells were pre-treated with Example 137 (SU1433) 1 h prior to stimulation with lymphotoxin for 4 h. Whole cell lysates were prepared and separated by SDS- PAGE. Blots were quantified from three independent experiments, the level of protein normalised against GAPDH (not shown) and the IC50 was determined. Figure 9. Effect of compounds Example 164 (SU1644), Example 190 (SU1680), Example 186 (SU1686), Example 167 (SU1688), Example 155 (SU1699) and Example 180 (SU1703) on the TNFa-stimulated phosphorylation of p105 and p65 and IkBa degradation in PC3M cells. Cells were pre-treated with the compounds 1 h prior to stimulation with TNFa for 0.5 h. Whole cell lysates were prepared and separated by SDS-PAGE with GAPDH used as a loading control. The results are representative of two independent experiments. Phenotypic effects in cells with exemplars from the series Cell culture [00383] PC3, PC3M, LNCaP AI, cells were grown in RPMI 1640 media and PANC1 and MiaPac-2 cells were grown in Dulbecco’s Modified Eagle’s Media (DMEM) which was supplemented with 10% (v/v) Foetal Calf Serum (FCS) (Charcoal-stripped for LNCaP AIs), L- glutamine (27 mg/ml) and penicillin/streptomycin (250 units/ml; 100μg/ml). All cells were incubated in a humidified atmosphere at 37 o C and 5% (v/v) CO2. Cells were cultured as a monolayer in 10 ml media in 75 cm 3 vented flasks and grown until subculture was required. Sub-culturing of cells [00384] Cells were grown as a monolayer until approximately 70-85% confluent, the media was then aspirated, and the cells washed twice with 1.5 ml sterile 5% (w/v) trypsin solution. The trypsin was aspirated, and the flasks were given a gentle tap to ensure cells were fully detached. The flask was then washed with 10 ml media to re-suspend the recovered cells for passage into flasks and plates with fresh media as appropriate. Cell viability determination: Cells (1000 cells/100 µl) were plated into 96 well plates and incubated for 24 hours at 37°C and 5% (v/v) CO 2 before being treated with SU1433. After incubation with SU1433 for 48 h, cell viability was measured using the alamarBlue® Assay (Thermofisher, UK). The media was removed and replaced with a 1:10 media to alamar blue solution. After a 1 h incubation at 37 °C and 5% CO 2 , the fluorescence was measured at 530- 560 nm excitation wavelength and 590 nm emission wavelength in a fluorescence plate reader. All treatment were measured in duplicate wells and repeated at least 3 times. The results represent the fractional survival of untreated controls ± SD. Results – Figure 10 Figure 10. Treatment with Example 137 (SU1433) for 48 hours reduced the viability of PC3M, LNCaP, PANC1 and MiaPaca-2 cells. Cellular clonogenic capacity determination: Cells were plated into 6 well plates at a density of 125 cells/well and incubated for 24 hat 37 °C and 5% (v/v) CO2 before being treated with Example compound (SU1XXX). For treatment all media was removed and replaced with Eaxmple compound (SUXXXX) (diluted in media). To allow colony formation the cells were incubated for 8 days at 37 °C and 5% (v/v) CO2 before being fixed in 100% methanol and visualised by staining with a solution of 1% (v/v) Giemsa (BDH Laboratory Supplies) and counted. All treatments were measured in duplicate wells and repeated at least 3 times. The results represent the fractional survival of untreated controls ± SD. Results – Figures 11 and 12 Figure 11. The effect of Example 137 (SU1433) on the clonogenic capacity of PC3M and PANC1 cells following 8-day continuous treatment. Figure 12. The effect of Example 137 (SU1433) and Example 164 (SU1644) on the clonogenic capacity of PC3M ells following 8-day continuous treatment. In vivo assessment of Example 137 (SU1433) in nude mice bearing PC3M xenografts [00385] Xenografts were established in nude mice by subcutaneous injection of 5 × 10 6 PC3M- Luc-C6 cells. After 8 days, mice bearing tumours of approximately 60 mm 3 in volume were randomised into 3 treatment groups of 8 mice in each. One group of mice received intraperitoneal injection (i.p.) of 50 mg/kg SU1433 once daily dissolved in a vehicle of 5% (v/v) DMSO, 5 % (v/v) solutol HS15 and 15% (w/v) hydroxypropyl-β-cyclodextrin in water for injection (90%) for a total of 21 days. Another group received once daily i.p. injection of the vehicle (100 µL) alone whilst the last group received no treatment. To monitor potential toxicity, body weight was measured daily, and experimental animals were evaluated for signs of distress using standard guidelines. Mice whose xenografts reached 1,900 mm 3 were euthanised. Subcutaneous tumours were measured with calipers immediately before treatment and every 2 or 3 days thereafter. On the assumption of ellipsoidal geometry, diameter measurements were converted to an approximate volume by multiplying half the longest diameter by the square of the mean of the 2 shorter diameters. For every animal, relative tumour volume (volume at any time point divided by volume immediately before treatment) was plotted against time, and the area under the time–volume curves was determined by trapezoidal approximation. The area under the time–volume curves was used as a measure of treatment effectiveness for the purpose of comparison between groups. To test for differences in tumour growth between experimental therapy groups, the Mann–Whitney U test with Dunn’s multiple comparisons test was used. Results – Figure 13 Figure 13. Example 137 (SU1433) inhibits tumour growth in nude mice bearing PC3M xenografts by approximately 60% over 21 days with a once daily i.p. dose of 50 mg/kg